<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="0" size="12" family="Times" color="#000000"/>
	<fontspec id="1" size="12" family="Times" color="#000000"/>
	<fontspec id="2" size="21" family="Times" color="#000000"/>
	<fontspec id="3" size="17" family="Times" color="#000000"/>
	<fontspec id="4" size="16" family="Times" color="#000000"/>
	<fontspec id="5" size="14" family="Times" color="#000000"/>
	<fontspec id="6" size="14" family="Times" color="#000000"/>
	<fontspec id="7" size="14" family="Times" color="#000000"/>
	<fontspec id="8" size="14" family="Times" color="#000000"/>
	<fontspec id="9" size="10" family="Times" color="#000000"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="439" width="44" height="19" font="1">Page 1 </text>
<text top="133" left="116" width="49" height="31" font="2"><b>2018</b></text>
<text top="137" left="164" width="4" height="25" font="3"><b> </b></text>
<text top="133" left="168" width="145" height="31" font="2"><b>ACC/AHA/HRS</b></text>
<text top="137" left="313" width="4" height="25" font="3"><b> </b></text>
<text top="133" left="318" width="490" height="31" font="2"><b>Guideline on the Evaluation and Management of </b></text>
<text top="162" left="123" width="677" height="31" font="2"><b>Patients With Bradycardia and Cardiac Conduction Delay: Executive </b></text>
<text top="192" left="411" width="100" height="31" font="2"><b>Summary </b></text>
<text top="268" left="94" width="735" height="23" font="4"><b>A Report of the American College of Cardiology/American Heart Association Task Force on Clinical </b></text>
<text top="290" left="271" width="380" height="23" font="4"><b>Practice Guidelines, and the Heart Rhythm Society </b></text>
<text top="332" left="94" width="734" height="21" font="5"><i><b>Developed in Collaboration With the American Association for Thoracic Surgery, the Pediatric &amp; Congenital </b></i></text>
<text top="352" left="243" width="436" height="21" font="5"><i><b>Electrophysiology Society, and the Society of Thoracic Surgeons </b></i></text>
<text top="390" left="102" width="719" height="21" font="5"><i><b>Endorsed by the American Association for Thoracic Surgery, the Pediatric &amp; Congenital Electrophysiology </b></i></text>
<text top="410" left="305" width="311" height="21" font="5"><i><b>Society, and the Society of Thoracic Surgeons</b> </i></text>
<text top="448" left="341" width="239" height="21" font="7"><b>WRITING COMMITTEE MEMBERS* </b></text>
<text top="469" left="295" width="333" height="21" font="8">Fred M. Kusumoto, MD, FACC, FAHA, FHRS, <i>Chair</i> </text>
<text top="489" left="275" width="372" height="21" font="8">Mark H. Schoenfeld, MD, FACC, FAHA, FHRS, <i>Vice Chair</i> </text>
<text top="509" left="89" width="184" height="21" font="8">Coletta Barrett, RN, FAHA† </text>
<text top="509" left="448" width="162" height="21" font="8">Richard Lee, MD, MBA# </text>
<text top="529" left="89" width="252" height="21" font="8">James R. Edgerton, MD, FACC, FHRS‡ </text>
<text top="529" left="448" width="283" height="21" font="8">Joseph E. Marine, MD, MBA, FACC, FHRS§ </text>
<text top="549" left="89" width="334" height="21" font="8">Kenneth A. Ellenbogen, MD, FACC, FAHA, FHRS*† </text>
<text top="549" left="448" width="391" height="21" font="8">Christopher J. McLeod, MB, ChB, PhD, FACC, FAHA, FHRS† </text>
<text top="569" left="89" width="236" height="21" font="8">Michael R. Gold, MD, PhD, FACC*§ </text>
<text top="569" left="448" width="177" height="21" font="8">Keith R. Oken, MD, FACC† </text>
<text top="590" left="89" width="313" height="21" font="8">Nora F. Goldschlager, MD, FACC, FAHA, FHRS† </text>
<text top="590" left="448" width="286" height="21" font="8">Kristen K. Patton, MD, FACC, FAHA, FHRS† </text>
<text top="610" left="89" width="166" height="21" font="8">Robert M. Hamilton, MD</text>
<text top="609" left="255" width="15" height="22" font="8">║ </text>
<text top="610" left="448" width="226" height="21" font="8">Cara N. Pellegrini, MD, FHRS*§** </text>
<text top="630" left="89" width="264" height="21" font="8">José A. Joglar, MD, FACC, FAHA, FHRS¶ </text>
<text top="630" left="448" width="306" height="21" font="8">Kimberly A. Selzman, MD, MPH, FACC, FHRS† </text>
<text top="650" left="89" width="132" height="21" font="8">Robert J. Kim, MD† </text>
<text top="650" left="448" width="193" height="21" font="8">Annemarie Thompson, MD† </text>
<text top="670" left="332" width="278" height="21" font="8">Paul D. Varosy, MD, FACC, FAHA, FHRS†† </text>
<text top="730" left="345" width="231" height="21" font="7"><b>ACC/AHA TASK FORCE MEMBERS </b></text>
<text top="751" left="325" width="271" height="21" font="8">Glenn N. Levine, MD, FACC, FAHA, <i>Chair</i> </text>
<text top="771" left="300" width="322" height="21" font="8">Patrick T. O’Gara, MD, MACC, FAHA, <i>Chair-Elect </i></text>
<text top="791" left="247" width="428" height="21" font="8">Jonathan L. Halperin, MD, FACC, FAHA,<i> Immediate Past Chair</i>‡‡ </text>
<text top="811" left="133" width="282" height="21" font="8">Sana M. Al-Khatib, MD, MHS, FACC, FAHA </text>
<text top="811" left="479" width="202" height="21" font="8">Samuel Gidding, MD, FAHA‡‡ </text>
<text top="831" left="133" width="238" height="21" font="8">Joshua A. Beckman, MD, MS, FAHA </text>
<text top="831" left="479" width="310" height="21" font="8">Zachary D. Goldberger, MD, MSc, FACC, FAHA </text>
<text top="851" left="133" width="239" height="21" font="8">Kim K. Birtcher, PharmD, MS, AACC </text>
<text top="851" left="479" width="222" height="21" font="8">Mark A. Hlatky, MD, FACC, FAHA </text>
<text top="872" left="133" width="279" height="21" font="8">Biykem Bozkurt, MD, PhD, FACC, FAHA‡‡ </text>
<text top="872" left="479" width="224" height="21" font="8">John Ikonomidis, MD, PhD, FAHA </text>
<text top="892" left="133" width="248" height="21" font="8">Ralph G. Brindis, MD, MPH, MACC‡‡ </text>
<text top="892" left="479" width="212" height="21" font="8">José A. Joglar, MD, FACC, FAHA </text>
<text top="912" left="133" width="206" height="21" font="8">Joaquin E. Cigarroa, MD, FACC </text>
<text top="912" left="479" width="198" height="21" font="8">Laura Mauri, MD, MSc, FAHA </text>
<text top="932" left="133" width="202" height="21" font="8">Lesley H. Curtis, PhD, FAHA‡‡ </text>
<text top="932" left="479" width="226" height="21" font="8">Mariann R. Piano, RN, PhD, FAHA </text>
<text top="952" left="133" width="251" height="21" font="8">Anita Deswal, MD, MPH, FACC, FAHA </text>
<text top="952" left="479" width="237" height="21" font="8">Susan J. Pressler, PhD, RN, FAHA‡‡ </text>
<text top="972" left="133" width="220" height="21" font="8">Lee A. Fleisher, MD, FACC, FAHA </text>
<text top="972" left="479" width="225" height="21" font="8">Barbara Riegel, PhD, RN, FAHA‡‡ </text>
<text top="992" left="133" width="189" height="21" font="8">Federico Gentile, MD, FACC </text>
<text top="992" left="479" width="247" height="21" font="8">Duminda N. Wijeysundera, MD, PhD </text>
<text top="1070" left="81" width="756" height="19" font="1">*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships</text>
<text top="1089" left="81" width="756" height="19" font="1">with industry may apply; see Appendix 1 for detailed information. †ACC/AHA Representative. ‡STS Representative. §HRS</text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="10" size="12" family="Times" color="#650715"/>
	<fontspec id="11" size="12" family="Times" color="#231f20"/>
	<fontspec id="12" size="12" family="Times" color="#231f20"/>
	<fontspec id="13" size="12" family="Times" color="#231f20"/>
	<fontspec id="14" size="12" family="Times" color="#000000"/>
	<fontspec id="15" size="12" family="Times" color="#000000"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="439" width="44" height="19" font="1">Page 2 </text>
<text top="124" left="81" width="99" height="19" font="1">Representative. </text>
<text top="124" left="180" width="660" height="20" font="1">║PACES Representative. ¶ACC/AHA Task Force on Clinical Practice Guidelines Liaison. #AATS Representative. </text>
<text top="142" left="81" width="760" height="19" font="1">**Dr. Pellegrini contributed to this article in her personal capacity. The views expressed are her own and do not necessarily </text>
<text top="161" left="81" width="761" height="19" font="1">represent the views of the US Department of Veterans Affairs or the US government. ††ACC/AHA Performance Measures </text>
<text top="179" left="81" width="548" height="19" font="1">Representative. ‡‡Former Task Force member; current member during the writing effort. </text>
<text top="197" left="81" width="3" height="19" font="1"> </text>
<text top="216" left="81" width="760" height="19" font="1">This document was approved by the American College of Cardiology Clinical Policy Approval Committee, the American Heart </text>
<text top="234" left="81" width="760" height="19" font="1">Association Science Advisory and Coordinating Committee, and the Heart Rhythm Society in August 2018, and the American </text>
<text top="252" left="81" width="349" height="19" font="1">Heart Association Executive Committee in October 2018. </text>
<text top="271" left="81" width="3" height="19" font="1"> </text>
<text top="289" left="81" width="342" height="19" font="1">Supplemental materials are available with this article at </text>
<text top="307" left="81" width="448" height="19" font="10"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627</a></text>
<text top="307" left="529" width="7" height="19" font="1"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="326" left="81" width="3" height="19" font="1"> </text>
<text top="344" left="81" width="760" height="19" font="1">The American Heart Association requests that this document be cited as follows: Kusumoto FM, Schoenfeld MH, Barrett C, </text>
<text top="362" left="81" width="760" height="19" font="1">Edgerton JR, Ellenbogen KA, Gold MR, Goldschlager NF, Hamilton RM, Joglar JA, Kim RJ, Lee R, Marine JE, McLeod CJ, Oken </text>
<text top="381" left="81" width="762" height="19" font="1">KR, Patton KK, Pellegrini C, Selzman KA, Thompson A, Varosy PD. 2018 ACC/AHA/HRS guideline on the evaluation and </text>
<text top="399" left="81" width="762" height="19" font="1">management of patients with bradycardia and cardiac conduction delay: executive summary: a report of the American </text>
<text top="417" left="81" width="760" height="19" font="1">College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. </text>
<text top="435" left="81" width="476" height="19" font="1">Circulation. 2018;:–. DOI: 10.1161/CIR.0000000000000627. </text>
<text top="454" left="81" width="3" height="19" font="1"> </text>
<text top="472" left="81" width="244" height="19" font="1">This article has been copublished in the </text>
<text top="471" left="325" width="393" height="20" font="11"><i>Journal of the American College of Cardiology </i>and <b>Heart</b>Rhythm.</text>
<text top="472" left="717" width="3" height="19" font="1"> </text>
<text top="490" left="81" width="3" height="19" font="1"> </text>
<text top="509" left="81" width="566" height="19" font="1">Copies: This document is available on the websites of the American College of Cardiology<a href="http://www.cardiosource.org/"> (</a></text>
<text top="509" left="647" width="80" height="19" font="10"><a href="http://www.cardiosource.org/">www.acc.org</a></text>
<text top="509" left="727" width="115" height="19" font="1"><a href="http://www.cardiosource.org/">)</a>, American Heart </text>
<text top="527" left="81" width="79" height="19" font="1">Association<a href="https://professional.heart.org/"> (</a></text>
<text top="527" left="160" width="135" height="19" font="10"><a href="https://professional.heart.org/">professional.heart.org</a></text>
<text top="527" left="296" width="213" height="19" font="1"><a href="https://professional.heart.org/">)</a>, and the Heart Rhythm Societ<a href="http://www.hrsonline.org/">y (</a></text>
<text top="527" left="509" width="117" height="19" font="10"><a href="http://www.hrsonline.org/">www.hrsonline.org</a></text>
<text top="527" left="626" width="216" height="19" font="1"><a href="http://www.hrsonline.org/">)</a>. A copy of the document is also </text>
<text top="545" left="81" width="79" height="19" font="1">available at<a href="https://professional.heart.org/statements"> </a></text>
<text top="545" left="160" width="257" height="19" font="10"><a href="https://professional.heart.org/statements">https://professional.heart.org/statements</a></text>
<text top="545" left="417" width="427" height="19" font="1"><a href="https://professional.heart.org/statements">  </a>by  selecting the “Guidelines &amp; Statements” button. To purchase </text>
<text top="564" left="81" width="505" height="19" font="1">additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com. </text>
<text top="582" left="81" width="3" height="19" font="1"> </text>
<text top="600" left="81" width="760" height="19" font="1">The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic </text>
<text top="618" left="81" width="760" height="19" font="1">reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, </text>
<text top="637" left="81" width="28" height="19" font="1">visit<a href="https://professional.heart.org/statements"> </a></text>
<text top="637" left="109" width="257" height="19" font="10"><a href="https://professional.heart.org/statements">https://professional.heart.org/statements</a></text>
<text top="637" left="366" width="475" height="19" font="1"><a href="https://professional.heart.org/statements">.</a> Select the “Guidelines &amp; Statements” drop-down menu near the top of the </text>
<text top="655" left="81" width="298" height="19" font="1">webpage, then click “Publication Development.” </text>
<text top="673" left="81" width="3" height="19" font="1"> </text>
<text top="692" left="81" width="759" height="19" font="1">Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted </text>
<text top="710" left="81" width="762" height="19" font="1">without the express permission of the American Heart Association. Instructions for obtaining permission are located at </text>
<text top="728" left="81" width="219" height="19" font="10"><a href="https://www.heart.org/permissions">https://www.heart.org/permissions</a></text>
<text top="728" left="300" width="542" height="19" font="1"><a href="https://www.heart.org/permissions">.</a> A link to the “Copyright Permissions Request Form” appears in the second paragraph </text>
<text top="747" left="81" width="5" height="19" font="1"><a href="https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form">(</a></text>
<text top="747" left="86" width="523" height="19" font="10"><a href="https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form">https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form</a></text>
<text top="747" left="608" width="12" height="19" font="1"><a href="https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form">).</a> </text>
<text top="765" left="81" width="3" height="19" font="1"> </text>
<text top="783" left="81" width="458" height="19" font="0"><b>(<i>Circulation</i></b><b>. 2018;000:e000–e000. DOI: 10.1161/CIR.0000000000000627) </b></text>
<text top="802" left="81" width="3" height="19" font="1"> </text>
<text top="820" left="81" width="761" height="19" font="1">© 2018 by the American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Rhythm </text>
<text top="838" left="81" width="51" height="19" font="1">Society. </text>
<text top="857" left="81" width="3" height="19" font="1"> </text>
<text top="874" left="81" width="413" height="20" font="15"><i>Circulation</i> is available at https://www.ahajournals.org/journal/circ </text>
<text top="893" left="81" width="3" height="19" font="1"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="16" size="11" family="Times" color="#000000"/>
	<fontspec id="17" size="11" family="Times" color="#000000"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="439" width="44" height="19" font="1">Page 3 </text>
<text top="124" left="399" width="125" height="21" font="7"><b>Table of Contents </b></text>
<text top="144" left="81" width="759" height="17" font="16"><a href="CIR.0000000000000627.html#5"><b>Top 10 Take-Home Messages .................................................................................................................................................................. 5</b> </a></text>
<text top="161" left="81" width="759" height="17" font="16"><a href="CIR.0000000000000627.html#6"><b>Preamble ................................................................................................................................................................................................ 6</b> </a></text>
<text top="177" left="87" width="748" height="17" font="16"><a href="CIR.0000000000000627.html#7"><b>1. Introduction .....................................................................................................................................................................................7</b> </a></text>
<text top="194" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#7">1.1. Methodology and Evidence Review ................................................................................................................................................... 7 </a></text>
<text top="210" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#7">1.2. Organization of the Writing Committee............................................................................................................................................. 7 </a></text>
<text top="227" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#7">1.3. Document Review and Approval ........................................................................................................................................................ 7 </a></text>
<text top="243" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#8">1.4. Scope of the Guideline ....................................................................................................................................................................... 8 </a></text>
<text top="260" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#10">1.5. Class of Recommendation and Level of Evidence ............................................................................................................................ 10 </a></text>
<text top="276" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#12">1.6. Abbreviations ................................................................................................................................................................................... 12 </a></text>
<text top="292" left="87" width="748" height="17" font="16"><a href="CIR.0000000000000627.html#13"><b>2. Epidemiology and Definitions ......................................................................................................................................................... 13</b> </a></text>
<text top="309" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#13">2.1. Definitions ........................................................................................................................................................................................ 13 </a></text>
<text top="325" left="87" width="748" height="17" font="16"><a href="CIR.0000000000000627.html#15"><b>3. General Evaluation of Patients With Documented or Suspected Bradycardia or Conduction Disorders ........................................... 15</b> </a></text>
<text top="342" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#15">3.1. History and Physical Examination of Patients With Documented or Suspected Bradycardia or Conduction Disorders .................. 15 </a></text>
<text top="359" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#23">3.2. Noninvasive Evaluation .................................................................................................................................................................... 23 </a></text>
<text top="375" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#23">3.2.1. Resting ECG in Patients With Documented or Suspected Bradycardia or Conduction Disorders ............................................ 23 </a></text>
<text top="391" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#23">3.2.2. Exercise Electrocardiographic Testing in Patients With Documented or Suspected Bradycardia or Conduction Disorders .... 23 </a></text>
<text top="408" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#23">3.2.3. Ambulatory Electrocardiography in Patients With Documented or Suspected Bradycardia or Conduction Disorders ........... 23 </a></text>
<text top="424" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#25">3.2.4. Imaging in Patients With Documented or Suspected Bradycardia or Conduction Disorders ................................................... 25 </a></text>
<text top="441" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#25">3.2.5. Laboratory Testing in Patients With Documented or Suspected Bradycardia or Conduction Disorders ................................. 25 </a></text>
<text top="457" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#26">3.2.6. Genetic Testing in Patients With Documented or Suspected Bradycardia or Conduction Disorders ....................................... 26 </a></text>
<text top="474" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#26">3.2.7. Sleep Apnea Evaluation and Treatment in Patients With Documented or Suspected Bradycardia or Conduction Disorders . 26 </a></text>
<text top="490" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#27">3.3. Invasive Testing ................................................................................................................................................................................ 27 </a></text>
<text top="507" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#27">3.3.1. Implantable Cardiac Monitor in Patients With Documented or Suspected Bradycardia or Conduction Disorders ................. 27 </a></text>
<text top="523" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#27">3.3.2. Electrophysiology Study in Patients With Documented or Suspected Bradycardia or Conduction Disorders ......................... 27 </a></text>
<text top="540" left="87" width="748" height="17" font="16"><a href="CIR.0000000000000627.html#28"><b>4. Bradycardia Attributable to Sinus Node Dysfunction ...................................................................................................................... 28</b> </a></text>
<text top="556" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#28">4.1. Acute Management of Sinus Node Dysfunction .............................................................................................................................. 28 </a></text>
<text top="573" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#30">4.1.1. Acute Management of Reversible Causes of Sinus Node Dysfunction ..................................................................................... 30 </a></text>
<text top="589" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#31">4.1.2. Acute Medical Therapy for Bradycardia ................................................................................................................................... 31 </a></text>
<text top="606" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#33">4.1.3. Temporary Pacing for Bradycardia Attributable to SND .......................................................................................................... 33 </a></text>
<text top="622" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#35">4.2. Chronic Therapy/Management of Bradycardia Attributable to SND ............................................................................................... 35 </a></text>
<text top="639" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#35">4.2.1. General Principles of Chronic Therapy/Management of Bradycardia Attributable to SND ..................................................... 35 </a></text>
<text top="655" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#35">4.2.2. Transient/Reversible Causes (Including Medications) of Bradycardia Attributable to SND ..................................................... 35 </a></text>
<text top="672" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#35">4.2.3. Additional Testing of Bradycardia Attributable to SND ............................................................................................................ 35 </a></text>
<text top="688" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#36">4.3.4. Permanent Pacing for Chronic Therapy/Management of Bradycardia Attributable to SND .................................................... 36 </a></text>
<text top="704" left="87" width="748" height="17" font="16"><a href="CIR.0000000000000627.html#38"><b>5. Bradycardia Attributable to Atrioventricular Block ......................................................................................................................... 38</b> </a></text>
<text top="721" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#38">5.1. Pathophysiology, Etiology, and Classification of Bradycardia Attributable to Atrioventricular Block .............................................. 38 </a></text>
<text top="737" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#39">5.2. Acute Management ......................................................................................................................................................................... 39 </a></text>
<text top="754" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#39">5.2.1. Acute Management of Reversible Causes of Bradycardia Attributable to Atrioventricular Block ........................................... 39 </a></text>
<text top="770" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#40">5.2.2. Acute Medical Therapy for Bradycardia Attributable to Atrioventricular Block ...................................................................... 40 </a></text>
<text top="787" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#40">5.2.3. Temporary Pacing for Atrioventricular Block ........................................................................................................................... 40 </a></text>
<text top="803" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#41">5.3. Chronic Therapy/Management of Bradycardia Attributable to Atrioventricular Block ................................................................... 41 </a></text>
<text top="820" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#43">5.3.1. General Principles of Chronic Therapy/Management of Bradycardia Attributable to Atrioventricular Block ......................... 43 </a></text>
<text top="836" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#43">5.3.2. Transient/Potentially Reversible Causes of Atrioventricular Block .......................................................................................... 43 </a></text>
<text top="853" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#44">5.3.3. Additional Testing for Chronic Therapy/Management of Bradycardia Attributable to Atrioventricular Block ........................ 44 </a></text>
<text top="869" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#44">5.3.4. Permanent Pacing .................................................................................................................................................................... 44 </a></text>
<text top="886" left="87" width="748" height="17" font="16"><a href="CIR.0000000000000627.html#47"><b>6. Conduction Disorders (With 1:1 Atrioventricular Conduction) ........................................................................................................ 47</b> </a></text>
<text top="902" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#47">6.1. Evaluation of Conduction Disorders ................................................................................................................................................. 47 </a></text>
<text top="919" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#50">6.2. Management of Conduction Disorders (With 1:1 Atrioventricular Conduction) ............................................................................. 50 </a></text>
<text top="935" left="87" width="748" height="17" font="16"><a href="CIR.0000000000000627.html#52"><b>7. Special Populations ........................................................................................................................................................................ 52</b> </a></text>
<text top="952" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#52">7.1. Perioperative Management ............................................................................................................................................................. 52 </a></text>
<text top="968" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#52">7.1.1. Patients at Risk for Bradycardia During Noncardiac Surgery or Procedures ............................................................................ 52 </a></text>
<text top="985" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#52">7.1.2. Postoperative Bradycardia and Conduction Disorders After Cardiac Surgery.......................................................................... 52 </a></text>
<text top="1001" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#56">7.2. Bradycardia Management for Adult Congenital Heart Disease ....................................................................................................... 56 </a></text>
<text top="1018" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#57">7.3. Management of Bradycardia in Patients With an Acute MI ............................................................................................................. 57 </a></text>
<text top="1034" left="97" width="731" height="17" font="17"><a href="CIR.0000000000000627.html#57">7.4. Neurologic Disorders ........................................................................................................................................................................ 57 </a></text>
<text top="1051" left="114" width="715" height="17" font="17"><a href="CIR.0000000000000627.html#57">7.4.1. Epilepsy .................................................................................................................................................................................... 57 </a></text>
<text top="1067" left="87" width="748" height="17" font="16"><a href="CIR.0000000000000627.html#58"><b>8. Evaluation of the Risks for Ventricular Arrhythmias in Patients Who Require Permanent Pacing .................................................... 58</b> </a></text>
<text top="1083" left="87" width="748" height="17" font="16"><a href="CIR.0000000000000627.html#58"><b>9. Shared Decision-Making ................................................................................................................................................................. 58</b> </a></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="439" width="44" height="19" font="1">Page 4 </text>
<text top="124" left="87" width="748" height="17" font="16"><a href="CIR.0000000000000627.html#59"><b>10. Discontinuation of Pacemaker Therapy ........................................................................................................................................ 59</b> </a></text>
<text top="140" left="89" width="744" height="17" font="16"><a href="CIR.0000000000000627.html#61"><b>Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2018 ACC/AHA/HRS Guideline on the Evaluation and </b></a></text>
<text top="157" left="87" width="748" height="17" font="16"><a href="CIR.0000000000000627.html#61"><b>Management of Patients With Bradycardia and Cardiac Conduction Delay (July 2018) ....................................................................... 61</b> </a></text>
<text top="173" left="88" width="745" height="17" font="16"><a href="CIR.0000000000000627.html#64"><b>Appendix 2. Abbreviated Reviewer Relationships With Industry and Other Entities—2018 ACC/AHA/HRS Guideline on the Evaluation </b></a></text>
<text top="190" left="87" width="748" height="17" font="16"><a href="CIR.0000000000000627.html#64"><b>and Management of Patients With Bradycardia and Cardiac Conduction Delay (August 2018)* ......................................................... 64</b> </a></text>
<text top="206" left="87" width="744" height="17" font="16"><a href="CIR.0000000000000627.html#67"><b>References ......................................................................................................................................................................................... 67</b></a></text>
<text top="203" left="831" width="4" height="21" font="8"><a href="CIR.0000000000000627.html#67"> </a></text>
<text top="223" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="439" width="44" height="19" font="1">Page 5 </text>
<text top="124" left="81" width="290" height="31" font="2"><b>Top 10 Take-Home Messages </b></text>
<text top="153" left="81" width="760" height="21" font="8">1.  Sinus node dysfunction is most often related to age-dependent progressive fibrosis of the sinus nodal tissue </text>
<text top="173" left="108" width="733" height="21" font="8">and surrounding atrial myocardium leading to abnormalities of sinus node and atrial impulse formation and </text>
<text top="193" left="108" width="599" height="21" font="8">propagation and will therefore result in various bradycardic or pause-related syndromes. </text>
<text top="214" left="81" width="760" height="21" font="8">2.  Both sleep disorders of breathing and nocturnal bradycardias are relatively common, and treatment of sleep </text>
<text top="234" left="108" width="734" height="21" font="8">apnea not only reduces the frequency of these arrhythmias but also may offer cardiovascular benefits. The </text>
<text top="254" left="108" width="735" height="21" font="8">presence of nocturnal bradycardias should prompt consideration for screening for sleep apnea, beginning </text>
<text top="274" left="108" width="735" height="21" font="8">with solicitation of suspicious symptoms. However, nocturnal bradycardia is not in itself an indication for </text>
<text top="294" left="108" width="130" height="21" font="8">permanent pacing. </text>
<text top="314" left="81" width="764" height="21" font="8">3.  The presence of left bundle branch block on electrocardiogram markedly increases the likelihood of </text>
<text top="334" left="108" width="733" height="21" font="8">underlying structural heart disease and of diagnosing left ventricular systolic dysfunction. Echocardiography </text>
<text top="355" left="108" width="735" height="21" font="8">is usually the most appropriate initial screening test for structural heart disease, including left ventricular </text>
<text top="375" left="108" width="139" height="21" font="8">systolic dysfunction. </text>
<text top="395" left="81" width="761" height="21" font="8">4.  In sinus node dysfunction, there is no established minimum heart rate or pause duration where permanent </text>
<text top="415" left="108" width="733" height="21" font="8">pacing is recommended. Establishing temporal correlation between symptoms and bradycardia is important </text>
<text top="435" left="108" width="386" height="21" font="8">when determining whether permanent pacing is needed. </text>
<text top="455" left="81" width="762" height="21" font="8">5.  In patients with acquired second-degree Mobitz type II atrioventricular block, high-grade atrioventricular </text>
<text top="475" left="108" width="732" height="21" font="8">block, or third-degree atrioventricular block not caused by reversible or physiologic causes, permanent pacing </text>
<text top="496" left="108" width="735" height="21" font="8">is recommended regardless  of symptoms. For all other types of atrioventricular block, in the absence of </text>
<text top="516" left="108" width="734" height="21" font="8">conditions associated with progressive atrioventricular conduction abnormalities, permanent pacing should </text>
<text top="536" left="108" width="675" height="21" font="8">generally be considered only in the presence of symptoms that correlate with atrioventricular block. </text>
<text top="556" left="81" width="760" height="21" font="8">6.  In patients with a left ventricular ejection fraction between 36% to 50% and atrioventricular block, who have </text>
<text top="576" left="108" width="737" height="21" font="8">an indication for permanent pacing and are expected to require ventricular pacing &gt;40% of the time, </text>
<text top="596" left="108" width="734" height="21" font="8">techniques that provide more physiologic ventricular activation (e.g., cardiac resynchronization therapy, His </text>
<text top="616" left="108" width="539" height="21" font="8">bundle pacing) are preferred to right ventricular pacing to prevent heart failure. </text>
<text top="636" left="81" width="765" height="21" font="8">7.  Because conduction system abnormalities are common after transcatheter aortic valve replacement, </text>
<text top="657" left="108" width="711" height="21" font="8">recommendations on postprocedure surveillance and pacemaker implantation are made in this guideline. </text>
<text top="677" left="81" width="761" height="21" font="8">8.  In patients with bradycardia who have indications for pacemaker implantation, shared decision-making and </text>
<text top="697" left="108" width="733" height="21" font="8">patient-centered care are endorsed and emphasized in this guideline. Treatment decisions are based on the </text>
<text top="717" left="108" width="508" height="21" font="8">best available evidence and on the patient’s goals of care and preferences.  </text>
<text top="737" left="81" width="760" height="21" font="8">9.  Using the principles of shared decision-making and informed consent/refusal, patients with decision-making </text>
<text top="757" left="108" width="735" height="21" font="8">capacity or his/her legally defined surrogate has the right to refuse or request withdrawal of pacemaker </text>
<text top="777" left="108" width="733" height="21" font="8">therapy, even if the patient is pacemaker dependent, which should be considered palliative, end-of-life care, </text>
<text top="797" left="108" width="732" height="21" font="8">and not physician-assisted suicide. However, any decision is complex, should involve all stakeholders, and will </text>
<text top="818" left="108" width="179" height="21" font="8">always be patient specific. </text>
<text top="838" left="81" width="759" height="21" font="8">10. Identifying patient populations that will benefit the most from emerging pacing technologies (e.g., His bundle </text>
<text top="858" left="108" width="736" height="21" font="8">pacing, transcatheter leadless pacing systems) will require further investigation as these modalities are </text>
<text top="878" left="108" width="233" height="21" font="8">incorporated into clinical practice. </text>
<text top="899" left="101" width="3" height="19" font="1"> </text>
<text top="899" left="317" width="3" height="19" font="1"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="18" size="14" family="Times" color="#650715"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="439" width="44" height="19" font="1">Page 6 </text>
<text top="124" left="81" width="106" height="31" font="2"><b>Preamble  </b></text>
<text top="177" left="81" width="762" height="21" font="8">Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated </text>
<text top="197" left="81" width="759" height="21" font="8">scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These </text>
<text top="217" left="81" width="761" height="21" font="8">guidelines, which are based on systematic methods to evaluate and classify evidence, provide a foundation for </text>
<text top="237" left="81" width="760" height="21" font="8">the delivery of quality cardiovascular care. The ACC and AHA sponsor the development and publication of clinical </text>
<text top="257" left="81" width="761" height="21" font="8">practice guidelines without commercial support, and members volunteer their time to the writing and review </text>
<text top="278" left="81" width="56" height="21" font="8">efforts.  </text>
<text top="298" left="135" width="706" height="21" font="8">Clinical practice guidelines provide recommendations applicable to patients with or at risk of developing </text>
<text top="318" left="81" width="760" height="21" font="8">cardiovascular disease. The focus is on medical practice in the United States, but these guidelines are relevant to </text>
<text top="338" left="81" width="762" height="21" font="8">patients throughout the world. Although guidelines may be used to inform regulatory or payer decisions, the </text>
<text top="358" left="81" width="760" height="21" font="8">intent is to improve quality of care and align with patients’ interests. Guidelines are intended to define practices </text>
<text top="378" left="81" width="726" height="21" font="8">meeting the needs of patients in most, but not all, circumstances, and should not replace clinical judgment.  </text>
<text top="398" left="135" width="713" height="21" font="8">Recommendations for guideline-directed management and therapy, which encompasses clinical </text>
<text top="418" left="81" width="762" height="21" font="8">evaluation, diagnostic testing, and both pharmacological and procedural treatments, are effective only when </text>
<text top="439" left="81" width="756" height="21" font="8">followed by both practitioners and patients. Adherence to recommendations can be enhanced by shared decision-</text>
<text top="459" left="81" width="763" height="21" font="8">making between clinicians and patients, with patient engagement in selecting interventions on the basis of </text>
<text top="479" left="81" width="517" height="21" font="8">individual values, preferences, and associated conditions and comorbidities.  </text>
<text top="499" left="135" width="709" height="21" font="8">The ACC/AHA Task Force on Clinical Practice Guidelines strives to ensure that the guideline writing </text>
<text top="519" left="81" width="759" height="21" font="8">committee both contains requisite expertise and is representative of the broader medical community by selecting </text>
<text top="539" left="81" width="761" height="21" font="8">experts from a broad array of backgrounds representing different geographic regions, sexes, races, ethnicities, </text>
<text top="559" left="81" width="762" height="21" font="8">intellectual perspectives/biases, and scopes of clinical practice, and by inviting organizations and professional </text>
<text top="580" left="81" width="761" height="21" font="8">societies with related interests and expertise to participate as partners or collaborators. The ACC and AHA have </text>
<text top="600" left="81" width="760" height="21" font="8">rigorous policies and methods to ensure that documents are developed without bias or improper influence. The </text>
<text top="620" left="81" width="773" height="21" font="8">complete policy on relationships with industry and other entities (RWI) can be found at </text>
<text top="640" left="81" width="720" height="21" font="18"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy</a></text>
<text top="640" left="801" width="12" height="21" font="8"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">. </a> </text>
<text top="660" left="135" width="706" height="21" font="8">Beginning in 2017, numerous modifications to the guidelines have been and continue to be implemented </text>
<text top="680" left="81" width="761" height="21" font="8">to make guidelines shorter and enhance “user friendliness.” Guidelines are written and presented in a modular </text>
<text top="700" left="81" width="765" height="21" font="8">knowledge chunk format, in which each chunk includes a table of recommendations, a brief synopsis, </text>
<text top="721" left="81" width="759" height="21" font="8">recommendation-specific supportive text and, when appropriate, flow diagrams or additional tables. Hyperlinked </text>
<text top="741" left="81" width="759" height="21" font="8">references are provided for each modular knowledge chunk to facilitate quick access and review. More structured </text>
<text top="761" left="81" width="759" height="21" font="8">guidelines—including word limits (“targets”) and a web guideline supplement for useful but noncritical tables and </text>
<text top="781" left="81" width="762" height="21" font="8">figures—are 2 such changes. This Preamble is an abbreviated version, with the detailed version available at: </text>
<text top="801" left="81" width="493" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627</a></text>
<text top="801" left="575" width="11" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a>  </text>
<text top="821" left="135" width="706" height="21" font="8">The reader is encouraged to consult the full-text guideline (P-1) for additional guidance and details about </text>
<text top="842" left="81" width="771" height="21" font="8">bradycardia and cardiac conduction delay, because  the executive summary contains mainly the </text>
<text top="862" left="81" width="130" height="21" font="8">recommendations. </text>
<text top="882" left="81" width="4" height="21" font="8"> </text>
<text top="901" left="81" width="227" height="21" font="6"><i>Glenn N. Levine, MD, FACC, FAHA </i></text>
<text top="921" left="81" width="386" height="22" font="6"><i>Chair, ACC/AHA Task Force on Clinical Practice Guidelines</i> </text>
<text top="951" left="81" width="4" height="21" font="8"> </text>
<text top="980" left="81" width="4" height="21" font="8"> </text>
<text top="980" left="297" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="19" size="20" family="Times" color="#000000"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="439" width="44" height="19" font="1">Page 7 </text>
<text top="142" left="81" width="154" height="31" font="2"><b>1. Introduction </b></text>
<text top="195" left="81" width="373" height="29" font="19"><b>1.1. Methodology and Evidence Review </b></text>
<text top="241" left="81" width="764" height="21" font="8">The recommendations listed in this guideline are, whenever possible, evidence based. An initial extensive </text>
<text top="261" left="81" width="760" height="21" font="8">evidence review, which included literature derived from research involving human subjects, published in English, </text>
<text top="281" left="81" width="760" height="21" font="8">and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research </text>
<text top="301" left="81" width="760" height="21" font="8">and Quality, and other selected databases relevant to this guideline, was conducted from January 2017  to </text>
<text top="321" left="81" width="760" height="21" font="8">September 2017. Key search words included but were not limited to the following: <i>AV block, bradycardia, bundle </i></text>
<text top="340" left="81" width="760" height="21" font="6"><i>branch block, conduction disturbance, left bundle branch block, loop recorder, pauses, permanent pacemaker, sick </i></text>
<text top="360" left="81" width="759" height="22" font="6"><i>sinus syndrome, sinus node dysfunction,</i> and <i>temporary pacemaker</i>. Additional relevant studies published through </text>
<text top="381" left="81" width="760" height="21" font="8">January 2018, during the guideline writing process, were also considered by the writing committee and added to </text>
<text top="402" left="81" width="762" height="21" font="8">the evidence tables when appropriate. The final evidence tables are included in the Online Data Supplement </text>
<text top="422" left="81" width="5" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">(</a></text>
<text top="422" left="86" width="494" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627</a></text>
<text top="422" left="580" width="261" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">) </a>and summarize the evidence used by </text>
<text top="442" left="81" width="764" height="21" font="8">the writing committee to formulate recommendations. References selected and published in the present </text>
<text top="462" left="81" width="342" height="21" font="8">document are representative and not all-inclusive. </text>
<text top="482" left="81" width="4" height="21" font="8"> </text>
<text top="482" left="108" width="4" height="21" font="8"> </text>
<text top="482" left="135" width="706" height="21" font="8">As noted in the detailed version of the Preamble, an independent evidence review committee  was </text>
<text top="502" left="81" width="761" height="21" font="8">commissioned to perform a formal systematic review of 1 critical clinical question related to bradycardia, the </text>
<text top="522" left="81" width="760" height="21" font="8">results of which were considered by the writing committee for incorporation into this guideline. Concurrent with </text>
<text top="543" left="81" width="760" height="21" font="8">this process, writing committee members evaluated study data relevant to the rest of the guideline. The findings </text>
<text top="563" left="81" width="760" height="21" font="8">of the evidence review committee and the writing committee members were formally presented and discussed, </text>
<text top="583" left="81" width="760" height="21" font="8">and then recommendations were developed. The systematic review, titled “Impact of Physiologic Versus Right </text>
<text top="603" left="81" width="759" height="21" font="8">Ventricular Pacing Among Patients With Left Ventricular Ejection Fraction Greater Than 35%: A Systematic Review </text>
<text top="623" left="81" width="762" height="21" font="8">for the 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and </text>
<text top="643" left="81" width="765" height="21" font="8">Cardiac Conduction Delay”  is published in conjunction with this guideline (S1-1)  and its respective data </text>
<text top="663" left="81" width="254" height="21" font="8">supplements are available online <a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000629">(</a></text>
<text top="663" left="335" width="493" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000629">https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000629</a></text>
<text top="664" left="828" width="13" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000629">).</a> </text>
<text top="684" left="81" width="580" height="21" font="8">The evidence review committee report informed recommendations in Section 6.4.4.1. </text>
<text top="713" left="81" width="415" height="29" font="19"><b>1.2. Organization of the Writing Committee  </b></text>
<text top="745" left="81" width="767" height="21" font="8">The writing committee consisted of  cardiac  electrophysiologists, clinicians, cardiologists, surgeons, an </text>
<text top="765" left="81" width="759" height="21" font="8">anesthesiologist, and a lay/patient representative. The writing committee included representatives from the ACC, </text>
<text top="785" left="81" width="762" height="21" font="8">AHA,  Heart Rhythm Society (HRS),  American Association for Thoracic Surgery (AATS), Pediatric &amp; Congenital </text>
<text top="805" left="81" width="763" height="21" font="8">Electrophysiology Society (PACES), and the Society of Thoracic Surgeons (STS).  ). Appendix 1 of the present </text>
<text top="825" left="81" width="762" height="21" font="8">document lists writing committee members’ relevant RWI. For the purposes of full transparency, the writing </text>
<text top="845" left="81" width="792" height="21" font="8">committee members’ comprehensive disclosure information is available online </text>
<text top="866" left="81" width="5" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">(</a></text>
<text top="866" left="86" width="494" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627</a></text>
<text top="866" left="580" width="13" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">).</a> </text>
<text top="895" left="81" width="351" height="29" font="19"><b>1.3. Document Review and Approval  </b></text>
<text top="927" left="81" width="762" height="21" font="8">This document was reviewed by 2 official reviewers each nominated by the ACC, AHA, and HRS; 1 official lay </text>
<text top="947" left="81" width="760" height="21" font="8">reviewer nominated by the AHA; 1 organizational reviewer each from the AATS, PACES, and STS; and 31 individual </text>
<text top="967" left="81" width="761" height="21" font="8">content reviewers. Reviewers’ RWI information was distributed to the writing committee and is published as an </text>
<text top="987" left="81" width="762" height="21" font="8">abbreviated table  in this document (Appendix 2).  The reviewers’ detailed RWI information is available online </text>
<text top="1007" left="81" width="5" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">(</a></text>
<text top="1007" left="86" width="494" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627</a></text>
<text top="1007" left="580" width="13" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">).</a> </text>
<text top="1027" left="135" width="706" height="21" font="8">This document was approved for publication by the governing bodies of the ACC, the AHA, and the HRS; </text>
<text top="1047" left="81" width="759" height="21" font="8">and was endorsed by the American Association for Thoracic Surgery, the Pediatric &amp; Congenital Electrophysiology </text>
<text top="1068" left="81" width="311" height="21" font="8">Society, and the Society of Thoracic Surgeons. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="8" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="439" width="44" height="19" font="1">Page 8 </text>
<text top="124" left="81" width="256" height="29" font="19"><b>1.4. Scope of the Guideline </b></text>
<text top="156" left="81" width="760" height="21" font="8">The purpose of this ACC/AHA/HRS guideline is to provide guidance to clinicians for the management of patients </text>
<text top="176" left="81" width="760" height="21" font="8">with bradycardia, or symptoms thought to be associated with bradycardia or cardiac conduction system disorders. </text>
<text top="196" left="81" width="762" height="21" font="8">This guideline supersedes the pacemaker recommendations made in the “ACC/AHA/HRS 2008 Guidelines for </text>
<text top="216" left="81" width="763" height="21" font="8">Device-Based Therapy of Cardiac Rhythm Abnormalities”  (S1.4-1,  S1.4-2)  and “2012 ACCF/AHA/HRS Focused </text>
<text top="236" left="81" width="763" height="21" font="8">Update Incorporated Into the ACCG/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm </text>
<text top="257" left="81" width="759" height="21" font="8">Abnormalities (S1.4-2). The guideline will be useful to general internists, family physicians, emergency physicians, </text>
<text top="277" left="81" width="764" height="21" font="8">anesthesiologists, surgeons, cardiologists, and arrhythmia specialists.  This document is aimed at the adult </text>
<text top="297" left="81" width="760" height="21" font="8">population (&gt;18 years of age) and offers no specific recommendations in pediatric patients, although some of the </text>
<text top="317" left="81" width="761" height="21" font="8">evidence review included pediatric patients. Although background on the pathophysiology and epidemiology of </text>
<text top="337" left="81" width="761" height="21" font="8">bradycardia and cardiac conduction disorders is summarized, this guideline is not intended to be an exhaustive </text>
<text top="357" left="81" width="756" height="21" font="8">review. Rather, it focuses on practical clinical evaluation and management. Specific objectives and goals include: </text>
<text top="386" left="108" width="733" height="22" font="8">•  Describe the clinical significance of bradycardia with respect to mortality, symptoms (e.g.,  syncope, </text>
<text top="407" left="135" width="708" height="21" font="8">impaired functional capacity), and exacerbations of associated disorders (e.g., ischemia, heart failure, </text>
<text top="427" left="135" width="198" height="21" font="8">provoked tachyarrhythmias). </text>
<text top="448" left="108" width="733" height="22" font="8">•  Address inherited and acquired disorders of the sinus node, atrioventricular node, His-Purkinje fibers, and </text>
<text top="469" left="135" width="706" height="21" font="8">intramyocardial conducting tissue, including the effects of medications, aging, metabolic derangements, </text>
<text top="489" left="135" width="709" height="21" font="8">trauma, radiation, infiltrative, ischemic, and inflammatory disorders, infectious and toxic agents and </text>
<text top="509" left="135" width="125" height="21" font="8">iatrogenic factors. </text>
<text top="529" left="108" width="734" height="22" font="8">•  Delineate the clinical presentation and general approach to clinical evaluation of patients with overt or </text>
<text top="550" left="135" width="323" height="21" font="8">suspected bradycardias or conduction diseases. </text>
<text top="570" left="108" width="735" height="22" font="8">•  Comprehensively evaluate the evidence supporting recommendations for the selection and timing of </text>
<text top="591" left="135" width="667" height="21" font="8">available diagnostic testing modalities, including monitoring devices and electrophysiologic testing. </text>
<text top="612" left="108" width="733" height="22" font="8">•  Define the evidence base supporting recommendations for the use of available treatment modalities, </text>
<text top="632" left="135" width="707" height="21" font="8">including lifestyle interventions, pharmacotherapy and external and implanted device-based therapies, </text>
<text top="652" left="135" width="520" height="21" font="8">with particular attention to indications for temporary and permanent pacing. </text>
<text top="673" left="108" width="733" height="22" font="8">•  Address special considerations that may be applicable to distinct populations based on age (&gt;18 years of </text>
<text top="694" left="135" width="305" height="21" font="8">age), comorbidities or other relevant factors. </text>
<text top="714" left="108" width="613" height="22" font="8">•  Identify knowledge gaps, pertinent trials in progress and directions for future research. </text>
<text top="744" left="81" width="8" height="21" font="8">  </text>
<text top="744" left="135" width="707" height="21" font="8">Table 1 lists other guidelines and pertinent documents that the writing committee considered for this </text>
<text top="764" left="81" width="761" height="21" font="8">guideline. The listed documents contain relevant information for the management of patients with bradycardia </text>
<text top="784" left="81" width="264" height="21" font="8">or cardiac conduction system disorder. </text>
<text top="813" left="81" width="4" height="21" font="8"> </text>
<text top="842" left="81" width="377" height="21" font="7"><b>Table 1. Associated Guidelines and Related References </b></text>
<text top="863" left="81" width="4" height="21" font="8"> </text>
<text top="893" left="283" width="31" height="19" font="0"><b>Title </b></text>
<text top="893" left="567" width="83" height="19" font="0"><b>Organization </b></text>
<text top="884" left="718" width="105" height="19" font="0"><b>Publication Year </b></text>
<text top="902" left="732" width="76" height="19" font="0"><b>(Reference) </b></text>
<text top="924" left="89" width="69" height="19" font="0"><b>Guidelines </b></text>
<text top="947" left="89" width="308" height="19" font="1">Ventricular arrhythmias and sudden cardiac death </text>
<text top="947" left="563" width="91" height="19" font="1">ACC/AHA/HRS </text>
<text top="947" left="728" width="84" height="19" font="1">2017 (S1.4-3) </text>
<text top="966" left="89" width="54" height="19" font="1">Syncope </text>
<text top="966" left="563" width="91" height="19" font="1">ACC/AHA/HRS </text>
<text top="966" left="728" width="84" height="19" font="1">2017 (S1.4-4) </text>
<text top="985" left="89" width="182" height="19" font="1">Stable ischemic heart disease </text>
<text top="985" left="523" width="167" height="19" font="1">ACC/AHA/AATS/PCNA/SCAI</text>
<text top="1003" left="593" width="30" height="19" font="1">/STS </text>
<text top="985" left="725" width="92" height="19" font="1">2014* (S1.4-5) </text>
<text top="1003" left="728" width="84" height="19" font="1">2012 (S1.4-6) </text>
<text top="1022" left="89" width="103" height="19" font="1">Atrial fibrillation </text>
<text top="1022" left="563" width="91" height="19" font="1">AHA/ACC/HRS </text>
<text top="1022" left="728" width="84" height="19" font="1">2014 (S1.4-7) </text>
<text top="1041" left="89" width="371" height="19" font="1">Perioperative cardiovascular evaluation and management of </text>
<text top="1060" left="89" width="250" height="19" font="1">patients undergoing non-cardiac surgery </text>
<text top="1041" left="578" width="61" height="19" font="1">ACC/AHA </text>
<text top="1041" left="728" width="84" height="19" font="1">2014 (S1.4-8) </text>
<text top="1079" left="89" width="277" height="19" font="1">Non–ST-elevation acute coronary syndromes </text>
<text top="1079" left="578" width="61" height="19" font="1">AHA/ACC </text>
<text top="1079" left="728" width="84" height="19" font="1">2014 (S1.4-9) </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="9" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="439" width="44" height="19" font="1">Page 9 </text>
<text top="125" left="89" width="80" height="19" font="1">Heart failure </text>
<text top="125" left="578" width="61" height="19" font="1">ACC/AHA </text>
<text top="125" left="724" width="92" height="19" font="1">2013 (S1.4-10) </text>
<text top="144" left="89" width="215" height="19" font="1">ST-elevation myocardial infarction  </text>
<text top="144" left="578" width="61" height="19" font="1">ACC/AHA </text>
<text top="144" left="724" width="92" height="19" font="1">2013 (S1.4-11) </text>
<text top="163" left="89" width="339" height="19" font="1">Device-based therapy for cardiac rhythm abnormalities </text>
<text top="163" left="563" width="91" height="19" font="1">ACC/AHA/HRS </text>
<text top="163" left="728" width="84" height="19" font="1">2013 (S1.4-2) </text>
<text top="182" left="89" width="229" height="19" font="1">Coronary artery bypass graft surgery  </text>
<text top="182" left="578" width="61" height="19" font="1">ACC/AHA </text>
<text top="182" left="724" width="92" height="19" font="1">2011 (S1.4-12) </text>
<text top="205" left="89" width="187" height="19" font="1">Hypertrophic cardiomyopathy </text>
<text top="205" left="578" width="61" height="19" font="1">ACC/AHA </text>
<text top="205" left="724" width="92" height="19" font="1">2011 (S1.4-13) </text>
<text top="225" left="89" width="224" height="19" font="12">Percutaneous coronary intervention </text>
<text top="225" left="313" width="3" height="19" font="1"> </text>
<text top="225" left="562" width="94" height="19" font="1">ACC/AHA/SCAI </text>
<text top="225" left="724" width="92" height="19" font="1">2011 (S1.4-14) </text>
<text top="244" left="89" width="376" height="19" font="1">Guidelines for cardiopulmonary resuscitation and emergency </text>
<text top="262" left="89" width="322" height="19" font="1">cardiovascular care—Part 9: post-cardiac arrest care </text>
<text top="244" left="594" width="30" height="19" font="1">AHA </text>
<text top="244" left="724" width="92" height="19" font="1">2010 (S1.4-15) </text>
<text top="284" left="89" width="157" height="19" font="0"><b>Other related references </b></text>
<text top="307" left="89" width="362" height="19" font="1">Expert consensus statement on cardiovascular implantable </text>
<text top="325" left="89" width="312" height="19" font="1">electronic device lead management and extraction </text>
<text top="307" left="595" width="28" height="19" font="1">HRS </text>
<text top="307" left="724" width="92" height="19" font="1">2017 (S1.4-16) </text>
<text top="344" left="89" width="326" height="19" font="1">Management of cardiac involvement associated with </text>
<text top="362" left="89" width="150" height="19" font="1">neuromuscular diseases </text>
<text top="344" left="594" width="30" height="19" font="1">AHA </text>
<text top="344" left="724" width="92" height="19" font="1">2017 (S1.4-17) </text>
<text top="381" left="89" width="373" height="19" font="1">Expert consensus statement on magnetic resonance imaging </text>
<text top="381" left="595" width="28" height="19" font="1">HRS </text>
<text top="381" left="724" width="92" height="19" font="1">2017 (S1.4-18) </text>
<text top="400" left="89" width="393" height="19" font="1">Eligibility and disqualification recommendations for competitive </text>
<text top="419" left="89" width="349" height="19" font="1">athletes with cardiovascular abnormalities: Task Force 9: </text>
<text top="437" left="89" width="223" height="19" font="1">arrhythmias and conduction defects </text>
<text top="400" left="578" width="61" height="19" font="1">ACC/AHA </text>
<text top="400" left="724" width="92" height="19" font="1">2015 (S1.4-19) </text>
<text top="456" left="89" width="386" height="19" font="1">Expert consensus statement on the diagnosis and treatment of </text>
<text top="474" left="89" width="395" height="19" font="1">postural tachycardia syndrome, inappropriate sinus tachycardia, </text>
<text top="493" left="89" width="143" height="19" font="1">and vasovagal syncope </text>
<text top="456" left="595" width="28" height="19" font="1">HRS </text>
<text top="456" left="724" width="92" height="19" font="1">2015 (S1.4-20) </text>
<text top="512" left="89" width="418" height="19" font="1">Expert consensus statement on the recognition and management of </text>
<text top="530" left="89" width="282" height="19" font="1">arrhythmias in adult congenital heart disease  </text>
<text top="512" left="573" width="72" height="19" font="1">PACES/HRS </text>
<text top="512" left="724" width="92" height="19" font="1">2014 (S1.4-21) </text>
<text top="549" left="89" width="415" height="19" font="1">Expert consensus statement on the use of implantable cardioverter-</text>
<text top="568" left="89" width="396" height="19" font="1">defibrillator therapy in patients who are not included or not well </text>
<text top="586" left="89" width="175" height="19" font="1">represented in clinical trials  </text>
<text top="549" left="563" width="91" height="19" font="1">HRS/ACC/AHA </text>
<text top="549" left="724" width="92" height="19" font="1">2014 (S1.4-22) </text>
<text top="605" left="89" width="405" height="19" font="1">Expert consensus statement on the diagnosis and management of </text>
<text top="623" left="89" width="296" height="19" font="1">arrhythmias associated with cardiac sarcoidosis  </text>
<text top="605" left="595" width="31" height="19" font="1">HRS  </text>
<text top="605" left="724" width="92" height="19" font="1">2014 (S1.4-23) </text>
<text top="642" left="89" width="329" height="19" font="1">Cardiac pacing and cardiac resynchronization therapy </text>
<text top="642" left="596" width="26" height="19" font="1">ESC </text>
<text top="642" left="724" width="92" height="19" font="1">2013 (S1.4-24) </text>
<text top="661" left="89" width="373" height="19" font="1">Expert consensus statement on pacemaker device and mode </text>
<text top="680" left="89" width="58" height="19" font="1">selection </text>
<text top="661" left="576" width="65" height="19" font="1">HRS/ACCF </text>
<text top="661" left="724" width="92" height="19" font="1">2012 (S1.4-25) </text>
<text top="699" left="89" width="407" height="19" font="1">Expert consensus statement on the state of genetic testing for the </text>
<text top="717" left="89" width="243" height="19" font="1">channelopathies and cardiomyopathies </text>
<text top="699" left="575" width="67" height="19" font="1">HRS/EHRA </text>
<text top="699" left="724" width="92" height="19" font="1">2011 (S1.4-26) </text>
<text top="736" left="89" width="410" height="19" font="1">Expert consensus statement on the management of cardiovascular </text>
<text top="754" left="89" width="418" height="19" font="1">implantable electronic devices (CIEDs) in patients nearing end of life </text>
<text top="773" left="89" width="224" height="19" font="1">or requesting withdrawal of therapy </text>
<text top="736" left="595" width="28" height="19" font="1">HRS </text>
<text top="736" left="724" width="92" height="19" font="1">2010 (S1.4-27) </text>
<text top="792" left="89" width="416" height="19" font="1">Recommendations for the standardization and interpretation of the </text>
<text top="810" left="89" width="337" height="19" font="1">electrocardiogram: part III: intraventricular conduction </text>
<text top="828" left="89" width="223" height="19" font="1">disturbances: a scientific statement  </text>
<text top="792" left="560" width="98" height="19" font="1">AHA/ACCF/HRS </text>
<text top="792" left="724" width="92" height="19" font="1">2009 (S1.4-28) </text>
<text top="847" left="89" width="416" height="19" font="1">Recommendations for the standardization and interpretation of the </text>
<text top="866" left="89" width="401" height="19" font="1">electrocardiogram: part V: electrocardiogram changes associated </text>
<text top="884" left="89" width="356" height="19" font="1">with cardiac chamber hypertrophy: a scientific statement  </text>
<text top="847" left="560" width="98" height="19" font="1">AHA/ACCF/HRS </text>
<text top="847" left="724" width="92" height="19" font="1">2009 (S1.4-29) </text>
<text top="903" left="81" width="113" height="19" font="1">*Focused Update. </text>
<text top="921" left="81" width="760" height="19" font="1">AATS indicates American Association for Thoracic Surgery; ACC, American College of Cardiology; ACCF, American College of </text>
<text top="940" left="81" width="759" height="19" font="1">Cardiology Foundation; AHA, American Heart Association; EHRA, European Heart Rhythm Association; ESC, European Society </text>
<text top="958" left="81" width="763" height="19" font="1">of Cardiology; HRS, Heart Rhythm Society; PACES, Pediatric &amp; Congenital Electrophysiology Society; PCNA, Preventive </text>
<text top="976" left="81" width="762" height="19" font="1">Cardiovascular Nurses Association; SCAI,  Society for Cardiovascular Angiography and Interventions; and  STS,  Society of </text>
<text top="995" left="81" width="118" height="19" font="1">Thoracic Surgeons. </text>
<text top="1022" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="10" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 10 </text>
<text top="124" left="81" width="494" height="29" font="19"><b>1.5. Class of Recommendation and Level of Evidence </b></text>
<text top="156" left="81" width="760" height="21" font="8">Recommendations are designated with both a class of recommendation (COR) and a level of evidence (LOE). The </text>
<text top="176" left="81" width="759" height="21" font="8">class of recommendation indicates the strength of recommendation, encompassing the estimated magnitude and </text>
<text top="196" left="81" width="760" height="21" font="8">certainty of benefit in proportion to risk. The level of evidence rates the quality of scientific evidence supporting </text>
<text top="216" left="81" width="760" height="21" font="8">the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources </text>
<text top="236" left="81" width="122" height="21" font="8">(Table 2) (S1.5-1). </text>
<text top="266" left="81" width="4" height="21" font="8"> </text>
<text top="305" left="81" width="4" height="21" font="8"> </text>
<text top="344" left="81" width="4" height="21" font="8"> </text>
<text top="344" left="297" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="11" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 11 </text>
<text top="124" left="81" width="702" height="21" font="7"><b>Table 2. Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, </b></text>
<text top="144" left="81" width="509" height="21" font="7"><b>Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015) </b></text>
<text top="869" left="783" width="4" height="21" font="8"> </text>
<text top="904" left="81" width="4" height="21" font="8"> </text>
<text top="904" left="297" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="12" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 12 </text>
<text top="124" left="81" width="176" height="29" font="19"><b>1.6. Abbreviations </b></text>
<text top="171" left="96" width="85" height="19" font="0"><b>Abbreviation </b></text>
<text top="171" left="217" width="107" height="19" font="0"><b>Meaning/Phrase </b></text>
<text top="190" left="96" width="39" height="19" font="1">ACHD </text>
<text top="190" left="217" width="187" height="19" font="1">adult congenital heart disease </text>
<text top="209" left="96" width="19" height="19" font="1">AF </text>
<text top="209" left="217" width="101" height="19" font="1">atrial fibrillation </text>
<text top="228" left="96" width="27" height="19" font="1">CRT </text>
<text top="228" left="217" width="210" height="19" font="1">cardiac resynchronization therapy </text>
<text top="247" left="96" width="28" height="19" font="1">ECG </text>
<text top="247" left="217" width="116" height="19" font="1">electrocardiogram </text>
<text top="266" left="96" width="25" height="19" font="1">EPS </text>
<text top="266" left="217" width="148" height="19" font="1">electrophysiology study </text>
<text top="285" left="96" width="34" height="19" font="1">LBBB </text>
<text top="285" left="217" width="151" height="19" font="1">left bundle branch block </text>
<text top="304" left="96" width="20" height="19" font="1">MI </text>
<text top="304" left="217" width="133" height="19" font="1">myocardial infarction </text>
<text top="323" left="96" width="29" height="19" font="1">SND </text>
<text top="323" left="217" width="144" height="19" font="1">sinus node dysfunction </text>
<text top="342" left="81" width="4" height="21" font="8"> </text>
<text top="342" left="297" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="13" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="20" size="7" family="Times" color="#000000"/>
	<fontspec id="21" size="12" family="Times" color="#1c1c1c"/>
	<fontspec id="22" size="12" family="Times" color="#1c1c1c"/>
	<fontspec id="23" size="16" family="Times" color="#000000"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 13 </text>
<text top="124" left="81" width="322" height="31" font="2"><b>2. Epidemiology and Definitions </b></text>
<text top="177" left="81" width="152" height="29" font="19"><b>2.1. Definitions  </b></text>
<text top="222" left="81" width="84" height="21" font="6"><i>See Table 3. </i></text>
<text top="262" left="81" width="196" height="21" font="7"><b>Table 3. Table of Definitions</b> </text>
<text top="282" left="81" width="4" height="21" font="8"> </text>
<text top="303" left="147" width="36" height="19" font="0"><b>Term </b></text>
<text top="303" left="464" width="157" height="19" font="0"><b>Definition or Description </b></text>
<text top="331" left="89" width="145" height="19" font="1">Sinus node dysfunction </text>
<text top="350" left="89" width="126" height="19" font="1">(with accompanying </text>
<text top="368" left="89" width="71" height="19" font="1">symptoms) </text>
<text top="331" left="253" width="263" height="20" font="1">•  Sinus bradycardia: Sinus rate &lt;50 bpm </text>
<text top="351" left="253" width="570" height="20" font="1">•  Ectopic atrial bradycardia: Atrial depolarization attributable to an atrial pacemaker other </text>
<text top="370" left="280" width="251" height="19" font="1">than the sinus node with a rate &lt;50 bpm </text>
<text top="388" left="253" width="539" height="20" font="1">•  Sinoatrial exit block: Evidence that blocked conduction between the sinus node and </text>
<text top="407" left="280" width="533" height="19" font="1">adjacent atrial tissue is present. Multiple electrocardiographic manifestations including </text>
<text top="425" left="280" width="353" height="19" font="1">“group beating” of atrial depolarization and sinus pauses. </text>
<text top="444" left="253" width="484" height="20" font="1">•  Sinus pause: Sinus node depolarizes &gt;3 s after the last atrial depolarization </text>
<text top="463" left="253" width="395" height="20" font="1">•  Sinus node arrest: No evidence of sinus node depolarization </text>
<text top="482" left="253" width="544" height="20" font="1">•  Tachycardia-bradycardia (“tachy-brady”) syndrome: Sinus bradycardia, ectopic atrial </text>
<text top="501" left="280" width="545" height="19" font="1">bradycardia, or sinus pause alternating with periods of abnormal atrial tachycardia, atrial </text>
<text top="519" left="280" width="42" height="19" font="1">flutter,</text>
<text top="521" left="322" width="3" height="17" font="17"> </text>
<text top="519" left="325" width="86" height="19" font="1">or AF (S2.1-1).</text>
<text top="519" left="412" width="2" height="12" font="20"> </text>
<text top="519" left="414" width="407" height="19" font="1">The tachycardia may be associated with suppression of sinus node </text>
<text top="537" left="280" width="524" height="19" font="1">automaticity and a sinus pause of variable duration when the tachycardia terminates. </text>
<text top="556" left="253" width="214" height="20" font="1">•  Chronotropic Incompetence: B</text>
<text top="557" left="467" width="349" height="19" font="21">roadly <b>defined</b> as the inability of the heart to increase its </text>
<text top="575" left="280" width="516" height="19" font="21">rate commensurate with increased activity or demand, in many studies translates to </text>
<text top="593" left="280" width="39" height="19" font="21">failure</text>
<text top="593" left="319" width="85" height="19" font="1"> to attain 80%</text>
<text top="590" left="404" width="4" height="23" font="23"> </text>
<text top="593" left="408" width="292" height="19" font="1">of expected heart rate reserve during exercise.  </text>
<text top="612" left="253" width="579" height="20" font="1">•  Isorhythmic dissociation: Atrial depolarization (from either the sinus node or ectopic atrial </text>
<text top="631" left="280" width="545" height="19" font="1">site) is slower than ventricular depolarization (from an atrioventricular nodal, His bundle, </text>
<text top="649" left="280" width="119" height="19" font="1">or ventricular site). </text>
<text top="668" left="89" width="135" height="19" font="1">Atrioventricular block </text>
<text top="686" left="89" width="51" height="19" font="1">(S2.1-2) </text>
<text top="668" left="252" width="11" height="18" font="1">• </text>
<text top="668" left="279" width="483" height="20" font="15"><i>First degree atrioventricular</i> <i>block:</i> P waves associated with 1:1 atrioventricular </text>
<text top="687" left="279" width="542" height="19" font="1">conduction and a PR interval &gt;200 ms (this is more accurately defined as atrioventricular </text>
<text top="705" left="279" width="240" height="19" font="1">delay because no P waves are blocked) </text>
<text top="724" left="252" width="11" height="18" font="1">• </text>
<text top="724" left="279" width="524" height="20" font="15"><i>Second degree atrioventricular</i> <i>block:</i> P waves with a constant rate (&lt;100 bpm) where </text>
<text top="743" left="279" width="304" height="19" font="1">atrioventricular conduction is present but not 1:1 </text>
<text top="766" left="282" width="9" height="12" font="1">o</text>
<text top="765" left="291" width="4" height="14" font="1"> </text>
<text top="761" left="306" width="473" height="19" font="1">Mobitz type I: P waves with a constant rate (&lt;100 bpm) with a periodic single </text>
<text top="779" left="306" width="518" height="19" font="1">nonconducted P wave associated with P waves before and after the nonconducted P </text>
<text top="798" left="306" width="209" height="19" font="1">wave with inconstant PR intervals </text>
<text top="821" left="282" width="9" height="12" font="1">o</text>
<text top="820" left="291" width="4" height="14" font="1"> </text>
<text top="816" left="306" width="480" height="19" font="1">Mobitz type II: P waves with a constant rate (&lt; 100 bpm) with a periodic single </text>
<text top="834" left="306" width="453" height="19" font="1">nonconducted P wave associated with other P waves before and after the </text>
<text top="853" left="306" width="487" height="19" font="1">nonconducted P wave with constant PR intervals (excluding 2:1 atrioventricular </text>
<text top="871" left="306" width="40" height="19" font="1">block) </text>
<text top="894" left="281" width="9" height="12" font="1">o</text>
<text top="893" left="290" width="4" height="14" font="1"> </text>
<text top="889" left="306" width="476" height="19" font="1">2:1 atrioventricular block: P waves with a constant rate (or near constant rate </text>
<text top="908" left="306" width="512" height="19" font="1">because of ventriculophasic sinus arrhythmia) rate (&lt;100 bpm) where every other P </text>
<text top="926" left="306" width="197" height="19" font="1">wave conducts to the ventricles </text>
<text top="949" left="282" width="9" height="12" font="1">o</text>
<text top="948" left="291" width="4" height="14" font="1"> </text>
<text top="944" left="306" width="514" height="19" font="1">Advanced, high-grade or high-degree atrioventricular block: ≥2 consecutive P waves </text>
<text top="962" left="306" width="519" height="19" font="1">at a constant physiologic rate that do not conduct to the ventricles with evidence for </text>
<text top="981" left="306" width="207" height="19" font="1">some atrioventricular conduction </text>
<text top="999" left="252" width="11" height="18" font="1">• </text>
<text top="999" left="279" width="552" height="20" font="15"><i>Third-degree atrioventricular</i> <i>block (complete heart block):</i> No evidence of atrioventricular </text>
<text top="1018" left="279" width="72" height="19" font="1">conduction </text>
<text top="1037" left="252" width="11" height="18" font="1">• </text>
<text top="1037" left="279" width="534" height="20" font="15"><i>Vagally mediated atrioventricular</i> <i>block:</i> Any type of atrioventricular block mediated by </text>
<text top="1056" left="279" width="210" height="19" font="1">heightened parasympathetic tone </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="14" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 14 </text>
<text top="125" left="252" width="11" height="18" font="1">• </text>
<text top="125" left="279" width="473" height="20" font="15"><i>Infranodal block:</i> atrioventricular conduction block where clinical evidence or </text>
<text top="144" left="279" width="507" height="19" font="1">electrophysiologic evidence suggests that the conduction block occurs distal to the </text>
<text top="162" left="279" width="133" height="19" font="1">atrioventricular node </text>
<text top="186" left="89" width="112" height="19" font="1">Conduction tissue </text>
<text top="204" left="89" width="99" height="19" font="1">disease (S2.1-2) </text>
<text top="186" left="252" width="201" height="20" font="1">•  RBBB (as defined in adults):  </text>
<text top="210" left="278" width="9" height="12" font="1">o</text>
<text top="209" left="287" width="4" height="14" font="1"> </text>
<text top="205" left="305" width="99" height="19" font="1">Complete RBBB </text>
<text top="224" left="305" width="111" height="19" font="1">1.  QRS duration </text>
<text top="223" left="416" width="8" height="21" font="8">≥</text>
<text top="224" left="425" width="47" height="19" font="1">120 ms </text>
<text top="244" left="305" width="258" height="19" font="1">2.  rsr′, rsR′, rSR′, or rarely a qR in leads V</text>
<text top="250" left="563" width="5" height="12" font="20">1</text>
<text top="243" left="568" width="4" height="21" font="8"> </text>
<text top="244" left="571" width="25" height="19" font="1">or V</text>
<text top="250" left="597" width="5" height="12" font="20">2</text>
<text top="244" left="601" width="200" height="19" font="1">. The R′ or r′ deflection is usually </text>
<text top="263" left="332" width="495" height="19" font="1">wider than the initial R wave. In a minority of patients, a wide and often notched </text>
<text top="283" left="332" width="229" height="19" font="1">R wave pattern may be seen in lead V</text>
<text top="289" left="561" width="5" height="12" font="20">1</text>
<text top="281" left="566" width="4" height="21" font="8"> </text>
<text top="283" left="570" width="54" height="19" font="1">and/or V</text>
<text top="289" left="623" width="5" height="12" font="20">2</text>
<text top="283" left="628" width="7" height="19" font="1">. </text>
<text top="303" left="305" width="427" height="19" font="1">3.  S wave of greater duration than R wave or &gt;40 ms in leads I and V</text>
<text top="309" left="732" width="5" height="12" font="20">6</text>
<text top="302" left="737" width="4" height="21" font="8"> </text>
<text top="303" left="741" width="55" height="19" font="1">in adults </text>
<text top="323" left="305" width="210" height="19" font="1">4.  Normal R peak time in leads V</text>
<text top="329" left="515" width="5" height="12" font="20">5</text>
<text top="322" left="520" width="4" height="21" font="8"> </text>
<text top="323" left="523" width="35" height="19" font="1">and V</text>
<text top="329" left="558" width="5" height="12" font="20">6</text>
<text top="322" left="563" width="4" height="21" font="8"> </text>
<text top="323" left="567" width="124" height="19" font="1">but &gt;50 ms in lead V</text>
<text top="329" left="691" width="5" height="12" font="20">1</text>
<text top="323" left="696" width="3" height="19" font="1"> </text>
<text top="347" left="278" width="9" height="12" font="1">o</text>
<text top="346" left="287" width="4" height="14" font="1"> </text>
<text top="342" left="305" width="509" height="19" font="1">Incomplete RBBB: Same QRS morphology criteria as complete RBBB but with a QRS </text>
<text top="360" left="305" width="213" height="19" font="1">duration between 110 and 119 ms </text>
<text top="379" left="253" width="3" height="19" font="1"> </text>
<text top="397" left="252" width="196" height="20" font="1">•  LBBB (as defined in adults): </text>
<text top="421" left="278" width="9" height="12" font="1">o</text>
<text top="420" left="287" width="4" height="14" font="1"> </text>
<text top="416" left="305" width="101" height="19" font="1">Complete LBBB: </text>
<text top="436" left="305" width="111" height="19" font="1">1.  QRS duration </text>
<text top="434" left="416" width="8" height="21" font="8">≥</text>
<text top="436" left="425" width="103" height="19" font="1">120 ms in adults </text>
<text top="454" left="305" width="329" height="19" font="1">2.  Broad notched or slurred R wave in leads I, aVL, V</text>
<text top="460" left="634" width="5" height="12" font="20">5</text>
<text top="454" left="639" width="42" height="19" font="1">, and V</text>
<text top="460" left="681" width="5" height="12" font="20">6</text>
<text top="454" left="686" width="134" height="19" font="1"> and an occasional RS </text>
<text top="473" left="332" width="72" height="19" font="1">pattern in V</text>
<text top="479" left="404" width="5" height="12" font="20">5</text>
<text top="473" left="409" width="38" height="19" font="1"> and V</text>
<text top="479" left="447" width="5" height="12" font="20">6</text>
<text top="473" left="452" width="308" height="19" font="1"> attributed to displaced transition of QRS complex </text>
<text top="491" left="305" width="197" height="19" font="1">3.  Absent Q waves in leads I, V</text>
<text top="497" left="502" width="5" height="12" font="20">5</text>
<text top="491" left="507" width="42" height="19" font="1">, and V</text>
<text top="497" left="549" width="5" height="12" font="20">6</text>
<text top="491" left="554" width="265" height="19" font="1">, but in the lead aVL, a narrow Q wave may </text>
<text top="510" left="332" width="312" height="19" font="1">be present in the absence of myocardial pathology </text>
<text top="528" left="305" width="208" height="19" font="1">4.  R peak time &gt;60 ms in leads V</text>
<text top="534" left="513" width="5" height="12" font="20">5</text>
<text top="528" left="518" width="38" height="19" font="1"> and V</text>
<text top="534" left="557" width="5" height="12" font="20">6</text>
<text top="528" left="561" width="133" height="19" font="1"> but normal in leads V</text>
<text top="534" left="695" width="5" height="12" font="20">1</text>
<text top="528" left="699" width="16" height="19" font="1">, V</text>
<text top="534" left="715" width="5" height="12" font="20">2</text>
<text top="528" left="720" width="42" height="19" font="1">, and V</text>
<text top="534" left="762" width="5" height="12" font="20">3</text>
<text top="528" left="767" width="45" height="19" font="1">, when </text>
<text top="546" left="332" width="371" height="19" font="1">small initial R waves can be discerned in the precordial leads </text>
<text top="564" left="305" width="343" height="19" font="1">5.  ST and T waves usually opposite in direction to QRS </text>
<text top="588" left="278" width="9" height="12" font="1">o</text>
<text top="587" left="287" width="4" height="14" font="1"> </text>
<text top="583" left="305" width="111" height="19" font="1">Incomplete LBBB: </text>
<text top="601" left="305" width="324" height="19" font="1">1.  QRS duration between 110 and 119 ms in adults </text>
<text top="619" left="305" width="323" height="19" font="1">2.  Presence of left ventricular hypertrophy pattern </text>
<text top="638" left="305" width="208" height="19" font="1">3.  R peak time &gt;60 ms in leads V</text>
<text top="643" left="513" width="5" height="12" font="20">4</text>
<text top="638" left="518" width="16" height="19" font="1">, V</text>
<text top="643" left="534" width="5" height="12" font="20">5</text>
<text top="638" left="539" width="42" height="19" font="1">, and V</text>
<text top="643" left="581" width="5" height="12" font="20">6</text>
<text top="638" left="586" width="3" height="19" font="1"> </text>
<text top="656" left="305" width="216" height="19" font="1">4.  Absence of Q wave in leads I, V</text>
<text top="662" left="521" width="5" height="12" font="20">5</text>
<text top="656" left="526" width="42" height="19" font="1">, and V</text>
<text top="662" left="568" width="7" height="12" font="20">6 </text>
<text top="674" left="332" width="3" height="19" font="1"> </text>
<text top="693" left="252" width="560" height="20" font="1">•  Nonspecific intraventricular conduction delay (as defined in adults): QRS duration &gt;110 </text>
<text top="712" left="279" width="393" height="19" font="1">ms where morphology criteria for RBBB or LBBB are not present </text>
<text top="730" left="279" width="3" height="19" font="1"> </text>
<text top="749" left="252" width="211" height="20" font="1">•  Left anterior fascicular block:  </text>
<text top="773" left="278" width="9" height="12" font="1">o</text>
<text top="771" left="287" width="4" height="14" font="1"> </text>
<text top="768" left="305" width="139" height="19" font="1">QRS duration &lt;120 ms </text>
<text top="791" left="278" width="9" height="12" font="1">o</text>
<text top="789" left="287" width="4" height="14" font="1"> </text>
<text top="786" left="305" width="256" height="19" font="1">Frontal plane axis between −45° and −90° </text>
<text top="809" left="278" width="9" height="12" font="1">o</text>
<text top="808" left="287" width="4" height="14" font="1"> </text>
<text top="804" left="305" width="229" height="19" font="1">qR (small r, tall R) pattern in lead aVL </text>
<text top="827" left="278" width="9" height="12" font="1">o</text>
<text top="826" left="287" width="4" height="14" font="1"> </text>
<text top="822" left="305" width="209" height="19" font="1">R-peak time in lead aVL of ≥45 ms </text>
<text top="846" left="278" width="9" height="12" font="1">o</text>
<text top="844" left="287" width="4" height="14" font="1"> </text>
<text top="841" left="305" width="301" height="19" font="1">rS pattern (small r, deep S) in leads II, III, and aVF </text>
<text top="859" left="253" width="3" height="19" font="1"> </text>
<text top="877" left="252" width="214" height="20" font="1">•  Left posterior fascicular block: </text>
<text top="901" left="278" width="9" height="12" font="1">o</text>
<text top="900" left="287" width="4" height="14" font="1"> </text>
<text top="896" left="305" width="139" height="19" font="1">QRS duration &lt;120 ms </text>
<text top="920" left="278" width="9" height="12" font="1">o</text>
<text top="918" left="287" width="4" height="14" font="1"> </text>
<text top="915" left="305" width="527" height="19" font="1">Frontal plane axis between 90° and 180° in adults. Because of the more rightward axis </text>
<text top="933" left="305" width="524" height="19" font="1">in children up to 16 years of age, this criterion should only be applied to them when a </text>
<text top="951" left="305" width="297" height="19" font="1">distinct rightward change in axis is documented. </text>
<text top="975" left="278" width="9" height="12" font="1">o</text>
<text top="973" left="287" width="4" height="14" font="1"> </text>
<text top="970" left="305" width="275" height="19" font="1">rS (small r, deep S) pattern in leads I and aVL </text>
<text top="993" left="278" width="9" height="12" font="1">o</text>
<text top="992" left="287" width="4" height="14" font="1"> </text>
<text top="988" left="305" width="279" height="19" font="1">qR (small q, tall R) pattern in leads III and aVF </text>
<text top="1007" left="81" width="405" height="19" font="1">Maximum predicted heart rate for age calculated as 220 – age (y). </text>
<text top="1025" left="81" width="751" height="19" font="1">AF indicates atrial fibrillation; bpm, beats per minute; LBBB, left bundle branch block; and RBBB, right bundle branch block. </text>
<text top="1044" left="81" width="3" height="19" font="1"> </text>
<text top="1062" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="15" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="24" size="9" family="Times" color="#000000"/>
	<fontspec id="25" size="10" family="Times" color="#000000"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 15 </text>
<text top="124" left="81" width="651" height="31" font="2"><b>3. General Evaluation of Patients With Documented or Suspected </b></text>
<text top="157" left="81" width="370" height="31" font="2"><b>Bradycardia or Conduction Disorders </b></text>
<text top="200" left="81" width="663" height="29" font="19"><b>3.1. History and Physical Examination of Patients With Documented or </b></text>
<text top="241" left="81" width="449" height="29" font="19"><b>Suspected Bradycardia or Conduction Disorders </b></text>
<text top="288" left="91" width="740" height="23" font="4"><b>Recommendation for History and Physical Examination in Patients With Documented or Suspected </b></text>
<text top="313" left="322" width="279" height="23" font="4"><b>Bradycardia or Conduction Disorders </b></text>
<text top="340" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="340" left="204" width="30" height="21" font="7"><b>LOE </b></text>
<text top="340" left="488" width="126" height="21" font="7"><b>Recommendation </b></text>
<text top="373" left="125" width="8" height="21" font="7"><b>I </b></text>
<text top="373" left="203" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="365" left="267" width="577" height="21" font="7"><b>1.  In patients with suspected bradycardia or conduction disorders a </b></text>
<text top="385" left="294" width="491" height="21" font="7"><b>comprehensive history and physical examination should be performed. </b></text>
<text top="406" left="81" width="4" height="21" font="8"> </text>
<text top="445" left="81" width="483" height="21" font="7"><b>Figure 1. Evaluation of Bradycardia and Conduction Disease Algorithm </b></text>
<text top="482" left="286" width="190" height="10" font="24">Patient with symptoms suggestive of </text>
<text top="496" left="296" width="170" height="10" font="24">or consistent with bradycardia or </text>
<text top="510" left="329" width="100" height="10" font="24">conduction disorder</text>
<text top="541" left="320" width="121" height="10" font="24">Comprehensive history </text>
<text top="555" left="315" width="133" height="10" font="24">and physical examination </text>
<text top="569" left="358" width="43" height="10" font="24">(Class I)</text>
<text top="723" left="108" width="85" height="10" font="24">SND Diagnostic </text>
<text top="737" left="121" width="54" height="10" font="24">algorithm†</text>
<text top="683" left="519" width="73" height="10" font="24">Nondiagnostic</text>
<text top="909" left="533" width="90" height="10" font="24">Ambulatory ECG </text>
<text top="923" left="545" width="54" height="10" font="24">monitoring</text>
<text top="920" left="599" width="11" height="15" font="24">║ </text>
<text top="937" left="555" width="43" height="10" font="24">(Class I)</text>
<text top="676" left="360" width="131" height="10" font="24">Conduction disorder with </text>
<text top="690" left="377" width="96" height="10" font="24">1:1 AV conduction </text>
<text top="683" left="257" width="46" height="10" font="24">AV Block</text>
<text top="683" left="134" width="29" height="10" font="24">SND*</text>
<text top="722" left="257" width="46" height="10" font="24">AV Block</text>
<text top="737" left="221" width="104" height="10" font="24">Diagnostic algorithm</text>
<text top="736" left="325" width="7" height="12" font="25">‡</text>
<text top="722" left="372" width="106" height="10" font="24">Conduction disorder </text>
<text top="737" left="368" width="104" height="10" font="24">Diagnostic algorithm</text>
<text top="736" left="472" width="7" height="12" font="25">§</text>
<text top="733" left="479" width="3" height="16" font="25"> </text>
<text top="842" left="568" width="15" height="10" font="24">No</text>
<text top="854" left="427" width="113" height="10" font="24">Exercise ECG testing </text>
<text top="868" left="456" width="52" height="10" font="24">(Class IIa)</text>
<text top="834" left="512" width="19" height="10" font="24">Yes</text>
<text top="887" left="521" width="37" height="10" font="24">Normal</text>
<text top="887" left="397" width="49" height="10" font="24">Abnormal</text>
<text top="603" left="367" width="25" height="10" font="24">ECG</text>
<text top="616" left="358" width="43" height="10" font="24">(Class I)</text>
<text top="960" left="429" width="110" height="10" font="24">Significant arrythmias</text>
<text top="970" left="618" width="73" height="10" font="24">No significant </text>
<text top="984" left="622" width="60" height="10" font="24">arrhythmias</text>
<text top="1049" left="387" width="46" height="10" font="24">AV Block</text>
<text top="1064" left="355" width="104" height="10" font="24">Diagnostic algorithm</text>
<text top="1063" left="459" width="7" height="12" font="25">‡</text>
<text top="1012" left="629" width="62" height="10" font="24">Observation</text>
<text top="1012" left="260" width="25" height="10" font="24">SND</text>
<text top="1050" left="231" width="85" height="10" font="24">SND Diagnostic </text>
<text top="1064" left="245" width="54" height="10" font="24">algorithm†</text>
<text top="1003" left="497" width="106" height="10" font="24">Conduction disorder </text>
<text top="1017" left="490" width="121" height="10" font="24">with 1:1 AV conduction </text>
<text top="1049" left="497" width="106" height="10" font="24">Conduction disorder </text>
<text top="1064" left="493" width="104" height="10" font="24">Diagnostic algorithm</text>
<text top="1063" left="598" width="7" height="12" font="25">§</text>
<text top="1012" left="387" width="46" height="10" font="24">AV Block</text>
<text top="790" left="514" width="87" height="10" font="24">Exercise-related </text>
<text top="804" left="529" width="56" height="10" font="24">symptoms </text>
<text top="555" left="490" width="71" height="10" font="24">Sleep apnea?</text>
<text top="603" left="470" width="112" height="10" font="24">Directed blood  testing</text>
<text top="616" left="500" width="52" height="10" font="24">(Class IIa)</text>
<text top="716" left="509" width="96" height="10" font="24">Echocardiography </text>
<text top="730" left="512" width="88" height="10" font="24">if structural heart </text>
<text top="744" left="508" width="95" height="10" font="24">disease suspected</text>
<text top="1040" left="681" width="56" height="10" font="24">Continued </text>
<text top="1054" left="678" width="62" height="10" font="24">concern for </text>
<text top="1068" left="674" width="67" height="10" font="24">bradycardia?</text>
<text top="843" left="600" width="55" height="10" font="24">Infrequent </text>
<text top="857" left="599" width="54" height="10" font="24">Symptoms</text>
<text top="871" left="597" width="58" height="10" font="24"> (&gt;30 days)</text>
<text top="852" left="712" width="21" height="10" font="24">ICM</text>
<text top="866" left="696" width="52" height="10" font="24">(Class IIa)</text>
<text top="1069" left="783" width="4" height="21" font="7"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="16" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 16 </text>
<text top="124" left="81" width="4" height="21" font="8"> </text>
<text top="153" left="81" width="359" height="19" font="1">Colors correspond to Class of Recommendation in Table 2. </text>
<text top="172" left="81" width="328" height="19" font="1">See Section 4 in the full-text guideline for discussion.  </text>
<text top="190" left="81" width="536" height="19" font="1">Dashed lines indicate possible optional strategies based on the specific clinical situation.</text>
<text top="188" left="617" width="4" height="21" font="7"><b> </b></text>
<text top="208" left="81" width="451" height="19" font="1">*Sinus bradycardia, ectopic atrial rhythm, junctional rhythm, sinus pause. </text>
<text top="227" left="81" width="202" height="19" font="1">†Refer to Section 3.3.2. Figure 2. </text>
<text top="245" left="81" width="202" height="19" font="1">‡Refer to Section 3.3.2. Figure 3. </text>
<text top="263" left="81" width="191" height="19" font="1">§Refer to Section 6.1. Figure 8. </text>
<text top="281" left="81" width="341" height="20" font="1">║Monitor choice based on the frequency of symptoms. </text>
<text top="300" left="81" width="490" height="19" font="1">AV indicates atrioventricular; and ECG, electrocardiogram/electrocardiographic. </text>
<text top="318" left="81" width="4" height="21" font="8"> </text>
<text top="338" left="81" width="4" height="21" font="7"><b> </b></text>
<text top="338" left="297" width="4" height="21" font="7"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="17" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 17 </text>
<text top="124" left="81" width="623" height="21" font="7"><b>Figure 2. Initial Evaluation of Suspected or Documented Sinus Node Dysfunction Algorithm </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="18" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 18 </text>
<text top="134" left="354" width="112" height="12" font="25">Evidence for sinus </text>
<text top="149" left="356" width="106" height="12" font="25">node dysfunction*</text>
<text top="403" left="197" width="22" height="12" font="25">Yes</text>
<text top="406" left="315" width="17" height="12" font="25">No</text>
<text top="244" left="165" width="157" height="12" font="25">Treat underlying cause as </text>
<text top="260" left="156" width="171" height="12" font="25">“needed, (e.g., sleep apnea”)</text>
<text top="276" left="217" width="49" height="12" font="25">(Class I)</text>
<text top="488" left="247" width="85" height="12" font="25">Transthoracic </text>
<text top="504" left="235" width="110" height="12" font="25">echocardiography </text>
<text top="520" left="257" width="60" height="12" font="25">(Class IIa)</text>
<text top="258" left="368" width="22" height="12" font="25">Yes</text>
<text top="536" left="452" width="17" height="12" font="25">No</text>
<text top="203" left="369" width="83" height="12" font="25">Reversible or </text>
<text top="219" left="356" width="105" height="12" font="25">physiologic cause</text>
<text top="331" left="221" width="65" height="12" font="25">Treatment </text>
<text top="347" left="218" width="67" height="12" font="25">effective or </text>
<text top="363" left="213" width="75" height="12" font="25">unnecessary</text>
<text top="427" left="142" width="50" height="12" font="25">Observe</text>
<text top="458" left="365" width="22" height="12" font="25">Yes</text>
<text top="569" left="259" width="62" height="12" font="25">Suspicion </text>
<text top="585" left="237" width="100" height="12" font="25">for infitrative CM,</text>
<text top="601" left="250" width="79" height="12" font="25">endocarditis, </text>
<text top="617" left="269" width="37" height="12" font="25">ACHD</text>
<text top="647" left="208" width="22" height="12" font="25">Yes</text>
<text top="677" left="91" width="117" height="12" font="25">Advanced imaging†</text>
<text top="693" left="119" width="60" height="12" font="25">(Class IIa)</text>
<text top="667" left="279" width="17" height="12" font="25">No</text>
<text top="762" left="426" width="62" height="12" font="25">Symptoms</text>
<text top="789" left="487" width="17" height="12" font="25">No</text>
<text top="798" left="445" width="22" height="12" font="25">Yes</text>
<text top="788" left="557" width="50" height="12" font="25">Observe</text>
<text top="1050" left="507" width="151" height="12" font="25">Electrophysiology study† </text>
<text top="1066" left="488" width="184" height="12" font="25">(if performed for other reasons)</text>
<text top="1082" left="550" width="60" height="12" font="25">(Class IIb)</text>
<text top="1123" left="407" width="140" height="12" font="25">Sinus  node dysfunction </text>
<text top="1139" left="414" width="122" height="12" font="25">treatment algorithm‡</text>
<text top="388" left="419" width="81" height="12" font="25">Suspicion for </text>
<text top="404" left="413" width="93" height="12" font="25">structural heart </text>
<text top="420" left="435" width="46" height="12" font="25">disease</text>
<text top="719" left="243" width="92" height="12" font="25">Treat identified </text>
<text top="735" left="247" width="79" height="12" font="25">abnormalities</text>
<text top="262" left="429" width="17" height="12" font="25">No</text>
<text top="832" left="432" width="54" height="12" font="25">Exercise </text>
<text top="848" left="437" width="40" height="12" font="25">related</text>
<text top="870" left="400" width="22" height="12" font="25">Yes</text>
<text top="872" left="552" width="17" height="12" font="25">No</text>
<text top="893" left="290" width="145" height="12" font="25">If not already performed:</text>
<text top="909" left="299" width="126" height="12" font="25">Exercise ECG testing</text>
<text top="924" left="332" width="60" height="12" font="25">(Class IIa)</text>
<text top="972" left="331" width="62" height="12" font="25">Diagnostic</text>
<text top="1028" left="352" width="22" height="12" font="25">Yes</text>
<text top="1004" left="407" width="17" height="12" font="25">No</text>
<text top="986" left="508" width="149" height="12" font="25">If not already performed: </text>
<text top="1002" left="498" width="166" height="12" font="25">Ambulatory ECG monitoring</text>
<text top="1018" left="556" width="49" height="12" font="25">(Class I)</text>
<text top="1143" left="680" width="4" height="21" font="7"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="19" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 19 </text>
<text top="124" left="81" width="362" height="19" font="1">Colors correspond to Class of Recommendation in Table 2.  </text>
<text top="142" left="81" width="328" height="19" font="1">See Section 4 in the full-text guideline for discussion.  </text>
<text top="161" left="81" width="720" height="19" font="1">*Sinus pauses, sinus bradycardia, junctional rhythm, ectopic atrial rhythm (all with heart rates &lt;50 bpm) while awake. </text>
<text top="179" left="81" width="761" height="19" font="1">†The electrophysiology test should not be done primarily for sinus node dysfunction. If electrophysiology testing is being </text>
<text top="197" left="81" width="761" height="19" font="1">performed for another reason (e.g. risk stratification for sudden cardiac death), evaluation of sinus node function may be </text>
<text top="216" left="81" width="558" height="19" font="1">useful to help inform whether an atrial lead for atrial pacing would have potential benefits. </text>
<text top="234" left="81" width="217" height="19" font="1">‡Refer to Section 4.3.4.1., Figure 6. </text>
<text top="252" left="81" width="731" height="19" font="1">ACHD indicates adult congenital heart disease; CM, cardiomyopathy; and ECG, electrocardiogram/electrocardiographic. </text>
<text top="270" left="81" width="4" height="21" font="7"><b> </b></text>
<text top="270" left="297" width="4" height="21" font="7"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="20" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 20 </text>
<text top="124" left="81" width="500" height="21" font="7"><b>Figure 3. Initial Evaluation of Suspected Atrioventricular Block Algorithm </b></text>
<text top="162" left="409" width="91" height="11" font="24">Evidence for AV </text>
<text top="176" left="437" width="30" height="11" font="24">Block</text>
<text top="433" left="313" width="21" height="11" font="24">Yes</text>
<text top="422" left="378" width="16" height="11" font="24">No</text>
<text top="279" left="250" width="144" height="11" font="24">Treat underlying cause as </text>
<text top="294" left="250" width="141" height="11" font="24">needed, e.g., sleep apnea</text>
<text top="309" left="298" width="45" height="11" font="24">(Class I)</text>
<text top="520" left="229" width="78" height="11" font="24">Transthoracic </text>
<text top="535" left="218" width="101" height="11" font="24">echocardiography </text>
<text top="549" left="244" width="45" height="11" font="24">(Class I)</text>
<text top="713" left="510" width="16" height="11" font="24">No</text>
<text top="259" left="384" width="21" height="11" font="24">Yes</text>
<text top="494" left="594" width="16" height="11" font="24">No</text>
<text top="393" left="545" width="40" height="11" font="24">Mobitz </text>
<text top="408" left="511" width="108" height="11" font="24">type II 2° AV Block, </text>
<text top="422" left="508" width="115" height="11" font="24">Advanced AV Block, </text>
<text top="437" left="523" width="85" height="11" font="24">complete heart </text>
<text top="452" left="549" width="28" height="11" font="24">block</text>
<text top="215" left="416" width="76" height="11" font="24">Reversible or </text>
<text top="229" left="404" width="97" height="11" font="24">Physiologic cause</text>
<text top="356" left="293" width="59" height="11" font="24">Treatment </text>
<text top="371" left="280" width="83" height="11" font="24">effective or not </text>
<text top="386" left="293" width="55" height="11" font="24">necessary</text>
<text top="459" left="297" width="46" height="11" font="24">Observe</text>
<text top="537" left="618" width="74" height="11" font="24">Suspicion for </text>
<text top="551" left="613" width="85" height="11" font="24">structural heart </text>
<text top="566" left="633" width="42" height="11" font="24">disease</text>
<text top="492" left="424" width="21" height="11" font="24">Yes</text>
<text top="592" left="240" width="57" height="11" font="24">Suspicion </text>
<text top="607" left="219" width="95" height="11" font="24">for infiltrative CM,</text>
<text top="621" left="211" width="113" height="11" font="24">endocarditis, ACHD, </text>
<text top="636" left="257" width="20" height="11" font="24">etc.</text>
<text top="659" left="203" width="21" height="11" font="24">Yes</text>
<text top="682" left="132" width="58" height="11" font="24">Advanced </text>
<text top="696" left="135" width="48" height="11" font="24">imaging*</text>
<text top="711" left="131" width="55" height="11" font="24">(Class IIa)</text>
<text top="683" left="259" width="16" height="11" font="24">No</text>
<text top="720" left="242" width="51" height="11" font="24">AV block </text>
<text top="735" left="241" width="55" height="11" font="24">treatment </text>
<text top="749" left="238" width="57" height="11" font="24">algorithm†</text>
<text top="634" left="461" width="57" height="11" font="24">Suspicion </text>
<text top="649" left="440" width="95" height="11" font="24">for infiltrative CM,</text>
<text top="664" left="432" width="113" height="11" font="24">endocarditis, ACHD, </text>
<text top="678" left="478" width="20" height="11" font="24">etc.</text>
<text top="713" left="433" width="21" height="11" font="24">Yes</text>
<text top="740" left="363" width="58" height="11" font="24">Advanced </text>
<text top="755" left="369" width="42" height="11" font="24">imaging</text>
<text top="769" left="362" width="55" height="11" font="24">(Class IIa)</text>
<text top="803" left="519" width="85" height="11" font="24">Treat identified </text>
<text top="817" left="523" width="73" height="11" font="24">abnormalities</text>
<text top="738" left="522" width="78" height="11" font="24">Transthoracic </text>
<text top="752" left="511" width="97" height="11" font="24">echocardiography</text>
<text top="767" left="531" width="55" height="11" font="24">(Class IIa)</text>
<text top="651" left="754" width="16" height="11" font="24">No</text>
<text top="878" left="253" width="46" height="11" font="24">Unclear </text>
<text top="892" left="227" width="94" height="11" font="24">e.g. 2:1 AV Block</text>
<text top="874" left="623" width="47" height="11" font="24">AV node</text>
<text top="871" left="670" width="6" height="15" font="24">‡</text>
<text top="888" left="609" width="81" height="11" font="24">(Mobitz Type I)</text>
<text top="928" left="621" width="57" height="11" font="24">Symptoms</text>
<text top="931" left="245" width="57" height="11" font="24">Symptoms</text>
<text top="842" left="733" width="60" height="11" font="24">Determine </text>
<text top="856" left="735" width="55" height="11" font="24">site of AV </text>
<text top="871" left="747" width="30" height="11" font="24">Block</text>
<text top="961" left="234" width="21" height="11" font="24">Yes</text>
<text top="957" left="283" width="16" height="11" font="24">No</text>
<text top="966" left="598" width="21" height="11" font="24">Yes</text>
<text top="1055" left="585" width="51" height="11" font="24">AV block </text>
<text top="1069" left="583" width="55" height="11" font="24">treatment </text>
<text top="1084" left="581" width="57" height="11" font="24">algorithm†</text>
<text top="1055" left="221" width="51" height="11" font="24">AV block </text>
<text top="1069" left="219" width="55" height="11" font="24">treatment </text>
<text top="1084" left="217" width="57" height="11" font="24">algorithm†</text>
<text top="1079" left="666" width="46" height="11" font="24">Observe</text>
<text top="961" left="667" width="16" height="11" font="24">No</text>
<text top="949" left="335" width="86" height="11" font="24">Exercise testing</text>
<text top="963" left="350" width="55" height="11" font="24">(Class IIa)</text>
<text top="999" left="330" width="100" height="11" font="24">Electrophysiology </text>
<text top="1013" left="364" width="32" height="11" font="24">study </text>
<text top="1028" left="350" width="55" height="11" font="24">(Class IIb)</text>
<text top="1050" left="353" width="47" height="11" font="24">AV node</text>
<text top="1079" left="355" width="46" height="11" font="24">Observe</text>
<text top="1055" left="505" width="51" height="11" font="24">AV block </text>
<text top="1069" left="503" width="55" height="11" font="24">treatment </text>
<text top="1084" left="501" width="57" height="11" font="24">algorithm†</text>
<text top="1017" left="459" width="54" height="11" font="24">Infranodal</text>
<text top="956" left="457" width="54" height="11" font="24">Infranodal</text>
<text top="259" left="504" width="16" height="11" font="24">No</text>
<text top="597" left="562" width="21" height="11" font="24">Yes</text>
<text top="885" left="111" width="54" height="11" font="24">Infranodal</text>
<text top="1055" left="114" width="51" height="11" font="24">AV block </text>
<text top="1069" left="112" width="55" height="11" font="24">treatment </text>
<text top="1084" left="109" width="57" height="11" font="24">algorithm†</text>
<text top="1086" left="825" width="4" height="21" font="7"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="21" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 21 </text>
<text top="124" left="81" width="359" height="19" font="1">Colors correspond to Class of Recommendation in Table 2. </text>
<text top="142" left="81" width="759" height="19" font="1">*Targeted Advanced Imaging—Magnetic Resonance Imaging (MRI): Amyloidosis, myocarditis, hemochromatosis, sarcoidosis, </text>
<text top="161" left="81" width="760" height="19" font="1">CHD, sinus of Valsalva aneurysm, aortic dissection, arrhythmogenic right ventricular cardiomyopathy; fluoro-deoxy-glucose </text>
<text top="179" left="81" width="761" height="19" font="1">(fludeoxyglucose)-positron emission tomography (FDG PET): sarcoidosis; 99m technetium pyrophosphate (Tc PYP) or 99m </text>
<text top="197" left="81" width="763" height="19" font="1">technetium 3,3-diphosphono-1,2-propanodicarboxylic acid (TC-DPD):  Transthyretin (TTR) amyloidosis; cardiac computed </text>
<text top="216" left="81" width="760" height="19" font="1">tomography (CT): CHD, sinus of Valsalva aneurysm, aortic dissection, arrhythmogenic right ventricular cardiomyopathy; echo </text>
<text top="234" left="81" width="762" height="19" font="1">longitudinal strain:  Amyloidosis; transesophageal echocardiogram (TEE):  Endocarditis, sinus of Valsalva aneurysm, aortic </text>
<text top="252" left="81" width="102" height="19" font="1">dissection, CHD. </text>
<text top="271" left="81" width="194" height="19" font="1">†Refer to Section 5.3., Figure 7. </text>
<text top="289" left="81" width="761" height="19" font="1">‡The atrioventricular node is more likely the site of block with second-degree Mobitz type I atrioventricular block and a </text>
<text top="307" left="81" width="631" height="19" font="1">narrow QRS complex or severe first-degree atrioventricular block (&gt;0.30 s) with a narrow QRS complex. </text>
<text top="326" left="81" width="760" height="19" font="1">AV indicates atrioventricular; ACHD, adult congenital heart disease; CHD, congenital heart disease; and CM, cardiomyopathy. </text>
<text top="344" left="81" width="4" height="21" font="8"> </text>
<text top="383" left="81" width="526" height="21" font="7"><b>Table 4. Medications That Can Induce/Exacerbate Bradycardia or Conduction</b></text>
<text top="384" left="607" width="66" height="19" font="1"> <b>Disorders</b> </text>
<text top="403" left="81" width="4" height="21" font="8"> </text>
<text top="424" left="459" width="3" height="19" font="0"><b> </b></text>
<text top="443" left="140" width="111" height="19" font="0"><b>Antihypertensive </b></text>
<text top="443" left="344" width="98" height="19" font="0"><b>Antiarrhythmic </b></text>
<text top="443" left="533" width="84" height="19" font="0"><b>Psychoactive </b></text>
<text top="443" left="736" width="40" height="19" font="0"><b>Other </b></text>
<text top="462" left="94" width="169" height="20" font="1">•  Beta adrenergic receptor </text>
<text top="481" left="107" width="148" height="19" font="1">blockers (including beta </text>
<text top="500" left="107" width="186" height="19" font="1">adrenergic blocking eye drops </text>
<text top="518" left="107" width="121" height="19" font="1">used for glaucoma) </text>
<text top="537" left="94" width="74" height="20" font="1">•  Clonidine </text>
<text top="556" left="94" width="95" height="20" font="1">•  Methyldopa  </text>
<text top="575" left="94" width="194" height="20" font="1">•  Non-dihydropyridine calcium </text>
<text top="594" left="107" width="106" height="19" font="1">channel blockers </text>
<text top="612" left="94" width="78" height="20" font="1">•  Reserpine </text>
<text top="462" left="314" width="81" height="20" font="1">•  Adenosine </text>
<text top="481" left="314" width="92" height="20" font="1">•  Amiodarone </text>
<text top="501" left="314" width="98" height="20" font="1">•  Dronedarone </text>
<text top="520" left="314" width="78" height="20" font="1">•  Flecainide </text>
<text top="539" left="314" width="101" height="20" font="1">•  Procainamide </text>
<text top="558" left="314" width="96" height="20" font="1">•  Propafenone </text>
<text top="577" left="314" width="76" height="20" font="1">•  Quinidine </text>
<text top="596" left="314" width="59" height="20" font="1">•  Sotalol </text>
<text top="462" left="485" width="81" height="20" font="1">•  Donepezil </text>
<text top="481" left="485" width="66" height="20" font="1">•  Lithium </text>
<text top="501" left="485" width="126" height="20" font="1">•  Opioid analgesics </text>
<text top="520" left="485" width="107" height="20" font="1">•  Phenothiazine </text>
<text top="539" left="501" width="101" height="19" font="1">antiemetics and </text>
<text top="557" left="501" width="90" height="19" font="1">antipsychotics </text>
<text top="575" left="485" width="82" height="20" font="1">•  Phenytoin </text>
<text top="595" left="485" width="137" height="20" font="1">•  Selective serotonin </text>
<text top="613" left="501" width="120" height="19" font="1">reuptake inhibitors </text>
<text top="632" left="485" width="13" height="22" font="23">• </text>
<text top="636" left="501" width="149" height="19" font="1">Tricyclic antidepressants</text>
<text top="633" left="651" width="4" height="23" font="23"> </text>
<text top="462" left="679" width="123" height="20" font="1">•  Anesthetic drugs </text>
<text top="481" left="696" width="65" height="19" font="1">(propofol) </text>
<text top="500" left="679" width="79" height="20" font="1">•  Cannabis  </text>
<text top="519" left="679" width="66" height="20" font="1">•  Digoxin </text>
<text top="538" left="679" width="85" height="20" font="1">•  Ivabradine </text>
<text top="557" left="679" width="123" height="20" font="1">•  Muscle relaxants </text>
<text top="576" left="696" width="134" height="19" font="1">(e.g., succinylcholine) </text>
<text top="655" left="81" width="4" height="21" font="8"> </text>
<text top="683" left="81" width="517" height="21" font="7"><b>Table 5. Conditions Associated With Bradycardia and Conduction Disorders</b> </text>
<text top="704" left="81" width="4" height="21" font="8"> </text>
<text top="725" left="89" width="54" height="19" font="0"><b>Intrinsic </b></text>
<text top="746" left="89" width="266" height="19" font="1">Cardiomyopathy (ischemic or nonischemic) </text>
<text top="769" left="89" width="153" height="19" font="1">Congenital heart disease </text>
<text top="793" left="89" width="133" height="19" font="1">Degenerative fibrosis </text>
<text top="817" left="89" width="145" height="19" font="1">Infection/inflammation </text>
<text top="835" left="100" width="122" height="20" font="1">•  Chagas disease </text>
<text top="854" left="100" width="95" height="20" font="1">•  Diphtheria </text>
<text top="873" left="100" width="170" height="20" font="1">•  Infectious endocarditis </text>
<text top="893" left="100" width="112" height="20" font="1">•  Lyme disease </text>
<text top="912" left="100" width="102" height="20" font="1">•  Myocarditis </text>
<text top="931" left="100" width="98" height="20" font="1">•  Sarcoidosis </text>
<text top="950" left="100" width="119" height="20" font="1">•  Toxoplasmosis </text>
<text top="969" left="89" width="127" height="19" font="1">Infiltrative disorders </text>
<text top="988" left="100" width="104" height="20" font="1">•  Amyloidosis </text>
<text top="1007" left="100" width="142" height="20" font="1">•  Hemochromatosis </text>
<text top="1026" left="100" width="98" height="20" font="1">•  Lymphoma </text>
<text top="1046" left="89" width="122" height="19" font="1">Ischemia/infarction </text>
<text top="1070" left="89" width="173" height="19" font="1">Rheumatological conditions </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="22" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 22 </text>
<text top="125" left="100" width="157" height="20" font="1">•  Rheumatoid arthritis </text>
<text top="144" left="100" width="107" height="20" font="1">•  Scleroderma </text>
<text top="163" left="100" width="216" height="20" font="1">•  Systemic lupus erythematosus </text>
<text top="183" left="89" width="189" height="19" font="1">Surgical or procedural trauma  </text>
<text top="202" left="100" width="409" height="20" font="1">•  Cardiac procedures such as ablation or cardiac catheterization </text>
<text top="221" left="100" width="229" height="20" font="1">•  Congenital heart disease surgery </text>
<text top="240" left="100" width="438" height="20" font="1">•  Septal myomectomy for hypertrophic obstructive cardiomyopathy  </text>
<text top="259" left="100" width="384" height="20" font="1">•  Valve surgery (including percutaneous valve replacement) </text>
<text top="278" left="89" width="56" height="19" font="0"><b>Extrinsic</b> </text>
<text top="299" left="89" width="152" height="19" font="1">Autonomic perturbation </text>
<text top="317" left="100" width="209" height="20" font="1">•  Carotid sinus hypersensitivity </text>
<text top="336" left="100" width="278" height="20" font="1">•  Neurally-mediated syncope/presyncope  </text>
<text top="355" left="100" width="159" height="20" font="1">•  Physical conditioning </text>
<text top="375" left="100" width="153" height="20" font="1">•  Situational syncope  </text>
<text top="398" left="128" width="9" height="12" font="1">o</text>
<text top="397" left="137" width="4" height="14" font="1"> </text>
<text top="393" left="155" width="42" height="19" font="1">Cough </text>
<text top="417" left="128" width="9" height="12" font="1">o</text>
<text top="416" left="137" width="4" height="14" font="1"> </text>
<text top="412" left="155" width="70" height="19" font="1">Defecation </text>
<text top="435" left="128" width="9" height="12" font="1">o</text>
<text top="434" left="137" width="4" height="14" font="1"> </text>
<text top="430" left="155" width="117" height="19" font="1">Glottic stimulation </text>
<text top="453" left="128" width="9" height="12" font="1">o</text>
<text top="452" left="137" width="4" height="14" font="1"> </text>
<text top="448" left="155" width="125" height="19" font="1">Medical procedures </text>
<text top="472" left="128" width="9" height="12" font="1">o</text>
<text top="470" left="137" width="4" height="14" font="1"> </text>
<text top="467" left="155" width="72" height="19" font="1">Micturition </text>
<text top="490" left="128" width="9" height="12" font="1">o</text>
<text top="489" left="137" width="4" height="14" font="1"> </text>
<text top="485" left="155" width="59" height="19" font="1">Vomiting </text>
<text top="504" left="100" width="247" height="20" font="1">•  Sleep (with or without sleep apnea) </text>
<text top="523" left="89" width="65" height="19" font="1">Metabolic </text>
<text top="542" left="100" width="80" height="20" font="1">•  Acidosis </text>
<text top="561" left="100" width="115" height="20" font="1">•  Hyperkalemia </text>
<text top="580" left="100" width="110" height="20" font="1">•  Hypokalemia </text>
<text top="599" left="100" width="110" height="20" font="1">•  Hypothermia </text>
<text top="618" left="100" width="128" height="20" font="1">•  Hypothyroidism </text>
<text top="637" left="100" width="80" height="20" font="1">•  Hypoxia </text>
<text top="657" left="81" width="543" height="19" font="1">Adapted with permission from Mangrum and DiMarco (S3.1-1) and Vogler et al. (S3.1-2). </text>
<text top="684" left="81" width="3" height="19" font="1"> </text>
<text top="721" left="81" width="3" height="19" font="1"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="23" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="26" size="19" family="Times" color="#000000"/>
	<fontspec id="27" size="19" family="Times" color="#000000"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 23 </text>
<text top="124" left="81" width="264" height="29" font="19"><b>3.2. Noninvasive Evaluation </b></text>
<text top="183" left="81" width="672" height="27" font="26"><i><b>3.2.1. Resting ECG in Patients With Documented or Suspected Bradycardia or </b></i></text>
<text top="209" left="81" width="190" height="27" font="26"><i><b>Conduction Disorders </b></i></text>
<text top="244" left="100" width="723" height="21" font="7"><b>Recommendation for Electrocardiogram (ECG) in Patients With Documented or Suspected Bradycardia or </b></text>
<text top="267" left="385" width="151" height="21" font="7"><b>Conduction Disorders </b></text>
<text top="290" left="122" width="494" height="21" font="8">Referenced studies that support the recommendation are summarized<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> in </a></text>
<text top="290" left="616" width="176" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 1</a></text>
<text top="290" left="792" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="315" left="92" width="33" height="21" font="7"><b>COR </b></text>
<text top="315" left="159" width="30" height="21" font="7"><b>LOE </b></text>
<text top="315" left="458" width="126" height="21" font="7"><b>Recommendation </b></text>
<text top="359" left="110" width="8" height="21" font="7"><b>I </b></text>
<text top="359" left="151" width="42" height="21" font="7"><b> B-NR </b></text>
<text top="340" left="210" width="573" height="21" font="7"><b>1.  In patients with suspected bradycardia or conduction disorder, a 12-lead ECG is </b></text>
<text top="360" left="237" width="595" height="21" font="7"><b>recommended to document rhythm, rate, and conduction, and to screen for structural </b></text>
<text top="380" left="237" width="360" height="21" font="7"><b>heart disease or systemic illness (S3.2.1-1–S3.2.1-4). </b></text>
<text top="401" left="81" width="4" height="21" font="8"> </text>
<text top="421" left="81" width="4" height="21" font="8"> </text>
<text top="469" left="81" width="761" height="27" font="27"><b>3.2.2. Exercise Electrocardiographic Testing in Patients With Documented or Suspected </b></text>
<text top="495" left="81" width="325" height="27" font="27"><b>Bradycardia or Conduction Disorders </b></text>
<text top="530" left="105" width="712" height="21" font="7"><b>Recommendations for Exercise Electrocardiographic Testing in Patients With Documented or Suspected </b></text>
<text top="551" left="333" width="256" height="21" font="7"><b>Bradycardia or Conduction Disorders </b></text>
<text top="571" left="132" width="474" height="21" font="8">Referenced studies that support recommendations are summarized<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> in </a></text>
<text top="571" left="606" width="176" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 2</a></text>
<text top="571" left="782" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="592" left="98" width="33" height="21" font="7"><b>COR </b></text>
<text top="592" left="163" width="30" height="21" font="7"><b>LOE </b></text>
<text top="592" left="459" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="634" left="104" width="21" height="21" font="7"><b>IIa </b></text>
<text top="634" left="159" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="615" left="218" width="615" height="21" font="7"><b>1.  In patients with suspected chronotropic incompetence, exercise electrocardiographic </b></text>
<text top="636" left="245" width="588" height="21" font="7"><b>testing is reasonable to ascertain the diagnosis and provide information on prognosis </b></text>
<text top="656" left="245" width="140" height="21" font="7"><b>(S3.2.2-1, S3.2.2-2).  </b></text>
<text top="695" left="104" width="21" height="21" font="7"><b>IIa </b></text>
<text top="695" left="161" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="677" left="218" width="615" height="21" font="7"><b>2.  In patients with exercise-related symptoms suspicious for bradycardia or conduction </b></text>
<text top="697" left="245" width="590" height="21" font="7"><b>disorders, or in patients with 2:1 atrioventricular block of unknown level, exercise </b></text>
<text top="717" left="245" width="426" height="21" font="7"><b>electrocardiographic testing is reasonable</b> <b>(S3.2.2-3, S3.2.2-4). </b></text>
<text top="738" left="81" width="4" height="21" font="8"> </text>
<text top="777" left="81" width="4" height="21" font="8"> </text>
<text top="825" left="81" width="766" height="27" font="27"><b>3.2.3. Ambulatory Electrocardiography in Patients With Documented or Suspected </b></text>
<text top="851" left="81" width="325" height="27" font="27"><b>Bradycardia or Conduction Disorders </b></text>
<text top="886" left="123" width="675" height="21" font="7"><b>Recommendation for Ambulatory Electrocardiography in Patients With Documented or Suspected </b></text>
<text top="906" left="333" width="256" height="21" font="7"><b>Bradycardia or Conduction Disorders </b></text>
<text top="927" left="122" width="494" height="21" font="8">Referenced studies that support the recommendation are summarized<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> in </a></text>
<text top="927" left="616" width="176" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 3</a></text>
<text top="927" left="792" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="947" left="104" width="33" height="21" font="7"><b>COR </b></text>
<text top="947" left="173" width="30" height="21" font="7"><b>LOE </b></text>
<text top="947" left="466" width="126" height="21" font="7"><b>Recommendation </b></text>
<text top="1009" left="116" width="8" height="21" font="7"><b>I </b></text>
<text top="1009" left="169" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="968" left="225" width="614" height="21" font="7"><b>1.  In the evaluation of patients with documented or suspected bradycardia or </b></text>
<text top="989" left="252" width="583" height="21" font="7"><b>conduction disorders, cardiac rhythm monitoring is useful to establish correlation </b></text>
<text top="1009" left="252" width="582" height="21" font="7"><b>between heart rate or conduction abnormalities with symptoms, with the specific </b></text>
<text top="1029" left="252" width="581" height="21" font="7"><b>type of cardiac monitor chosen based on the frequency and nature of symptoms, as </b></text>
<text top="1049" left="252" width="335" height="21" font="7"><b>well as patient preferences (S3.2.3-1–S3.2.3-12).</b> </text>
<text top="1070" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="24" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 24 </text>
<text top="124" left="81" width="237" height="21" font="7"><b>Table 6. Cardiac Rhythm Monitors</b> </text>
<text top="144" left="81" width="4" height="21" font="8"> </text>
<text top="165" left="93" width="111" height="19" font="0"><b>Types of Monitor</b> </text>
<text top="165" left="358" width="120" height="19" font="0"><b>Device Description</b> </text>
<text top="165" left="677" width="109" height="19" font="0"><b>Patient Selection</b> </text>
<text top="184" left="89" width="86" height="19" font="1">Nonphysician </text>
<text top="202" left="89" width="68" height="19" font="1">prescribed </text>
<text top="221" left="89" width="79" height="19" font="1">smartphone-</text>
<text top="239" left="89" width="95" height="19" font="1">based systems  </text>
<text top="184" left="218" width="339" height="20" font="1">•  Commercially available smartphone–based systems </text>
<text top="204" left="218" width="397" height="20" font="1">•  Can record a rhythm strip when the patient has symptoms or </text>
<text top="222" left="240" width="264" height="19" font="1">continuously depending on the technology </text>
<text top="184" left="629" width="201" height="19" font="1">Patient access to the technology </text>
<text top="258" left="89" width="98" height="19" font="1">Holter monitor  </text>
<text top="258" left="219" width="373" height="20" font="1">•  Continuous recording for 24–72 h; up to 2 wk with newer </text>
<text top="277" left="240" width="51" height="19" font="1">models  </text>
<text top="296" left="219" width="365" height="20" font="1">•  Symptom rhythm correlation can be achieved through a </text>
<text top="315" left="240" width="334" height="19" font="1">patient event diary and patient-activated annotations  </text>
<text top="258" left="630" width="190" height="19" font="1">Symptoms frequent enough to </text>
<text top="276" left="630" width="164" height="19" font="1">be detected within a short </text>
<text top="295" left="630" width="108" height="19" font="1">period (24–72 h)  </text>
<text top="313" left="630" width="87" height="19" font="1">of monitoring </text>
<text top="334" left="89" width="112" height="19" font="1">Patient-activated, </text>
<text top="352" left="89" width="99" height="19" font="1">transtelephonic </text>
<text top="370" left="89" width="95" height="19" font="1">monitor (event </text>
<text top="389" left="89" width="61" height="19" font="1">monitor)  </text>
<text top="334" left="219" width="390" height="19" font="1">A recording device that transmits patient-activated data (live or </text>
<text top="352" left="219" width="343" height="19" font="1">stored) via an analog telephone line to a central remote </text>
<text top="370" left="219" width="253" height="19" font="1">monitoring station (e.g., physician office) </text>
<text top="334" left="630" width="172" height="20" font="1">•  Frequent, spontaneous </text>
<text top="353" left="657" width="153" height="19" font="1">symptoms likely to recur </text>
<text top="371" left="657" width="92" height="19" font="1">within 2–6 wk  </text>
<text top="390" left="630" width="199" height="20" font="1">•  Limited use in patients with </text>
<text top="409" left="657" width="155" height="19" font="1">incapacitating symptoms </text>
<text top="428" left="89" width="84" height="19" font="1">External loop </text>
<text top="446" left="89" width="108" height="19" font="1">recorder (patient </text>
<text top="464" left="89" width="48" height="19" font="1">or auto </text>
<text top="483" left="89" width="71" height="19" font="1">triggered)* </text>
<text top="428" left="219" width="381" height="20" font="1">•  A device that continuously records and stores rhythm data </text>
<text top="447" left="240" width="142" height="19" font="1">over weeks to months  </text>
<text top="465" left="219" width="332" height="20" font="1">•  Patient activated, or auto triggered (e.g., to record </text>
<text top="484" left="240" width="370" height="19" font="1">asymptomatic arrhythmias) to provide a recording of events </text>
<text top="503" left="240" width="354" height="19" font="1">antecedent to (3–14 min), during, and after (1–4 min) the </text>
<text top="521" left="240" width="101" height="19" font="1">triggered event  </text>
<text top="539" left="219" width="396" height="20" font="1">•  Newer models are equipped with a cellular telephone, which </text>
<text top="558" left="240" width="331" height="19" font="1">transmits triggered data automatically over a wireless </text>
<text top="577" left="240" width="251" height="19" font="1">network to a remote monitoring system  </text>
<text top="428" left="630" width="145" height="19" font="1">Frequent, spontaneous </text>
<text top="446" left="630" width="199" height="19" font="1">symptoms potentially related to </text>
<text top="464" left="630" width="164" height="19" font="1">bradycardia or conduction </text>
<text top="483" left="630" width="187" height="19" font="1">disorder, likely to recur within </text>
<text top="501" left="630" width="47" height="19" font="1">2–6 wk </text>
<text top="596" left="89" width="91" height="19" font="1">External patch </text>
<text top="614" left="89" width="62" height="19" font="1">recorders </text>
<text top="596" left="219" width="376" height="20" font="1">•  Patch device that continuously records and stores rhythm </text>
<text top="615" left="240" width="355" height="19" font="1">data, with patient-trigger capability to allow for symptom-</text>
<text top="633" left="240" width="122" height="19" font="1">rhythm correlation  </text>
<text top="652" left="219" width="358" height="20" font="1">•  No leads or wires, and adhesive to chest wall/sternum  </text>
<text top="671" left="219" width="243" height="20" font="1">•  Various models record from 2–14 d  </text>
<text top="690" left="219" width="323" height="20" font="1">•  Offers accurate means of assessing burden of AF  </text>
<text top="709" left="219" width="332" height="20" font="1">•  Patient activated, or auto triggered (e.g., to record </text>
<text top="728" left="240" width="370" height="19" font="1">asymptomatic arrhythmias) to provide a recording of events </text>
<text top="746" left="240" width="323" height="19" font="1">antecedent to, during, and after the triggered event  </text>
<text top="596" left="630" width="178" height="20" font="1">•  Can be considered as an </text>
<text top="615" left="657" width="170" height="19" font="1">alternative to external loop </text>
<text top="633" left="657" width="60" height="19" font="1">recorder  </text>
<text top="652" left="630" width="199" height="20" font="1">•  Given that it is leadless, can </text>
<text top="670" left="657" width="163" height="19" font="1">be accurately self-applied, </text>
<text top="689" left="657" width="122" height="19" font="1">and is largely water </text>
<text top="707" left="657" width="156" height="19" font="1">resistant, it may be more </text>
<text top="725" left="657" width="130" height="19" font="1">comfortable and less </text>
<text top="744" left="657" width="133" height="19" font="1">cumbersome than an </text>
<text top="762" left="657" width="144" height="19" font="1">external loop recorder, </text>
<text top="780" left="657" width="134" height="19" font="1">potentially improving </text>
<text top="799" left="657" width="77" height="19" font="1">compliance  </text>
<text top="817" left="630" width="196" height="20" font="1">•  Unlike Holter monitors and </text>
<text top="836" left="657" width="165" height="19" font="1">other external monitors, it </text>
<text top="854" left="657" width="175" height="19" font="1">offers only 1-lead recording  </text>
<text top="874" left="89" width="93" height="19" font="1">Mobile cardiac </text>
<text top="892" left="89" width="68" height="19" font="1">outpatient </text>
<text top="910" left="89" width="67" height="19" font="1">telemetry  </text>
<text top="874" left="219" width="368" height="20" font="1">•  Device that records and transmits data (up to 30 d) from </text>
<text top="893" left="240" width="335" height="19" font="1">preprogrammed arrhythmias or patient activation to a </text>
<text top="911" left="240" width="264" height="19" font="1">communication hub at the patient’s home  </text>
<text top="929" left="219" width="326" height="20" font="1">•  Significant arrhythmias are detected; the monitor </text>
<text top="948" left="240" width="357" height="19" font="1">automatically transmits the patient’s electrocardiographic </text>
<text top="967" left="240" width="358" height="19" font="1">data through a wireless network to the central monitoring </text>
<text top="985" left="240" width="342" height="19" font="1">station, which is attended by trained technicians 24 h/d </text>
<text top="874" left="630" width="180" height="20" font="1">•  Spontaneous symptoms, </text>
<text top="893" left="657" width="132" height="19" font="1">potentially related to </text>
<text top="911" left="657" width="164" height="19" font="1">bradycardia or conduction </text>
<text top="929" left="657" width="170" height="19" font="1">disorder, that are too brief, </text>
<text top="948" left="657" width="110" height="19" font="1">too subtle, or too </text>
<text top="966" left="657" width="148" height="19" font="1">infrequent to be readily </text>
<text top="984" left="657" width="159" height="19" font="1">documented with patient </text>
<text top="1002" left="657" width="118" height="19" font="1">activated monitors </text>
<text top="1021" left="630" width="194" height="20" font="1">•  In high-risk patients whose </text>
<text top="1040" left="657" width="161" height="19" font="1">rhythm requires real-time </text>
<text top="1058" left="657" width="74" height="19" font="1">monitoring  </text>
<text top="1077" left="81" width="572" height="19" font="1">*Higher yield in patients who are able to record a diary to correlate with possible arrhythmia. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="25" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="28" size="8" family="Times" color="#000000"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 25 </text>
<text top="124" left="81" width="330" height="19" font="1">Adapted with permission from Shen et al. (S3.2.3-13). </text>
<text top="142" left="81" width="182" height="19" font="1">AF indicates atrial fibrillation. </text>
<text top="160" left="81" width="4" height="21" font="8"> </text>
<text top="190" left="81" width="4" height="21" font="8"> </text>
<text top="237" left="81" width="745" height="27" font="27"><b>3.2.4. Imaging in Patients With Documented or Suspected Bradycardia or Conduction </b></text>
<text top="262" left="81" width="83" height="27" font="27"><b>Disorders</b></text>
<text top="267" left="164" width="4" height="21" font="8"> </text>
<text top="298" left="191" width="541" height="21" font="7"><b>Recommendations for Cardiac Imaging in Bradycardia or Conduction Disorders </b></text>
<text top="318" left="108" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="318" left="582" width="224" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 3 and 4</a></text>
<text top="318" left="806" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="339" left="101" width="33" height="21" font="7"><b>COR </b></text>
<text top="339" left="170" width="30" height="21" font="7"><b>LOE </b></text>
<text top="339" left="462" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="401" left="113" width="8" height="21" font="7"><b>I </b></text>
<text top="401" left="166" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="363" left="223" width="609" height="21" font="7"><b>1.  In patients with newly identified left bundle branch block  (LBBB),  second-degree </b></text>
<text top="383" left="250" width="579" height="21" font="7"><b>Mobitz type II atrioventricular  block, high-grade  atrioventricular block, or third-</b></text>
<text top="403" left="250" width="584" height="21" font="7"><b>degree atrioventricular block with or without apparent structural heart disease or </b></text>
<text top="423" left="250" width="579" height="21" font="7"><b>coronary artery disease, transthoracic echocardiography is recommended (S3.2.4-1–</b></text>
<text top="443" left="250" width="80" height="21" font="7"><b>S3.2.4-10).  </b></text>
<text top="503" left="107" width="21" height="21" font="7"><b>IIa </b></text>
<text top="503" left="166" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="464" left="223" width="610" height="21" font="7"><b>2.  In selected patients presenting with bradycardia or conduction disorders other than </b></text>
<text top="484" left="250" width="582" height="21" font="7"><b>LBBB,  second-degree Mobitz type II atrioventricular block, high-grade </b></text>
<text top="504" left="250" width="594" height="21" font="7"><b>atrioventricular block, or third-degree  atrioventricular block, transthoracic </b></text>
<text top="524" left="250" width="583" height="21" font="7"><b>echocardiography  is reasonable  if structural heart disease is suspected</b>  <b>(S3.2.4-3, </b></text>
<text top="545" left="250" width="152" height="21" font="7"><b>S3.2.4-11–S3.2.4-13).  </b></text>
<text top="604" left="107" width="21" height="21" font="7"><b>IIa </b></text>
<text top="604" left="168" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="566" left="223" width="609" height="21" font="7"><b>3.  In selected patients with bradycardia or bundle branch block, disease-specific </b></text>
<text top="586" left="250" width="583" height="21" font="7"><b>advanced imaging (e.g., transesophageal echocardiography, computed tomography, </b></text>
<text top="606" left="250" width="583" height="21" font="7"><b>cardiac magnetic resonance imaging, or nuclear imaging) is reasonable if structural </b></text>
<text top="626" left="250" width="579" height="21" font="7"><b>heart disease is suspected yet not confirmed by other diagnostic modalities (S3.2.4-</b></text>
<text top="646" left="250" width="102" height="21" font="7"><b>14–S3.2.4-22). </b></text>
<text top="674" left="95" width="45" height="21" font="7"><b>III: No </b></text>
<text top="697" left="91" width="53" height="21" font="7"><b>Benefit </b></text>
<text top="686" left="166" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="667" left="223" width="609" height="21" font="7"><b>4.  In the evaluation of patients with asymptomatic sinus bradycardia or first-degree </b></text>
<text top="687" left="250" width="585" height="21" font="7"><b>atrioventricular  block and no clinical evidence of structural heart disease, routine </b></text>
<text top="707" left="250" width="373" height="21" font="7"><b>cardiac imaging is not indicated (S3.2.4-22–S3.2.4-24). </b></text>
<text top="728" left="81" width="4" height="21" font="8"> </text>
<text top="768" left="81" width="4" height="21" font="8"> </text>
<text top="806" left="81" width="734" height="27" font="27"><b>3.2.5. Laboratory Testing in Patients With Documented or Suspected Bradycardia or </b></text>
<text top="831" left="81" width="193" height="27" font="27"><b>Conduction Disorders </b></text>
<text top="867" left="119" width="684" height="21" font="7"><b>Recommendation for Laboratory Testing in Patients With Documented or Suspected Bradycardia or </b></text>
<text top="887" left="385" width="151" height="21" font="7"><b>Conduction Disorders </b></text>
<text top="908" left="104" width="33" height="21" font="7"><b>COR </b></text>
<text top="908" left="177" width="30" height="21" font="7"><b>LOE </b></text>
<text top="908" left="469" width="126" height="21" font="7"><b>Recommendation </b></text>
<text top="952" left="110" width="21" height="21" font="7"><b>IIa </b></text>
<text top="952" left="174" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="933" left="231" width="601" height="21" font="7"><b>1.  In patients with bradycardia, laboratory tests (e.g., thyroid function tests, Lyme titer, </b></text>
<text top="953" left="251" width="581" height="21" font="7"><b>potassium, pH) based on clinical suspicion for a potential underlying cause are </b></text>
<text top="973" left="251" width="213" height="21" font="7"><b>reasonable (S3.2.5-1–S3.2.5-4).</b></text>
<text top="973" left="464" width="2" height="13" font="28"> </text>
<text top="973" left="467" width="4" height="21" font="8"> </text>
<text top="995" left="81" width="4" height="21" font="8"> </text>
<text top="1034" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="26" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 26 </text>
<text top="133" left="81" width="766" height="27" font="27"><b>3.2.6. Genetic Testing in Patients With Documented or Suspected Bradycardia or </b></text>
<text top="158" left="81" width="193" height="27" font="27"><b>Conduction Disorders </b></text>
<text top="194" left="100" width="722" height="21" font="7"><b>Recommendations for Genetic Testing in Documented or Suspected Bradycardia or Conduction Disorders </b></text>
<text top="222" left="101" width="33" height="21" font="7"><b>COR </b></text>
<text top="222" left="174" width="30" height="21" font="7"><b>LOE </b></text>
<text top="222" left="466" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="271" left="114" width="8" height="21" font="7"><b>I </b></text>
<text top="271" left="170" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="251" left="231" width="602" height="21" font="7"><b>1.  In patients in whom a conduction disorder-causative mutation has been identified, </b></text>
<text top="271" left="256" width="576" height="21" font="7"><b>genetic counseling and mutation-specific genetic testing of first-degree relatives is </b></text>
<text top="291" left="256" width="383" height="21" font="7"><b>recommended to identify similarly affected individuals. </b></text>
<text top="332" left="107" width="21" height="21" font="7"><b>IIb </b></text>
<text top="332" left="170" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="312" left="231" width="601" height="21" font="7"><b>2.  In patients with inherited conduction disease, genetic  counseling and  targeted </b></text>
<text top="332" left="256" width="577" height="21" font="7"><b>testing may be considered to facilitate cascade screening of relatives as part of the </b></text>
<text top="352" left="256" width="155" height="21" font="7"><b>diagnostic evaluation. </b></text>
<text top="373" left="81" width="4" height="21" font="8"> </text>
<text top="402" left="81" width="4" height="21" font="8"> </text>
<text top="440" left="81" width="768" height="27" font="27"><b>3.2.7. Sleep Apnea Evaluation and Treatment in Patients  With Documented or </b></text>
<text top="466" left="81" width="424" height="27" font="27"><b>Suspected Bradycardia or Conduction Disorders  </b></text>
<text top="501" left="102" width="719" height="21" font="7"><b>Recommendation for Sleep Apnea Evaluation and Treatment in Patients With Documented or Suspected </b></text>
<text top="521" left="333" width="256" height="21" font="7"><b>Bradycardia or Conduction Disorders </b></text>
<text top="541" left="132" width="474" height="21" font="8">Referenced studies that support recommendations are summarized<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> in </a></text>
<text top="541" left="606" width="176" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 5</a></text>
<text top="541" left="782" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="563" left="105" width="33" height="21" font="7"><b>COR </b></text>
<text top="563" left="169" width="30" height="21" font="7"><b>LOE </b></text>
<text top="563" left="465" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="620" left="113" width="8" height="21" font="7"><b>I </b></text>
<text top="620" left="169" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="585" left="231" width="606" height="21" font="7"><b>1.  In patients with documented or suspected bradycardia or conduction disorder </b></text>
<text top="605" left="257" width="578" height="21" font="7"><b>during sleep, screening for symptoms of sleep apnea syndrome is recommended </b></text>
<text top="625" left="257" width="572" height="21" font="7"><b>with subsequent confirmatory testing directed by clinical suspicion (S3.2.7-1–S3.2.7-</b></text>
<text top="646" left="256" width="34" height="21" font="7"><b>11). </b> </text>
<text top="706" left="113" width="8" height="21" font="7"><b>I </b></text>
<text top="706" left="169" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="675" left="231" width="602" height="21" font="7"><b>2.  In patients with sleep-related bradycardia or conduction disorder and documented </b></text>
<text top="696" left="257" width="579" height="21" font="7"><b>obstructive sleep apnea, treatment directed specifically at the sleep apnea (e.g. </b></text>
<text top="716" left="257" width="572" height="21" font="7"><b>continuous positive airway pressure and weight loss) is recommended (S3.2.7-12–</b></text>
<text top="736" left="257" width="80" height="21" font="7"><b>S3.2.7-16).  </b></text>
<text top="777" left="107" width="21" height="21" font="7"><b>IIa </b></text>
<text top="777" left="169" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="757" left="231" width="603" height="21" font="7"><b>3.  In patients who have previously received or are being considered for a permanent </b></text>
<text top="777" left="257" width="576" height="21" font="7"><b>pacemaker for bradycardia or conduction disorder, screening for sleep  apnea </b></text>
<text top="797" left="257" width="320" height="21" font="7"><b>syndrome is reasonable (S3.2.7-10, S3.2.7-11). </b></text>
<text top="818" left="81" width="4" height="21" font="8"> </text>
<text top="847" left="81" width="4" height="21" font="8"> </text>
<text top="873" left="81" width="4" height="21" font="8"> </text>
<text top="867" left="297" width="5" height="29" font="19"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="27" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 27 </text>
<text top="124" left="81" width="194" height="29" font="19"><b>3.3. Invasive Testing </b></text>
<text top="169" left="81" width="769" height="27" font="27"><b>3.3.1. Implantable Cardiac Monitor in Patients With Documented or Suspected </b></text>
<text top="195" left="81" width="325" height="27" font="27"><b>Bradycardia or Conduction Disorders </b></text>
<text top="230" left="94" width="735" height="21" font="7"><b>Recommendation for Implantable Cardiac Monitor in Patients With Documented or Suspected Bradycardia </b></text>
<text top="250" left="376" width="170" height="21" font="7"><b>or Conduction Disorders </b></text>
<text top="271" left="122" width="494" height="21" font="8">Referenced studies that support the recommendation are summarized<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> in </a></text>
<text top="271" left="616" width="180" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 6.</a></text>
<text top="271" left="796" width="4" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="291" left="99" width="33" height="21" font="7"><b>COR </b></text>
<text top="291" left="169" width="30" height="21" font="7"><b>LOE </b></text>
<text top="291" left="466" width="126" height="21" font="7"><b>Recommendation </b></text>
<text top="342" left="105" width="21" height="21" font="7"><b>IIa </b></text>
<text top="342" left="167" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="312" left="226" width="608" height="21" font="7"><b>1.  In patients with infrequent symptoms (&gt;30 days between symptoms) suspected to </b></text>
<text top="332" left="253" width="582" height="21" font="7"><b>be caused by bradycardia, long-term ambulatory monitoring with an implantable </b></text>
<text top="353" left="253" width="584" height="21" font="7"><b>cardiac monitor is reasonable if initial noninvasive evaluation is nondiagnostic </b></text>
<text top="373" left="253" width="137" height="21" font="7"><b>(S3.3.1-1–S3.3.1-3). </b></text>
<text top="394" left="81" width="4" height="21" font="8"> </text>
<text top="423" left="81" width="4" height="21" font="8"> </text>
<text top="443" left="81" width="761" height="27" font="27"><b>3.3.2. Electrophysiology Study in Patients With Documented or Suspected Bradycardia </b></text>
<text top="468" left="81" width="216" height="27" font="27"><b>or Conduction Disorders </b></text>
<text top="504" left="96" width="731" height="21" font="7"><b>Recommendation for Electrophysiology Testing in Patients With Documented or Suspected Bradycardia or </b></text>
<text top="524" left="385" width="151" height="21" font="7"><b>Conduction Disorders </b></text>
<text top="544" left="132" width="474" height="21" font="8">Referenced studies that support recommendations are summarized i<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">n </a></text>
<text top="544" left="606" width="176" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 7</a></text>
<text top="544" left="782" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="565" left="100" width="33" height="21" font="7"><b>COR </b></text>
<text top="565" left="169" width="30" height="21" font="7"><b>LOE </b></text>
<text top="565" left="465" width="126" height="21" font="7"><b>Recommendation </b></text>
<text top="616" left="106" width="21" height="21" font="7"><b>IIb </b></text>
<text top="616" left="167" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="586" left="224" width="615" height="21" font="7"><b>1.  In patients with symptoms suspected to be attributable  to bradycardia, an </b></text>
<text top="606" left="251" width="581" height="21" font="7"><b>electrophysiology study (EPS) may be considered in selected patients for diagnosis </b></text>
<text top="626" left="251" width="584" height="21" font="7"><b>of, and elucidation of bradycardia mechanism, if initial non-invasive evaluation is </b></text>
<text top="647" left="251" width="241" height="21" font="7"><b>nondiagnostic</b> <b>(S3.3.2-1–S3.3.2-5).  </b></text>
<text top="667" left="81" width="4" height="21" font="7"><b> </b></text>
<text top="667" left="297" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="28" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="29" size="14" family="Times" color="#222a35"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 28 </text>
<text top="142" left="81" width="547" height="31" font="2"><b>4. Bradycardia Attributable to Sinus Node Dysfunction  </b></text>
<text top="180" left="81" width="481" height="29" font="19"><b>4.1. Acute Management of Sinus Node Dysfunction </b></text>
<text top="212" left="81" width="4" height="21" font="29"> </text>
<text top="241" left="81" width="4" height="21" font="7"><b> </b></text>
<text top="241" left="297" width="4" height="21" font="7"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="29" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 29 </text>
<text top="124" left="81" width="264" height="21" font="7"><b>Figure 4. Acute Bradycardia Algorithm</b> </text>
<text top="1081" left="637" width="4" height="21" font="8"> </text>
<text top="160" left="377" width="36" height="11" font="25">Acute </text>
<text top="176" left="360" width="67" height="11" font="25">Bradycardia</text>
<text top="255" left="337" width="116" height="11" font="25">Assess for and treat </text>
<text top="270" left="344" width="102" height="11" font="25">reversible causes </text>
<text top="285" left="372" width="43" height="11" font="25">(COR I)</text>
<text top="460" left="380" width="31" height="11" font="25">Drug </text>
<text top="475" left="365" width="57" height="11" font="25">Toxicity?†</text>
<text top="846" left="468" width="21" height="11" font="25">Yes</text>
<text top="561" left="269" width="91" height="11" font="25">Anti-digoxin Fab</text>
<text top="576" left="288" width="54" height="11" font="25">(COR IIa)</text>
<text top="469" left="285" width="21" height="11" font="25">Yes</text>
<text top="838" left="531" width="82" height="11" font="25">Aminophylline </text>
<text top="853" left="543" width="54" height="11" font="25">(COR IIb)</text>
<text top="910" left="354" width="81" height="11" font="25">Beta-agonists </text>
<text top="925" left="366" width="54" height="11" font="25">(COR IIb)</text>
<text top="596" left="194" width="72" height="11" font="25">IV Glucagon </text>
<text top="611" left="201" width="54" height="11" font="25">(COR IIa)</text>
<text top="563" left="104" width="64" height="11" font="25">IV Calcium </text>
<text top="578" left="108" width="54" height="11" font="25">(COR IIa)</text>
<text top="208" left="352" width="83" height="11" font="25">VS, H+P, ECG</text>
<text top="223" left="330" width="128" height="11" font="25">Assessment of stability</text>
<text top="336" left="495" width="16" height="11" font="25">No</text>
<text top="328" left="539" width="87" height="11" font="25">Evaluation and </text>
<text top="343" left="548" width="65" height="11" font="25">observation</text>
<text top="800" left="384" width="16" height="11" font="25">No</text>
<text top="838" left="373" width="43" height="11" font="25">MI with </text>
<text top="853" left="363" width="58" height="11" font="25">AV Block?</text>
<text top="885" left="383" width="16" height="11" font="25">No</text>
<text top="647" left="365" width="61" height="11" font="25">Continued </text>
<text top="662" left="361" width="64" height="11" font="25">symptoms?</text>
<text top="1063" left="355" width="79" height="11" font="25">Acute Pacing </text>
<text top="1078" left="362" width="60" height="11" font="25">Algorithm‡</text>
<text top="694" left="383" width="21" height="11" font="25">Yes</text>
<text top="647" left="180" width="104" height="11" font="25">High dose Insulin  </text>
<text top="663" left="201" width="54" height="11" font="25">(COR IIa)</text>
<text top="678" left="228" width="3" height="11" font="25"> </text>
<text top="469" left="210" width="35" height="11" font="25">Type?</text>
<text top="512" left="89" width="98" height="11" font="25">Calcium channel </text>
<text top="528" left="115" width="41" height="11" font="25">blocker</text>
<text top="513" left="215" width="29" height="11" font="25">Beta </text>
<text top="528" left="208" width="41" height="11" font="25">blocker</text>
<text top="519" left="294" width="42" height="11" font="25">Digoxin</text>
<text top="552" left="385" width="16" height="11" font="25">No</text>
<text top="375" left="383" width="21" height="11" font="25">Yes</text>
<text top="404" left="368" width="55" height="11" font="25">Atropine* </text>
<text top="419" left="365" width="57" height="11" font="25">(Class IIa)</text>
<text top="751" left="248" width="21" height="11" font="25">Yes</text>
<text top="745" left="137" width="79" height="11" font="25">Acute Pacing </text>
<text top="760" left="144" width="60" height="11" font="25">Algorithm‡</text>
<text top="984" left="364" width="61" height="11" font="25">Continued </text>
<text top="999" left="360" width="64" height="11" font="25">symptoms?</text>
<text top="1035" left="381" width="21" height="11" font="25">Yes</text>
<text top="740" left="341" width="108" height="11" font="25">Severe symptoms/ </text>
<text top="755" left="345" width="101" height="11" font="25">hemodynamically </text>
<text top="770" left="370" width="47" height="11" font="25">unstable</text>
<text top="945" left="381" width="21" height="11" font="25">Yes</text>
<text top="324" left="367" width="57" height="11" font="25">Moderate </text>
<text top="339" left="337" width="113" height="11" font="25">or severe symptoms</text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="30" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 30 </text>
<text top="124" left="81" width="359" height="19" font="1">Colors correspond to Class of Recommendation in Table 2. </text>
<text top="142" left="81" width="398" height="19" font="1">See Sections 5.3. and 6.3. in the full-text guideline for discussion. </text>
<text top="161" left="81" width="394" height="19" font="1">*Atropine should not be given in patients after heart transplant. </text>
<text top="179" left="81" width="764" height="19" font="1">†In patients with drug toxicity and severe symptoms, preparation for pacing should proceed simultaneously with </text>
<text top="197" left="81" width="258" height="19" font="1">pharmacologic treatment of drug toxicity. </text>
<text top="216" left="81" width="206" height="19" font="1">‡Refer to Section 4.1.3., Figure 5. </text>
<text top="234" left="81" width="761" height="19" font="1">AADs indicates anti-arrhythmic drugs; AV, atrioventricular; BB, beta blocker; CCB, calcium channel blocker; COR, Class of </text>
<text top="252" left="81" width="760" height="19" font="1">Recommendation; ECG, electrocardiographic; H+P, history and physical examination; IMI, inferior myocardial infarction; IV, </text>
<text top="271" left="81" width="400" height="19" font="1">intravenous; PM, pacemaker; S/P, status post; and VS, vital signs. </text>
<text top="289" left="81" width="4" height="21" font="8"> </text>
<text top="318" left="81" width="4" height="21" font="8"> </text>
<text top="356" left="81" width="648" height="27" font="27"><b>4.1.1. Acute Management of Reversible Causes of Sinus Node Dysfunction </b></text>
<text top="391" left="97" width="729" height="21" font="7"><b>Recommendation for Acute Management of Reversible Causes for Bradycardia Attributable to Sinus Node </b></text>
<text top="411" left="418" width="86" height="21" font="7"><b>Dysfunction </b></text>
<text top="440" left="101" width="33" height="21" font="7"><b>COR </b></text>
<text top="440" left="170" width="30" height="21" font="7"><b>LOE </b></text>
<text top="440" left="466" width="126" height="21" font="7"><b>Recommendation </b></text>
<text top="478" left="113" width="8" height="21" font="7"><b>I </b></text>
<text top="478" left="167" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="468" left="225" width="609" height="21" font="7"><b>1.  In symptomatic patients presenting with sinus node dysfunction (SND), evaluation </b></text>
<text top="488" left="250" width="364" height="21" font="7"><b>and treatment of reversible causes is recommended. </b></text>
<text top="509" left="81" width="4" height="21" font="8"> </text>
<text top="538" left="81" width="535" height="21" font="7"><b>Table 7. Common Potentially Reversible or Treatable Causes of SND (S4.1.1-1) </b></text>
<text top="558" left="81" width="4" height="21" font="8"> </text>
<text top="580" left="89" width="364" height="19" font="1">Acute myocardial ischemia or infarction (S4.1.1-2–S4.1.1-4) </text>
<text top="599" left="89" width="163" height="19" font="1">Athletic training (S4.1.1-5) </text>
<text top="618" left="89" width="165" height="19" font="1">Atrial fibrillation (S4.1.1-6) </text>
<text top="637" left="89" width="98" height="19" font="1">Cardiac surgery </text>
<text top="655" left="114" width="714" height="20" font="1">•  Valve replacement (S4.1.1-7, S4.1.1-8), maze procedure (S4.1.1-7), coronary artery bypass graft (S4.1.1-9, S4.1.1-</text>
<text top="674" left="141" width="27" height="19" font="1">10)  </text>
<text top="693" left="89" width="103" height="19" font="1">Drugs or toxins* </text>
<text top="712" left="116" width="409" height="20" font="1">•  Toluene, organophosphates, tetrodotoxin, cocaine (S4.1.1-11) </text>
<text top="732" left="89" width="146" height="19" font="1">Electrolyte abnormality </text>
<text top="750" left="116" width="503" height="20" font="1">•  Hyperkalemia (S4.1.1-12), hypokalemia (S4.1.1-13), hypoglycemia (S4.1.1-14)  </text>
<text top="770" left="89" width="100" height="19" font="1">Heart transplant</text>
<text top="768" left="190" width="4" height="21" font="8"> </text>
<text top="770" left="194" width="494" height="19" font="1">(S4.1.1-15): Acute rejection, chronic rejection, remodeling (S4.1.1-16, S4.1.1-17)  </text>
<text top="789" left="89" width="97" height="19" font="1">Hypervagotonia</text>
<text top="787" left="186" width="4" height="21" font="8"> </text>
<text top="789" left="190" width="134" height="19" font="1">(S4.1.1-18, S4.1.1-19) </text>
<text top="808" left="89" width="83" height="19" font="1">Hypothermia </text>
<text top="826" left="116" width="586" height="20" font="1">•  Therapeutic (post-cardiac arrest cooling (S4.1.1-20)) or environmental exposure (S4.1.1-21) </text>
<text top="846" left="89" width="170" height="19" font="1">Hypothyroidism (S4.1.1-22) </text>
<text top="865" left="89" width="117" height="19" font="1">Hypovolemic shock</text>
<text top="863" left="207" width="4" height="21" font="8"> </text>
<text top="865" left="211" width="70" height="19" font="1">(S4.1.1-23) </text>
<text top="884" left="89" width="203" height="19" font="1">Hypoxemia, hypercarbia, acidosis</text>
<text top="882" left="293" width="4" height="21" font="8"> </text>
<text top="884" left="296" width="70" height="19" font="1">(S4.1.1-24) </text>
<text top="902" left="116" width="397" height="20" font="1">•  Sleep apnea, respiratory insufficiency (suffocation, drowning</text>
<text top="901" left="513" width="4" height="21" font="8"> </text>
<text top="903" left="517" width="111" height="19" font="1">(S4.1.1-25), stroke</text>
<text top="901" left="628" width="4" height="21" font="8"> </text>
<text top="903" left="632" width="169" height="19" font="1">(S4.1.1-26), drug overdose) </text>
<text top="922" left="89" width="131" height="19" font="1">Infection (S4.1.1-27)  </text>
<text top="941" left="116" width="501" height="20" font="1">•  Lyme disease (S4.1.1-28), legionella, psittacosis, typhoid fever, typhus, listeria</text>
<text top="940" left="617" width="4" height="21" font="8"> </text>
<text top="941" left="621" width="211" height="19" font="1">(S4.1.1-29), malaria, leptospirosis, </text>
<text top="960" left="143" width="401" height="19" font="1">Dengue fever, viral hemorrhagic fevers, Guillain-Barre (S4.1.1-30) </text>
<text top="979" left="89" width="86" height="19" font="1">Medications* </text>
<text top="997" left="116" width="716" height="20" font="1">•  Beta blockers, non-dihydropyridine calcium channel blockers, digoxin (S4.1.1-31), antiarrhythmic drugs, lithium </text>
<text top="1016" left="143" width="354" height="19" font="1">(S4.1.1-32), methyldopa, risperidone, cisplatin, interferon </text>
<text top="1035" left="81" width="75" height="19" font="1">*Partial list. </text>
<text top="1054" left="81" width="235" height="19" font="1">SND indicates sinus node dysfunction. </text>
<text top="1081" left="81" width="3" height="19" font="1"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="31" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 31 </text>
<text top="124" left="81" width="398" height="27" font="27"><b>4.1.2. Acute Medical Therapy for Bradycardia </b></text>
<text top="158" left="81" width="445" height="23" font="4"><b>4.1.2.1. Atropine and Beta-Agonists for Bradycardia to SND </b></text>
<text top="186" left="163" width="597" height="21" font="7"><b>Recommendations for Atropine and Beta-Agonists for Bradycardia Attributable to SND </b></text>
<text top="206" left="94" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="206" left="568" width="260" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 8, 9, 10, and </a></text>
<text top="226" left="449" width="17" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">11</a></text>
<text top="226" left="465" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="254" left="101" width="33" height="21" font="7"><b>COR </b></text>
<text top="254" left="174" width="30" height="21" font="7"><b>LOE </b></text>
<text top="254" left="466" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="293" left="107" width="21" height="21" font="7"><b>IIa </b></text>
<text top="293" left="171" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="283" left="232" width="604" height="21" font="7"><b>1.  In patients with SND  associated  with symptoms or hemodynamic compromise, </b></text>
<text top="303" left="259" width="469" height="21" font="7"><b>atropine is reasonable to increase sinus rate</b> <b>(S4.1.2.1-1–S4.1.2.1-4). </b></text>
<text top="354" left="107" width="21" height="21" font="7"><b>IIb </b></text>
<text top="354" left="171" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="324" left="231" width="601" height="21" font="7"><b>2.  In patients with SND associated with symptoms or hemodynamic compromise who </b></text>
<text top="344" left="258" width="574" height="21" font="7"><b>are at low likelihood of coronary ischemia, isoproterenol, dopamine, dobutamine, </b></text>
<text top="364" left="258" width="576" height="21" font="7"><b>or epinephrine may be considered to increase heart rate and improve symptoms </b></text>
<text top="384" left="258" width="167" height="21" font="7"><b>(S4.1.2.1-5–S4.1.2.1-11).</b></text>
<text top="383" left="425" width="4" height="23" font="4"><b> </b></text>
<text top="415" left="107" width="21" height="21" font="7"><b>III: </b></text>
<text top="435" left="97" width="42" height="21" font="7"><b>Harm </b></text>
<text top="425" left="171" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="405" left="231" width="602" height="21" font="7"><b>3.  In patients who have undergone heart transplant without evidence for autonomic </b></text>
<text top="425" left="258" width="574" height="21" font="7"><b>reinnervation, atropine should not be used to treat sinus bradycardia</b> <b>(S4.1.2.1-12, </b></text>
<text top="445" left="258" width="90" height="21" font="7"><b>S4.1.2.1-13). </b></text>
<text top="466" left="81" width="4" height="21" font="8"> </text>
<text top="495" left="81" width="670" height="21" font="7"><b>Table 8. Acute Medical Management of Bradycardia Attributable to SND or Atrioventricular Block</b> </text>
<text top="516" left="81" width="4" height="21" font="8"> </text>
<text top="536" left="89" width="74" height="19" font="0"><b>Medication </b></text>
<text top="536" left="219" width="49" height="19" font="0"><b>Dosage </b></text>
<text top="536" left="563" width="71" height="19" font="0"><b>Comments </b></text>
<text top="556" left="89" width="344" height="19" font="1">Symptomatic sinus bradycardia or atrioventricular block </text>
<text top="575" left="89" width="57" height="19" font="1">Atropine </text>
<text top="575" left="219" width="335" height="19" font="1">0.5-1 mg IV (may be repeated every 3-5 min to a </text>
<text top="593" left="219" width="300" height="19" font="1">maximum dose of 3 mg) (S4.1.2.4-8–S4.1.2.4-12) </text>
<text top="575" left="563" width="3" height="19" font="1"> </text>
<text top="612" left="89" width="66" height="19" font="1">Dopamine </text>
<text top="612" left="219" width="332" height="19" font="1">5 to 20 mcg/kg/min IV. starting at 5 mcg/kg/min and </text>
<text top="631" left="219" width="328" height="19" font="1">increasing by 5 mcg/kg/min every 2 min (S4.1.2.4-13) </text>
<text top="612" left="563" width="271" height="19" font="1">Dosages of &gt;20 mcg/kg/min  may result in </text>
<text top="631" left="563" width="197" height="19" font="1">vasoconstriction or arrhythmias </text>
<text top="649" left="89" width="86" height="19" font="1">Isoproterenol </text>
<text top="649" left="219" width="333" height="19" font="1">20-60 mcg IV bolus followed doses of 10-20 mcg, or </text>
<text top="668" left="219" width="339" height="19" font="1">infusion of 1-20 mcg/min based on heart rate </text>
<text top="686" left="219" width="216" height="19" font="1">response (S4.1.2.4-14–S4.1.2.4-20) </text>
<text top="649" left="563" width="278" height="19" font="1">Monitor for potential development of </text>
<text top="668" left="563" width="122" height="19" font="1">ischemic chest pain </text>
<text top="705" left="89" width="77" height="19" font="1">Epinephrine </text>
<text top="705" left="219" width="332" height="19" font="1">2-10 mcg/min IV or 0.1-0.5 mcg/kg/min IV titrated to </text>
<text top="724" left="219" width="84" height="19" font="1">desired effect</text>
<text top="722" left="303" width="4" height="21" font="8"> </text>
<text top="724" left="306" width="157" height="19" font="1">(S4.1.2.4-19, S4.1.2.4-21) </text>
<text top="705" left="563" width="3" height="19" font="1"> </text>
<text top="742" left="89" width="487" height="19" font="1">Second- or third-degree atrioventricular block associated with acute inferior MI </text>
<text top="762" left="89" width="92" height="19" font="1">Aminophylline </text>
<text top="762" left="219" width="102" height="19" font="1">250-mg IV bolus </text>
<text top="762" left="563" width="3" height="19" font="1"> </text>
<text top="781" left="89" width="211" height="19" font="1">Calcium channel blocker overdose </text>
<text top="800" left="89" width="154" height="19" font="1">10% calcium </text>
<text top="818" left="89" width="53" height="19" font="1">chloride </text>
<text top="800" left="219" width="332" height="19" font="1">1-2 g IV every 10-20 min or an infusion of 0.2-0.4 </text>
<text top="818" left="219" width="212" height="19" font="1">mL/kg/h (S4.1.2.4-22–S4.1.2.4-24) </text>
<text top="800" left="563" width="3" height="19" font="1"> </text>
<text top="837" left="89" width="154" height="19" font="1">10% calcium </text>
<text top="855" left="89" width="63" height="19" font="1">gluconate </text>
<text top="837" left="219" width="332" height="19" font="1">3-6 g IV every 10-20 min or an infusion at 0.6-1.2 </text>
<text top="855" left="219" width="212" height="19" font="1">mL/kg/h (S4.1.2.4-22–S4.1.2.4-24) </text>
<text top="837" left="563" width="3" height="19" font="1"> </text>
<text top="874" left="89" width="307" height="19" font="1">Beta-blocker or calcium channel blocker overdose </text>
<text top="894" left="89" width="61" height="19" font="1">Glucagon </text>
<text top="894" left="219" width="332" height="19" font="1">3-10 mg IV with infusion of 3-5 mg/h (S4.1.2.4-25, </text>
<text top="912" left="219" width="76" height="19" font="1">S4.1.2.4-26) </text>
<text top="894" left="563" width="3" height="19" font="1"> </text>
<text top="931" left="89" width="121" height="19" font="1">High dose insulin </text>
<text top="949" left="89" width="51" height="19" font="1">therapy </text>
<text top="931" left="219" width="334" height="19" font="1">IV bolus of 1 unit/kg followed by an infusion of 0.5 </text>
<text top="949" left="219" width="303" height="19" font="1">units/kg/h (S4.1.2.4-24, S4.1.2.4-27, S4.1.2.4-28). </text>
<text top="931" left="563" width="224" height="19" font="1">Follow glucose and potassium levels </text>
<text top="968" left="89" width="109" height="19" font="1">Digoxin overdose </text>
<text top="987" left="89" width="127" height="19" font="1">Digoxin antibody </text>
<text top="1006" left="89" width="60" height="19" font="1">fragment </text>
<text top="987" left="219" width="334" height="19" font="1">Dosage is dependent on amount ingested or known </text>
<text top="1006" left="219" width="293" height="19" font="1">digoxin concentration (S4.1.2.4-29–S4.1.2.4-36) </text>
<text top="988" left="566" width="268" height="20" font="1">•  One vial binds approximately 0.5 mg of </text>
<text top="1006" left="583" width="51" height="19" font="1">digoxin. </text>
<text top="1025" left="566" width="212" height="20" font="1">•  Administer over at least 30 min </text>
<text top="1044" left="566" width="125" height="20" font="1">•  May be repeated </text>
<text top="1064" left="89" width="133" height="19" font="1">Post-heart transplant </text>
<text top="1083" left="89" width="92" height="19" font="1">Aminophylline </text>
<text top="1083" left="219" width="301" height="19" font="1">6 mg/kg in 100-200 mL of IV fluid over 20-30 min </text>
<text top="1083" left="563" width="3" height="19" font="1"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="32" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 32 </text>
<text top="125" left="89" width="82" height="19" font="1">Theophylline </text>
<text top="125" left="219" width="335" height="19" font="1">300 mg IV, followed by oral dose of 5-10 mg/kg/d </text>
<text top="143" left="219" width="108" height="19" font="1">titrated to effect  </text>
<text top="125" left="568" width="261" height="20" font="1">•  Therapeutic serum levels range from 10-</text>
<text top="144" left="583" width="71" height="19" font="1">20 mcg/mL </text>
<text top="162" left="568" width="269" height="20" font="1">•  Usual posttransplant dosages average </text>
<text top="181" left="583" width="115" height="19" font="1">450 mg±100 mg/d </text>
<text top="201" left="89" width="109" height="19" font="1">Spinal cord injury </text>
<text top="220" left="89" width="92" height="19" font="1">Aminophylline </text>
<text top="220" left="219" width="335" height="19" font="1">6  mg/kg in 100-200 mL of IV fluid over 20-30 min </text>
<text top="238" left="219" width="73" height="19" font="1">(S4.1.2.4-7) </text>
<text top="220" left="563" width="3" height="19" font="1"> </text>
<text top="257" left="89" width="82" height="19" font="1">Theophylline </text>
<text top="257" left="219" width="328" height="19" font="1">Oral dose of 5-10 mg/kg/d titrated to effect (S4.1.2.4-</text>
<text top="275" left="219" width="16" height="19" font="1">6) </text>
<text top="257" left="563" width="275" height="19" font="1">Effective dosages often result in serum </text>
<text top="275" left="563" width="266" height="19" font="1">levels below the usual effective range of 10-</text>
<text top="294" left="563" width="71" height="19" font="1">20 mcg/mL </text>
<text top="313" left="81" width="521" height="19" font="1">IV indicates intravenous; MI, myocardial infarction; and SND, sinus node dysfunction. </text>
<text top="340" left="81" width="4" height="21" font="8"> </text>
<text top="369" left="81" width="4" height="21" font="8"> </text>
<text top="389" left="81" width="760" height="23" font="4"><b>4.1.2.2. Therapy of Beta Blocker and Calcium Channel Blocker Mediated Bradycardia Attributable</b> <b>to </b></text>
<text top="411" left="81" width="223" height="23" font="4"><b>SND or Atrioventricular Block </b></text>
<text top="438" left="120" width="683" height="21" font="7"><b>Recommendations for Therapy of Beta-Blocker and Calcium Channel Blocker Mediated Bradycardia </b></text>
<text top="458" left="128" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="458" left="602" width="185" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 12</a></text>
<text top="458" left="786" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="483" left="100" width="33" height="21" font="7"><b>COR </b></text>
<text top="483" left="172" width="30" height="21" font="7"><b>LOE </b></text>
<text top="483" left="465" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="529" left="106" width="21" height="21" font="7"><b>IIa </b></text>
<text top="529" left="170" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="509" left="231" width="611" height="21" font="7"><b>1.  In patients with bradycardia associated with symptoms or hemodynamic </b></text>
<text top="529" left="258" width="576" height="21" font="7"><b>compromise because of calcium channel blocker overdose, intravenous calcium is </b></text>
<text top="549" left="258" width="559" height="21" font="7"><b>reasonable to increase heart rate and improve symptoms</b> <b>(S4.1.2.2-1–S4.1.2.2-3). </b></text>
<text top="590" left="106" width="21" height="21" font="7"><b>IIa </b></text>
<text top="590" left="170" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="570" left="231" width="610" height="21" font="7"><b>2.  In patients with bradycardia associated with symptoms or hemodynamic </b></text>
<text top="590" left="258" width="574" height="21" font="7"><b>compromise because of beta-blocker or calcium channel blocker overdose, glucagon </b></text>
<text top="610" left="258" width="573" height="21" font="7"><b>is reasonable to increase heart rate and improve symptoms (S4.1.2.2-4, S4.1.2.2-5). </b></text>
<text top="661" left="106" width="21" height="21" font="7"><b>IIa </b></text>
<text top="661" left="170" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="631" left="231" width="611" height="21" font="7"><b>3.  In patients with  bradycardia associated with symptoms or hemodynamic </b></text>
<text top="651" left="258" width="577" height="21" font="7"><b>compromise  because of beta-blocker or calcium channel blocker overdose, high </b></text>
<text top="671" left="258" width="574" height="21" font="7"><b>dose insulin therapy is reasonable to increase heart rate and improve symptoms</b> </text>
<text top="692" left="258" width="166" height="21" font="7"><b>(S4.1.2.2-6, S4.1.2.2-7).  </b></text>
<text top="712" left="81" width="4" height="21" font="8"> </text>
<text top="742" left="81" width="4" height="21" font="8"> </text>
<text top="763" left="81" width="4" height="21" font="8"> </text>
<text top="762" left="297" width="4" height="23" font="4"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="33" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 33 </text>
<text top="124" left="81" width="760" height="23" font="4"><b>4.1.2.3. Therapy of Digoxin Mediated Bradycardia Attributable to Either SND or Atrioventricular Block </b></text>
<text top="151" left="103" width="715" height="21" font="7"><b>Recommendations for Therapy of Digoxin Mediated Bradycardia Attributable to SND or Atrioventricular </b></text>
<text top="171" left="440" width="41" height="21" font="7"><b>Block </b></text>
<text top="191" left="98" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="191" left="572" width="252" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 13, 14, and </a></text>
<text top="212" left="449" width="17" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">15</a></text>
<text top="212" left="465" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="240" left="100" width="33" height="21" font="7"><b>COR </b></text>
<text top="240" left="172" width="30" height="21" font="7"><b>LOE </b></text>
<text top="240" left="465" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="288" left="106" width="21" height="21" font="7"><b>IIa </b></text>
<text top="288" left="170" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="268" left="231" width="610" height="21" font="7"><b>1.  In patients with bradycardia  associated with symptoms or hemodynamic </b></text>
<text top="288" left="258" width="575" height="21" font="7"><b>compromise in the setting of digoxin toxicity, digoxin Fab antibody  fragment  is </b></text>
<text top="308" left="258" width="559" height="21" font="7"><b>reasonable to increase heart rate and improve symptoms</b> <b>(S4.1.2.3-1–S4.1.2.3-8). </b></text>
<text top="339" left="94" width="45" height="21" font="7"><b>III: No </b></text>
<text top="359" left="90" width="53" height="21" font="7"><b>Benefit </b></text>
<text top="349" left="170" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="329" left="231" width="610" height="21" font="7"><b>2.  In patients with bradycardia  associated with symptoms or hemodynamic </b></text>
<text top="349" left="258" width="580" height="21" font="7"><b>compromise  attributable  to digoxin toxicity, dialysis is not recommended for </b></text>
<text top="369" left="258" width="218" height="21" font="7"><b>removal of digoxin</b> <b>(S4.1.2.3-9). </b></text>
<text top="390" left="81" width="4" height="21" font="8"> </text>
<text top="420" left="81" width="4" height="21" font="8"> </text>
<text top="440" left="81" width="565" height="23" font="4"><b>4.1.2.4. Aminophylline or Theophylline for Bradycardia Attributable to SND </b></text>
<text top="467" left="159" width="604" height="21" font="7"><b>Recommendations for Theophylline/Aminophylline for Bradycardia Attributable to SND</b> </text>
<text top="487" left="100" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="487" left="574" width="240" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 16 and 17</a></text>
<text top="487" left="814" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="515" left="100" width="33" height="21" font="7"><b>COR </b></text>
<text top="515" left="172" width="30" height="21" font="7"><b>LOE </b></text>
<text top="515" left="465" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="554" left="106" width="21" height="21" font="7"><b>IIa </b></text>
<text top="554" left="170" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="544" left="231" width="601" height="21" font="7"><b>1.  In post-heart transplant patients, aminophylline or theophylline is reasonable  to </b></text>
<text top="564" left="258" width="439" height="21" font="7"><b>increase heart rate if clinically indicated</b> <b>(S4.1.2.4-1–S4.1.2.4-4). </b></text>
<text top="605" left="106" width="21" height="21" font="7"><b>IIa </b></text>
<text top="605" left="170" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="585" left="231" width="601" height="21" font="7"><b>2.  In patients with SND associated with symptoms or hemodynamic compromise in the </b></text>
<text top="605" left="258" width="575" height="21" font="7"><b>setting of acute spinal cord injury, aminophylline or theophylline is reasonable to </b></text>
<text top="625" left="258" width="465" height="21" font="7"><b>increase heart rate and improve symptoms (S4.1.2.4-5–S4.1.2.4-7).  </b></text>
<text top="646" left="81" width="4" height="21" font="8"> </text>
<text top="675" left="81" width="4" height="21" font="8"> </text>
<text top="713" left="81" width="533" height="27" font="26"><i><b>4.1.3. Temporary Pacing for Bradycardia Attributable to SND </b></i></text>
<text top="749" left="195" width="532" height="21" font="7"><b>Recommendations for Temporary Pacing for Bradycardia Attributable</b> <b>to SND </b></text>
<text top="769" left="100" width="474" height="21" font="8">Referenced studies that support recommendations are summarized i<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">n </a></text>
<text top="769" left="574" width="248" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 18, 19, 20, </a></text>
<text top="789" left="434" width="46" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">and 21</a></text>
<text top="789" left="480" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="817" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="817" left="208" width="30" height="21" font="7"><b>LOE </b></text>
<text top="817" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="876" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="876" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="846" left="276" width="561" height="21" font="7"><b>1.  In patients with persistent hemodynamically unstable SND  refractory to </b></text>
<text top="866" left="303" width="533" height="21" font="7"><b>medical therapy, temporary transvenous pacing is reasonable  to increase </b></text>
<text top="886" left="303" width="530" height="21" font="7"><b>heart rate and improve symptoms until a permanent pacemaker is placed or </b></text>
<text top="906" left="303" width="317" height="21" font="7"><b>the bradycardia resolves</b> <b>(S4.1.3-1–S4.1.3-15). </b></text>
<text top="957" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="957" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="927" left="276" width="558" height="21" font="7"><b>2.  In patients with SND with severe symptoms or hemodynamic compromise, </b></text>
<text top="947" left="304" width="530" height="21" font="7"><b>temporary transcutaneous pacing may be considered to increase heart rate </b></text>
<text top="967" left="304" width="535" height="21" font="7"><b>and improve symptoms until a temporary  transvenous  or permanent </b></text>
<text top="987" left="304" width="490" height="21" font="7"><b>pacemaker is placed or the bradycardia resolves (S4.1.3-16–S4.1.3-21).  </b></text>
<text top="1038" left="98" width="63" height="21" font="7"><b>III: Harm </b></text>
<text top="1038" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="1008" left="276" width="560" height="21" font="7"><b>3.  In patients with SND  with minimal  and/or infrequent symptoms without </b></text>
<text top="1028" left="304" width="529" height="21" font="7"><b>hemodynamic compromise, temporary  transcutaneous or  transvenous </b></text>
<text top="1048" left="304" width="525" height="21" font="7"><b>pacing should not be performed</b> <b>(S4.1.3-1, S4.1.3-2, S4.1.3-8, S4.1.3-9, S4.1.3-</b></text>
<text top="1069" left="304" width="244" height="21" font="7"><b>11, S4.1.3-12, S4.1.3-14, S4.1.3-22). </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="34" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="30" size="17" family="Times" color="#000000"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 34 </text>
<text top="124" left="81" width="223" height="21" font="7"><b>Figure 5. Acute Pacing Algorithm</b></text>
<text top="125" left="304" width="3" height="19" font="0"><b> </b></text>
<text top="144" left="81" width="3" height="19" font="1"> </text>
<text top="952" left="817" width="3" height="19" font="1"> </text>
<text top="967" left="81" width="3" height="19" font="1"> </text>
<text top="985" left="81" width="359" height="19" font="1">Colors correspond to Class of Recommendation in Table 2. </text>
<text top="1003" left="81" width="398" height="19" font="1">See Sections 5.4. and 6.3. in the full-text guideline for discussion. </text>
<text top="1022" left="81" width="676" height="19" font="1">*Refer to Section 4.3.4.1., Figure 6 for chronic SND and Section 5.3., Figure 7 for chronic atrioventricular block  </text>
<text top="1040" left="81" width="696" height="19" font="1">†Careful management of anesthesia to avoid or minimize the use of drugs associated with bradycardia is required.</text>
<text top="1038" left="777" width="4" height="21" font="8"> </text>
<text top="1067" left="81" width="4" height="21" font="8"> </text>
<text top="670" left="564" width="97" height="18" font="30">Prolonged </text>
<text top="694" left="532" width="161" height="18" font="30">temporary pacing </text>
<text top="718" left="576" width="66" height="18" font="30">needed</text>
<text top="777" left="545" width="34" height="18" font="30">Yes</text>
<text top="853" left="450" width="115" height="18" font="30">Externalized </text>
<text top="877" left="458" width="102" height="18" font="30">permanent </text>
<text top="901" left="454" width="108" height="18" font="30">pacing lead </text>
<text top="925" left="460" width="91" height="18" font="30">(Class IIa)</text>
<text top="186" left="216" width="222" height="18" font="30">Hemodynamic instability </text>
<text top="210" left="219" width="211" height="18" font="30">despite  medical therapy</text>
<text top="495" left="99" width="150" height="18" font="30">Transcutaneous </text>
<text top="519" left="93" width="155" height="18" font="30">pacing (Class IIb)</text>
<text top="305" left="286" width="80" height="18" font="30">Critically </text>
<text top="329" left="287" width="81" height="18" font="30">ill due to </text>
<text top="353" left="272" width="111" height="18" font="30">bradycardia </text>
<text top="406" left="206" width="34" height="18" font="30">Yes</text>
<text top="406" left="383" width="26" height="18" font="30">No</text>
<text top="606" left="385" width="34" height="18" font="30">Yes</text>
<text top="606" left="526" width="26" height="18" font="30">No</text>
<text top="776" left="667" width="26" height="18" font="30">No</text>
<text top="666" left="259" width="174" height="18" font="30">Implant Permanent </text>
<text top="690" left="284" width="118" height="18" font="30">pacemaker*†</text>
<text top="853" left="678" width="102" height="18" font="30">Temporary </text>
<text top="877" left="672" width="115" height="18" font="30">transvenous </text>
<text top="901" left="676" width="107" height="18" font="30">pacing wire </text>
<text top="925" left="681" width="91" height="18" font="30">(Class IIa)</text>
<text top="471" left="419" width="103" height="18" font="30">Permanent </text>
<text top="495" left="356" width="230" height="18" font="30">pacemaker indicated and </text>
<text top="519" left="370" width="199" height="18" font="30">capability immediately </text>
<text top="543" left="429" width="78" height="18" font="30">available</text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="35" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 35 </text>
<text top="133" left="81" width="663" height="29" font="19"><b>4.2. Chronic Therapy/Management of Bradycardia Attributable to SND </b></text>
<text top="178" left="81" width="761" height="27" font="26"><i><b>4.2.1. General Principles of Chronic Therapy/Management of Bradycardia Attributable </b></i></text>
<text top="204" left="81" width="65" height="27" font="26"><i><b>to SND </b></i></text>
<text top="239" left="98" width="726" height="21" font="7"><b>Recommendations for General Principles of Chronic Therapy/Management of Bradycardia Attributable to </b></text>
<text top="259" left="444" width="33" height="21" font="7"><b>SND </b></text>
<text top="280" left="109" width="33" height="21" font="7"><b>COR </b></text>
<text top="280" left="194" width="30" height="21" font="7"><b>LOE </b></text>
<text top="280" left="479" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="321" left="94" width="63" height="21" font="7"><b>III: Harm </b></text>
<text top="321" left="192" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="301" left="259" width="576" height="21" font="7"><b>1.  In asymptomatic individuals with sinus bradycardia or sinus pauses that are </b></text>
<text top="321" left="284" width="549" height="21" font="7"><b>secondary to physiologically elevated parasympathetic tone, permanent pacing </b></text>
<text top="341" left="284" width="312" height="21" font="7"><b>should not be performed (S4.2.1-1–S4.2.1-7). </b></text>
<text top="382" left="94" width="63" height="21" font="7"><b>III: Harm </b></text>
<text top="382" left="192" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="362" left="258" width="580" height="21" font="7"><b>2.  In patients with sleep-related sinus bradycardia or transient sinus pauses </b></text>
<text top="382" left="282" width="550" height="21" font="7"><b>occurring during sleep, permanent pacing should not be performed unless other </b></text>
<text top="403" left="282" width="374" height="21" font="7"><b>indications for pacing are present (S4.2.1-1–S4.2.1-7).  </b></text>
<text top="444" left="94" width="63" height="21" font="7"><b>III: Harm </b></text>
<text top="444" left="192" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="423" left="258" width="576" height="21" font="7"><b>3.  In patients with asymptomatic SND, or in those in whom the symptoms have </b></text>
<text top="444" left="282" width="555" height="21" font="7"><b>been documented to occur in the absence of bradycardia or chronotropic </b></text>
<text top="464" left="282" width="546" height="21" font="7"><b>incompetence, permanent pacing should not be performed (S4.2.1-5–S4.2.1-7). </b></text>
<text top="485" left="81" width="4" height="21" font="8"> </text>
<text top="523" left="81" width="761" height="27" font="26"><i><b>4.2.2. Transient/Reversible Causes (Including Medications) of Bradycardia Attributable </b></i></text>
<text top="549" left="81" width="65" height="27" font="26"><i><b>to SND </b></i></text>
<text top="584" left="216" width="490" height="21" font="7"><b>Recommendation for Transient/Reversible Causes of Sinus Bradycardia </b></text>
<text top="605" left="107" width="33" height="21" font="7"><b>COR </b></text>
<text top="605" left="193" width="30" height="21" font="7"><b>LOE </b></text>
<text top="605" left="482" width="126" height="21" font="7"><b>Recommendation </b></text>
<text top="646" left="120" width="8" height="21" font="7"><b>I </b></text>
<text top="646" left="189" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="626" left="258" width="578" height="21" font="7"><b>1.  Patients presenting with symptomatic  SND  secondary to a reversible cause </b></text>
<text top="646" left="283" width="550" height="21" font="7"><b>should first be managed by directing the therapy at eliminating or mitigating the </b></text>
<text top="666" left="283" width="143" height="21" font="7"><b>offending condition. </b></text>
<text top="687" left="81" width="4" height="21" font="8"> </text>
<text top="725" left="81" width="527" height="27" font="26"><i><b>4.2.3. Additional Testing of Bradycardia Attributable to SND </b></i></text>
<text top="760" left="197" width="527" height="21" font="7"><b>Recommendations for Additional Testing of Bradycardia Attributable</b> <b>to SND </b></text>
<text top="781" left="107" width="33" height="21" font="7"><b>COR </b></text>
<text top="781" left="193" width="30" height="21" font="7"><b>LOE </b></text>
<text top="781" left="479" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="822" left="113" width="21" height="21" font="7"><b>IIb </b></text>
<text top="822" left="189" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="802" left="258" width="585" height="21" font="7"><b>1.  In patients with symptoms suggestive of bradycardia (e.g., syncope, </b></text>
<text top="822" left="282" width="550" height="21" font="7"><b>lightheadedness)  who are also  undergoing an EPS  for another indication, </b></text>
<text top="842" left="282" width="494" height="21" font="7"><b>evaluation of sinus node function as part of the EPS may be considered. </b></text>
<text top="883" left="113" width="21" height="21" font="7"><b>IIb </b></text>
<text top="883" left="189" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="863" left="258" width="576" height="21" font="7"><b>2.  In symptomatic patients with suspected SND, EPS for the assessment of sinus </b></text>
<text top="883" left="282" width="552" height="21" font="7"><b>node function may be considered when the diagnosis remains uncertain after </b></text>
<text top="904" left="282" width="352" height="21" font="7"><b>initial noninvasive evaluations</b> <b>(S4.2.3-1–S4.2.3-5).  </b></text>
<text top="935" left="101" width="45" height="21" font="7"><b>III: No </b></text>
<text top="955" left="97" width="53" height="21" font="7"><b>Benefit </b></text>
<text top="945" left="190" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="924" left="258" width="581" height="21" font="7"><b>3.  In patients with asymptomatic sinus bradycardia, an EPS  should not be </b></text>
<text top="945" left="282" width="547" height="21" font="7"><b>performed unless other indications for electrophysiological testing exist (S4.2.3-</b></text>
<text top="965" left="282" width="85" height="21" font="7"><b>6, S4.2.3-7). </b></text>
<text top="986" left="81" width="4" height="21" font="8"> </text>
<text top="1006" left="81" width="4" height="21" font="8"> </text>
<text top="1006" left="297" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="36" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 36 </text>
<text top="124" left="81" width="761" height="27" font="26"><i><b>4.3.4. Permanent Pacing for Chronic Therapy/Management of Bradycardia Attributable </b></i></text>
<text top="149" left="81" width="65" height="27" font="26"><i><b>to SND </b></i></text>
<text top="185" left="95" width="732" height="21" font="7"><b>Recommendations for Permanent Pacing for Chronic Therapy/Management of Bradycardia Attributable</b> <b>to </b></text>
<text top="205" left="444" width="33" height="21" font="7"><b>SND</b> </text>
<text top="225" left="100" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="225" left="574" width="240" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 24 and 25</a></text>
<text top="225" left="814" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="246" left="105" width="33" height="21" font="7"><b>COR </b></text>
<text top="246" left="182" width="30" height="21" font="7"><b>LOE </b></text>
<text top="246" left="470" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="277" left="117" width="8" height="21" font="7"><b>I </b></text>
<text top="277" left="179" width="35" height="21" font="7"><b>C-LD</b> </text>
<text top="267" left="240" width="592" height="21" font="7"><b>1.  In patients with symptoms that are directly attributable to SND, permanent pacing </b></text>
<text top="287" left="265" width="535" height="21" font="7"><b>is indicated to increase heart rate and improve symptoms (S4.3.4-1, S4.3.4-2). </b></text>
<text top="338" left="117" width="8" height="21" font="7"><b>I </b></text>
<text top="338" left="179" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="308" left="240" width="596" height="21" font="7"><b>2.  In patients who develop symptomatic sinus bradycardia as a consequence of </b></text>
<text top="328" left="265" width="571" height="21" font="7"><b>guideline-directed management and therapy  for which there is no alternative </b></text>
<text top="348" left="265" width="567" height="21" font="7"><b>treatment  and continued treatment is clinically necessary, permanent pacing  is </b></text>
<text top="368" left="265" width="425" height="21" font="7"><b>recommended to increase heart rate and improve symptoms. </b></text>
<text top="409" left="111" width="21" height="21" font="7"><b>IIa </b></text>
<text top="409" left="179" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="389" left="240" width="592" height="21" font="7"><b>3.  For patients with tachy-brady syndrome  and symptoms attributable  to </b></text>
<text top="409" left="265" width="570" height="21" font="7"><b>bradycardia, permanent pacing is reasonable  to increase heart rate and reduce </b></text>
<text top="429" left="265" width="287" height="21" font="7"><b>symptoms attributable to hypoperfusion. </b></text>
<text top="470" left="111" width="21" height="21" font="7"><b>IIa </b></text>
<text top="470" left="179" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="450" left="240" width="592" height="21" font="7"><b>4.  In patients with symptomatic chronotropic incompetence, permanent pacing with </b></text>
<text top="470" left="265" width="568" height="21" font="7"><b>rate-responsive programming is reasonable to increase exertional heart rates and </b></text>
<text top="491" left="265" width="140" height="21" font="7"><b>improve symptoms. </b></text>
<text top="532" left="111" width="21" height="21" font="7"><b>IIb </b></text>
<text top="532" left="179" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="512" left="240" width="596" height="21" font="7"><b>5.  In patients with symptoms that are likely attributable  to  SND, a trial of oral </b></text>
<text top="532" left="265" width="569" height="21" font="7"><b>theophylline may be considered to increase heart rate, improve symptoms, and </b></text>
<text top="552" left="265" width="535" height="21" font="7"><b>help determine the potential effects of permanent pacing (S4.3.4-3, S4.3.4-4). </b></text>
<text top="573" left="81" width="4" height="21" font="8"> </text>
<text top="593" left="81" width="4" height="21" font="8"> </text>
<text top="632" left="81" width="760" height="23" font="4"><b>4.3.4.1. Permanent Pacing Techniques and Methods for Chronic Therapy/Management of Bradycardia </b></text>
<text top="654" left="81" width="152" height="23" font="4"><b>Attributable to SND </b></text>
<text top="681" left="102" width="717" height="21" font="7"><b>Recommendations for Permanent Pacing Techniques and Methods for Chronic Therapy/Management of </b></text>
<text top="701" left="348" width="225" height="21" font="7"><b>Bradycardia Attributable</b> <b>to SND</b> </text>
<text top="722" left="128" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="722" left="602" width="185" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 25</a></text>
<text top="722" left="786" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="742" left="105" width="33" height="21" font="7"><b>COR </b></text>
<text top="742" left="182" width="30" height="21" font="7"><b>LOE </b></text>
<text top="742" left="470" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="773" left="117" width="8" height="21" font="7"><b>I </b></text>
<text top="773" left="183" width="27" height="21" font="7"><b>B-R </b></text>
<text top="763" left="240" width="592" height="21" font="7"><b>1.  In symptomatic patients with SND, atrial-based pacing is recommended over single </b></text>
<text top="783" left="266" width="353" height="21" font="7"><b>chamber ventricular pacing (S4.3.4.1-1–S4.3.4.1-4). </b></text>
<text top="825" left="117" width="8" height="21" font="7"><b>I </b></text>
<text top="825" left="183" width="27" height="21" font="7"><b>B-R </b></text>
<text top="804" left="240" width="593" height="21" font="7"><b>2.  In symptomatic patients with SND and intact atrioventricular conduction without </b></text>
<text top="825" left="265" width="571" height="21" font="7"><b>evidence of conduction abnormalities, dual chamber or single chamber atrial </b></text>
<text top="845" left="265" width="253" height="21" font="7"><b>pacing is recommended (S4.3.4.1-5). </b></text>
<text top="886" left="111" width="21" height="21" font="7"><b>IIa </b></text>
<text top="886" left="183" width="27" height="21" font="7"><b>B-R </b></text>
<text top="866" left="240" width="592" height="21" font="7"><b>3.  In symptomatic patients with SND who have dual chamber pacemakers and intact </b></text>
<text top="886" left="265" width="574" height="21" font="7"><b>atrioventricular  conduction, it is reasonable to program the dual chamber </b></text>
<text top="906" left="265" width="377" height="21" font="7"><b>pacemaker to minimize ventricular pacing (S4.3.4.1-6). </b></text>
<text top="957" left="111" width="21" height="21" font="7"><b>IIa </b></text>
<text top="957" left="179" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="927" left="240" width="595" height="21" font="7"><b>4.  In symptomatic patients with SND  in which frequent ventricular pacing is not </b></text>
<text top="947" left="265" width="569" height="21" font="7"><b>expected or the patient has significant comorbidities that are otherwise likely to </b></text>
<text top="967" left="265" width="568" height="21" font="7"><b>determine the survival and clinical outcomes, single chamber ventricular pacing is </b></text>
<text top="987" left="265" width="88" height="21" font="7"><b>reasonable.  </b></text>
<text top="1008" left="81" width="4" height="21" font="8"> </text>
<text top="1028" left="81" width="4" height="21" font="7"><b> </b></text>
<text top="1028" left="297" width="4" height="21" font="7"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="37" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 37 </text>
<text top="124" left="81" width="320" height="21" font="7"><b>Figure 6. Chronic SND Management Algorithm </b></text>
<text top="972" left="826" width="4" height="21" font="8"> </text>
<text top="997" left="81" width="362" height="19" font="1">Colors correspond to Class of Recommendation in Table 2.  </text>
<text top="1015" left="81" width="397" height="19" font="1">See Sections 4.3. and 5.5. in the full text guideline for discussion. </text>
<text top="1034" left="81" width="536" height="19" font="1">Dashed lines indicate possible optional strategies based on the specific clinical situation.</text>
<text top="1052" left="81" width="728" height="19" font="1">*Symptomatic patients with very infrequent need for pacing for rate support or patients with significant comorbidities. </text>
<text top="1070" left="81" width="761" height="19" font="1">AV indicates atrioventricular; GDMT, guideline-directed management and therapy; PPM, permanent pacemaker; and RV, </text>
<text top="1089" left="81" width="105" height="19" font="1">right ventricular. </text>
<text top="155" left="429" width="154" height="14" font="1">Sinus node dysfunction</text>
<text top="404" left="366" width="25" height="14" font="1">Yes</text>
<text top="404" left="558" width="143" height="14" font="1">No (or asymptomatic)</text>
<text top="477" left="204" width="121" height="14" font="1">Permanent pacing</text>
<text top="495" left="234" width="60" height="14" font="1"> (Class I)</text>
<text top="477" left="450" width="112" height="14" font="1">Oral theophylline</text>
<text top="495" left="472" width="68" height="14" font="1">(Class IIb)</text>
<text top="425" left="454" width="103" height="14" font="1">Likely/uncertain</text>
<text top="927" left="339" width="142" height="14" font="1">Program to minimize </text>
<text top="945" left="349" width="120" height="14" font="1">ventricular pacing </text>
<text top="963" left="373" width="68" height="14" font="1">(Class IIa)</text>
<text top="200" left="444" width="128" height="14" font="1">Confirm symptoms </text>
<text top="218" left="444" width="128" height="14" font="1">Rule out reversible </text>
<text top="236" left="483" width="48" height="14" font="1">causes</text>
<text top="438" left="708" width="80" height="14" font="1">Observation</text>
<text top="477" left="688" width="121" height="14" font="1">Permanent pacing</text>
<text top="495" left="692" width="113" height="14" font="1"> (Class III: Harm)</text>
<text top="259" left="251" width="31" height="14" font="1">Due </text>
<text top="277" left="205" width="124" height="14" font="1">to required GDMT </text>
<text top="295" left="215" width="104" height="14" font="1">(no reasonable </text>
<text top="313" left="227" width="74" height="14" font="1">alternative)</text>
<text top="372" left="252" width="25" height="14" font="1">Yes</text>
<text top="340" left="335" width="19" height="14" font="1">No</text>
<text top="321" left="471" width="75" height="14" font="1">Symptoms </text>
<text top="339" left="462" width="93" height="14" font="1">correlate with </text>
<text top="357" left="467" width="78" height="14" font="1">bradycardia</text>
<text top="558" left="231" width="72" height="14" font="1">Infrequent </text>
<text top="576" left="202" width="130" height="14" font="1">pacing? Significant </text>
<text top="594" left="216" width="96" height="14" font="1">comorbidities?</text>
<text top="724" left="279" width="53" height="14" font="1">Normal </text>
<text top="742" left="255" width="100" height="14" font="1">AV conduction </text>
<text top="760" left="257" width="96" height="14" font="1">and reason to </text>
<text top="777" left="262" width="87" height="14" font="1">avoid an RV </text>
<text top="795" left="284" width="36" height="14" font="1">lead?</text>
<text top="637" left="196" width="25" height="14" font="1">Yes</text>
<text top="637" left="289" width="19" height="14" font="1">No</text>
<text top="679" left="97" width="109" height="14" font="1">Single chamber </text>
<text top="697" left="90" width="120" height="14" font="1">ventricular pacing </text>
<text top="715" left="115" width="68" height="14" font="1">(Class IIa)</text>
<text top="832" left="250" width="25" height="14" font="1">Yes</text>
<text top="832" left="339" width="19" height="14" font="1">No</text>
<text top="865" left="336" width="142" height="14" font="1">Dual chamber pacing</text>
<text top="883" left="379" width="56" height="14" font="1">(Class I)</text>
<text top="866" left="159" width="109" height="14" font="1">Single chamber </text>
<text top="884" left="171" width="86" height="14" font="1">atrial pacing </text>
<text top="902" left="183" width="56" height="14" font="1">(Class I)</text>
<text top="549" left="473" width="72" height="14" font="1">Response </text>
<text top="567" left="432" width="153" height="14" font="1">suggests symptomatic </text>
<text top="585" left="470" width="77" height="14" font="1">sinus node </text>
<text top="603" left="464" width="84" height="14" font="1">dysfunction?</text>
<text top="645" left="494" width="25" height="14" font="1">Yes</text>
<text top="630" left="568" width="19" height="14" font="1">No</text>
<text top="688" left="476" width="61" height="14" font="1">Willing to</text>
<text top="706" left="459" width="94" height="14" font="1"> have a PPM?</text>
<text top="738" left="430" width="25" height="14" font="1">Yes</text>
<text top="738" left="560" width="19" height="14" font="1">No</text>
<text top="779" left="568" width="112" height="14" font="1">Oral theophylline</text>
<text top="797" left="590" width="68" height="14" font="1">(Class IIb)</text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="38" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 38 </text>
<text top="124" left="81" width="522" height="31" font="2"><b>5. Bradycardia Attributable to Atrioventricular Block </b></text>
<text top="162" left="81" width="761" height="29" font="19"><b>5.1. Pathophysiology, Etiology, and Classification of Bradycardia Attributable to </b></text>
<text top="189" left="81" width="209" height="29" font="19"><b>Atrioventricular Block </b></text>
<text top="222" left="81" width="288" height="21" font="7"><b>Table 9. Etiology of Atrioventricular Block</b> </text>
<text top="242" left="81" width="4" height="21" font="8"> </text>
<text top="263" left="89" width="119" height="19" font="1">Congenital/genetic </text>
<text top="284" left="100" width="505" height="20" font="1">•  Congenital AV block (associated with maternal systemic lupus erythematosus) </text>
<text top="303" left="100" width="258" height="20" font="1">•  Congenital heart defects (e.g., L-TGA) </text>
<text top="322" left="100" width="226" height="20" font="1">•  Genetic (e.g., SCN5A mutations) </text>
<text top="342" left="89" width="63" height="19" font="1">Infectious </text>
<text top="362" left="100" width="111" height="20" font="1">•  Lyme carditis </text>
<text top="381" left="100" width="307" height="20" font="1">•  Bacterial endocarditis with perivalvar abscess </text>
<text top="401" left="100" width="166" height="20" font="1">•  Acute rheumatic fever </text>
<text top="420" left="100" width="122" height="20" font="1">•  Chagas disease </text>
<text top="439" left="100" width="119" height="20" font="1">•  Toxoplasmosis </text>
<text top="458" left="89" width="155" height="19" font="1">Inflammatory/infiltrative </text>
<text top="479" left="100" width="102" height="20" font="1">•  Myocarditis </text>
<text top="498" left="100" width="104" height="20" font="1">•  Amyloidosis </text>
<text top="517" left="100" width="146" height="20" font="1">•  Cardiac sarcoidosis </text>
<text top="536" left="100" width="569" height="20" font="1">•  Rheumatologic disease: Systemic sclerosis, SLE, RA, reactive arthritis (Reiter’s syndrome) </text>
<text top="555" left="100" width="289" height="20" font="1">•  Other cardiomyopathy-idiopathic, valvular </text>
<text top="575" left="89" width="56" height="19" font="1">Ischemic </text>
<text top="595" left="100" width="86" height="20" font="1">•  Acute MI </text>
<text top="614" left="100" width="461" height="20" font="1">•  Coronary ischemia without infarction—unstable angina, variant angina </text>
<text top="634" left="100" width="236" height="20" font="1">•  Chronic ischemic cardiomyopathy </text>
<text top="653" left="89" width="85" height="19" font="1">Degenerative </text>
<text top="674" left="100" width="203" height="20" font="1">•  Lev’s and Lenegre’s diseases </text>
<text top="694" left="89" width="293" height="19" font="1">Vagotonic-associated with increased vagal tone </text>
<text top="714" left="100" width="216" height="20" font="1">•  Sleep, obstructive sleep apnea </text>
<text top="733" left="100" width="220" height="20" font="1">•  High-level athletic conditioning </text>
<text top="753" left="100" width="139" height="20" font="1">•  Neurocardiogenic </text>
<text top="772" left="89" width="132" height="19" font="1">Metabolic/endocrine </text>
<text top="793" left="100" width="150" height="20" font="1">•  Acid-base disorders </text>
<text top="812" left="100" width="488" height="20" font="1">•  Poisoning/overdose (e.g., mercury, cyanide, carbon monoxide, mad honey) </text>
<text top="831" left="100" width="396" height="20" font="1">•  Thyroid disease (both hypothyroidism and hyperthyroidism) </text>
<text top="850" left="100" width="417" height="20" font="1">•  Adrenal disease (e.g., pheochromocytoma, hypoaldosteronism) </text>
<text top="870" left="89" width="93" height="19" font="1">Other diseases </text>
<text top="890" left="100" width="595" height="20" font="1">•  Neuromuscular diseases (e.g., myotonic dystrophy, Kearns-Sayre syndrome, Erb’s dystrophy) </text>
<text top="909" left="100" width="98" height="20" font="1">•  Lymphoma </text>
<text top="929" left="89" width="65" height="19" font="1">Iatrogenic </text>
<text top="949" left="100" width="147" height="20" font="1">•  Medication related </text>
<text top="973" left="128" width="9" height="12" font="1">o</text>
<text top="972" left="137" width="4" height="14" font="1"> </text>
<text top="968" left="155" width="268" height="19" font="1">Beta blockers, verapamil, diltiazem, digoxin </text>
<text top="991" left="128" width="9" height="12" font="1">o</text>
<text top="990" left="137" width="4" height="14" font="1"> </text>
<text top="986" left="155" width="133" height="19" font="1">Antiarrhythmic drugs </text>
<text top="1010" left="128" width="9" height="12" font="1">o</text>
<text top="1008" left="137" width="4" height="14" font="1"> </text>
<text top="1005" left="155" width="99" height="19" font="1">Neutraceuticals </text>
<text top="1023" left="100" width="137" height="20" font="1">•  Catheter ablation </text>
<text top="1042" left="100" width="275" height="20" font="1">•  Cardiac surgery, especially valve surgery </text>
<text top="1061" left="100" width="208" height="20" font="1">•  TAVR, alcohol septal ablation </text>
<text top="1081" left="81" width="3" height="19" font="1"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="39" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="435" width="51" height="19" font="1">Page 39 </text>
<text top="124" left="81" width="760" height="19" font="1">RA indicates rheumatoid arthritis; MI, myocardial infarction; SLE, systemic lupus erythematosus; and TAVR, transcatheter </text>
<text top="142" left="81" width="158" height="19" font="1">aortic valve replacement.<b> </b></text>
<text top="160" left="135" width="4" height="21" font="8"> </text>
<text top="189" left="81" width="230" height="29" font="19"><b>5.2. Acute Management </b></text>
<text top="235" left="81" width="761" height="27" font="26"><i><b>5.2.1.  Acute Management of Reversible Causes of Bradycardia Attributable  to </b></i></text>
<text top="261" left="81" width="199" height="27" font="26"><i><b>Atrioventricular Block  </b></i></text>
<text top="296" left="136" width="649" height="21" font="7"><b>Recommendations for Acute Management of Reversible Causes of Bradycardia Attributable</b> <b>to </b></text>
<text top="316" left="384" width="153" height="21" font="7"><b>Atrioventricular Block </b></text>
<text top="336" left="128" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="336" left="602" width="185" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 26</a></text>
<text top="336" left="786" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="365" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="365" left="208" width="30" height="21" font="7"><b>LOE </b></text>
<text top="365" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="423" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="423" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="393" left="276" width="557" height="21" font="7"><b>1.  Patients with transient or reversible causes of atrioventricular block, such as </b></text>
<text top="413" left="303" width="531" height="21" font="7"><b>Lyme carditis or drug toxicity, should have medical therapy and supportive </b></text>
<text top="433" left="303" width="530" height="21" font="7"><b>care, including temporary transvenous pacing if necessary, before </b></text>
<text top="453" left="303" width="448" height="21" font="7"><b>determination of need for permanent pacing</b> <b>(S5.2.1-1–S5.2.1-5). </b></text>
<text top="515" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="515" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="474" left="276" width="557" height="21" font="7"><b>2.  In selected patients with symptomatic second-degree or third-degree </b></text>
<text top="494" left="303" width="529" height="21" font="7"><b>atrioventricular block who are on chronic stable doses of medically necessary </b></text>
<text top="515" left="303" width="535" height="21" font="7"><b>antiarrhythmic or beta-blocker therapy, it is reasonable to proceed to </b></text>
<text top="535" left="303" width="538" height="21" font="7"><b>permanent pacing without further observation for drug washout or </b></text>
<text top="555" left="303" width="226" height="21" font="7"><b>reversibility</b> <b>(S5.2.1-6–S5.2.1-9).  </b></text>
<text top="616" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="616" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="576" left="276" width="557" height="21" font="7"><b>3.  In patients with second-degree or third-degree  atrioventricular  block </b></text>
<text top="596" left="303" width="536" height="21" font="7"><b>associated with cardiac sarcoidosis, permanent pacing,</b>  <b>with additional </b></text>
<text top="616" left="303" width="530" height="21" font="7"><b>defibrillator capability if needed and meaningful survival of greater than 1 </b></text>
<text top="636" left="303" width="530" height="21" font="7"><b>year is expected, without further observation for reversibility is reasonable</b> </text>
<text top="656" left="303" width="157" height="21" font="7"><b>(S5.2.1-10, S5.2.1-11).  </b></text>
<text top="707" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="707" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="677" left="276" width="557" height="21" font="7"><b>4.  In patients with symptomatic second-degree or third-degree atrioventricular </b></text>
<text top="697" left="303" width="533" height="21" font="7"><b>block associated with thyroid function abnormalities but without clinical </b></text>
<text top="717" left="303" width="532" height="21" font="7"><b>myxedema, permanent pacing without further observation for reversibility </b></text>
<text top="738" left="303" width="215" height="21" font="7"><b>may be considered (S5.2.1-12). </b></text>
<text top="759" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="40" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="31" size="11" family="Times" color="#000000"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">40</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="142" left="81" width="728" height="27" font="26"><i><b>5.2.2. Acute Medical Therapy for Bradycardia Attributable to Atrioventricular Block </b></i></text>
<text top="177" left="118" width="686" height="21" font="7"><b>Recommendations for Acute Medical Therapy for Bradycardia Attributable to Atrioventricular</b> <b>Block </b></text>
<text top="197" left="100" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="197" left="574" width="240" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 27 and 28</a></text>
<text top="197" left="814" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="226" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="226" left="208" width="30" height="21" font="7"><b>LOE </b></text>
<text top="226" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="294" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="294" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="254" left="275" width="557" height="21" font="7"><b>1.  For patients with second-degree or third-degree  atrioventricular</b>  <b>block </b></text>
<text top="274" left="302" width="531" height="21" font="7"><b>believed to be at the atrioventricular</b> <b>nodal level associated with symptoms </b></text>
<text top="294" left="302" width="542" height="21" font="7"><b>or hemodynamic compromise, atropine is reasonable to improve </b></text>
<text top="314" left="302" width="530" height="21" font="7"><b>atrioventricular</b> <b>conduction, increase ventricular rate, and improve symptoms</b> </text>
<text top="335" left="302" width="141" height="21" font="7"><b>(S5.2.2-1–S5.2.2-3).  </b></text>
<text top="406" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="406" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="355" left="275" width="557" height="21" font="7"><b>2.  For patients with second-degree or third-degree  atrioventricular</b>  <b>block </b></text>
<text top="376" left="302" width="531" height="21" font="7"><b>associated with symptoms or hemodynamic compromise and who have low </b></text>
<text top="396" left="302" width="540" height="21" font="7"><b>likelihood for coronary ischemia, beta-adrenergic agonists, such as </b></text>
<text top="416" left="302" width="530" height="21" font="7"><b>isoproterenol, dopamine, dobutamine, or epinephrine, may be considered to </b></text>
<text top="436" left="302" width="531" height="21" font="7"><b>improve atrioventricular</b> <b>conduction, increase ventricular rate, and improve </b></text>
<text top="456" left="302" width="216" height="21" font="7"><b>symptoms</b> <b>(S5.2.2-3–S5.2.2-7).  </b></text>
<text top="517" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="517" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="477" left="275" width="557" height="21" font="7"><b>3.  For patients with second-degree or third-degree  atrioventricular</b>  <b>block </b></text>
<text top="497" left="302" width="533" height="21" font="7"><b>associated with symptoms or hemodynamic compromise in the setting of </b></text>
<text top="517" left="302" width="531" height="21" font="7"><b>acute inferior myocardial infarction (MI), intravenous aminophylline may be </b></text>
<text top="537" left="302" width="530" height="21" font="7"><b>considered to improve atrioventricular</b> <b>conduction, increase ventricular rate, </b></text>
<text top="558" left="302" width="314" height="21" font="7"><b>and improve symptoms (S5.2.2-8–S5.2.2-11).  </b></text>
<text top="579" left="81" width="4" height="21" font="8"> </text>
<text top="599" left="81" width="4" height="21" font="8"> </text>
<text top="637" left="81" width="441" height="27" font="26"><i><b>5.2.3. Temporary Pacing for Atrioventricular Block </b></i></text>
<text top="672" left="135" width="652" height="21" font="7"><b>Recommendations for Temporary Pacing for Bradycardia Attributable to Atrioventricular Block </b></text>
<text top="692" left="100" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="692" left="574" width="240" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 29 and 30</a></text>
<text top="692" left="814" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="721" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="721" left="208" width="30" height="21" font="7"><b>LOE </b></text>
<text top="721" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="779" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="779" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="749" left="276" width="557" height="21" font="7"><b>1.  For patients with second-degree  or  third-degree  atrioventricular  block </b></text>
<text top="769" left="303" width="529" height="21" font="7"><b>associated with symptoms or hemodynamic compromise that is refractory to </b></text>
<text top="789" left="303" width="533" height="21" font="7"><b>medical therapy, temporary transvenous pacing is reasonable  to increase </b></text>
<text top="809" left="303" width="379" height="21" font="7"><b>heart rate and improve symptoms</b> <b>(S5.2.3-1–S5.2.3-7).  </b></text>
<text top="850" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="850" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="830" left="276" width="561" height="21" font="7"><b>2.  For patients who require prolonged temporary transvenous pacing, it is </b></text>
<text top="850" left="303" width="530" height="21" font="7"><b>reasonable to choose an externalized permanent active fixation lead over a </b></text>
<text top="871" left="303" width="482" height="21" font="7"><b>standard passive fixation temporary pacing lead</b> <b>(S5.2.3-8–S5.2.3-14)</b>.<b>  </b></text>
<text top="932" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="932" left="209" width="27" height="21" font="7"><b>B-R </b></text>
<text top="891" left="276" width="559" height="21" font="7"><b>3.  For patients with second-degree or third-degree atrioventricular block and </b></text>
<text top="912" left="303" width="533" height="21" font="7"><b>hemodynamic compromise refractory to antibradycardic medical therapy, </b></text>
<text top="932" left="303" width="534" height="21" font="7"><b>temporary transcutaneous pacing may be considered until a temporary </b></text>
<text top="952" left="303" width="534" height="21" font="7"><b>transvenous or permanent pacemaker is placed or the bradyarrhythmia </b></text>
<text top="972" left="303" width="218" height="21" font="7"><b>resolves</b> <b>(S5.2.3-15–S5.2.3-20).  </b></text>
<text top="993" left="108" width="4" height="21" font="8"> </text>
<text top="1022" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="41" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">41</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="618" height="29" font="19"><b>5.3. Chronic Therapy/Management of Bradycardia Attributable to </b></text>
<text top="151" left="81" width="209" height="29" font="19"><b>Atrioventricular Block </b></text>
<text top="183" left="81" width="4" height="21" font="8"> </text>
<text top="212" left="81" width="719" height="21" font="7"><b>Figure 7. Management of Bradycardia or Pauses Attributable</b> <b>to Chronic Atrioventricular Block Algorithm </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="42" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">42</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="1073" left="667" width="3" height="19" font="1"> </text>
<text top="1088" left="81" width="3" height="19" font="1"> </text>
<text top="137" left="352" width="40" height="9" font="20">AV Block</text>
<text top="183" left="197" width="56" height="9" font="20">Marked first </text>
<text top="195" left="185" width="74" height="9" font="20">degree AV Block</text>
<text top="181" left="418" width="62" height="9" font="20">Mobitz Type I </text>
<text top="193" left="436" width="23" height="9" font="20">block</text>
<text top="186" left="584" width="73" height="9" font="20">Complete Heart </text>
<text top="198" left="581" width="77" height="9" font="20">Block (acquired), </text>
<text top="210" left="588" width="64" height="9" font="20">Advanced AV </text>
<text top="221" left="605" width="27" height="9" font="20">Block,</text>
<text top="233" left="586" width="65" height="9" font="20">Mobitz Type II,</text>
<text top="245" left="591" width="58" height="9" font="20">Evidence for </text>
<text top="257" left="583" width="71" height="9" font="20">Infranodal Block</text>
<text top="233" left="197" width="51" height="9" font="20">Symptoms*</text>
<text top="256" left="276" width="13" height="9" font="20">No</text>
<text top="256" left="166" width="17" height="9" font="20">Yes</text>
<text top="297" left="298" width="52" height="9" font="20">Lamin A/C, </text>
<text top="309" left="289" width="70" height="9" font="20">Neuromuscular </text>
<text top="321" left="305" width="35" height="9" font="20">disease</text>
<text top="349" left="298" width="17" height="9" font="20">Yes</text>
<text top="350" left="334" width="13" height="9" font="20">No</text>
<text top="445" left="87" width="51" height="9" font="20">Permanent </text>
<text top="457" left="97" width="29" height="9" font="20">pacing</text>
<text top="469" left="87" width="48" height="9" font="20"> (Class IIa)</text>
<text top="377" left="331" width="53" height="9" font="20">Observation</text>
<text top="440" left="334" width="51" height="9" font="20">Permanent </text>
<text top="451" left="344" width="29" height="9" font="20">pacing</text>
<text top="463" left="336" width="48" height="9" font="20"> (Class III: </text>
<text top="475" left="344" width="28" height="9" font="20">Harm)</text>
<text top="233" left="422" width="51" height="9" font="20">Symptoms*</text>
<text top="262" left="460" width="13" height="9" font="20">No</text>
<text top="445" left="396" width="51" height="9" font="20">Permanent </text>
<text top="457" left="406" width="29" height="9" font="20">pacing</text>
<text top="469" left="397" width="48" height="9" font="20"> (Class IIa)</text>
<text top="262" left="417" width="17" height="9" font="20">Yes</text>
<text top="301" left="486" width="70" height="9" font="20">Neuromuscular </text>
<text top="313" left="467" width="109" height="9" font="20">disease associated with </text>
<text top="325" left="454" width="135" height="9" font="20">progressive conduction tissue </text>
<text top="337" left="502" width="36" height="9" font="20">disorder</text>
<text top="370" left="496" width="17" height="9" font="20">Yes</text>
<text top="370" left="524" width="13" height="9" font="20">No</text>
<text top="445" left="463" width="51" height="9" font="20">Permanent </text>
<text top="457" left="472" width="29" height="9" font="20">pacing</text>
<text top="469" left="467" width="40" height="9" font="20"> (Class I)</text>
<text top="399" left="526" width="53" height="9" font="20">Observation</text>
<text top="440" left="529" width="51" height="9" font="20">Permanent </text>
<text top="451" left="538" width="29" height="9" font="20">pacing</text>
<text top="463" left="531" width="48" height="9" font="20"> (Class III: </text>
<text top="475" left="539" width="28" height="9" font="20">Harm)</text>
<text top="445" left="594" width="51" height="9" font="20">Permanent </text>
<text top="457" left="604" width="29" height="9" font="20">pacing</text>
<text top="469" left="599" width="40" height="9" font="20"> (Class I)</text>
<text top="523" left="293" width="168" height="9" font="20">Consider risk of ventricular arrhythmia</text>
<text top="535" left="359" width="37" height="9" font="20">(Class I)</text>
<text top="1002" left="302" width="150" height="9" font="20">Pacing to maintain physiologic left</text>
<text top="1014" left="331" width="91" height="9" font="20">ventricular activation</text>
<text top="1026" left="354" width="45" height="9" font="20">(Class IIa)</text>
<text top="445" left="157" width="51" height="9" font="20">Permanent </text>
<text top="457" left="167" width="29" height="9" font="20">pacing</text>
<text top="469" left="157" width="48" height="9" font="20"> (Class IIb)</text>
<text top="445" left="262" width="51" height="9" font="20">Permanent </text>
<text top="457" left="272" width="29" height="9" font="20">pacing</text>
<text top="469" left="262" width="48" height="9" font="20"> (Class IIa)</text>
<text top="371" left="273" width="30" height="9" font="20">Lamin </text>
<text top="383" left="275" width="22" height="9" font="20">A/C†</text>
<text top="373" left="148" width="70" height="9" font="20">Neuromuscular </text>
<text top="385" left="161" width="40" height="9" font="20">disease‡</text>
<text top="379" left="242" width="13" height="9" font="20">No</text>
<text top="410" left="278" width="17" height="9" font="20">Yes</text>
<text top="411" left="173" width="17" height="9" font="20">Yes</text>
<text top="565" left="360" width="37" height="9" font="20">Cardiac </text>
<text top="577" left="320" width="118" height="9" font="20">resynchronization therapy </text>
<text top="589" left="295" width="167" height="9" font="20">candidate because of HF symptoms? </text>
<text top="601" left="347" width="60" height="9" font="20">(LVEF &lt;35%)</text>
<text top="621" left="430" width="17" height="9" font="20">Yes</text>
<text top="628" left="370" width="13" height="9" font="20">No</text>
<text top="665" left="336" width="85" height="9" font="20">Infrequent pacing? </text>
<text top="677" left="321" width="113" height="9" font="20">Significant comorbidities?</text>
<text top="621" left="510" width="35" height="9" font="20">GDMT§</text>
<text top="692" left="492" width="73" height="9" font="20">Single chamber </text>
<text top="704" left="488" width="78" height="9" font="20">ventricular pacing</text>
<text top="716" left="508" width="37" height="9" font="20">(Class I)</text>
<text top="711" left="370" width="13" height="9" font="20">No</text>
<text top="704" left="427" width="17" height="9" font="20">Yes</text>
<text top="742" left="353" width="51" height="9" font="20">Permanent </text>
<text top="754" left="341" width="72" height="9" font="20">atrial fibrillation?</text>
<text top="778" left="426" width="17" height="9" font="20">Yes</text>
<text top="766" left="492" width="73" height="9" font="20">Single chamber </text>
<text top="778" left="488" width="78" height="9" font="20">ventricular pacing</text>
<text top="790" left="508" width="37" height="9" font="20">(Class I)</text>
<text top="786" left="369" width="13" height="9" font="20">No</text>
<text top="812" left="330" width="94" height="9" font="20">Dual chamber pacing</text>
<text top="824" left="358" width="37" height="9" font="20">(Class I)</text>
<text top="874" left="350" width="53" height="9" font="20">LVEF &gt;50%</text>
<text top="844" left="370" width="13" height="9" font="20">No</text>
<text top="906" left="370" width="13" height="9" font="20">No</text>
<text top="897" left="405" width="17" height="9" font="20">Yes</text>
<text top="891" left="454" width="126" height="9" font="20">Right ventricular pacing lead</text>
<text top="903" left="494" width="45" height="9" font="20">(Class IIa)</text>
<text top="932" left="356" width="45" height="9" font="20">Predicted </text>
<text top="944" left="345" width="63" height="9" font="20">pacing &lt;40%?</text>
<text top="980" left="370" width="13" height="9" font="20">No</text>
<text top="966" left="406" width="17" height="9" font="20">Yes</text>
<text top="960" left="454" width="126" height="9" font="20">Right ventricular pacing lead</text>
<text top="972" left="494" width="45" height="9" font="20">(Class IIa)</text>
<text top="1059" left="337" width="82" height="9" font="20">His bundle pacing </text>
<text top="1071" left="354" width="45" height="9" font="20">(Class IIb)</text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="43" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="32" size="14" family="Times" color="#ee1c25"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">43</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="359" height="19" font="1">Colors correspond to Class of Recommendation in Table 2. </text>
<text top="142" left="81" width="367" height="19" font="1">Refer to Section 6.4. in the full-text guideline for discussion. </text>
<text top="161" left="81" width="302" height="19" font="1">*Symptoms correlate with atrioventricular block. </text>
<text top="179" left="81" width="173" height="19" font="1">†PR interval &gt;240 ms, LBBB. </text>
<text top="197" left="81" width="336" height="19" font="1">‡PR interval &gt;240 ms, QRS &gt;120 ms or fascicular block. </text>
<text top="216" left="81" width="304" height="19" font="1">§Refer to heart failure guidelines (S5.3-1, S5.3-2). </text>
<text top="234" left="81" width="759" height="19" font="1">AV indicates atrioventricular; GDMT, guideline directed management and therapy; HF, heart failure; LBBB, left bundle branch </text>
<text top="252" left="81" width="303" height="19" font="1">block; and LVEF, left ventricular ejection fraction. </text>
<text top="270" left="81" width="4" height="21" font="8"> </text>
<text top="319" left="81" width="761" height="27" font="26"><i><b>5.3.1. General Principles of Chronic Therapy/Management of Bradycardia Attributable </b></i></text>
<text top="344" left="81" width="218" height="27" font="26"><i><b>to Atrioventricular Block </b></i></text>
<text top="380" left="98" width="726" height="21" font="7"><b>Recommendations for General Principles of Chronic Therapy/Management of Bradycardia Attributable to </b></text>
<text top="400" left="384" width="153" height="21" font="7"><b>Atrioventricular Block </b></text>
<text top="420" left="100" width="474" height="21" font="8">Referenced studies that support recommendations are summarized i<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">n </a></text>
<text top="420" left="574" width="248" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 31, 32, 33, </a></text>
<text top="440" left="434" width="46" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">and 34</a></text>
<text top="440" left="480" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="468" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="468" left="209" width="30" height="21" font="7"><b>LOE </b></text>
<text top="468" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="537" left="98" width="60" height="21" font="7"><b>III: Harm</b></text>
<text top="537" left="158" width="4" height="21" font="32"><b> </b></text>
<text top="537" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="497" left="277" width="556" height="21" font="7"><b>1.  In patients with first-degree atrioventricular block or second-degree Mobitz </b></text>
<text top="517" left="304" width="529" height="21" font="7"><b>type I (Wenckebach) or 2:1 atrioventricular block which is believed to be at </b></text>
<text top="537" left="304" width="528" height="21" font="7"><b>the level of the atrioventricular node, with symptoms that do not temporally </b></text>
<text top="557" left="304" width="530" height="21" font="7"><b>correspond to the atrioventricular block, permanent pacing should not be </b></text>
<text top="577" left="304" width="189" height="21" font="7"><b>performed (S5.3-1–S5.3-7). </b></text>
<text top="628" left="98" width="63" height="21" font="7"><b>III: Harm </b></text>
<text top="628" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="598" left="277" width="552" height="21" font="7"><b>2.  In asymptomatic patients with first-degree atrioventricular block or second-</b></text>
<text top="618" left="304" width="531" height="21" font="7"><b>degree Mobitz type I (Wenckebach) or 2:1 atrioventricular  block which is </b></text>
<text top="638" left="304" width="530" height="21" font="7"><b>believed to be at the level of the atrioventricular node, permanent pacing </b></text>
<text top="658" left="304" width="299" height="21" font="7"><b>should not be performed (S5.3-4–S5.3-10).  </b></text>
<text top="680" left="81" width="4" height="21" font="8"> </text>
<text top="709" left="81" width="4" height="21" font="8"> </text>
<text top="747" left="81" width="625" height="27" font="26"><i><b>5.3.2. Transient/Potentially Reversible Causes of Atrioventricular Block  </b></i></text>
<text top="782" left="152" width="618" height="21" font="7"><b>Recommendations for Potentially Reversible or Transient Causes of Atrioventricular Block </b></text>
<text top="802" left="100" width="522" height="21" font="8">Referenced studies that support recommendations are summarized in Online<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="802" left="622" width="200" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Data Supplements 34, 35, 36, </a></text>
<text top="822" left="434" width="46" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">and 37</a></text>
<text top="822" left="480" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="851" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="851" left="210" width="30" height="21" font="7"><b>LOE </b></text>
<text top="851" left="489" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="909" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="909" left="207" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="879" left="278" width="555" height="21" font="7"><b>1.  In patients with symptomatic atrioventricular block attributable to a known </b></text>
<text top="899" left="305" width="527" height="21" font="7"><b>reversible cause in whom the atrioventricular block does not resolve despite </b></text>
<text top="919" left="305" width="527" height="21" font="7"><b>treatment of the underlying cause, permanent pacing is recommended</b> </text>
<text top="939" left="305" width="141" height="21" font="7"><b>(S5.3.2-1–S5.3.2-3).  </b></text>
<text top="990" left="99" width="63" height="21" font="7"><b>III: Harm </b></text>
<text top="990" left="207" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="960" left="278" width="557" height="21" font="7"><b>2.  In patients who had acute atrioventricular  block  attributable  to a known </b></text>
<text top="980" left="305" width="527" height="21" font="7"><b>reversible and non-recurrent cause, and have had complete resolution of the </b></text>
<text top="1001" left="305" width="530" height="21" font="7"><b>atrioventricular  block with treatment of the underlying cause, permanent </b></text>
<text top="1021" left="305" width="427" height="21" font="7"><b>pacing should not be performed</b> <b>(S5.3.2-1, S5.3.2-4–S5.3.2-9).  </b></text>
<text top="1052" left="99" width="63" height="21" font="7"><b>III: Harm </b></text>
<text top="1052" left="207" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="1042" left="278" width="554" height="21" font="7"><b>3.  In patients with asymptomatic vagally mediated atrioventricular  block, </b></text>
<text top="1062" left="305" width="449" height="21" font="7"><b>permanent pacing should not be performed</b> <b>(S5.3.2-6–S5.3.2-10). </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="44" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">44</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="761" height="27" font="26"><i><b>5.3.3. Additional Testing for Chronic Therapy/Management of Bradycardia Attributable </b></i></text>
<text top="149" left="81" width="218" height="27" font="26"><i><b>to Atrioventricular Block </b></i></text>
<text top="185" left="95" width="733" height="21" font="7"><b>Recommendations for Additional Testing for Chronic Therapy/Management of Bradycardia Attributable</b> <b>to </b></text>
<text top="205" left="384" width="153" height="21" font="7"><b>Atrioventricular Block </b></text>
<text top="225" left="100" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="225" left="574" width="240" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 37 and 38</a></text>
<text top="225" left="814" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="253" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="253" left="209" width="30" height="21" font="7"><b>LOE </b></text>
<text top="253" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="322" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="322" left="210" width="27" height="21" font="7"><b>B-R </b></text>
<text top="282" left="277" width="561" height="21" font="7"><b>1.  In patients with symptoms  (e.g., lightheadedness, dizziness) of unclear </b></text>
<text top="302" left="304" width="528" height="21" font="7"><b>etiology who have first-degree  atrioventricular  block or second-degree </b></text>
<text top="322" left="304" width="529" height="21" font="7"><b>Mobitz type I atrioventricular block on ECG, ambulatory electrocardiographic </b></text>
<text top="342" left="304" width="531" height="21" font="7"><b>monitoring is reasonable to establish correlation between symptoms and </b></text>
<text top="362" left="304" width="294" height="21" font="7"><b>rhythm abnormalities (S5.3.3-1–S5.3.3-4).  </b></text>
<text top="413" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="413" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="383" left="277" width="557" height="21" font="7"><b>2.  In patients with exertional symptoms (e.g., chest pain, shortness of breath) </b></text>
<text top="403" left="304" width="529" height="21" font="7"><b>who have first-degree or second-degree Mobitz type I atrioventricular block </b></text>
<text top="423" left="304" width="530" height="21" font="7"><b>at rest, an exercise treadmill test is reasonable to determine whether they </b></text>
<text top="444" left="304" width="392" height="21" font="7"><b>may benefit from permanent pacing (S5.3.3-5, S5.3.3-6)</b>.<b>  </b></text>
<text top="485" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="485" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="465" left="277" width="555" height="21" font="7"><b>3.  In selected patients with second-degree atrioventricular block, an EPS may be </b></text>
<text top="485" left="304" width="531" height="21" font="7"><b>considered to determine the level of the block and to determine whether </b></text>
<text top="505" left="304" width="423" height="21" font="7"><b>they may benefit from permanent pacing (S5.3.3-7–S5.3.3-9). </b></text>
<text top="566" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="566" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="526" left="277" width="556" height="21" font="7"><b>4.  In selected patients with second-degree atrioventricular block, carotid sinus </b></text>
<text top="546" left="304" width="530" height="21" font="7"><b>massage and/or pharmacological challenge with atropine, isoproterenol, or </b></text>
<text top="566" left="304" width="529" height="21" font="7"><b>procainamide may be considered to determine the level of the block and to </b></text>
<text top="586" left="304" width="525" height="21" font="7"><b>determine whether they may benefit from permanent pacing (S5.3.3-10–</b></text>
<text top="606" left="304" width="80" height="21" font="7"><b>S5.3.3-12).  </b></text>
<text top="627" left="81" width="4" height="21" font="8"> </text>
<text top="656" left="81" width="4" height="21" font="8"> </text>
<text top="694" left="81" width="218" height="27" font="26"><i><b>5.3.4. Permanent Pacing </b></i></text>
<text top="730" left="95" width="732" height="21" font="7"><b>Recommendations for Permanent Pacing for Chronic Therapy/Management of Bradycardia Attributable to </b></text>
<text top="750" left="384" width="153" height="21" font="7"><b>Atrioventricular Block </b></text>
<text top="770" left="98" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="770" left="572" width="253" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 34, 39, and </a></text>
<text top="790" left="449" width="17" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">40</a></text>
<text top="790" left="465" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="819" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="819" left="209" width="30" height="21" font="7"><b>LOE </b></text>
<text top="819" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="877" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="877" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="847" left="277" width="555" height="21" font="7"><b>1.  In patients with acquired second-degree Mobitz type II atrioventricular block, </b></text>
<text top="867" left="304" width="529" height="21" font="7"><b>high-grade atrioventricular block, or third-degree atrioventricular block not </b></text>
<text top="887" left="304" width="535" height="21" font="7"><b>attributable  to reversible or physiologic causes, permanent pacing is </b></text>
<text top="907" left="304" width="407" height="21" font="7"><b>recommended regardless of symptoms (S5.3.4-1–S5.3.4-7). </b></text>
<text top="989" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="989" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="928" left="277" width="563" height="21" font="7"><b>2.  In patients with neuromuscular diseases  associated with conduction </b></text>
<text top="948" left="304" width="528" height="21" font="7"><b>disorders, including muscular dystrophy (such as myotonic dystrophy type 1) </b></text>
<text top="969" left="304" width="528" height="21" font="7"><b>or Kearns-Sayre syndrome, who have evidence of second-degree </b></text>
<text top="989" left="304" width="529" height="21" font="7"><b>atrioventricular block, third-degree atrioventricular block, or an HV interval </b></text>
<text top="1009" left="304" width="533" height="21" font="7"><b>of  70 ms  or greater, regardless of symptoms, permanent pacing, with </b></text>
<text top="1029" left="304" width="528" height="21" font="7"><b>additional defibrillator capability if needed and meaningful survival of </b></text>
<text top="1049" left="304" width="487" height="21" font="7"><b>greater than 1 year is expected, is recommended (S5.3.4-8–S5.3.4-15).  </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="45" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">45</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="145" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="145" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="125" left="277" width="563" height="21" font="7"><b>3.  In patients with permanent atrial fibrillation (AF)  and symptomatic </b></text>
<text top="145" left="304" width="525" height="21" font="7"><b>bradycardia, permanent pacing is recommended (S5.3.4-2, S5.3.4-16, S5.3.4-</b></text>
<text top="165" left="304" width="30" height="21" font="7"><b>17). </b></text>
<text top="226" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="226" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="186" left="277" width="566" height="21" font="7"><b>4.  In patients who develop symptomatic atrioventricular  block as a </b></text>
<text top="206" left="304" width="528" height="21" font="7"><b>consequence of guideline-directed management and therapy for which there </b></text>
<text top="226" left="304" width="529" height="21" font="7"><b>is no alternative treatment and continued treatment is clinically necessary, </b></text>
<text top="246" left="304" width="533" height="21" font="7"><b>permanent pacing is recommended to increase heart rate and improve </b></text>
<text top="266" left="304" width="229" height="21" font="7"><b>symptoms (S5.3.4-18–S5.3.4-24). </b></text>
<text top="337" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="337" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="287" left="277" width="555" height="21" font="7"><b>5.  In patients with an infiltrative cardiomyopathy, such as cardiac sarcoidosis or </b></text>
<text top="307" left="304" width="525" height="21" font="7"><b>amyloidosis, and second-degree Mobitz type II atrioventricular block, high-</b></text>
<text top="327" left="304" width="528" height="21" font="7"><b>grade  atrioventricular  block, or third-degree  atrioventricular  block, </b></text>
<text top="348" left="304" width="528" height="21" font="7"><b>permanent pacing, with additional defibrillator capability if needed  and </b></text>
<text top="368" left="304" width="525" height="21" font="7"><b>meaningful survival of greater than 1 year is expected, is reasonable</b> <b>(S5.3.4-</b></text>
<text top="388" left="304" width="105" height="21" font="7"><b>25–S5.3.4-30).  </b></text>
<text top="449" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="449" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="409" left="277" width="556" height="21" font="7"><b>6.  In patients with lamin A/C gene mutations, including Limb Girdle and Emery </b></text>
<text top="429" left="304" width="530" height="21" font="7"><b>Dreifuss muscular dystrophies, with a PR interval greater than 240 ms and </b></text>
<text top="449" left="304" width="531" height="21" font="7"><b>LBBB, permanent pacing, with additional defibrillator capability if needed </b></text>
<text top="469" left="304" width="528" height="21" font="7"><b>and meaningful survival of  greater than  1 year is expected, is reasonable</b> </text>
<text top="489" left="304" width="157" height="21" font="7"><b>(S5.3.4-31–S5.3.4-33).  </b></text>
<text top="540" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="540" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="510" left="277" width="562" height="21" font="7"><b>7.  In patients with marked first-degree or second-degree Mobitz type I </b></text>
<text top="530" left="304" width="528" height="21" font="7"><b>(Wenckebach)  atrioventricular  block with symptoms that are clearly </b></text>
<text top="551" left="304" width="531" height="21" font="7"><b>attributable to the atrioventricular  block, permanent pacing is reasonable </b></text>
<text top="571" left="304" width="157" height="21" font="7"><b>(S5.3.4-34–S5.3.4-37).  </b></text>
<text top="632" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="632" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="592" left="277" width="555" height="21" font="7"><b>8.  In patients with neuromuscular diseases, such as myotonic dystrophy type 1, </b></text>
<text top="612" left="304" width="529" height="21" font="7"><b>with a PR interval greater than 240 ms, a QRS duration greater than 120 ms, </b></text>
<text top="632" left="304" width="528" height="21" font="7"><b>or fascicular block, permanent pacing, with additional defibrillator capability </b></text>
<text top="652" left="304" width="528" height="21" font="7"><b>if needed and meaningful survival of greater than 1 year is expected, may be </b></text>
<text top="672" left="304" width="300" height="21" font="7"><b>considered (S5.3.4-9–S5.3.4-13, S5.3.4-15).  </b></text>
<text top="693" left="81" width="4" height="21" font="8"> </text>
<text top="722" left="81" width="4" height="21" font="8"> </text>
<text top="751" left="81" width="4" height="21" font="8"> </text>
<text top="751" left="297" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="46" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="33" size="8" family="Times" color="#000000"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">46</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="760" height="23" font="4"><b>5.3.4.1. Permanent Pacing Techniques and Methods for Chronic Therapy/Management of Bradycardia </b></text>
<text top="146" left="81" width="283" height="23" font="4"><b>Attributable to Atrioventricular Block</b> </text>
<text top="173" left="102" width="717" height="21" font="7"><b>Recommendations for Permanent Pacing Techniques and Methods for Chronic Therapy/Management of </b></text>
<text top="193" left="288" width="345" height="21" font="7"><b>Bradycardia Attributable to Atrioventricular Block </b></text>
<text top="213" left="102" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="213" left="576" width="240" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 39 and 40</a></text>
<text top="213" left="816" width="4" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="234" left="367" width="55" height="21" font="8">and the<a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000629"> </a></text>
<text top="234" left="422" width="125" height="21" font="18"><a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000629">Systematic Review</a></text>
<text top="234" left="547" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000629">.</a> </text>
<text top="262" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="262" left="209" width="30" height="21" font="7"><b>LOE </b></text>
<text top="262" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="310" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="310" left="217" width="14" height="21" font="7"><b>A </b></text>
<text top="290" left="277" width="560" height="21" font="7"><b>1.  In patients with SND  and  atrioventricular  block  who require permanent </b></text>
<text top="310" left="304" width="537" height="21" font="7"><b>pacing, dual chamber pacing is recommended over single chamber </b></text>
<text top="330" left="304" width="289" height="21" font="7"><b>ventricular pacing (S5.3.4.1-1–S5.3.4.1-7). </b></text>
<text top="391" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="391" left="217" width="14" height="21" font="7"><b>A </b></text>
<text top="351" left="277" width="556" height="21" font="7"><b>2.  In select patients with atrioventricular block who require permanent pacing </b></text>
<text top="371" left="304" width="529" height="21" font="7"><b>in whom frequent ventricular pacing is not expected, or who have significant </b></text>
<text top="391" left="304" width="531" height="21" font="7"><b>comorbidities that are likely to determine clinical outcomes and that may </b></text>
<text top="412" left="304" width="528" height="21" font="7"><b>limit the benefit of dual chamber pacing, single chamber ventricular pacing is </b></text>
<text top="432" left="304" width="390" height="21" font="7"><b>effective (S5.3.4.1-1–S5.3.4.1-6, S5.3.4.1-8–S5.3.4.1-10).  </b></text>
<text top="473" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="473" left="210" width="27" height="21" font="7"><b>B-R </b></text>
<text top="453" left="277" width="558" height="21" font="7"><b>3.  For patients in sinus rhythm with a single chamber ventricular pacemaker </b></text>
<text top="473" left="304" width="529" height="21" font="7"><b>who develop pacemaker syndrome, revising to a dual chamber pacemaker is </b></text>
<text top="493" left="304" width="506" height="21" font="7"><b>recommended (S5.3.4.1-1, S5.3.4.1-2, S5.3.4.1-5, S5.3.4.1-8–S5.3.4.1-10).  </b></text>
<text top="564" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="564" left="204" width="24" height="21" font="7"><b>B-R</b></text>
<text top="564" left="228" width="11" height="13" font="33"><b>SR</b></text>
<text top="564" left="239" width="4" height="21" font="7"><b> </b></text>
<text top="514" left="277" width="555" height="21" font="7"><b>4.  In patients with atrioventricular block who have an indication for permanent </b></text>
<text top="534" left="304" width="528" height="21" font="7"><b>pacing with a left ventricular ejection fraction between 36% and 50% and are </b></text>
<text top="554" left="304" width="532" height="21" font="7"><b>expected to require ventricular pacing more  than 40% of the time, it is </b></text>
<text top="574" left="304" width="530" height="21" font="7"><b>reasonable to choose pacing methods that maintain physiologic ventricular </b></text>
<text top="594" left="304" width="528" height="21" font="7"><b>activation (e.g., cardiac resynchronization therapy [CRT] or His bundle pacing) </b></text>
<text top="615" left="304" width="452" height="21" font="7"><b>over right ventricular pacing (S5.3.4.1-7, S5.3.4.1-11–S5.3.4.1-19)  </b></text>
<text top="686" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="686" left="210" width="27" height="21" font="7"><b>B-R </b></text>
<text top="636" left="277" width="555" height="21" font="7"><b>5.  In patients with atrioventricular block who have an indication for permanent </b></text>
<text top="656" left="304" width="528" height="21" font="7"><b>pacing with a left ventricular ejection fraction between 36% and 50% and are </b></text>
<text top="676" left="304" width="533" height="21" font="7"><b>expected to require ventricular pacing less than 40% of the time, it is </b></text>
<text top="696" left="304" width="533" height="21" font="7"><b>reasonable to choose right ventricular pacing over pacing methods that </b></text>
<text top="716" left="304" width="530" height="21" font="7"><b>maintain physiologic ventricular activation (e.g., CRT or His bundle pacing) </b></text>
<text top="736" left="304" width="351" height="21" font="7"><b>(S5.3.4.1-15, S5.3.4.1-16, S5.3.4.1-20, S5.3.4.1-21).  </b></text>
<text top="787" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="787" left="204" width="24" height="21" font="7"><b>B-R</b></text>
<text top="787" left="228" width="11" height="13" font="33"><b>SR</b></text>
<text top="787" left="239" width="4" height="21" font="7"><b> </b></text>
<text top="757" left="277" width="556" height="21" font="7"><b>6.  In patients with atrioventricular block at the level of the atrioventricular node </b></text>
<text top="777" left="304" width="531" height="21" font="7"><b>who have an indication for permanent pacing, His bundle pacing may be </b></text>
<text top="797" left="304" width="528" height="21" font="7"><b>considered to maintain physiologic ventricular activation  (S5.3.4.1-19, </b></text>
<text top="818" left="304" width="174" height="21" font="7"><b>S5.3.4.1-22–S5.3.4.1-25). </b></text>
<text top="859" left="98" width="63" height="21" font="7"><b>III: Harm </b></text>
<text top="859" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="838" left="277" width="559" height="21" font="7"><b>7.  In patients with permanent or persistent AF  in whom a rhythm control </b></text>
<text top="859" left="304" width="534" height="21" font="7"><b>strategy is not planned, implantation of an atrial lead should not be </b></text>
<text top="879" left="304" width="256" height="21" font="7"><b>performed (S5.3.4.1-26, S5.3.4.1-27). </b></text>
<text top="900" left="81" width="190" height="19" font="1">SR indicates systematic review.</text>
<text top="898" left="271" width="4" height="21" font="7"><b> </b></text>
<text top="927" left="81" width="4" height="21" font="8"> </text>
<text top="956" left="81" width="5" height="31" font="2"><b> </b></text>
<text top="956" left="297" width="5" height="31" font="2"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="47" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">47</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="637" height="31" font="2"><b>6. Conduction Disorders (With 1:1 Atrioventricular Conduction)  </b></text>
<text top="162" left="81" width="375" height="29" font="19"><b>6.1. Evaluation of Conduction Disorders </b></text>
<text top="195" left="114" width="694" height="21" font="7"><b>Recommendations for Evaluation of Conduction Disorders (With 1:1 Atrioventricular Conduction and </b></text>
<text top="215" left="392" width="139" height="21" font="7"><b>Normal PR Interval) </b></text>
<text top="235" left="100" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="235" left="574" width="240" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 41 and 42</a></text>
<text top="235" left="814" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="263" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="263" left="211" width="30" height="21" font="7"><b>LOE </b></text>
<text top="263" left="491" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="302" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="302" left="207" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="292" left="282" width="553" height="21" font="7"><b>1.  In patients with newly detected LBBB, a transthoracic echocardiogram to </b></text>
<text top="312" left="309" width="455" height="21" font="7"><b>exclude structural heart disease is recommended</b> <b>(S6.1-1–S6.1-3).  </b></text>
<text top="353" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="353" left="209" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="333" left="282" width="559" height="21" font="7"><b>2.  In symptomatic patients with conduction system disease, in whom </b></text>
<text top="353" left="309" width="524" height="21" font="7"><b>atrioventricular  block is suspected, ambulatory electrocardiographic </b></text>
<text top="373" left="309" width="260" height="21" font="7"><b>monitoring is useful (S6.1-4–S6.1-11). </b></text>
<text top="414" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="414" left="207" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="394" left="282" width="553" height="21" font="7"><b>3.  In selected patients presenting with intraventricular conduction disorders </b></text>
<text top="414" left="309" width="524" height="21" font="7"><b>other than LBBB, transthoracic echocardiography is reasonable if structural </b></text>
<text top="434" left="309" width="361" height="21" font="7"><b>heart disease is suspected (S6.1-3, S6.1-12, S6.1-13). </b></text>
<text top="475" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="475" left="207" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="455" left="282" width="551" height="21" font="7"><b>4.  In patients with symptoms suggestive of intermittent bradycardia  (e.g., </b></text>
<text top="475" left="309" width="527" height="21" font="7"><b>lightheadedness, syncope), with conduction system disease identified by </b></text>
<text top="495" left="309" width="527" height="21" font="7"><b>ECG and no demonstrated atrioventricular block, EPS is reasonable (S6.1-14).  </b></text>
<text top="536" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="536" left="209" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="516" left="282" width="550" height="21" font="7"><b>5.  In selected patients with LBBB in whom structural heart disease is suspected </b></text>
<text top="536" left="309" width="526" height="21" font="7"><b>and echocardiogram is unrevealing, advanced imaging (e.g.,  cardiac MRI, </b></text>
<text top="557" left="309" width="460" height="21" font="7"><b>computed tomography, or nuclear studies) is reasonable (S6.1-15). </b></text>
<text top="608" left="120" width="21" height="21" font="7"><b>IIb </b></text>
<text top="608" left="209" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="577" left="282" width="550" height="21" font="7"><b>6.  In selected asymptomatic patients with extensive conduction system disease </b></text>
<text top="598" left="309" width="523" height="21" font="7"><b>(bifascicular or trifascicular block), ambulatory electrocardiographic </b></text>
<text top="618" left="309" width="528" height="21" font="7"><b>recording may be considered to document suspected higher degree of </b></text>
<text top="638" left="309" width="262" height="21" font="7"><b>atrioventricular block (S6.1-4, S6.1-6). </b></text>
<text top="669" left="120" width="21" height="21" font="7"><b>IIb </b></text>
<text top="669" left="209" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="659" left="282" width="555" height="21" font="7"><b>7.  In selected asymptomatic patients with LBBB  in whom ischemic heart </b></text>
<text top="679" left="309" width="527" height="21" font="7"><b>disease is suspected, stress testing with imaging may be considered</b> <b>(S6.1-2).  </b></text>
<text top="700" left="81" width="4" height="21" font="7"><b> </b></text>
<text top="729" left="81" width="4" height="21" font="7"><b> </b></text>
<text top="729" left="297" width="4" height="21" font="7"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="48" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">48</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="381" height="21" font="7"><b>Figure 8. Evaluation of Conduction Disorders Algorithm</b> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="49" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">49</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="1078" left="639" width="4" height="21" font="7"><b> </b></text>
<text top="133" left="284" width="76" height="12" font="25">Evidence for </text>
<text top="148" left="263" width="115" height="12" font="25">conduction disorder</text>
<text top="423" left="141" width="22" height="12" font="25">Yes</text>
<text top="425" left="196" width="17" height="12" font="25">No</text>
<text top="285" left="90" width="155" height="12" font="25">Treat underlying cause as </text>
<text top="301" left="100" width="132" height="12" font="25">needed, e.g., ischemia</text>
<text top="263" left="237" width="22" height="12" font="25">Yes</text>
<text top="475" left="335" width="17" height="12" font="25">No</text>
<text top="199" left="289" width="66" height="12" font="25">Reversible </text>
<text top="214" left="279" width="86" height="12" font="25">or Physiologic </text>
<text top="230" left="303" width="35" height="12" font="25">cause</text>
<text top="350" left="136" width="64" height="12" font="25">Treatment </text>
<text top="366" left="123" width="89" height="12" font="25">effective or not </text>
<text top="382" left="136" width="60" height="12" font="25">necessary</text>
<text top="451" left="112" width="50" height="12" font="25">Observe</text>
<text top="476" left="267" width="22" height="12" font="25">Yes</text>
<text top="509" left="377" width="61" height="12" font="25">Suspicion </text>
<text top="525" left="355" width="102" height="12" font="25">for infiltrative CM,</text>
<text top="541" left="346" width="119" height="12" font="25">endocarditis, ACHD,</text>
<text top="557" left="393" width="25" height="12" font="25"> etc.</text>
<text top="578" left="364" width="22" height="12" font="25">Yes</text>
<text top="572" left="208" width="116" height="12" font="25">Advanced imaging†</text>
<text top="588" left="236" width="60" height="12" font="25">(Class IIb)</text>
<text top="592" left="400" width="17" height="12" font="25">No</text>
<text top="633" left="391" width="29" height="12" font="25">Type</text>
<text top="648" left="365" width="86" height="12" font="25"> of conduction </text>
<text top="664" left="382" width="48" height="12" font="25">disorder</text>
<text top="722" left="389" width="33" height="12" font="25">LBBB</text>
<text top="399" left="298" width="48" height="12" font="25">Genetic </text>
<text top="414" left="264" width="119" height="12" font="25">disorder associated </text>
<text top="430" left="275" width="93" height="12" font="25">with conduction </text>
<text top="446" left="298" width="46" height="12" font="25">disease</text>
<text top="851" left="362" width="91" height="12" font="25">Treat identified </text>
<text top="866" left="367" width="78" height="12" font="25">abnormalities</text>
<text top="287" left="312" width="17" height="12" font="25">No</text>
<text top="974" left="349" width="22" height="12" font="25">Yes</text>
<text top="913" left="375" width="66" height="12" font="25">Symptoms </text>
<text top="929" left="333" width="148" height="12" font="25">suggestive of intermittent </text>
<text top="944" left="371" width="68" height="12" font="25">bradycardia</text>
<text top="976" left="452" width="17" height="12" font="25">No</text>
<text top="1007" left="232" width="171" height="12" font="25">Ambulatory ECG Monitoring‡</text>
<text top="1023" left="293" width="49" height="12" font="25">(Class I)</text>
<text top="504" left="169" width="128" height="12" font="25">Conduction disorders </text>
<text top="520" left="172" width="118" height="12" font="25">treatment algorithm*</text>
<text top="714" left="517" width="115" height="12" font="25">RBBB or fascicular </text>
<text top="730" left="557" width="30" height="12" font="25">block</text>
<text top="766" left="366" width="84" height="12" font="25">Transthoracic </text>
<text top="782" left="353" width="104" height="12" font="25">echocardiography</text>
<text top="798" left="381" width="49" height="12" font="25">(Class I)</text>
<text top="766" left="532" width="84" height="12" font="25">Transthoracic </text>
<text top="782" left="520" width="104" height="12" font="25">echocardiography</text>
<text top="798" left="542" width="60" height="12" font="25">(Class IIa)</text>
<text top="1006" left="434" width="171" height="12" font="25">Ambulatory ECG Monitoring§</text>
<text top="1021" left="490" width="60" height="12" font="25">(Class IIb)</text>
<text top="1058" left="248" width="137" height="12" font="25">Electrophysiology study</text>
<text top="1074" left="287" width="60" height="12" font="25">(Class IIa)</text>
<text top="1066" left="495" width="50" height="12" font="25">Observe</text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="50" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">50</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="362" height="19" font="1">Colors correspond to Class of Recommendation in Table 2.  </text>
<text top="142" left="81" width="339" height="19" font="1">See Section 7.4. in the full-text guideline for discussion. </text>
<text top="161" left="81" width="194" height="19" font="1">*Refer to Section 6.2., Figure 9. </text>
<text top="179" left="81" width="759" height="19" font="1">†Advanced imaging could include magnetic resonance imaging, computed tomography,  or  transesophageal </text>
<text top="197" left="81" width="117" height="19" font="1">echocardiography. </text>
<text top="216" left="81" width="338" height="19" font="1">‡Monitor choice based on the frequency of symptoms. </text>
<text top="234" left="81" width="567" height="19" font="1">§Extensive conduction disease (e.g., first degree atrioventricular block combined with LBBB). </text>
<text top="252" left="81" width="759" height="19" font="1">ACHD indicates adult congenital heart disease; CM, cardiomyopathy; ECG, electrocardiogram/electrocardiographic; LBBB, left </text>
<text top="271" left="81" width="361" height="19" font="1">bundle branch block; and RBBB, right bundle branch block. </text>
<text top="298" left="81" width="3" height="19" font="1"> </text>
<text top="325" left="81" width="4" height="21" font="8"> </text>
<text top="354" left="81" width="647" height="29" font="19"><b>6.2. Management of Conduction Disorders (With 1:1 Atrioventricular </b></text>
<text top="382" left="81" width="119" height="29" font="19"><b>Conduction) </b></text>
<text top="414" left="104" width="713" height="21" font="7"><b>Recommendations for Management of Conduction Disorders (With 1:1 Atrioventricular Conduction and </b></text>
<text top="434" left="388" width="145" height="21" font="7"><b>Normal PR Intervals) </b></text>
<text top="455" left="98" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="455" left="572" width="253" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 41, 42, and </a></text>
<text top="475" left="449" width="17" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">43</a></text>
<text top="475" left="465" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="503" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="503" left="211" width="30" height="21" font="7"><b>LOE </b></text>
<text top="503" left="491" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="551" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="551" left="209" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="531" left="282" width="550" height="21" font="7"><b>1.  In patients with syncope and bundle branch block who are found to have an </b></text>
<text top="551" left="309" width="523" height="21" font="7"><b>HV interval 70 ms  or greater  or evidence of infranodal block at  EPS, </b></text>
<text top="572" left="309" width="353" height="21" font="7"><b>permanent pacing is recommended (S6.2-1, S6.2-2) </b></text>
<text top="603" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="603" left="209" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="593" left="282" width="555" height="21" font="7"><b>2.  In patients with alternating bundle branch block, permanent pacing is </b></text>
<text top="613" left="309" width="164" height="21" font="7"><b>recommended (S6.2-3). </b></text>
<text top="664" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="664" left="209" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="634" left="282" width="560" height="21" font="7"><b>3.  In patients with Kearns-Sayre syndrome and conduction disorders, </b></text>
<text top="654" left="309" width="526" height="21" font="7"><b>permanent pacing is reasonable,  with additional defibrillator capability if </b></text>
<text top="674" left="309" width="520" height="21" font="7"><b>appropriate and meaningful survival of greater than 1 year is expected</b> <b>(S6.2-</b></text>
<text top="694" left="309" width="76" height="21" font="7"><b>4, S6.2-5).  </b></text>
<text top="745" left="120" width="21" height="21" font="7"><b>IIb </b></text>
<text top="745" left="209" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="715" left="282" width="550" height="21" font="7"><b>4.  In patients with Anderson-Fabry disease and QRS prolongation greater than </b></text>
<text top="735" left="309" width="524" height="21" font="7"><b>110 ms, permanent pacing, with additional defibrillator capability if needed </b></text>
<text top="755" left="309" width="529" height="21" font="7"><b>and meaningful survival of greater than  1 year is expected,</b>  <b>may be </b></text>
<text top="775" left="309" width="190" height="21" font="7"><b>considered (S6.2-6, S6.2-7). </b></text>
<text top="816" left="120" width="21" height="21" font="7"><b>IIb </b></text>
<text top="816" left="209" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="796" left="282" width="550" height="21" font="7"><b>5.  In patients with heart failure, a mildly to moderately reduced left ventricular </b></text>
<text top="816" left="309" width="524" height="21" font="7"><b>ejection fraction (36%–50%), and LBBB (QRS ≥150 ms), CRT therapy may be </b></text>
<text top="836" left="309" width="190" height="21" font="7"><b>considered (S6.2-8, S6.2-9). </b></text>
<text top="877" left="99" width="63" height="21" font="7"><b>III: Harm </b></text>
<text top="877" left="207" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="857" left="282" width="558" height="21" font="7"><b>6.  In asymptomatic patients with isolated conduction disease and 1:1 </b></text>
<text top="877" left="309" width="529" height="21" font="7"><b>atrioventricular conduction, permanent pacing is not indicated (in the </b></text>
<text top="898" left="309" width="403" height="21" font="7"><b>absence of other indications for pacing) (S6.2-10–S6.2-15). </b></text>
<text top="919" left="81" width="4" height="21" font="8"> </text>
<text top="948" left="81" width="4" height="21" font="8"> </text>
<text top="948" left="297" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="51" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">51</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="400" height="21" font="7"><b>Figure 9. Management of Conduction Disorders Algorithm </b></text>
<text top="913" left="826" width="3" height="19" font="1"> </text>
<text top="928" left="81" width="359" height="19" font="1">Colors correspond to Class of Recommendation in Table 2. </text>
<text top="946" left="81" width="761" height="19" font="1">*For severe first-degree atrioventricular block or first-degree atrioventricular block with an accompanying neuromuscular </text>
<text top="966" left="81" width="178" height="19" font="1">disease, also refer to Section </text>
<text top="964" left="259" width="33" height="21" font="8">5.3., </text>
<text top="966" left="292" width="276" height="19" font="1">Figure 7, the atrioventricular block algorithm.</text>
<text top="963" left="569" width="4" height="23" font="23"> </text>
<text top="966" left="573" width="3" height="19" font="1"> </text>
<text top="984" left="81" width="182" height="19" font="1">†See Section 3.3.2., Figure 3.  </text>
<text top="1003" left="81" width="761" height="19" font="1">AV indicates atrioventricular; BBB, bundle branch block; HF, heart failure; LBBB, left bundle branch block; and LVEF, left </text>
<text top="1021" left="81" width="173" height="19" font="1">ventricular ejection fraction.</text>
<text top="1019" left="254" width="4" height="21" font="7"><b> </b></text>
<text top="1048" left="81" width="4" height="21" font="7"><b> </b></text>
<text top="1068" left="81" width="4" height="21" font="8"> </text>
<text top="1068" left="297" width="4" height="21" font="8"> </text>
<text top="165" left="181" width="171" height="17" font="23">Conduction disorder:</text>
<text top="187" left="152" width="228" height="17" font="23">BBB or fascicular block with</text>
<text top="209" left="187" width="157" height="17" font="23">1:1 AV conduction*</text>
<text top="429" left="222" width="94" height="17" font="23">Alternating </text>
<text top="451" left="248" width="37" height="17" font="23">BBB</text>
<text top="502" left="253" width="24" height="17" font="23">No</text>
<text top="371" left="252" width="24" height="17" font="23">No</text>
<text top="477" left="623" width="150" height="17" font="23">Permanent pacing</text>
<text top="499" left="661" width="74" height="17" font="23"> (Class I)</text>
<text top="749" left="221" width="87" height="17" font="23">Symptoms</text>
<text top="771" left="184" width="166" height="17" font="23">suggest intermittent </text>
<text top="793" left="223" width="83" height="17" font="23">AV block?</text>
<text top="877" left="104" width="166" height="17" font="23">AV block diagnostic </text>
<text top="899" left="142" width="86" height="17" font="23">algorithm†</text>
<text top="835" left="218" width="31" height="17" font="23">Yes</text>
<text top="888" left="322" width="99" height="17" font="23">Observation</text>
<text top="836" left="321" width="24" height="17" font="23">No</text>
<text top="490" left="402" width="31" height="17" font="23">Yes</text>
<text top="575" left="176" width="178" height="17" font="23">LVEF 36-50%, LBBB,</text>
<text top="597" left="139" width="258" height="17" font="23"> QRS &gt;150 ms, and Class II or </text>
<text top="620" left="176" width="179" height="17" font="23">greater HF symptoms</text>
<text top="692" left="253" width="24" height="17" font="23">No</text>
<text top="682" left="390" width="31" height="17" font="23">Yes</text>
<text top="657" left="595" width="220" height="17" font="23">Cardiac resynchronization </text>
<text top="679" left="672" width="62" height="17" font="23">therapy</text>
<text top="702" left="658" width="89" height="17" font="23"> (Class IIb)</text>
<text top="270" left="228" width="82" height="17" font="23">Syncope, </text>
<text top="293" left="227" width="83" height="17" font="23">BBB, and </text>
<text top="315" left="223" width="87" height="17" font="23">HV &gt;70ms</text>
<text top="352" left="404" width="31" height="17" font="23">Yes</text>
<text top="339" left="623" width="150" height="17" font="23">Permanent pacing</text>
<text top="361" left="661" width="74" height="17" font="23"> (Class I)</text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="52" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">52</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="223" height="31" font="2"><b>7. Special Populations </b></text>
<text top="162" left="81" width="302" height="29" font="19"><b>7.1. Perioperative Management </b></text>
<text top="208" left="81" width="697" height="27" font="26"><i><b>7.1.1. Patients at Risk for Bradycardia During Noncardiac Surgery or Procedures </b></i></text>
<text top="243" left="131" width="660" height="21" font="7"><b>Recommendations for Patients at Risk for Bradycardia During Noncardiac Surgery or Procedures </b></text>
<text top="263" left="98" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="263" left="572" width="253" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 42, 44, and </a></text>
<text top="283" left="449" width="17" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">45</a></text>
<text top="283" left="465" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="312" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="312" left="208" width="30" height="21" font="7"><b>LOE </b></text>
<text top="312" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="370" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="370" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="340" left="275" width="561" height="21" font="7"><b>1.  In patients who are thought to be at high risk for the development of </b></text>
<text top="360" left="304" width="528" height="21" font="7"><b>intraoperative or periprocedural bradycardia because of  patient </b></text>
<text top="380" left="304" width="529" height="21" font="7"><b>characteristics or procedure type, placement of transcutaneous pacing pads </b></text>
<text top="400" left="304" width="231" height="21" font="7"><b>is reasonable (S7.1.1-1–S7.1.1-3). </b></text>
<text top="447" left="98" width="63" height="21" font="7"><b>III: Harm </b></text>
<text top="447" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="421" left="275" width="561" height="21" font="7"><b>2.  In patients with LBBB  who require pulmonary artery catheterization for </b></text>
<text top="441" left="304" width="535" height="21" font="7"><b>intraoperative monitoring, routine prophylactic temporary transvenous </b></text>
<text top="461" left="304" width="364" height="21" font="7"><b>pacing should not be performed (S7.1.1-4, S7.1.1-5).  </b></text>
<text top="493" left="81" width="4" height="21" font="8"> </text>
<text top="522" left="81" width="4" height="21" font="8"> </text>
<text top="560" left="81" width="714" height="27" font="26"><i><b>7.1.2. Postoperative Bradycardia and Conduction Disorders After Cardiac Surgery  </b></i></text>
<text top="595" left="81" width="240" height="23" font="4"><b>7.1.2.1. Coronary Artery Bypass </b></text>
<text top="622" left="199" width="523" height="21" font="7"><b>Recommendations for Pacing After Isolated Coronary Artery Bypass Surgery</b> </text>
<text top="642" left="128" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="642" left="602" width="185" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 47</a></text>
<text top="642" left="786" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="670" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="670" left="208" width="30" height="21" font="7"><b>LOE </b></text>
<text top="670" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="729" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="729" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="699" left="275" width="557" height="21" font="7"><b>1.  In patients who have new postoperative SND  or  atrioventricular  block </b></text>
<text top="719" left="304" width="528" height="21" font="7"><b>associated with persistent symptoms or hemodynamic instability that does </b></text>
<text top="739" left="304" width="529" height="21" font="7"><b>not resolve after isolated coronary artery bypass surgery, permanent pacing </b></text>
<text top="759" left="304" width="403" height="21" font="7"><b>is recommended before discharge (S7.1.2.1-1–S7.1.2.1-9).  </b></text>
<text top="800" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="800" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="780" left="275" width="562" height="21" font="7"><b>2.  In patients undergoing isolated coronary artery bypass surgery, routine </b></text>
<text top="800" left="304" width="528" height="21" font="7"><b>placement of temporary epicardial pacing wires is reasonable (S7.1.2.1-5, </b></text>
<text top="820" left="304" width="174" height="21" font="7"><b>S7.1.2.1-10, S7.1.2.1-11). </b></text>
<text top="861" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="861" left="205" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="841" left="275" width="557" height="21" font="7"><b>3.  In patients undergoing coronary artery bypass surgery who will likely require </b></text>
<text top="861" left="304" width="530" height="21" font="7"><b>future CRT or ventricular pacing, intraoperative placement of a permanent </b></text>
<text top="881" left="304" width="347" height="21" font="7"><b>epicardial left ventricular lead may be considered. </b></text>
<text top="902" left="81" width="4" height="21" font="8"> </text>
<text top="932" left="81" width="4" height="21" font="8"> </text>
<text top="953" left="81" width="4" height="21" font="8"> </text>
<text top="952" left="297" width="4" height="23" font="4"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="53" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">53</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="170" height="23" font="4"><b>7.1.2.2. Surgery for AF </b></text>
<text top="151" left="289" width="344" height="21" font="7"><b>Recommendations for Pacing After Surgery for AF</b> </text>
<text top="171" left="128" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="171" left="602" width="185" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 48</a></text>
<text top="171" left="786" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="199" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="199" left="208" width="30" height="21" font="7"><b>LOE </b></text>
<text top="199" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="242" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="242" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="228" left="275" width="562" height="21" font="7"><b>1.  In patients undergoing surgery for AF,  routine placement of temporary </b></text>
<text top="248" left="304" width="441" height="21" font="7"><b>epicardial pacing wires is recommended (S7.1.2.2-1–S7.1.2.2-4). </b></text>
<text top="306" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="306" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="276" left="275" width="557" height="21" font="7"><b>2.  In patients who have new postoperative SND  or  atrioventricular  block </b></text>
<text top="296" left="304" width="528" height="21" font="7"><b>associated with symptoms or hemodynamic instability that does not resolve </b></text>
<text top="317" left="304" width="528" height="21" font="7"><b>after surgery for AF, permanent pacing is recommended before  discharge </b></text>
<text top="337" left="304" width="163" height="21" font="7"><b>(S7.1.2.2-1–S7.1.2.2-4). </b></text>
<text top="381" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="381" left="205" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="358" left="275" width="557" height="21" font="7"><b>3.  In patients undergoing surgery for AF who will likely require future CRT or </b></text>
<text top="378" left="304" width="530" height="21" font="7"><b>ventricular pacing, intraoperative placement of a permanent epicardial left </b></text>
<text top="398" left="304" width="249" height="21" font="7"><b>ventricular lead may be considered. </b></text>
<text top="424" left="81" width="4" height="21" font="8"> </text>
<text top="454" left="81" width="4" height="21" font="8"> </text>
<text top="483" left="81" width="187" height="23" font="4"><b>7.1.2.3. Valvular Surgery </b></text>
<text top="508" left="81" width="363" height="21" font="6"><i>7.1.2.3.1. Surgical Aortic Valve Replacement or Repair </i></text>
<text top="530" left="268" width="386" height="21" font="7"><b>Recommendations for Pacing After Aortic Valve Surgery</b> </text>
<text top="550" left="128" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="550" left="602" width="185" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 48</a></text>
<text top="550" left="786" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="578" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="578" left="208" width="30" height="21" font="7"><b>LOE </b></text>
<text top="578" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="627" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="627" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="607" left="275" width="557" height="21" font="7"><b>1.  In patients undergoing surgical aortic valve replacement or repair, routine </b></text>
<text top="627" left="304" width="525" height="21" font="7"><b>placement of temporary epicardial pacing wires is recommended (S7.1.2.3.1-</b></text>
<text top="647" left="304" width="110" height="21" font="7"><b>1–S7.1.2.3.1-3). </b></text>
<text top="698" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="698" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="668" left="275" width="557" height="21" font="7"><b>2.  In patients who have new postoperative SND  or  atrioventricular  block </b></text>
<text top="688" left="304" width="528" height="21" font="7"><b>associated with persistent symptoms or hemodynamic instability that does </b></text>
<text top="708" left="304" width="540" height="21" font="7"><b>not  resolve after aortic valve replacement, permanent pacing is </b></text>
<text top="728" left="304" width="414" height="21" font="7"><b>recommended before discharge (S7.1.2.3.1-1–S7.1.2.3.1-5).  </b></text>
<text top="769" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="769" left="205" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="749" left="275" width="557" height="21" font="7"><b>3.  In patients undergoing aortic valve surgery who will likely require future CRT </b></text>
<text top="769" left="304" width="528" height="21" font="7"><b>or ventricular pacing, intraoperative placement of a permanent epicardial left </b></text>
<text top="790" left="304" width="253" height="21" font="7"><b>ventricular lead may be considered.  </b></text>
<text top="811" left="81" width="4" height="21" font="8"> </text>
<text top="831" left="81" width="4" height="21" font="8"> </text>
<text top="851" left="81" width="4" height="21" font="8"> </text>
<text top="850" left="297" width="4" height="21" font="6"><i> </i></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="54" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">54</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="123" left="81" width="211" height="21" font="6"><i>7.1.2.3.2. Mitral Valve Surgery  </i></text>
<text top="145" left="267" width="387" height="21" font="7"><b>Recommendations for Pacing After Mitral Valve Surgery</b> </text>
<text top="165" left="128" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="165" left="602" width="185" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 48</a></text>
<text top="165" left="786" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="193" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="193" left="208" width="30" height="21" font="7"><b>LOE </b></text>
<text top="193" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="252" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="252" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="222" left="275" width="557" height="21" font="7"><b>1.  In patients who have new postoperative SND  or  atrioventricular  block </b></text>
<text top="242" left="304" width="528" height="21" font="7"><b>associated with persistent symptoms or hemodynamic instability that does </b></text>
<text top="262" left="304" width="532" height="21" font="7"><b>not  resolve after mitral valve repair or replacement surgery, permanent </b></text>
<text top="282" left="304" width="472" height="21" font="7"><b>pacing is recommended before discharge (S7.1.2.3.2-1, S7.1.2.3.2-2). </b></text>
<text top="313" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="313" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="303" left="275" width="557" height="21" font="7"><b>2.  In patients undergoing mitral valve surgery, routine placement of temporary </b></text>
<text top="323" left="304" width="446" height="21" font="7"><b>epicardial pacing wires is reasonable ( S7.1.2.3.2-1–S7.1.2.3.2-3). </b></text>
<text top="367" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="367" left="205" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="344" left="275" width="558" height="21" font="7"><b>3.  In patients undergoing surgical mitral valve repair or replacement who will </b></text>
<text top="364" left="304" width="528" height="21" font="7"><b>likely require future CRT or ventricular pacing, intraoperative placement of a </b></text>
<text top="384" left="304" width="431" height="21" font="7"><b>permanent epicardial left ventricular lead may be considered.  </b></text>
<text top="411" left="81" width="4" height="21" font="8"> </text>
<text top="431" left="81" width="4" height="21" font="8"> </text>
<text top="450" left="81" width="226" height="21" font="6"><i>7.1.2.3.3. Tricuspid Valve Surgery </i></text>
<text top="472" left="257" width="407" height="21" font="7"><b>Recommendations for Pacing After Tricuspid Valve Surgery</b> </text>
<text top="492" left="128" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="492" left="602" width="185" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 48</a></text>
<text top="492" left="786" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="520" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="520" left="208" width="30" height="21" font="7"><b>LOE </b></text>
<text top="520" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="569" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="569" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="549" left="275" width="564" height="21" font="7"><b>1.  In patients undergoing tricuspid valve surgery,  routine placement of </b></text>
<text top="569" left="304" width="525" height="21" font="7"><b>temporary epicardial pacing wires is recommended (S7.1.2.3.3-1–S7.1.2.3.3-</b></text>
<text top="589" left="304" width="22" height="21" font="7"><b>4). </b></text>
<text top="640" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="640" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="610" left="275" width="557" height="21" font="7"><b>2.  In patients who have new postoperative SND  or  atrioventricular  block </b></text>
<text top="630" left="304" width="528" height="21" font="7"><b>associated with symptoms or hemodynamic instability that does not resolve </b></text>
<text top="650" left="304" width="528" height="21" font="7"><b>after tricuspid valve surgery, permanent pacing is recommended before </b></text>
<text top="670" left="304" width="261" height="21" font="7"><b>discharge (S7.1.2.3.3-1–S7.1.2.3.3-4).  </b></text>
<text top="721" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="721" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="691" left="275" width="561" height="21" font="7"><b>3.  In patients who are undergoing tricuspid valve  replacement or tricuspid </b></text>
<text top="711" left="304" width="529" height="21" font="7"><b>repair with high risk for postoperative atrioventricular block, intraoperative </b></text>
<text top="731" left="304" width="531" height="21" font="7"><b>placement of permanent epicardial leads at the time of cardiac surgery is </b></text>
<text top="751" left="304" width="268" height="21" font="7"><b>reasonable (S7.1.2.3.3-1–S7.1.2.3.3-5). </b></text>
<text top="772" left="81" width="4" height="21" font="8"> </text>
<text top="802" left="81" width="4" height="21" font="8"> </text>
<text top="823" left="81" width="4" height="21" font="8"> </text>
<text top="822" left="297" width="4" height="23" font="4"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="55" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">55</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="365" height="23" font="4"><b>7.1.2.4. Transcatheter Aortic Valve Replacement </b></text>
<text top="151" left="136" width="650" height="21" font="7"><b>Recommendations for Conduction Disturbances After Transcatheter Aortic Valve Replacement </b></text>
<text top="171" left="128" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="171" left="602" width="185" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 49</a></text>
<text top="171" left="786" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="199" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="199" left="208" width="30" height="21" font="7"><b>LOE </b></text>
<text top="199" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="258" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="258" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="228" left="275" width="559" height="21" font="7"><b>1.  In patients who have new  atrioventricular  block after transcatheter aortic </b></text>
<text top="248" left="304" width="531" height="21" font="7"><b>valve replacement  associated with symptoms or hemodynamic instability </b></text>
<text top="268" left="304" width="528" height="21" font="7"><b>that does not resolve, permanent pacing is recommended before discharge </b></text>
<text top="288" left="304" width="166" height="21" font="7"><b>(S7.1.2.4-1–S7.1.2.4-4).</b> <b> </b></text>
<text top="329" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="329" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="309" left="275" width="556" height="21" font="7"><b>2.  In patients with new persistent bundle branch block after transcatheter aortic </b></text>
<text top="329" left="304" width="536" height="21" font="7"><b>valve replacement, careful surveillance for bradycardia is reasonable </b></text>
<text top="349" left="304" width="166" height="21" font="7"><b>(S7.1.2.4-5, S7.1.2.4-6).  </b></text>
<text top="395" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="395" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="370" left="275" width="563" height="21" font="7"><b>3.  In patients with new persistent LBBB  after  transcatheter aortic valve </b></text>
<text top="390" left="304" width="531" height="21" font="7"><b>replacement, implantation of a permanent pacemaker may be considered </b></text>
<text top="411" left="304" width="250" height="21" font="7"><b>(S7.1.2.4-4, S7.1.2.4-7–S7.1.2.4-10).  </b></text>
<text top="441" left="81" width="4" height="21" font="8"> </text>
<text top="461" left="81" width="4" height="21" font="8"> </text>
<text top="481" left="81" width="557" height="23" font="4"><b>7.1.2.5. Heart Transplant, Surgical Myectomy, and Alcohol Septal Ablation </b></text>
<text top="506" left="81" width="614" height="21" font="6"><i>7.1.2.5.1. Surgical Myectomy and Alcohol Septal Ablation for Hypertrophic Cardiomyopathy </i></text>
<text top="538" left="98" width="734" height="21" font="7"><b>Recommendations for Patients Undergoing Surgical Myectomy or Alcohol Septal Ablation for Hypertrophic </b></text>
<text top="558" left="406" width="118" height="21" font="7"><b>Cardiomyopathy </b></text>
<text top="579" left="104" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="579" left="578" width="240" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplements 51 and 52</a></text>
<text top="579" left="818" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="607" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="607" left="208" width="30" height="21" font="7"><b>LOE </b></text>
<text top="607" left="492" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="665" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="665" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="635" left="277" width="519" height="21" font="7"><b>1.  In patients with second-degree Mobitz type II atrioventricular  block,</b></text>
<text top="640" left="797" width="3" height="15" font="25"> </text>
<text top="635" left="802" width="35" height="21" font="7"><b>high-</b></text>
<text top="655" left="304" width="536" height="21" font="7"><b>grade  atrioventricular  block, or persistent  complete  atrioventricular  block </b></text>
<text top="675" left="304" width="541" height="21" font="7"><b>after alcohol septal ablation or surgical myectomy, permanent pacing is </b></text>
<text top="696" left="304" width="410" height="21" font="7"><b>recommended before discharge (S7.1.2.5.1-1–S7.1.2.5.1-4). </b></text>
<text top="757" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="757" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="717" left="277" width="573" height="21" font="7"><b>2.  In selected patients with hypertrophic cardiomyopathy who require </b></text>
<text top="737" left="304" width="538" height="21" font="7"><b>permanent pacing for rate support after alcohol septal ablation or surgical </b></text>
<text top="757" left="304" width="540" height="21" font="7"><b>myectomy  and are at high risk for sudden cardiac death and meaningful </b></text>
<text top="777" left="304" width="536" height="21" font="7"><b>survival of greater than 1 year is expected, selecting a device with defibrillator </b></text>
<text top="797" left="304" width="364" height="21" font="7"><b>capabilities is reasonable (S7.1.2.5.1-5–S7.1.2.5.1-7). </b></text>
<text top="848" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="848" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="818" left="277" width="566" height="21" font="7"><b>3.  In patients with hypertrophic cardiomyopathy who undergo alcohol septal </b></text>
<text top="838" left="304" width="536" height="21" font="7"><b>ablation and who are at risk for developing  late  atrioventricular  block, </b></text>
<text top="858" left="304" width="540" height="21" font="7"><b>prolonged ambulatory electrocardiographic  monitoring may be considered </b></text>
<text top="878" left="304" width="454" height="21" font="7"><b>(S7.1.2.5.1-1, S7.1.2.5.1-2, S7.1.2.5.1-4, S7.1.2.5.1-7, S7.1.2.5.1-8). </b></text>
<text top="922" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="922" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="899" left="277" width="564" height="21" font="7"><b>4.  In patients with hypertrophic cardiomyopathy, evaluation of ventriculoatrial </b></text>
<text top="919" left="304" width="536" height="21" font="7"><b>conduction by EPS at the time of alcohol septal ablation may be considered for </b></text>
<text top="940" left="304" width="420" height="21" font="7"><b>identifying future risk of atrioventricular block (S7.1.2.5.1-9). </b></text>
<text top="966" left="81" width="4" height="21" font="8"> </text>
<text top="995" left="81" width="4" height="21" font="8"> </text>
<text top="1021" left="81" width="4" height="21" font="8"> </text>
<text top="1015" left="297" width="5" height="29" font="19"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="56" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">56</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="620" height="29" font="19"><b>7.2. Bradycardia Management for Adult Congenital Heart Disease  </b></text>
<text top="157" left="124" width="673" height="21" font="7"><b>Recommendations for Management of Bradycardia in Adults With Adult Congenital Heart Disease </b></text>
<text top="177" left="128" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="177" left="602" width="185" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 53</a></text>
<text top="177" left="786" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="205" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="205" left="209" width="30" height="21" font="7"><b>LOE </b></text>
<text top="205" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="253" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="253" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="233" left="277" width="555" height="21" font="7"><b>1.  In adults with adult congenital heart disease (ACHD )and symptomatic SND </b></text>
<text top="253" left="304" width="541" height="21" font="7"><b>or chronotropic incompetence, atrial based permanent pacing is </b></text>
<text top="274" left="304" width="219" height="21" font="7"><b>recommended</b> <b>(S7.2-1–S7.2-6).  </b></text>
<text top="305" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="305" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="294" left="277" width="555" height="21" font="7"><b>2.  In adults with ACHD and symptomatic bradycardia related to atrioventricular </b></text>
<text top="315" left="304" width="406" height="21" font="7"><b>block, permanent pacing is recommended (S7.2-7–S7.2-9).  </b></text>
<text top="366" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="366" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="335" left="277" width="565" height="21" font="7"><b>3.  In adults with  congenital complete atrioventricular  block with any </b></text>
<text top="356" left="304" width="525" height="21" font="7"><b>symptomatic bradycardia, a wide QRS escape rhythm, mean daytime heart-</b></text>
<text top="376" left="304" width="529" height="21" font="7"><b>rate below 50 bpm, complex ventricular ectopy, or ventricular dysfunction, </b></text>
<text top="396" left="304" width="378" height="21" font="7"><b>permanent pacing is recommended (S7.2-10, S7.2-11).  </b></text>
<text top="447" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="447" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="417" left="277" width="555" height="21" font="7"><b>4.  In adults with ACHD and postoperative second-degree  Mobitz  type II </b></text>
<text top="437" left="304" width="528" height="21" font="7"><b>atrioventricular  block,  high-grade  atrioventricular  block, or third-degree </b></text>
<text top="457" left="304" width="530" height="21" font="7"><b>atrioventricular block that is not expected to resolve, permanent pacing is </b></text>
<text top="477" left="304" width="235" height="21" font="7"><b>recommended (S7.2-12, S7.2-13).  </b></text>
<text top="508" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="508" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="498" left="277" width="556" height="21" font="7"><b>5.  In asymptomatic adults with congenital complete atrioventricular  block, </b></text>
<text top="518" left="304" width="346" height="21" font="7"><b>permanent pacing is reasonable (S7.2-7–S7.2-11).  </b></text>
<text top="559" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="559" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="539" left="277" width="556" height="21" font="7"><b>6.  In adults with repaired ACHD who require permanent pacing for bradycardic </b></text>
<text top="559" left="304" width="538" height="21" font="7"><b>indications, a bradycardia device with atrial antitachycardia pacing </b></text>
<text top="579" left="304" width="307" height="21" font="7"><b>capabilities is reasonable (S7.2-14, S7.2-15).  </b></text>
<text top="620" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="620" left="205" width="37" height="21" font="7"><b>C-EO </b></text>
<text top="600" left="277" width="555" height="21" font="7"><b>7.   In adults with ACHD with preexisting sinus node and/or atrioventricular </b></text>
<text top="620" left="304" width="534" height="21" font="7"><b>conduction disease who are undergoing cardiac surgery, intraoperative </b></text>
<text top="641" left="304" width="432" height="21" font="7"><b>placement of epicardial permanent pacing leads is reasonable. </b></text>
<text top="672" left="119" width="21" height="21" font="7"><b>IIb </b></text>
<text top="672" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="661" left="277" width="556" height="21" font="7"><b>8.  In adults with ACHD and pacemakers, atrial-based permanent pacing for the </b></text>
<text top="682" left="304" width="531" height="21" font="7"><b>prevention of atrial arrhythmias may be considered (S7.2-3–S7.2-5, S7.2-16).  </b></text>
<text top="723" left="98" width="63" height="21" font="7"><b>III: Harm </b></text>
<text top="723" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="702" left="277" width="558" height="21" font="7"><b>9.  In selected adults with ACHD and venous to systemic intracardiac shunts, </b></text>
<text top="723" left="304" width="525" height="21" font="7"><b>placement of endocardial pacing leads is potentially harmful (S7.2-17, S7.2-</b></text>
<text top="743" left="304" width="30" height="21" font="7"><b>18). </b></text>
<text top="764" left="81" width="4" height="21" font="8"> </text>
<text top="793" left="81" width="4" height="21" font="8"> </text>
<text top="828" left="81" width="4" height="21" font="8"> </text>
<text top="822" left="297" width="5" height="29" font="19"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="57" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">57</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="590" height="29" font="19"><b>7.3. Management of Bradycardia in Patients With an Acute MI  </b></text>
<text top="157" left="191" width="540" height="21" font="7"><b>Recommendations for Management of Bradycardia in the Context of Acute MI </b></text>
<text top="177" left="128" width="474" height="21" font="8">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="177" left="602" width="185" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 54</a></text>
<text top="177" left="786" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="205" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="205" left="209" width="30" height="21" font="7"><b>LOE </b></text>
<text top="205" left="488" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="253" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="253" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="233" left="277" width="557" height="21" font="7"><b>1.  In patients presenting with an acute MI, temporary pacing is indicated for </b></text>
<text top="253" left="304" width="528" height="21" font="7"><b>medically  refractory symptomatic or hemodynamically significant </b></text>
<text top="274" left="304" width="474" height="21" font="7"><b>bradycardia related to SND or atrioventricular block (S7.3-1–S7.3-4).  </b></text>
<text top="315" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="315" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="294" left="277" width="556" height="21" font="7"><b>2.  Patients who present with SND or atrioventricular block in the setting of an </b></text>
<text top="315" left="304" width="530" height="21" font="7"><b>acute MI should undergo a waiting period before determining the need for </b></text>
<text top="335" left="304" width="290" height="21" font="7"><b>permanent pacing (S7.3-1, S7.3-4–S7.3-7). </b></text>
<text top="386" left="126" width="8" height="21" font="7"><b>I </b></text>
<text top="386" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="356" left="277" width="555" height="21" font="7"><b>3.  In patients presenting with an acute MI with second-degree Mobitz type II </b></text>
<text top="376" left="304" width="528" height="21" font="7"><b>atrioventricular block, high-grade atrioventricular block, alternating bundle </b></text>
<text top="396" left="304" width="528" height="21" font="7"><b>branch block, or third-degree atrioventricular block (persistent or infranodal), </b></text>
<text top="416" left="304" width="473" height="21" font="7"><b>permanent pacing is indicated after a waiting period (S7.3-7, S7.3-8). </b></text>
<text top="467" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="467" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="437" left="277" width="562" height="21" font="7"><b>4.  In patients with an acute MI with symptomatic or hemodynamically </b></text>
<text top="457" left="304" width="529" height="21" font="7"><b>significant sinus bradycardia or atrioventricular  block at the level of the </b></text>
<text top="477" left="304" width="525" height="21" font="7"><b>atrioventricular node, the administration of atropine is reasonable (S7.3-9–</b></text>
<text top="497" left="304" width="68" height="21" font="7"><b>S7.3-11).  </b></text>
<text top="538" left="98" width="63" height="21" font="7"><b>III: Harm </b></text>
<text top="538" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="518" left="277" width="561" height="21" font="7"><b>5.  In patients with an acute MI and transient atrioventricular  block that </b></text>
<text top="538" left="304" width="529" height="21" font="7"><b>resolves, permanent pacing should not be performed (S7.3-1, S7.3-4, S7.3-7, </b></text>
<text top="558" left="304" width="127" height="21" font="7"><b>S7.3-12–S7.3-16).  </b></text>
<text top="610" left="98" width="63" height="21" font="7"><b>III: Harm </b></text>
<text top="610" left="204" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="579" left="277" width="558" height="21" font="7"><b>6.  In patients with an acute MI and a new bundle  branch block or isolated </b></text>
<text top="600" left="304" width="528" height="21" font="7"><b>fascicular block in the absence of second-degree or third-degree </b></text>
<text top="620" left="304" width="525" height="21" font="7"><b>atrioventricular block, permanent pacing should not be performed (S7.3-17–</b></text>
<text top="640" left="304" width="68" height="21" font="7"><b>S7.3-19).  </b></text>
<text top="661" left="81" width="4" height="21" font="8"> </text>
<text top="690" left="81" width="4" height="21" font="8"> </text>
<text top="719" left="81" width="241" height="29" font="19"><b>7.4. Neurologic Disorders </b></text>
<text top="765" left="81" width="129" height="27" font="26"><i><b>7.4.1. Epilepsy </b></i></text>
<text top="800" left="203" width="517" height="21" font="7"><b>Recommendation for Patients With Epilepsy and Symptomatic Bradycardia </b></text>
<text top="820" left="118" width="494" height="21" font="8">Referenced studies that support the recommendation are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="820" left="612" width="184" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 55</a></text>
<text top="820" left="796" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="848" left="114" width="33" height="21" font="7"><b>COR </b></text>
<text top="848" left="208" width="30" height="21" font="7"><b>LOE </b></text>
<text top="848" left="491" width="126" height="21" font="7"><b>Recommendation </b></text>
<text top="907" left="120" width="21" height="21" font="7"><b>IIa </b></text>
<text top="907" left="206" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="877" left="275" width="559" height="21" font="7"><b>1.  In patients with epilepsy associated with severe symptomatic bradycardia </b></text>
<text top="897" left="304" width="528" height="21" font="7"><b>(ictal bradycardia) where antiepileptic medications are ineffective, </b></text>
<text top="917" left="304" width="533" height="21" font="7"><b>permanent pacing is reasonable for reducing the severity of symptoms </b></text>
<text top="937" left="304" width="133" height="21" font="7"><b>(S7.4.1-1–S7.4.1-4).</b></text>
<text top="936" left="437" width="4" height="23" font="4"><b> </b></text>
<text top="958" left="81" width="4" height="21" font="8"> </text>
<text top="987" left="81" width="4" height="21" font="8"> </text>
<text top="1008" left="81" width="4" height="21" font="8"> </text>
<text top="1008" left="297" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="58" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">58</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="761" height="31" font="2"><b>8. Evaluation of the Risks for Ventricular Arrhythmias in Patients Who </b></text>
<text top="153" left="81" width="268" height="31" font="2"><b>Require Permanent Pacing </b></text>
<text top="192" left="94" width="733" height="21" font="7"><b>Recommendation for Management of Bradycardia and Conduction Tissue Disease in Patients Who Require </b></text>
<text top="212" left="227" width="468" height="21" font="7"><b>Pacing Therapy and May Also Be at Risk for Ventricular Arrhythmias </b></text>
<text top="232" left="118" width="494" height="21" font="8">Referenced studies that support the recommendation are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="232" left="612" width="184" height="21" font="18"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">Online Data Supplement 56</a></text>
<text top="232" left="796" width="8" height="21" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="261" left="104" width="33" height="21" font="7"><b>COR </b></text>
<text top="261" left="179" width="30" height="21" font="7"><b>LOE </b></text>
<text top="261" left="472" width="126" height="21" font="7"><b>Recommendation </b></text>
<text top="309" left="116" width="8" height="21" font="7"><b>I </b></text>
<text top="309" left="175" width="38" height="21" font="7"><b>B-NR </b></text>
<text top="289" left="238" width="600" height="21" font="7"><b>1.  In patients who require permanent pacing therapy, before  implantation, an </b></text>
<text top="309" left="265" width="574" height="21" font="7"><b>assessment of the risk of future ventricular arrhythmias and need for an </b></text>
<text top="329" left="265" width="494" height="21" font="7"><b>implantable cardioverter defibrillator should be performed (S8-1–S8-7). </b></text>
<text top="350" left="81" width="4" height="21" font="8"> </text>
<text top="379" left="81" width="4" height="21" font="8"> </text>
<text top="418" left="81" width="270" height="31" font="2"><b>9. Shared Decision-Making </b></text>
<text top="457" left="106" width="706" height="21" font="7"><b>Recommendations for Shared Decision-Making for Pacemaker Implantation in the Setting of Guideline-</b></text>
<text top="477" left="320" width="281" height="21" font="7"><b>Based Indications for Bradycardia Pacing </b></text>
<text top="507" left="104" width="33" height="21" font="7"><b>COR </b></text>
<text top="507" left="181" width="30" height="21" font="7"><b>LOE </b></text>
<text top="507" left="470" width="132" height="21" font="7"><b>Recommendations </b></text>
<text top="562" left="117" width="8" height="21" font="7"><b>I </b></text>
<text top="562" left="178" width="35" height="21" font="7"><b>C-LD</b> </text>
<text top="537" left="240" width="594" height="21" font="7"><b>1.  In patients with symptomatic bradycardia or conduction disorder, clinicians and </b></text>
<text top="557" left="267" width="566" height="21" font="7"><b>patients should engage in a shared decision-making approach in which treatment </b></text>
<text top="577" left="267" width="569" height="21" font="7"><b>decisions are based not only on the best available evidence, but also on the </b></text>
<text top="597" left="267" width="411" height="21" font="7"><b>patient’s goals of care, preferences, and values</b> <b>(S9-1–S9-6). </b></text>
<text top="654" left="117" width="8" height="21" font="7"><b>I </b></text>
<text top="654" left="178" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="618" left="240" width="597" height="21" font="7"><b>2.  Patients considering implantation of a pacemaker or  with a pacemaker that </b></text>
<text top="638" left="267" width="570" height="21" font="7"><b>requires lead revision or generator change should be informed of procedural </b></text>
<text top="658" left="267" width="567" height="21" font="7"><b>benefits and risks, including the potential short and long-term complications and </b></text>
<text top="678" left="267" width="566" height="21" font="7"><b>possible alternative therapy, if any, in light of their goals of care, preferences, and </b></text>
<text top="698" left="267" width="133" height="21" font="7"><b>values (S9-1–S9-6). </b></text>
<text top="745" left="98" width="45" height="21" font="7"><b>III: No </b></text>
<text top="765" left="94" width="53" height="21" font="7"><b>Benefit </b></text>
<text top="755" left="178" width="35" height="21" font="7"><b>C-LD </b></text>
<text top="719" left="240" width="598" height="21" font="7"><b>3.  In patients with indications for permanent pacing but also with significant </b></text>
<text top="739" left="267" width="568" height="21" font="7"><b>comorbidities such that pacing therapy is unlikely to provide meaningful clinical </b></text>
<text top="760" left="267" width="573" height="21" font="7"><b>benefit, or if patient goals of care strongly preclude pacemaker therapy, </b></text>
<text top="780" left="267" width="562" height="21" font="7"><b>implantation or replacement of a pacemaker should not be performed (S9-1–S9-</b></text>
<text top="800" left="267" width="22" height="21" font="7"><b>6). </b></text>
<text top="821" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="59" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">59</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="142" left="81" width="426" height="31" font="2"><b>10. Discontinuation of Pacemaker Therapy </b></text>
<text top="181" left="251" width="419" height="21" font="7"><b>Recommendation for Discontinuation of Pacemaker Therapy </b></text>
<text top="211" left="104" width="33" height="21" font="7"><b>COR </b></text>
<text top="211" left="181" width="30" height="21" font="7"><b>LOE </b></text>
<text top="211" left="473" width="126" height="21" font="7"><b>Recommendation </b></text>
<text top="281" left="110" width="21" height="21" font="7"><b>IIa </b></text>
<text top="281" left="178" width="35" height="21" font="7"><b>C-LD</b> </text>
<text top="241" left="240" width="597" height="21" font="7"><b>1.  In patients who present for pacemaker pulse generator replacement, or for </b></text>
<text top="261" left="270" width="564" height="21" font="7"><b>management of pacemaker related complications, in whom the original pacing </b></text>
<text top="281" left="270" width="562" height="21" font="7"><b>indication has resolved or is in question, discontinuation of pacemaker therapy is </b></text>
<text top="301" left="270" width="565" height="21" font="7"><b>reasonable after evaluation of symptoms during a period of monitoring while </b></text>
<text top="321" left="270" width="245" height="21" font="7"><b>pacing therapy is off</b> <b>(S10-1, S10-2). </b></text>
<text top="342" left="81" width="4" height="21" font="8"> </text>
<text top="371" left="81" width="4" height="21" font="8"> </text>
<text top="392" left="81" width="4" height="23" font="23"> </text>
<text top="391" left="297" width="4" height="23" font="4"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="60" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">60</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="154" height="23" font="4"><b>Presidents and Staff </b></text>
<text top="155" left="81" width="4" height="21" font="8"> </text>
<text top="184" left="81" width="218" height="21" font="5"><i><b>American College of Cardiology </b></i></text>
<text top="204" left="81" width="288" height="21" font="8">C. Michael Valentine, MD, FACC, President </text>
<text top="224" left="81" width="400" height="21" font="8">Timothy W. Attebery, MBA, FACHE, Chief Executive Officer  </text>
<text top="244" left="81" width="706" height="21" font="8">William J. Oetgen, MD, MBA, FACC, Executive Vice President, Science, Education, Quality, and Publishing  </text>
<text top="264" left="81" width="555" height="21" font="8">MaryAnne Elma, MPH, Senior Director, Science, Education, Quality, and Publishing </text>
<text top="285" left="81" width="589" height="21" font="8">Amelia Scholtz, PhD, Publications Manager, Science, Education, Quality, and Publishing  </text>
<text top="305" left="81" width="4" height="21" font="8"> </text>
<text top="334" left="81" width="420" height="21" font="5"><i><b>American College of Cardiology/American Heart Association  </b></i></text>
<text top="354" left="81" width="485" height="21" font="8">Katherine A. Sheehan, PhD, Director, Guideline Strategy and Operations </text>
<text top="374" left="81" width="367" height="21" font="8">Abdul R. Abdullah, MD, Science and Medicine Advisor  </text>
<text top="394" left="81" width="347" height="21" font="8">Thomas S. D. Getchius, Manager, Guideline Science </text>
<text top="415" left="81" width="444" height="21" font="8">Sam Shahid, MBBS, MPH, Associate Science and Medicine Advisor </text>
<text top="435" left="81" width="561" height="21" font="8">Zainab Shipchandler, MPH, Associate Guideline Advisor, Clinical Practice Guidelines </text>
<text top="455" left="81" width="4" height="21" font="8"> </text>
<text top="484" left="81" width="194" height="21" font="5"><i><b>American Heart Association </b></i></text>
<text top="504" left="81" width="259" height="21" font="8">Ivor J. Benjamin, MD, FAHA, President </text>
<text top="524" left="81" width="253" height="21" font="8">Nancy Brown, Chief Executive Officer </text>
<text top="544" left="81" width="462" height="21" font="8">Rose Marie Robertson, MD, FAHA, Chief Science and Medical Officer </text>
<text top="564" left="81" width="625" height="21" font="8">Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice President, Office of Science Operations </text>
<text top="585" left="81" width="399" height="21" font="8">Paul St. Laurent, DNP, APRN, Science and Medicine Advisor </text>
<text top="605" left="81" width="698" height="21" font="8">Jody Hundley, Production and Operations Manager, Scientific Publications, Office of Science Operations </text>
<text top="635" left="81" width="4" height="21" font="8"> </text>
<text top="665" left="81" width="4" height="21" font="8"> </text>
<text top="695" left="81" width="260" height="21" font="7"><b>Key Words</b>: AHA Scientific Statements </text>
<text top="695" left="341" width="434" height="22" font="8">■ ablation ■ ambulatory electrocardiography ■ aminophylline ■ </text>
<text top="715" left="81" width="148" height="21" font="8">atrioventricular block </text>
<text top="715" left="229" width="570" height="22" font="8">■ atropine ■ AV block ■ beta-adrenergic agonist ■ bradyarrhythmia ■ bradycardia ■ </text>
<text top="736" left="81" width="141" height="21" font="8">bundle branch block </text>
<text top="735" left="222" width="572" height="22" font="8">■ cardiac pacing ■ cardiac resynchronization therapy ■ cardiac sinus pause ■ cardiac </text>
<text top="756" left="81" width="55" height="21" font="8">surgery </text>
<text top="755" left="136" width="695" height="22" font="8">■ congenital heart disease ■ digoxin antibodies Fab fragments ■ electrocardiogram ■ glucagon ■ heart </text>
<text top="776" left="81" width="40" height="21" font="8">block </text>
<text top="775" left="120" width="701" height="22" font="8">■ Holter monitoring ■ intraoperative ■ isoproterenol ■ lamin A-C ■ left bundle branch block ■ muscular </text>
<text top="796" left="81" width="82" height="21" font="8">dystrophies </text>
<text top="795" left="163" width="675" height="22" font="8">■ myocardial infarction ■ myotonic dystrophy ■ pacemaker ■ pacing ■ preoperative ■ quality of life </text>
<text top="816" left="81" width="752" height="22" font="8">■ right bundle branch block ■ sarcoidosis ■ shared decision making ■ sick sinus syndrome ■ sinus arrest ■ sinus </text>
<text top="836" left="81" width="154" height="21" font="8">bradycardia syndrome </text>
<text top="836" left="235" width="600" height="22" font="8">■ sinus node dysfunction ■ spinal cord injuries ■ syncope ■ theophylline ■ transcatheter </text>
<text top="857" left="81" width="174" height="21" font="8">aortic valve replacement. </text>
<text top="895" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="61" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="34" size="11" family="Times" color="#000000"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="859" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="859" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="857" left="412" width="15" height="19" font="1">61</text>
<text top="856" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="994" height="31" font="2"><b>Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2018 ACC/AHA/HRS </b></text>
<text top="153" left="81" width="994" height="31" font="2"><b>Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction </b></text>
<text top="183" left="81" width="179" height="31" font="2"><b>Delay (July 2018)  </b></text>
<text top="255" left="89" width="66" height="17" font="16"><b>Committee </b></text>
<text top="271" left="89" width="51" height="17" font="16"><b>Member </b></text>
<text top="271" left="181" width="75" height="17" font="16"><b>Employment </b></text>
<text top="271" left="353" width="64" height="17" font="16"><b>Consultant </b></text>
<text top="255" left="488" width="54" height="17" font="16"><b>Speakers </b></text>
<text top="271" left="488" width="43" height="17" font="16"><b>Bureau </b></text>
<text top="238" left="587" width="70" height="17" font="16"><b>Ownership/ </b></text>
<text top="255" left="587" width="74" height="17" font="16"><b>Partnership/ </b></text>
<text top="271" left="587" width="52" height="17" font="16"><b>Principal </b></text>
<text top="271" left="685" width="106" height="17" font="16"><b>Personal Research </b></text>
<text top="222" left="808" width="75" height="17" font="16"><b>Institutional, </b></text>
<text top="238" left="808" width="104" height="17" font="16"><b>Organizational, or </b></text>
<text top="255" left="808" width="88" height="17" font="16"><b>Other Financial </b></text>
<text top="271" left="808" width="44" height="17" font="16"><b>Benefit </b></text>
<text top="271" left="931" width="87" height="17" font="16"><b>Expert Witness </b></text>
<text top="222" left="1035" width="40" height="17" font="16"><b>Voting </b></text>
<text top="238" left="1035" width="51" height="17" font="16"><b>Recusals </b></text>
<text top="255" left="1035" width="17" height="17" font="16"><b>by </b></text>
<text top="271" left="1035" width="51" height="17" font="16"><b>Section* </b></text>
<text top="288" left="89" width="46" height="17" font="17">Fred M. </text>
<text top="305" left="89" width="59" height="17" font="17">Kusumoto </text>
<text top="321" left="89" width="40" height="18" font="34"><i>(Chair)</i> </text>
<text top="288" left="181" width="145" height="17" font="17">Mayo Clinic—Professor of </text>
<text top="305" left="181" width="54" height="17" font="17">Medicine </text>
<text top="288" left="353" width="33" height="17" font="17">None </text>
<text top="288" left="488" width="33" height="17" font="17">None </text>
<text top="288" left="587" width="33" height="17" font="17">None </text>
<text top="288" left="685" width="33" height="17" font="17">None </text>
<text top="288" left="808" width="33" height="17" font="17">None </text>
<text top="288" left="931" width="33" height="17" font="17">None </text>
<text top="288" left="1035" width="33" height="17" font="17">None </text>
<text top="339" left="89" width="47" height="17" font="17">Mark H. </text>
<text top="355" left="89" width="64" height="17" font="17">Schoenfeld </text>
<text top="371" left="89" width="66" height="18" font="34"><i>(Vice Chair)</i> </text>
<text top="339" left="181" width="138" height="17" font="17">Yale University School of </text>
<text top="355" left="181" width="105" height="17" font="17">Medicine—Clinical </text>
<text top="371" left="181" width="123" height="17" font="17">Professor of Medicine </text>
<text top="339" left="353" width="33" height="17" font="17">None </text>
<text top="339" left="488" width="33" height="17" font="17">None </text>
<text top="339" left="587" width="33" height="17" font="17">None </text>
<text top="339" left="685" width="33" height="17" font="17">None </text>
<text top="339" left="808" width="33" height="17" font="17">None </text>
<text top="339" left="931" width="33" height="17" font="17">None </text>
<text top="339" left="1035" width="33" height="17" font="17">None </text>
<text top="389" left="89" width="56" height="17" font="17">Coletta C. </text>
<text top="405" left="89" width="42" height="17" font="17">Barrett </text>
<text top="389" left="181" width="89" height="17" font="17">American Heart </text>
<text top="405" left="181" width="145" height="17" font="17">Association—Chairman of </text>
<text top="422" left="181" width="57" height="17" font="17">the Board </text>
<text top="389" left="353" width="33" height="17" font="17">None </text>
<text top="389" left="488" width="33" height="17" font="17">None </text>
<text top="389" left="587" width="33" height="17" font="17">None </text>
<text top="389" left="685" width="33" height="17" font="17">None </text>
<text top="389" left="808" width="33" height="17" font="17">None </text>
<text top="389" left="931" width="33" height="17" font="17">None </text>
<text top="389" left="1035" width="33" height="17" font="17">None </text>
<text top="439" left="89" width="50" height="17" font="17">James R. </text>
<text top="455" left="89" width="53" height="17" font="17">Edgerton </text>
<text top="439" left="181" width="152" height="17" font="17">The Heart Hospital Baylor—</text>
<text top="455" left="181" width="120" height="17" font="17">Director of Education </text>
<text top="439" left="353" width="33" height="17" font="17">None </text>
<text top="439" left="488" width="33" height="17" font="17">None </text>
<text top="439" left="587" width="33" height="17" font="17">None </text>
<text top="439" left="685" width="33" height="17" font="17">None </text>
<text top="439" left="808" width="33" height="17" font="17">None </text>
<text top="439" left="931" width="33" height="17" font="17">None </text>
<text top="439" left="1035" width="33" height="17" font="17">None </text>
<text top="486" left="89" width="63" height="17" font="17">Kenneth A. </text>
<text top="503" left="89" width="64" height="17" font="17">Ellenbogen </text>
<text top="486" left="181" width="122" height="17" font="17">VCU Medical Center—</text>
<text top="503" left="181" width="93" height="17" font="17">Director, Clinical </text>
<text top="519" left="181" width="100" height="17" font="17">Electrophysiology </text>
<text top="486" left="357" width="73" height="18" font="17">•  Biotronik† </text>
<text top="504" left="357" width="114" height="18" font="17">•  Boston Scientific† </text>
<text top="521" left="357" width="59" height="18" font="17">•  Janssen </text>
<text top="538" left="370" width="93" height="17" font="17">Pharmaceuticals </text>
<text top="555" left="357" width="81" height="18" font="17">•  Medtronic† </text>
<text top="572" left="357" width="54" height="18" font="17">•  Pfizer† </text>
<text top="589" left="357" width="112" height="18" font="17">•  St. Jude Medical† </text>
<text top="486" left="492" width="65" height="18" font="17">•  Biosense </text>
<text top="503" left="505" width="57" height="17" font="17">Webster† </text>
<text top="520" left="492" width="73" height="18" font="17">•  Biotronik† </text>
<text top="537" left="492" width="55" height="18" font="17">•  Boston </text>
<text top="554" left="505" width="59" height="17" font="17">Scientific† </text>
<text top="571" left="492" width="81" height="18" font="17">•  Medtronic† </text>
<text top="588" left="492" width="59" height="18" font="17">•  St. Jude </text>
<text top="605" left="505" width="53" height="17" font="17">Medical† </text>
<text top="486" left="590" width="33" height="17" font="17">None </text>
<text top="486" left="688" width="65" height="18" font="17">•  Biosense </text>
<text top="503" left="702" width="57" height="17" font="17">Webster† </text>
<text top="520" left="688" width="55" height="18" font="17">•  Boston </text>
<text top="537" left="702" width="59" height="17" font="17">Scientific† </text>
<text top="554" left="688" width="81" height="18" font="17">•  Medtronic† </text>
<text top="571" left="688" width="102" height="18" font="17">•  Sanofi-Aventis† </text>
<text top="588" left="688" width="74" height="18" font="17">•  Medtronic </text>
<text top="605" left="702" width="51" height="17" font="17">(DSMB)† </text>
<text top="486" left="811" width="65" height="18" font="17">•  Biosense </text>
<text top="503" left="824" width="57" height="17" font="17">Webster† </text>
<text top="520" left="811" width="55" height="18" font="17">•  Boston </text>
<text top="537" left="824" width="59" height="17" font="17">Scientific† </text>
<text top="554" left="811" width="81" height="18" font="17">•  Medtronic† </text>
<text top="571" left="811" width="95" height="18" font="17">•  Sanofi-Aventis </text>
<text top="486" left="931" width="33" height="17" font="17">None </text>
<text top="486" left="1035" width="34" height="17" font="17">4.3.1, </text>
<text top="503" left="1035" width="61" height="17" font="17">4.3.2, 5, 6, </text>
<text top="519" left="1035" width="60" height="17" font="17">7, 8, 9, 11, </text>
<text top="536" left="1035" width="17" height="17" font="17">13 </text>
<text top="622" left="89" width="61" height="17" font="17">Michael R. </text>
<text top="639" left="89" width="29" height="17" font="17">Gold </text>
<text top="622" left="181" width="154" height="17" font="17">Medical University of South </text>
<text top="639" left="181" width="155" height="17" font="17">Carolina—Director, Division </text>
<text top="655" left="181" width="154" height="17" font="17">of Cardiology and Professor </text>
<text top="672" left="181" width="68" height="17" font="17">of Medicine </text>
<text top="622" left="357" width="114" height="17" font="17">•  Boston Scientific† </text>
<text top="639" left="357" width="74" height="17" font="17">•  Medtronic </text>
<text top="655" left="357" width="106" height="17" font="17">•  St. Jude Medical </text>
<text top="622" left="492" width="33" height="17" font="17">None </text>
<text top="622" left="590" width="33" height="17" font="17">None </text>
<text top="623" left="688" width="55" height="18" font="17">•  Boston </text>
<text top="639" left="702" width="59" height="17" font="17">Scientific‡ </text>
<text top="656" left="688" width="59" height="18" font="17">•  St. Jude </text>
<text top="673" left="702" width="53" height="17" font="17">Medical‡ </text>
<text top="622" left="811" width="33" height="17" font="17">None </text>
<text top="622" left="931" width="33" height="17" font="17">None </text>
<text top="622" left="1035" width="61" height="17" font="17">4.3.1, 5, 6, </text>
<text top="639" left="1035" width="60" height="17" font="17">7, 8, 9, 11, </text>
<text top="655" left="1035" width="17" height="17" font="17">13 </text>
<text top="690" left="89" width="43" height="17" font="17">Nora F. </text>
<text top="707" left="89" width="74" height="17" font="17">Goldschlager </text>
<text top="690" left="181" width="151" height="17" font="17">University of California San </text>
<text top="707" left="181" width="133" height="17" font="17">Francisco—Professor of </text>
<text top="723" left="181" width="96" height="17" font="17">Clinical Medicine </text>
<text top="690" left="353" width="33" height="17" font="17">None </text>
<text top="690" left="488" width="33" height="17" font="17">None </text>
<text top="690" left="587" width="36" height="17" font="17">None  </text>
<text top="690" left="685" width="33" height="17" font="17">None </text>
<text top="690" left="808" width="33" height="17" font="17">None </text>
<text top="690" left="931" width="33" height="17" font="17">None </text>
<text top="690" left="1035" width="33" height="17" font="17">None </text>
<text top="741" left="89" width="59" height="17" font="17">Robert M. </text>
<text top="757" left="89" width="54" height="17" font="17">Hamilton </text>
<text top="741" left="181" width="129" height="17" font="17">University of Toronto—</text>
<text top="757" left="181" width="126" height="17" font="17">Professor of Pediatrics </text>
<text top="741" left="353" width="33" height="17" font="17">None </text>
<text top="741" left="488" width="33" height="17" font="17">None </text>
<text top="741" left="587" width="36" height="17" font="17">None  </text>
<text top="741" left="685" width="33" height="17" font="17">None </text>
<text top="741" left="808" width="33" height="17" font="17">None </text>
<text top="741" left="931" width="33" height="17" font="17">None </text>
<text top="741" left="1035" width="33" height="17" font="17">None </text>
<text top="457" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="62" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="859" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="859" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="857" left="412" width="15" height="19" font="1">62</text>
<text top="856" left="428" width="4" height="21" font="8"> </text>
<text top="125" left="89" width="237" height="17" font="17">José A. Joglar  UT Southwestern Medical </text>
<text top="141" left="181" width="107" height="17" font="17">Center University—</text>
<text top="158" left="181" width="124" height="17" font="17">Associate Professor of </text>
<text top="174" left="181" width="100" height="17" font="17">Internal Medicine </text>
<text top="125" left="353" width="33" height="17" font="17">None </text>
<text top="125" left="488" width="33" height="17" font="17">None </text>
<text top="125" left="587" width="36" height="17" font="17">None  </text>
<text top="125" left="685" width="33" height="17" font="17">None </text>
<text top="125" left="808" width="33" height="17" font="17">None </text>
<text top="125" left="931" width="33" height="17" font="17">None </text>
<text top="125" left="1035" width="33" height="17" font="17">None </text>
<text top="191" left="89" width="249" height="17" font="17">Robert J. Kim  University of Florida College </text>
<text top="208" left="181" width="130" height="17" font="17">of Medicine—Assistant </text>
<text top="224" left="181" width="55" height="17" font="17">Professor </text>
<text top="191" left="353" width="33" height="17" font="17">None </text>
<text top="191" left="488" width="33" height="17" font="17">None </text>
<text top="191" left="587" width="36" height="17" font="17">None  </text>
<text top="191" left="685" width="33" height="17" font="17">None </text>
<text top="191" left="808" width="33" height="17" font="17">None </text>
<text top="191" left="931" width="33" height="17" font="17">None </text>
<text top="191" left="1035" width="33" height="17" font="17">None </text>
<text top="242" left="89" width="67" height="17" font="17">Richard Lee </text>
<text top="242" left="181" width="107" height="17" font="17">St. Louis University </text>
<text top="258" left="181" width="130" height="17" font="17">Hospital—Co–Director, </text>
<text top="275" left="181" width="148" height="17" font="17">Center for Comprehensive </text>
<text top="291" left="181" width="112" height="17" font="17">Cardiovascular Care </text>
<text top="242" left="353" width="33" height="17" font="17">None </text>
<text top="242" left="488" width="33" height="17" font="17">None </text>
<text top="242" left="587" width="36" height="17" font="17">None  </text>
<text top="242" left="685" width="33" height="17" font="17">None </text>
<text top="242" left="808" width="33" height="17" font="17">None </text>
<text top="242" left="931" width="33" height="17" font="17">None </text>
<text top="242" left="1035" width="33" height="17" font="17">None </text>
<text top="308" left="89" width="54" height="17" font="17">Joseph E. </text>
<text top="325" left="89" width="43" height="17" font="17">Marine </text>
<text top="308" left="181" width="149" height="17" font="17">Johns Hopkins University—</text>
<text top="325" left="181" width="124" height="17" font="17">Associate Professor of </text>
<text top="341" left="181" width="54" height="17" font="17">Medicine </text>
<text top="308" left="353" width="33" height="17" font="17">None </text>
<text top="308" left="488" width="33" height="17" font="17">None </text>
<text top="308" left="587" width="36" height="17" font="17">None  </text>
<text top="308" left="685" width="33" height="17" font="17">None </text>
<text top="308" left="808" width="33" height="17" font="17">None </text>
<text top="308" left="931" width="33" height="17" font="17">None </text>
<text top="308" left="1035" width="33" height="17" font="17">None </text>
<text top="359" left="89" width="78" height="17" font="17">Christopher J. </text>
<text top="375" left="89" width="47" height="17" font="17">McLeod </text>
<text top="359" left="181" width="148" height="17" font="17">Mayo Clinic—Co–Director, </text>
<text top="375" left="181" width="144" height="17" font="17">Division of Cardiovascular </text>
<text top="391" left="181" width="50" height="17" font="17">Diseases </text>
<text top="359" left="353" width="33" height="17" font="17">None </text>
<text top="359" left="488" width="33" height="17" font="17">None </text>
<text top="359" left="587" width="36" height="17" font="17">None  </text>
<text top="359" left="685" width="33" height="17" font="17">None </text>
<text top="359" left="808" width="33" height="17" font="17">None </text>
<text top="359" left="931" width="33" height="17" font="17">None </text>
<text top="359" left="1035" width="33" height="17" font="17">None </text>
<text top="409" left="89" width="218" height="17" font="17">Keith R. Oken  Mayo Clinic—Program </text>
<text top="425" left="181" width="135" height="17" font="17">Director, Cardiovascular </text>
<text top="442" left="181" width="135" height="17" font="17">Diseases Fellowship and </text>
<text top="458" left="181" width="122" height="17" font="17">Assistant Professor of </text>
<text top="475" left="181" width="54" height="17" font="17">Medicine </text>
<text top="409" left="353" width="33" height="17" font="17">None </text>
<text top="409" left="488" width="33" height="17" font="17">None </text>
<text top="409" left="587" width="36" height="17" font="17">None  </text>
<text top="409" left="685" width="33" height="17" font="17">None </text>
<text top="409" left="808" width="33" height="17" font="17">None </text>
<text top="409" left="931" width="33" height="17" font="17">None </text>
<text top="409" left="1035" width="33" height="17" font="17">None </text>
<text top="492" left="89" width="55" height="17" font="17">Kristen K. </text>
<text top="508" left="89" width="40" height="17" font="17">Patton </text>
<text top="492" left="181" width="151" height="17" font="17">University of Washington—</text>
<text top="508" left="181" width="123" height="17" font="17">Professor of Medicine </text>
<text top="492" left="353" width="33" height="17" font="17">None </text>
<text top="492" left="488" width="33" height="17" font="17">None </text>
<text top="492" left="587" width="36" height="17" font="17">None  </text>
<text top="492" left="685" width="33" height="17" font="17">None </text>
<text top="492" left="808" width="33" height="17" font="17">None </text>
<text top="492" left="931" width="33" height="17" font="17">None </text>
<text top="492" left="1035" width="33" height="17" font="17">None </text>
<text top="539" left="89" width="28" height="17" font="17">Cara </text>
<text top="556" left="89" width="54" height="17" font="17">Pellegrini </text>
<text top="539" left="181" width="151" height="17" font="17">University of California San </text>
<text top="556" left="181" width="108" height="17" font="17">Francisco School of </text>
<text top="572" left="181" width="118" height="17" font="17">Medicine—Associate </text>
<text top="589" left="181" width="55" height="17" font="17">Professor </text>
<text top="539" left="353" width="54" height="18" font="17">• Abbott  </text>
<text top="556" left="353" width="71" height="18" font="17">• Medtronic </text>
<text top="539" left="488" width="33" height="17" font="17">None </text>
<text top="539" left="587" width="36" height="17" font="17">None  </text>
<text top="539" left="685" width="33" height="17" font="17">None </text>
<text top="539" left="808" width="33" height="17" font="17">None </text>
<text top="539" left="931" width="33" height="17" font="17">None </text>
<text top="539" left="1035" width="61" height="17" font="17">4.3.1, 5, 6, </text>
<text top="556" left="1035" width="60" height="17" font="17">7, 8, 9, 11, </text>
<text top="572" left="1035" width="17" height="17" font="17">13 </text>
<text top="606" left="89" width="66" height="17" font="17">Kimberly A. </text>
<text top="622" left="89" width="49" height="17" font="17">Selzman </text>
<text top="606" left="181" width="156" height="17" font="17">University of Utah School of </text>
<text top="622" left="181" width="118" height="17" font="17">Medicine—Associate </text>
<text top="639" left="181" width="123" height="17" font="17">Professor of Medicine </text>
<text top="606" left="353" width="33" height="17" font="17">None </text>
<text top="606" left="488" width="33" height="17" font="17">None </text>
<text top="606" left="587" width="36" height="17" font="17">None  </text>
<text top="606" left="685" width="33" height="17" font="17">None </text>
<text top="606" left="808" width="33" height="17" font="17">None </text>
<text top="606" left="931" width="33" height="17" font="17">None </text>
<text top="606" left="1035" width="33" height="17" font="17">None </text>
<text top="656" left="89" width="63" height="17" font="17">Annemarie </text>
<text top="672" left="89" width="61" height="17" font="17">Thompson </text>
<text top="656" left="181" width="144" height="17" font="17">Duke University School of </text>
<text top="672" left="181" width="133" height="17" font="17">Medicine—Professor of </text>
<text top="689" left="181" width="110" height="17" font="17">Anesthesiology and </text>
<text top="705" left="181" width="54" height="17" font="17">Medicine </text>
<text top="656" left="353" width="33" height="17" font="17">None </text>
<text top="656" left="488" width="33" height="17" font="17">None </text>
<text top="656" left="587" width="36" height="17" font="17">None  </text>
<text top="656" left="685" width="33" height="17" font="17">None </text>
<text top="656" left="808" width="33" height="17" font="17">None </text>
<text top="656" left="931" width="33" height="17" font="17">None </text>
<text top="656" left="1035" width="33" height="17" font="17">None </text>
<text top="723" left="89" width="41" height="17" font="17">Paul D. </text>
<text top="739" left="89" width="40" height="17" font="17">Varosy </text>
<text top="723" left="181" width="155" height="17" font="17">VA Eastern Colorado Health </text>
<text top="739" left="181" width="131" height="17" font="17">Care System—Director, </text>
<text top="756" left="181" width="147" height="17" font="17">Cardiac Electrophysiology; </text>
<text top="772" left="181" width="135" height="17" font="17">University of Colorado—</text>
<text top="789" left="181" width="124" height="17" font="17">Associate Professor of </text>
<text top="805" left="181" width="54" height="17" font="17">Medicine </text>
<text top="723" left="353" width="33" height="17" font="17">None </text>
<text top="723" left="488" width="33" height="17" font="17">None </text>
<text top="723" left="587" width="36" height="17" font="17">None  </text>
<text top="723" left="685" width="33" height="17" font="17">None </text>
<text top="723" left="808" width="33" height="17" font="17">None </text>
<text top="723" left="931" width="33" height="17" font="17">None </text>
<text top="723" left="1035" width="33" height="17" font="17">None </text>
<text top="457" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="63" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="859" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="859" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="857" left="412" width="15" height="19" font="1">63</text>
<text top="856" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="1029" height="19" font="1">This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships </text>
<text top="142" left="81" width="1029" height="19" font="1">were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does </text>
<text top="161" left="81" width="1031" height="19" font="1">not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents </text>
<text top="179" left="81" width="1030" height="19" font="1">ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the </text>
<text top="197" left="81" width="1030" height="19" font="1">person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the </text>
<text top="216" left="81" width="542" height="19" font="1">purpose of transparency. Relationships in this table are modest unless otherwise noted.  </text>
<text top="234" left="135" width="975" height="19" font="1">According to the ACC/AHA, a person has a <i>relevant</i> relationship IF: a) the <i>relationship or interest</i> relates to the same or similar subject matter, intellectual property </text>
<text top="252" left="81" width="1030" height="19" font="1">or asset, topic, or issue addressed in the <i>document;</i> or b) the <i>company/entity</i> (with whom the relationship exists) makes a drug, drug class, or device addressed in the </text>
<text top="270" left="81" width="1031" height="20" font="15"><i>document</i> or makes a competing drug or device addressed in the <i>document</i>; or c) the <i>person or a member of the person’s household</i>, has a reasonable potential for </text>
<text top="289" left="81" width="689" height="19" font="1">financial, professional or other personal gain or loss as a result of the issues/content addressed in the <i>document</i>.<b> </b></text>
<text top="307" left="81" width="3" height="19" font="1"> </text>
<text top="326" left="81" width="1029" height="19" font="1">*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. </text>
<text top="344" left="81" width="360" height="19" font="1">Section numbers pertain to those in the full-text guideline. </text>
<text top="362" left="81" width="154" height="19" font="1">†Significant relationship. </text>
<text top="381" left="81" width="134" height="19" font="1">‡No financial benefit. </text>
<text top="399" left="81" width="3" height="19" font="1"> </text>
<text top="417" left="81" width="1030" height="19" font="1">CMS reported payments from Cardiofocus to Dr. Kusumoto in 2016 and 2017. Dr. Kusumoto has established that the study he participated in ended in 2014 and was </text>
<text top="435" left="81" width="115" height="19" font="1">published in 2015. </text>
<text top="454" left="81" width="1031" height="19" font="1">CMS reported consulting payments to Dr. Lee from Abbott, Cryolife and Maquet in 2016. Dr. Lee has established that his participation with the companies ended in </text>
<text top="472" left="81" width="88" height="19" font="1">January 2015. </text>
<text top="490" left="81" width="745" height="19" font="1">CMS reported research payments from Medtronic to Dr. McLeod in 2016 and 2017. Dr. McLeod is disputing the payments.</text>
<text top="492" left="826" width="3" height="17" font="17"> </text>
<text top="509" left="81" width="3" height="19" font="1"> </text>
<text top="527" left="81" width="1029" height="19" font="1">ACC indicates American College of Cardiology; AHA, American Heart Association; DSMB, data safety monitoring board; HRS, Heart Rhythm Society; UT, University of Texas; </text>
<text top="545" left="81" width="408" height="19" font="1">VA, Veterans Affairs; and VCU, Virginia Commonwealth University. </text>
<text top="563" left="81" width="4" height="21" font="8"> </text>
<text top="603" left="81" width="4" height="21" font="8"> </text>
<text top="457" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="64" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="35" size="12" family="Times" color="#303030"/>
	<fontspec id="36" size="12" family="Times" color="#222222"/>
	<fontspec id="37" size="12" family="Times" color="#ff0000"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="859" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="859" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="857" left="412" width="15" height="19" font="1">64</text>
<text top="856" left="428" width="4" height="21" font="8"> </text>
<text top="124" left="81" width="119" height="31" font="2"><b>Appendix 2.</b></text>
<text top="131" left="200" width="4" height="21" font="7"><b> </b></text>
<text top="124" left="204" width="764" height="31" font="2"><b>Abbreviated Reviewer Relationships With Industry and Other Entities—2018 </b></text>
<text top="153" left="81" width="1023" height="31" font="2"><b>ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac </b></text>
<text top="182" left="81" width="337" height="31" font="2"><b>Conduction Delay (August 2018)* </b></text>
<text top="213" left="146" width="62" height="19" font="0"><b>Reviewer </b></text>
<text top="213" left="374" width="99" height="19" font="0"><b>Representation </b></text>
<text top="213" left="724" width="83" height="19" font="0"><b>Employment </b></text>
<text top="213" left="963" width="137" height="19" font="0"><b>Comprehensive RWI? </b></text>
<text top="232" left="89" width="88" height="19" font="1">Yong-Mei Cha </text>
<text top="232" left="277" width="147" height="19" font="1">Official Reviewer—AHA </text>
<text top="232" left="583" width="294" height="19" font="1">Mayo Clinic, Division of Cardiovascular Diseases </text>
<text top="232" left="1021" width="21" height="19" font="1">No </text>
<text top="251" left="89" width="140" height="19" font="1">Zachary D. Goldberger </text>
<text top="251" left="277" width="264" height="19" font="1">Official Reviewer—ACC/AHA Task Force on </text>
<text top="269" left="277" width="166" height="19" font="1">Clinical Practice Guidelines </text>
<text top="251" left="583" width="346" height="19" font="1">University of Washington School of Medicine—Assistant </text>
<text top="269" left="583" width="355" height="19" font="1">Professor of Medicine; Division of Cardiology, Harborview </text>
<text top="287" left="583" width="96" height="19" font="1">Medical Center </text>
<text top="251" left="1021" width="21" height="19" font="1">No </text>
<text top="307" left="89" width="107" height="19" font="1">Richard J. Kovacs </text>
<text top="307" left="277" width="268" height="19" font="1">Official Reviewer—ACC Science and Quality </text>
<text top="325" left="277" width="72" height="19" font="1">Committee </text>
<text top="307" left="583" width="237" height="19" font="35">Indiana University School of Medicine, </text>
<text top="307" left="820" width="112" height="19" font="1">Krannert Institute </text>
<text top="325" left="583" width="278" height="19" font="1">of Cardiology—Professor of Clinical Medicine </text>
<text top="307" left="1019" width="24" height="19" font="35">Yes </text>
<text top="344" left="89" width="95" height="19" font="1">Kevin F. Kwaku </text>
<text top="344" left="277" width="147" height="19" font="1">Official Reviewer—AHA </text>
<text top="344" left="583" width="187" height="19" font="1">Dartmouth-Hitchcock Medical </text>
<text top="344" left="1021" width="21" height="19" font="1">No </text>
<text top="363" left="89" width="121" height="19" font="1">Daniel M. Philbin Jr </text>
<text top="363" left="277" width="267" height="19" font="1">Official Reviewer—ACC Board of Governors </text>
<text top="363" left="583" width="176" height="19" font="1">New England Heart Institute </text>
<text top="363" left="1019" width="24" height="19" font="1">Yes </text>
<text top="382" left="89" width="91" height="19" font="1">Peter A. Brady </text>
<text top="382" left="277" width="190" height="19" font="1">Organizational Reviewer—HRS </text>
<text top="382" left="583" width="189" height="19" font="1">Mayo Clinic, Mayo Foundation </text>
<text top="382" left="1021" width="21" height="19" font="1">No </text>
<text top="401" left="89" width="92" height="19" font="1">Ratika Parkash </text>
<text top="401" left="277" width="190" height="19" font="1">Organizational Reviewer—HRS </text>
<text top="401" left="583" width="345" height="19" font="1">Dalhousie University and Nova Scotia Health Authority—</text>
<text top="419" left="583" width="362" height="19" font="1">Professor of Medicine, Division of Cardiology (Arrhythmia); </text>
<text top="438" left="583" width="271" height="19" font="1">Director of Research, Division of Cardiology  </text>
<text top="401" left="1019" width="24" height="19" font="1">Yes </text>
<text top="457" left="89" width="111" height="19" font="1">Jonathan Philpott </text>
<text top="457" left="277" width="187" height="19" font="1">Organizational Reviewer—STS </text>
<text top="457" left="583" width="231" height="19" font="1">Mid-Atlantic Cardiothoracic Surgeons </text>
<text top="457" left="1019" width="24" height="19" font="1">Yes </text>
<text top="476" left="89" width="94" height="19" font="1">Kevin Shannon </text>
<text top="476" left="277" width="204" height="19" font="1">Organizational Reviewer—PACES </text>
<text top="476" left="583" width="335" height="19" font="1">Mattel Children's Hospital at UCLA—Clinical Professor, </text>
<text top="494" left="583" width="193" height="19" font="1">Division of Pediatric Cardiology </text>
<text top="476" left="1019" width="24" height="19" font="1">Yes </text>
<text top="513" left="89" width="96" height="19" font="1">Gus J. Vlahakes </text>
<text top="513" left="277" width="197" height="19" font="1">Organizational Reviewer—AATS </text>
<text top="513" left="583" width="319" height="19" font="1">Harvard Medical School and Massachusetts General </text>
<text top="532" left="583" width="191" height="19" font="1">Hospital—Professor of Surgery </text>
<text top="513" left="1021" width="21" height="19" font="1">No </text>
<text top="551" left="89" width="92" height="19" font="1">Nazem Akoum </text>
<text top="551" left="277" width="113" height="19" font="1">Content Reviewer </text>
<text top="551" left="583" width="158" height="19" font="1">University of Washington </text>
<text top="551" left="1021" width="21" height="19" font="1">No </text>
<text top="570" left="89" width="112" height="19" font="1">Sana M. Al-Khatib </text>
<text top="570" left="277" width="270" height="19" font="1">Content Reviewer—ACC/AHA Task Force on </text>
<text top="588" left="277" width="170" height="19" font="1">Clinical Practice Guidelines  </text>
<text top="570" left="583" width="346" height="19" font="1">Duke Clinical Research Institute— Professor of Medicine </text>
<text top="570" left="1019" width="24" height="19" font="1">Yes </text>
<text top="607" left="89" width="120" height="19" font="1">Joshua A. Beckman </text>
<text top="607" left="277" width="270" height="19" font="1">Content Reviewer—ACC/AHA Task Force on </text>
<text top="625" left="277" width="170" height="19" font="1">Clinical Practice Guidelines  </text>
<text top="607" left="583" width="363" height="19" font="1">Vanderbilt University Medical Center— Director, Section of </text>
<text top="625" left="583" width="115" height="19" font="1">Vascular Medicine </text>
<text top="607" left="1019" width="24" height="19" font="1">Yes </text>
<text top="644" left="89" width="94" height="19" font="1">Kim K. Birtcher </text>
<text top="644" left="277" width="270" height="19" font="1">Content Reviewer—ACC/AHA Task Force on </text>
<text top="663" left="277" width="170" height="19" font="1">Clinical Practice Guidelines  </text>
<text top="644" left="583" width="320" height="19" font="1">University of Houston College of Pharmacy—Clinical </text>
<text top="663" left="583" width="61" height="19" font="1">Professor </text>
<text top="644" left="1019" width="24" height="19" font="1">Yes </text>
<text top="682" left="89" width="107" height="19" font="1">Mitchell I. Cohen </text>
<text top="682" left="277" width="165" height="19" font="1">Content Reviewer—PACES </text>
<text top="682" left="583" width="189" height="19" font="35">Pediatric Cardiology Associates</text>
<text top="682" left="772" width="3" height="19" font="1"> </text>
<text top="682" left="1021" width="21" height="19" font="35">No </text>
<text top="701" left="89" width="159" height="19" font="1">Freddy Del-Carpio Munoz </text>
<text top="701" left="277" width="206" height="19" font="1">Content Reviewer—ERC Member </text>
<text top="701" left="583" width="74" height="19" font="1">Mayo Clinic </text>
<text top="701" left="1021" width="21" height="19" font="1">No </text>
<text top="720" left="89" width="98" height="19" font="1">Bernard Dennis </text>
<text top="720" left="277" width="267" height="19" font="1">Content Reviewer—ACC/AHA Lay Reviewer </text>
<text top="720" left="583" width="136" height="19" font="36">Dennis Associates, LLC</text>
<text top="720" left="720" width="3" height="19" font="1"> </text>
<text top="720" left="1021" width="21" height="19" font="36">No </text>
<text top="739" left="89" width="83" height="19" font="1">Anita Deswal </text>
<text top="739" left="277" width="270" height="19" font="1">Content Reviewer—ACC/AHA Task Force on </text>
<text top="757" left="277" width="170" height="19" font="1">Clinical Practice Guidelines  </text>
<text top="739" left="583" width="357" height="19" font="1">Michael E. DeBakey VA Medical Center—Chief, Cardiology;</text>
<text top="739" left="941" width="3" height="19" font="37"> </text>
<text top="757" left="583" width="314" height="19" font="1">Baylor College of Medicine—Professor of Medicine </text>
<text top="739" left="1019" width="24" height="19" font="1">Yes </text>
<text top="776" left="89" width="114" height="19" font="1">Andrew E. Epstein </text>
<text top="776" left="277" width="113" height="19" font="1">Content Reviewer </text>
<text top="776" left="583" width="354" height="19" font="1">The Hospital of the University of Pennsylvania—Professor </text>
<text top="795" left="583" width="76" height="19" font="1">of Medicine </text>
<text top="776" left="1019" width="24" height="19" font="1">Yes </text>
<text top="457" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="65" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="859" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="859" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="857" left="412" width="15" height="19" font="1">65</text>
<text top="856" left="428" width="4" height="21" font="8"> </text>
<text top="125" left="89" width="99" height="19" font="1">Michael E. Field </text>
<text top="125" left="277" width="113" height="19" font="1">Content Reviewer </text>
<text top="125" left="583" width="332" height="19" font="1">University of Wisconsin School of Medicine and Public </text>
<text top="143" left="583" width="344" height="19" font="1">Health—Director, Clinical Electrophysiology and Cardiac </text>
<text top="161" left="583" width="120" height="19" font="1">Arrhythmia Service </text>
<text top="125" left="1021" width="21" height="19" font="1">No </text>
<text top="181" left="89" width="139" height="19" font="1">Michael S. Firstenberg </text>
<text top="181" left="277" width="267" height="19" font="1">Content Reviewer—ACC Surgeons Member </text>
<text top="199" left="277" width="193" height="19" font="1">Section and Leadership Council </text>
<text top="181" left="583" width="352" height="19" font="1">The Medical Center of Aurora—Chair, Cardiovascular and </text>
<text top="199" left="583" width="142" height="19" font="1">Cardiothoracic Surgery </text>
<text top="181" left="1019" width="24" height="19" font="1">Yes </text>
<text top="218" left="89" width="88" height="19" font="1">John D. Fisher </text>
<text top="218" left="277" width="262" height="19" font="1">Content Reviewer—ACC Electrophysiology </text>
<text top="236" left="277" width="140" height="19" font="1">Member Section Chair </text>
<text top="218" left="583" width="326" height="19" font="1">Montefiore Medical Center— Program Director CCEP </text>
<text top="218" left="1019" width="24" height="19" font="1">Yes </text>
<text top="255" left="89" width="104" height="19" font="1">Federico Gentile </text>
<text top="255" left="277" width="270" height="19" font="1">Content Reviewer—ACC/AHA Task Force on </text>
<text top="274" left="277" width="170" height="19" font="1">Clinical Practice Guidelines  </text>
<text top="255" left="583" width="175" height="19" font="1">Centro Cardiologico Gentile  </text>
<text top="255" left="1021" width="21" height="19" font="1">No </text>
<text top="293" left="89" width="88" height="19" font="1">Anne M. Gillis </text>
<text top="293" left="277" width="113" height="19" font="1">Content Reviewer </text>
<text top="293" left="583" width="129" height="19" font="1">University of Calgary </text>
<text top="293" left="1019" width="24" height="19" font="1">Yes </text>
<text top="335" left="89" width="99" height="19" font="1">Bulent Gorenek </text>
<text top="335" left="277" width="113" height="19" font="1">Content Reviewer </text>
<text top="335" left="583" width="351" height="19" font="1">Eskisehir Osmangazi University Cardiology Department— </text>
<text top="353" left="583" width="145" height="19" font="1">Professor of Cardiology </text>
<text top="335" left="1019" width="24" height="19" font="1">Yes </text>
<text top="376" left="89" width="138" height="19" font="1">Mohamed H. Hamdan </text>
<text top="376" left="277" width="113" height="19" font="1">Content Reviewer </text>
<text top="376" left="583" width="361" height="19" font="1">University of Wisconsin-Madison— Chief of Cardiovascular </text>
<text top="395" left="583" width="60" height="19" font="1">Medicine </text>
<text top="376" left="1019" width="24" height="19" font="1">Yes </text>
<text top="418" left="89" width="99" height="19" font="1">Glenn N. Levine </text>
<text top="418" left="277" width="270" height="19" font="1">Content Reviewer—ACC/AHA Task Force on </text>
<text top="436" left="277" width="166" height="19" font="1">Clinical Practice Guidelines </text>
<text top="418" left="583" width="321" height="19" font="1">Baylor College of Medicine— Professor of Medicine; </text>
<text top="436" left="583" width="335" height="19" font="1">Michael E. DeBakey Medical Center—Director, Cardiac </text>
<text top="455" left="583" width="61" height="19" font="1">Care Unit </text>
<text top="418" left="1019" width="24" height="19" font="1">Yes </text>
<text top="474" left="89" width="77" height="19" font="1">Mark S. Link </text>
<text top="474" left="277" width="113" height="19" font="1">Content Reviewer </text>
<text top="474" left="583" width="205" height="19" font="1">UT Southwestern Medical Center </text>
<text top="474" left="1019" width="24" height="19" font="1">Yes </text>
<text top="516" left="89" width="124" height="19" font="1">Daniel L. Lustgarten </text>
<text top="516" left="277" width="113" height="19" font="1">Content Reviewer </text>
<text top="516" left="583" width="258" height="19" font="1">University of Vermont School of Medicine </text>
<text top="516" left="1019" width="24" height="19" font="1">Yes </text>
<text top="558" left="89" width="99" height="19" font="1">Siva K. Mulpuru </text>
<text top="558" left="277" width="206" height="19" font="1">Content Reviewer—ERC Member </text>
<text top="558" left="583" width="207" height="19" font="1">Mayo Clinic—Associate Professor </text>
<text top="558" left="1019" width="24" height="19" font="1">Yes </text>
<text top="599" left="89" width="106" height="19" font="1">Patrick T. O’Gara </text>
<text top="599" left="277" width="270" height="19" font="1">Content Reviewer—ACC/AHA Task Force on </text>
<text top="618" left="277" width="166" height="19" font="1">Clinical Practice Guidelines </text>
<text top="599" left="583" width="354" height="19" font="1">Harvard Medical School—Professor of Medicine; Brigham </text>
<text top="618" left="583" width="321" height="19" font="1">and Women’s Hospital—Director, Strategic Planning </text>
<text top="599" left="1019" width="24" height="19" font="1">Yes </text>
<text top="641" left="89" width="100" height="19" font="1">Brian Olshansky </text>
<text top="641" left="277" width="113" height="19" font="1">Content Reviewer </text>
<text top="641" left="583" width="137" height="19" font="1">Professor of Medicine </text>
<text top="641" left="1019" width="24" height="19" font="1">Yes </text>
<text top="683" left="89" width="82" height="19" font="1">David S. Park </text>
<text top="683" left="277" width="153" height="19" font="1">Content Reviewer—AHA </text>
<text top="683" left="583" width="356" height="19" font="1">NYU Langone Health—Assistant Professor, Department of </text>
<text top="701" left="583" width="60" height="19" font="1">Medicine </text>
<text top="683" left="1021" width="21" height="19" font="1">No </text>
<text top="725" left="89" width="93" height="19" font="1">Mariann Piano </text>
<text top="725" left="277" width="270" height="19" font="1">Content Reviewer—ACC/AHA Task Force on </text>
<text top="743" left="277" width="166" height="19" font="1">Clinical Practice Guidelines </text>
<text top="725" left="583" width="320" height="19" font="1">Vanderbilt University School of Nursing—Nancy and </text>
<text top="743" left="583" width="356" height="19" font="1">Hilliard Travis Professor of Nursing; Senior Associate Dean </text>
<text top="762" left="583" width="80" height="19" font="1">for Research </text>
<text top="725" left="1019" width="24" height="19" font="1">Yes </text>
<text top="781" left="89" width="96" height="19" font="1">Merritt H. Raitt </text>
<text top="781" left="277" width="214" height="19" font="1">Content Reviewer—ERC Vice Chair </text>
<text top="781" left="583" width="341" height="19" font="1">Oregon Heath &amp; Science University; VA Portland Health </text>
<text top="799" left="583" width="165" height="19" font="1">Care System—Cardiologist </text>
<text top="781" left="1021" width="21" height="19" font="1">No </text>
<text top="457" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="66" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="859" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="859" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="857" left="412" width="15" height="19" font="1">66</text>
<text top="856" left="428" width="4" height="21" font="8"> </text>
<text top="125" left="89" width="77" height="19" font="1">Satish R. Raj </text>
<text top="125" left="277" width="113" height="19" font="1">Content Reviewer </text>
<text top="125" left="583" width="129" height="19" font="1">University of Calgary </text>
<text top="125" left="1019" width="24" height="19" font="1">Yes </text>
<text top="167" left="89" width="104" height="19" font="1">Win-Kuang Shen </text>
<text top="167" left="277" width="113" height="19" font="1">Content Reviewer </text>
<text top="167" left="583" width="319" height="19" font="1">Mayo Clinic Arizona, Phoenix Campus—Professor of </text>
<text top="185" left="583" width="345" height="19" font="1">Medicine; Chair, Department of Cardiovascular Diseases </text>
<text top="167" left="1021" width="21" height="19" font="1">No </text>
<text top="209" left="89" width="111" height="19" font="1">David J. Slotwiner </text>
<text top="209" left="277" width="185" height="19" font="1">Content Reviewer—ERC Chair </text>
<text top="209" left="583" width="297" height="19" font="1">Weill Cornell Medical College—Chief, Division of </text>
<text top="227" left="583" width="314" height="19" font="1">Cardiology; Assistant Professor of Clinical Medicine </text>
<text top="209" left="1021" width="21" height="19" font="1">No </text>
<text top="250" left="89" width="106" height="19" font="1">Cynthia M. Tracy </text>
<text top="250" left="277" width="113" height="19" font="1">Content Reviewer </text>
<text top="250" left="583" width="349" height="19" font="1">The George Washington University School of Medicine &amp; </text>
<text top="269" left="583" width="365" height="19" font="1">Health Sciences—Professor of Medicine; Associate Director </text>
<text top="287" left="583" width="84" height="19" font="1">of Cardiology </text>
<text top="250" left="1019" width="24" height="19" font="1">Yes </text>
<text top="306" left="89" width="125" height="19" font="1">Richard G. Trohman </text>
<text top="306" left="277" width="113" height="19" font="1">Content Reviewer </text>
<text top="306" left="583" width="195" height="19" font="1">Rush University Medical Center </text>
<text top="306" left="1019" width="24" height="19" font="1">Yes </text>
<text top="348" left="89" width="128" height="19" font="1">Gaurav A. Upadhyay </text>
<text top="348" left="277" width="262" height="19" font="1">Content Reviewer—ACC Electrophysiology </text>
<text top="366" left="277" width="105" height="19" font="1">Member Section </text>
<text top="348" left="583" width="364" height="19" font="1">The University of Chicago Medicine—Assistant Professor of </text>
<text top="366" left="583" width="206" height="19" font="1">Medicine; Director, Heart Station </text>
<text top="348" left="1019" width="24" height="19" font="1">Yes </text>
<text top="390" left="81" width="1028" height="19" font="1">This table represents all relationships of reviewers with industry and other entities that were reported at the time of peer review, including those not deemed to be </text>
<text top="408" left="81" width="1027" height="19" font="1">relevant to this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A </text>
<text top="426" left="81" width="1027" height="19" font="1">person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership </text>
<text top="445" left="81" width="1027" height="19" font="1">of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the </text>
<text top="463" left="81" width="1026" height="19" font="1">previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise </text>
<text top="481" left="81" width="648" height="19" font="1">noted. Names are listed in alphabetical order within each category of review. Please refer to<a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy"> </a></text>
<text top="481" left="729" width="375" height="19" font="10"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">http://www.acc.org/guidelines/about-guidelines-and-clinical-</a></text>
<text top="500" left="81" width="279" height="19" font="10"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">documents/relationships-with-industry-policy</a></text>
<text top="500" left="360" width="751" height="19" font="1"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">  </a>for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing </text>
<text top="518" left="81" width="81" height="19" font="1">Committees. </text>
<text top="536" left="81" width="3" height="19" font="1"> </text>
<text top="555" left="81" width="343" height="19" font="1">*Detailed reviewer disclosures can be found at this link:<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627"> </a></text>
<text top="555" left="424" width="449" height="19" font="10"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627</a></text>
<text top="555" left="873" width="7" height="19" font="1"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000627">.</a> </text>
<text top="573" left="81" width="3" height="19" font="1"> </text>
<text top="591" left="81" width="1032" height="19" font="1">AATS  indicates American Association for Thoracic Surgery; ACC, American College of Cardiology; AHA, American Heart Association; CCEP,  Clinical Cardiac </text>
<text top="609" left="81" width="1027" height="19" font="1">Electrophysiology; ERC, evidence review committee; HRS, Heart Rhythm Society; LLC, limited liability company, NYU, New York University; PACES, Pediatric &amp; Congenital </text>
<text top="628" left="81" width="963" height="19" font="1">Electrophysiology Society; STS, the Society of Thoracic Surgeons; UCLA, University of California, Los Angeles; UT, University of Texas; and VA, Veterans Affairs. </text>
<text top="646" left="81" width="4" height="21" font="8"> </text>
<text top="666" left="81" width="4" height="21" font="8"> </text>
<text top="666" left="297" width="4" height="21" font="8"> </text>
<text top="457" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="67" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">67</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="110" left="81" width="115" height="31" font="2"><b>References </b></text>
<text top="139" left="81" width="106" height="31" font="2"><b>Preamble  </b></text>
<text top="178" left="81" width="27" height="19" font="1">P-1. </text>
<text top="178" left="167" width="609" height="19" font="1">Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and </text>
<text top="197" left="167" width="599" height="19" font="1">management of patients with bradycardia and cardiac conduction delay: a report of the American </text>
<text top="215" left="167" width="610" height="19" font="1">College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the </text>
<text top="233" left="167" width="302" height="19" font="1">Heart Rhythm Society. Circulation. 2018;In press. </text>
<text top="251" left="81" width="4" height="21" font="8"> </text>
<text top="271" left="81" width="159" height="31" font="2"><b>1. Introduction  </b></text>
<text top="310" left="81" width="34" height="19" font="1">S1-1. </text>
<text top="310" left="167" width="625" height="19" font="1">Slotwiner DJ, Raitt MH, Del-Carpio Munoz F, et al. Impact of physiologic versus right ventricular pacing </text>
<text top="328" left="167" width="607" height="19" font="1">among patients with left ventricular ejection fraction greater than 35%: a systematic review for the </text>
<text top="347" left="167" width="607" height="19" font="1">2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and </text>
<text top="365" left="167" width="620" height="19" font="1">cardiac conduction delay: a report of the American College of Cardiology/American Heart Association </text>
<text top="383" left="167" width="605" height="19" font="1">Task Force on Clinical Practice Guidleines and the Heart Rhythm Society. Circulation. 2018;In press. </text>
<text top="401" left="81" width="3" height="19" font="1"> </text>
<text top="419" left="81" width="239" height="27" font="27"><b>1.4. Scope of the Guideline </b></text>
<text top="454" left="81" width="45" height="19" font="1">S1.4-1. </text>
<text top="454" left="167" width="620" height="19" font="1">Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy </text>
<text top="473" left="167" width="590" height="19" font="1">of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart </text>
<text top="491" left="167" width="628" height="19" font="1">Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 </text>
<text top="509" left="167" width="619" height="19" font="1">Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Developed in </text>
<text top="528" left="167" width="607" height="19" font="1">collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. </text>
<text top="546" left="167" width="202" height="19" font="1">Circulation. 2008;117:e350–408. </text>
<text top="564" left="81" width="45" height="19" font="1">S1.4-2. </text>
<text top="564" left="167" width="615" height="19" font="1">Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into </text>
<text top="582" left="167" width="589" height="19" font="1">the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a </text>
<text top="601" left="167" width="611" height="19" font="1">report of the American College of Cardiology Foundation/American Heart Association Task Force on </text>
<text top="619" left="167" width="439" height="19" font="1">Practice Guidelines and the Heart Rhythm Society. 2012;127:e283–352. </text>
<text top="637" left="81" width="45" height="19" font="1">S1.4-3. </text>
<text top="637" left="167" width="611" height="19" font="1">Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of </text>
<text top="656" left="167" width="597" height="19" font="1">patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the </text>
<text top="674" left="167" width="622" height="19" font="1">American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines </text>
<text top="692" left="167" width="392" height="19" font="1">and the Heart Rhythm Society. Circulation. 2018;138:e272–391. </text>
<text top="711" left="81" width="45" height="19" font="1">S1.4-4. </text>
<text top="711" left="167" width="567" height="19" font="1">Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and </text>
<text top="729" left="167" width="629" height="19" font="1">management of patients with syncope: a report of the American College of Cardiology/American Heart </text>
<text top="747" left="167" width="589" height="19" font="1">Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. </text>
<text top="766" left="167" width="121" height="19" font="1">2017;136:e60–122. </text>
<text top="784" left="81" width="45" height="19" font="1">S1.4-5. </text>
<text top="784" left="167" width="617" height="19" font="1">Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of </text>
<text top="802" left="167" width="594" height="19" font="1">the guideline for the diagnosis and management of patients with stable ischemic heart disease: a </text>
<text top="821" left="167" width="589" height="19" font="1">report of the American College of Cardiology/American Heart Association Task Force on Practice </text>
<text top="839" left="167" width="592" height="19" font="1">Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses </text>
<text top="857" left="167" width="578" height="19" font="1">Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic </text>
<text top="876" left="167" width="258" height="19" font="1">Surgeons. Circulation. 2014;130:1749–67. </text>
<text top="894" left="81" width="45" height="19" font="1">S1.4-6. </text>
<text top="894" left="167" width="591" height="19" font="1">Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the </text>
<text top="912" left="167" width="609" height="19" font="1">diagnosis and management of patients with stable ischemic heart disease: a report of the American </text>
<text top="930" left="167" width="617" height="19" font="1">College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and </text>
<text top="949" left="167" width="552" height="19" font="1">the American College of Physicians, American Association for Thoracic Surgery, Preventive </text>
<text top="967" left="167" width="598" height="19" font="1">Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and </text>
<text top="985" left="167" width="384" height="19" font="1">Society of Thoracic Surgeons. Circulation. 2012;126:e354–471. </text>
<text top="1004" left="81" width="45" height="19" font="1">S1.4-7. </text>
<text top="1004" left="167" width="609" height="19" font="1">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients </text>
<text top="1022" left="167" width="627" height="19" font="1">with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task </text>
<text top="1040" left="167" width="564" height="19" font="1">Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;130:e199–267. </text>
<text top="1059" left="81" width="45" height="19" font="1">S1.4-8. </text>
<text top="1059" left="167" width="554" height="19" font="1">Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative </text>
<text top="1077" left="167" width="628" height="19" font="1">cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="68" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">68</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="167" width="577" height="19" font="1">American College of Cardiology/American Heart Association Task Force on practice guidelines. </text>
<text top="129" left="167" width="202" height="19" font="1">Circulation. 2014;130:e278–333. </text>
<text top="147" left="81" width="45" height="19" font="1">S1.4-9. </text>
<text top="147" left="167" width="577" height="19" font="1">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of </text>
<text top="165" left="167" width="578" height="19" font="1">patients with non-ST-elevation acute coronary syndromes: a report of the American College of </text>
<text top="184" left="167" width="625" height="19" font="1">Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344–</text>
<text top="202" left="167" width="30" height="19" font="1">426. </text>
<text top="221" left="81" width="53" height="19" font="1">S1.4-10. </text>
<text top="221" left="167" width="629" height="19" font="1">Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a </text>
<text top="239" left="167" width="611" height="19" font="1">report of the American College of Cardiology Foundation/American Heart Association Task Force on </text>
<text top="257" left="167" width="325" height="19" font="1">Practice Guidelines. Circulation. 2013;128:e240–327. </text>
<text top="275" left="81" width="53" height="19" font="1">S1.4-11. </text>
<text top="275" left="167" width="584" height="19" font="1">O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-</text>
<text top="294" left="167" width="621" height="19" font="1">elevation myocardial infarction: a report of the American College of Cardiology Foundation/American </text>
<text top="312" left="167" width="523" height="19" font="1">Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362–425. </text>
<text top="330" left="81" width="53" height="19" font="1">S1.4-12. </text>
<text top="330" left="167" width="588" height="19" font="1">Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft </text>
<text top="349" left="167" width="617" height="19" font="1">surgery. a report of the American College of Cardiology Foundation/American Heart Association Task </text>
<text top="367" left="167" width="613" height="19" font="1">Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic </text>
<text top="385" left="167" width="604" height="19" font="1">Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. Circulation. </text>
<text top="404" left="167" width="129" height="19" font="1">2011;124:e652–735. </text>
<text top="422" left="81" width="53" height="19" font="1">S1.4-13. </text>
<text top="422" left="167" width="602" height="19" font="1">Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of </text>
<text top="440" left="167" width="613" height="19" font="1">hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American </text>
<text top="458" left="167" width="605" height="19" font="1">Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American </text>
<text top="477" left="167" width="619" height="19" font="1">Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear </text>
<text top="495" left="167" width="576" height="19" font="1">Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular </text>
<text top="513" left="167" width="605" height="19" font="1">Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2011;124:e783–831. </text>
<text top="532" left="81" width="53" height="19" font="1">S1.4-14. </text>
<text top="532" left="167" width="620" height="19" font="1">Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary </text>
<text top="550" left="167" width="617" height="19" font="1">intervention: a report of the American College of Cardiology Foundation/American Heart Association </text>
<text top="568" left="167" width="613" height="19" font="1">Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. </text>
<text top="587" left="167" width="199" height="19" font="1">Circulation. 2011;124:e574-651. </text>
<text top="605" left="81" width="53" height="19" font="1">S1.4-15. </text>
<text top="605" left="167" width="611" height="19" font="1">Peberdy MA, Callaway CW, Neumar RW, et al. Part 9: post-cardiac arrest care: 2010 American Heart </text>
<text top="623" left="167" width="571" height="19" font="1">Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. </text>
<text top="642" left="167" width="191" height="19" font="1">Circulation. 2010;122:S768-86. </text>
<text top="660" left="81" width="53" height="19" font="1">S1.4-16. </text>
<text top="660" left="167" width="552" height="19" font="1">Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on </text>
<text top="678" left="167" width="576" height="19" font="1">cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. </text>
<text top="696" left="167" width="111" height="19" font="1">2017;14:e503-51. </text>
<text top="715" left="81" width="53" height="19" font="1">S1.4-17. </text>
<text top="715" left="167" width="576" height="19" font="1">Feingold B, Mahle WT, Auerbach S, et al. Management of cardiac involvement associated with </text>
<text top="733" left="167" width="594" height="19" font="1">neuromuscular diseases: a scientific statement from the American Heart Association. Circulation. </text>
<text top="752" left="167" width="118" height="19" font="1">2017;136:e200-31. </text>
<text top="770" left="81" width="53" height="19" font="1">S1.4-18. </text>
<text top="770" left="167" width="582" height="19" font="1">Indik JH, Gimbel JR, Abe H, et al. 2017 HRS expert consensus statement on magnetic resonance </text>
<text top="788" left="167" width="616" height="19" font="1">imaging and radiation exposure in patients with cardiovascular implantable electronic devices. Heart </text>
<text top="806" left="167" width="166" height="19" font="1">Rhythm. 2017;14:e97-153. </text>
<text top="825" left="81" width="53" height="19" font="1">S1.4-19. </text>
<text top="825" left="167" width="554" height="19" font="1">Zipes DP, Link MS, Ackerman MJ, et al. Eligibility and disqualification recommendations for </text>
<text top="843" left="167" width="600" height="19" font="1">competitive athletes with cardiovascular abnormalities: Task Force 9: arrhythmias and conduction </text>
<text top="861" left="167" width="567" height="19" font="1">defects: a scientific statement from the American Heart Association and American College of </text>
<text top="880" left="167" width="266" height="19" font="1">Cardiology. Circulation. 2015;132:e315–25. </text>
<text top="898" left="81" width="53" height="19" font="1">S1.4-20. </text>
<text top="898" left="167" width="626" height="19" font="1">Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement </text>
<text top="916" left="167" width="606" height="19" font="1">on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, </text>
<text top="935" left="167" width="342" height="19" font="1">and vasovagal syncope. Heart Rhythm. 2015;12:e41-63. </text>
<text top="953" left="81" width="53" height="19" font="1">S1.4-21. </text>
<text top="953" left="167" width="614" height="19" font="1">Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and </text>
<text top="971" left="167" width="620" height="19" font="1">management of arrhythmias in adult congenital heart disease: developed in partnership between the </text>
<text top="990" left="167" width="626" height="19" font="1">Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Heart </text>
<text top="1008" left="167" width="166" height="19" font="1">Rhythm. 2014;11:e102-65. </text>
<text top="1026" left="81" width="53" height="19" font="1">S1.4-22. </text>
<text top="1026" left="167" width="610" height="19" font="1">Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of </text>
<text top="1044" left="167" width="552" height="19" font="1">implantable cardioverter-defibrillator therapy in patients who are not included or not well </text>
<text top="1063" left="167" width="362" height="19" font="1">represented in clinical trials. Circulation. 2014;130:94–125. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="69" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">69</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="53" height="19" font="1">S1.4-23. </text>
<text top="111" left="167" width="555" height="19" font="1">Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and </text>
<text top="129" left="167" width="600" height="19" font="1">management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305-23. </text>
<text top="147" left="81" width="53" height="19" font="1">S1.4-24. </text>
<text top="147" left="167" width="608" height="19" font="1">Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac </text>
<text top="165" left="167" width="605" height="19" font="1">resynchronization therapy: the Task Force on Cardiac Pacing and Resynchronization Therapy of the </text>
<text top="184" left="167" width="605" height="19" font="1">European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm </text>
<text top="202" left="167" width="315" height="19" font="1">Association (EHRA). Eur Heart J. 2013;34:2281-329. </text>
<text top="221" left="81" width="53" height="19" font="1">S1.4-25. </text>
<text top="221" left="167" width="588" height="19" font="1">Gillis AM, Russo AM, Ellenbogen KA, et al. HRS/ACCF expert consensus statement on pacemaker </text>
<text top="239" left="167" width="389" height="19" font="1">device and mode selection. J Am Coll Cardiol. 2012;60:682-703. </text>
<text top="257" left="81" width="53" height="19" font="1">S1.4-26. </text>
<text top="257" left="167" width="585" height="19" font="1">Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of </text>
<text top="275" left="167" width="594" height="19" font="1">genetic testing for the channelopathies and cardiomyopathies this document was developed as a </text>
<text top="294" left="167" width="602" height="19" font="1">partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association </text>
<text top="312" left="167" width="246" height="19" font="1">(EHRA). Heart Rhythm. 2011;8:1308-39. </text>
<text top="330" left="81" width="53" height="19" font="1">S1.4-27. </text>
<text top="330" left="167" width="575" height="19" font="1">Lampert R, Hayes DL, Annas GJ, et al. HRS expert consensus statement on the management of </text>
<text top="349" left="167" width="594" height="19" font="1">cardiovascular implantable electronic devices (CIEDs) in patients nearing end of life or requesting </text>
<text top="367" left="167" width="339" height="19" font="1">withdrawal of therapy. Heart Rhythm. 2010;7:1008-26. </text>
<text top="385" left="81" width="53" height="19" font="1">S1.4-28. </text>
<text top="385" left="167" width="607" height="19" font="1">Surawicz B, Childers R, Deal BJ, et al. AHA/ACCF/HRS recommendations for the standardization and </text>
<text top="404" left="167" width="619" height="19" font="1">interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific </text>
<text top="422" left="167" width="602" height="19" font="1">statement from the American Heart Association Electrocardiography and Arrhythmias Committee, </text>
<text top="440" left="167" width="620" height="19" font="1">Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm </text>
<text top="458" left="167" width="243" height="19" font="1">Society. Circulation. 2009;119:e235-40. </text>
<text top="477" left="81" width="53" height="19" font="1">S1.4-29. </text>
<text top="477" left="167" width="620" height="19" font="1">Hancock EW, Deal BJ, Mirvis DM, et al. AHA/ACCF/HRS recommendations for the standardization and </text>
<text top="495" left="167" width="607" height="19" font="1">interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac </text>
<text top="513" left="167" width="504" height="19" font="1">chamber hypertrophy: a scientific statement from the American Heart Association </text>
<text top="532" left="167" width="626" height="19" font="1">Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College </text>
<text top="550" left="167" width="543" height="19" font="1">of Cardiology Foundation; and the Heart Rhythm Society. Circulation. 2009;119:e251-61. </text>
<text top="568" left="81" width="4" height="21" font="8"> </text>
<text top="588" left="81" width="461" height="27" font="27"><b>1.5. Class of Recommendation and Level of Evidence </b></text>
<text top="623" left="81" width="45" height="19" font="1">S1.5-1. </text>
<text top="623" left="162" width="629" height="19" font="1">Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/AHA clinical practice guideline </text>
<text top="641" left="162" width="629" height="19" font="1">recommendation classification system: a report of the American College of Cardiology/American Heart </text>
<text top="660" left="162" width="537" height="19" font="1">Association Task Force on Clinical Practice Guidelines. Circulation. 2015;133:1426-1428. </text>
<text top="678" left="81" width="4" height="21" font="8"> </text>
<text top="698" left="81" width="322" height="31" font="2"><b>2. Epidemiology and Definitions </b></text>
<text top="736" left="81" width="137" height="27" font="27"><b>2.1. Definitions </b></text>
<text top="767" left="81" width="45" height="19" font="1">S2.1-1. </text>
<text top="767" left="167" width="595" height="19" font="1">Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult </text>
<text top="785" left="167" width="615" height="19" font="1">patients with supraventricular tachycardia: a report of the American College of Cardiology/American </text>
<text top="803" left="167" width="627" height="19" font="1">Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. </text>
<text top="822" left="167" width="118" height="19" font="1">2016;133:e506-74. </text>
<text top="840" left="81" width="45" height="19" font="1">S2.1-2. </text>
<text top="840" left="167" width="607" height="19" font="1">Surawicz B, Childers R, Deal BJ, et al. AHA/ACCF/HRS recommendations for the standardization and </text>
<text top="858" left="167" width="619" height="19" font="1">interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific </text>
<text top="876" left="167" width="602" height="19" font="1">statement from the American Heart Association Electrocardiography and Arrhythmias Committee, </text>
<text top="895" left="167" width="620" height="19" font="1">Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm </text>
<text top="913" left="167" width="243" height="19" font="1">Society. Circulation. 2009;119:e235-40. </text>
<text top="931" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="70" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="38" size="16" family="Times" color="#000000"/>
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">70</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="110" left="81" width="651" height="31" font="2"><b>3. General Evaluation of Patients With Documented or Suspected </b></text>
<text top="139" left="81" width="370" height="31" font="2"><b>Bradycardia or Conduction Disorders </b></text>
<text top="178" left="81" width="713" height="27" font="27"><b>3.1. History and Physical Examination of Patients With Documented or Suspected </b></text>
<text top="203" left="81" width="325" height="27" font="27"><b>Bradycardia or Conduction Disorders </b></text>
<text top="234" left="81" width="45" height="19" font="1">S3.1-1. </text>
<text top="234" left="167" width="549" height="19" font="1">Mangrum JM, DiMarco JP. The evaluation and management of bradycardia. N Engl J Med. </text>
<text top="252" left="167" width="103" height="19" font="1">2000;342:703-9. </text>
<text top="271" left="81" width="45" height="19" font="1">S3.1-2. </text>
<text top="271" left="167" width="613" height="19" font="1">Vogler J, Breithardt G, Eckardt L. Bradyarrhythmias and conduction blocks. Rev Esp Cardiol (Engl Ed). </text>
<text top="289" left="167" width="103" height="19" font="1">2012;65:656-67. </text>
<text top="307" left="81" width="4" height="21" font="8"> </text>
<text top="327" left="81" width="242" height="27" font="27"><b>3.2. Noninvasive Evaluation</b></text>
<text top="326" left="322" width="5" height="29" font="19"><b> </b></text>
<text top="357" left="81" width="665" height="23" font="38"><i><b>3.2.1. Resting ECG in Patients With Documented or Suspected Bradycardia or Conduction </b></i></text>
<text top="382" left="81" width="74" height="23" font="38"><i><b>Disorders </b></i></text>
<text top="417" left="81" width="57" height="19" font="1">S3.2.1-1. </text>
<text top="417" left="167" width="589" height="19" font="1">Del Rosso A, Ungar A, Maggi R, et al. Clinical predictors of cardiac syncope at initial evaluation in </text>
<text top="435" left="167" width="543" height="19" font="1">patients referred urgently to a general hospital: the EGSYS score. Heart. 2008;94:1620-6. </text>
<text top="454" left="81" width="57" height="19" font="1">S3.2.1-2. </text>
<text top="454" left="167" width="559" height="19" font="1">Linzer M, Yang EH, Estes NA 3rd, et al. Diagnosing syncope. Part 1: value of history, physical </text>
<text top="472" left="167" width="623" height="19" font="1">examination, and electrocardiography. Clinical Efficacy Assessment Project of the American College of </text>
<text top="490" left="167" width="285" height="19" font="1">Physicians. Ann Intern Med. 1997;126:989-96. </text>
<text top="509" left="81" width="57" height="19" font="1">S3.2.1-3. </text>
<text top="509" left="167" width="627" height="19" font="1">Perez-Rodon J, Martinez-Alday J, Baron-Esquivias G, et al. Prognostic value of the electrocardiogram in </text>
<text top="527" left="167" width="596" height="19" font="1">patients with syncope: data from the group for syncope study in the emergency room (GESINUR). </text>
<text top="545" left="167" width="204" height="19" font="1">Heart Rhythm. 2014;11:2035-44. </text>
<text top="563" left="81" width="57" height="19" font="1">S3.2.1-4. </text>
<text top="563" left="167" width="629" height="19" font="1">Thiruganasambandamoorthy V, Hess EP, Turko E, et al. Defining abnormal electrocardiography in adult </text>
<text top="582" left="167" width="552" height="19" font="1">emergency department syncope patients: the Ottawa Electrocardiographic Criteria. CJEM. </text>
<text top="600" left="167" width="103" height="19" font="1">2012;14:248-58. </text>
<text top="618" left="81" width="4" height="21" font="8"> </text>
<text top="638" left="81" width="650" height="23" font="38"><i><b>3.2.2. Exercise Electrocardiographic Testing in Patients With Documented or Suspected </b></i></text>
<text top="664" left="81" width="278" height="23" font="38"><i><b>Bradycardia or Conduction Disorders </b></i></text>
<text top="698" left="81" width="57" height="19" font="1">S3.2.2-1. </text>
<text top="698" left="167" width="607" height="19" font="1">Lauer MS, Francis GS, Okin PM, et al. Impaired chronotropic response to exercise stress testing as a </text>
<text top="716" left="167" width="285" height="19" font="1">predictor of mortality. JAMA. 1999;281:524-9. </text>
<text top="735" left="81" width="57" height="19" font="1">S3.2.2-2. </text>
<text top="735" left="167" width="597" height="19" font="1">Savonen KP, Kiviniemi V, Laukkanen JA, et al. Chronotropic incompetence and mortality in middle-</text>
<text top="753" left="167" width="559" height="19" font="1">aged men with known or suspected coronary heart disease. Eur Heart J. 2008;29:1896-902. </text>
<text top="771" left="81" width="57" height="19" font="1">S3.2.2-3. </text>
<text top="771" left="167" width="605" height="19" font="1">Doi A, Tsuchihashi K, Kyuma M, et al. Diagnostic implications of modified treadmill and head-up tilt </text>
<text top="790" left="167" width="623" height="19" font="1">tests in exercise-related syncope: comparative studies with situational and/or vasovagal syncope. Can </text>
<text top="808" left="167" width="154" height="19" font="1">J Cardiol. 2002;18:960-6. </text>
<text top="826" left="81" width="57" height="19" font="1">S3.2.2-4. </text>
<text top="826" left="167" width="600" height="19" font="1">Woelfel AK, Simpson RJ Jr, Gettes LS, et al. Exercise-induced distal atrioventricular block. J Am Coll </text>
<text top="845" left="167" width="146" height="19" font="1">Cardiol. 1983;2:578-81. </text>
<text top="863" left="81" width="4" height="21" font="8"> </text>
<text top="883" left="81" width="713" height="23" font="4"><b>3.2.3. Ambulatory Electrocardiography in Patients With Documented or Suspected Bradycardia </b></text>
<text top="908" left="81" width="185" height="23" font="4"><b>or Conduction Disorders </b></text>
<text top="942" left="81" width="57" height="19" font="1">S3.2.3-1. </text>
<text top="942" left="167" width="598" height="19" font="1">Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour Holter monitoring with 14-day </text>
<text top="961" left="167" width="526" height="19" font="1">novel adhesive patch electrocardiographic monitoring. Am J Med. 2014;127:95.e11-7. </text>
<text top="979" left="81" width="57" height="19" font="1">S3.2.3-2. </text>
<text top="979" left="167" width="604" height="19" font="1">Brown AP, Dawkins KD, Davies JG. Detection of arrhythmias: use of a patient-activated ambulatory </text>
<text top="998" left="167" width="518" height="19" font="1">electrocardiogram device with a solid-state memory loop. Br Heart J. 1987;58:251-3. </text>
<text top="1016" left="81" width="57" height="19" font="1">S3.2.3-3. </text>
<text top="1016" left="167" width="591" height="19" font="1">Cumbee SR, Pryor RE, Linzer M. Cardiac loop ECG recording: a new noninvasive diagnostic test in </text>
<text top="1034" left="167" width="297" height="19" font="1">recurrent syncope. South Med J. 1990;83:39-43. </text>
<text top="1052" left="81" width="57" height="19" font="1">S3.2.3-4. </text>
<text top="1052" left="167" width="622" height="19" font="1">Gibson TC, Heitzman MR. Diagnostic efficacy of 24-hour electrocardiographic monitoring for syncope. </text>
<text top="1071" left="167" width="186" height="19" font="1">Am J Cardiol. 1984;53:1013-7. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="71" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">71</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="57" height="19" font="1">S3.2.3-5. </text>
<text top="111" left="167" width="619" height="19" font="1">Joshi AK, Kowey PR, Prystowsky EN, et al. First experience with a mobile cardiac outpatient telemetry </text>
<text top="129" left="167" width="614" height="19" font="1">(MCOT) system for the diagnosis and management of cardiac arrhythmia. Am J Cardiol. 2005;95:878-</text>
<text top="147" left="167" width="22" height="19" font="1">81. </text>
<text top="165" left="81" width="57" height="19" font="1">S3.2.3-6. </text>
<text top="165" left="167" width="588" height="19" font="1">Linzer M, Yang EH, Estes NA 3rd, et al. Diagnosing syncope. Part 2: unexplained syncope. Clinical </text>
<text top="184" left="167" width="614" height="19" font="1">Efficacy Assessment Project of the American College of Physicians. Ann Intern Med. 1997;127:76-86. </text>
<text top="202" left="81" width="57" height="19" font="1">S3.2.3-7. </text>
<text top="202" left="167" width="619" height="19" font="1">Locati ET, Moya A, Oliveira M, et al. External prolonged electrocardiogram monitoring in unexplained </text>
<text top="221" left="167" width="547" height="19" font="1">syncope and palpitations: results of the SYNARR-Flash study. Europace. 2016;18:1265-72. </text>
<text top="239" left="81" width="57" height="19" font="1">S3.2.3-8. </text>
<text top="239" left="167" width="590" height="19" font="1">Reiffel JA, Schwarzberg R, Murry M. Comparison of autotriggered memory loop recorders versus </text>
<text top="257" left="167" width="586" height="19" font="1">standard loop recorders versus 24-hour Holter monitors for arrhythmia detection. Am J Cardiol. </text>
<text top="275" left="167" width="103" height="19" font="1">2005;95:1055-9. </text>
<text top="294" left="81" width="57" height="19" font="1">S3.2.3-9. </text>
<text top="294" left="167" width="618" height="19" font="1">Rosenberg MA, Samuel M, Thosani A, et al. Use of a noninvasive continuous monitoring device in the </text>
<text top="312" left="167" width="553" height="19" font="1">management of atrial fibrillation: a pilot study. Pacing Clin Electrophysiol. 2013;36:328-33. </text>
<text top="330" left="81" width="64" height="19" font="1">S3.2.3-10. </text>
<text top="330" left="167" width="598" height="19" font="1">Rothman SA, Laughlin JC, Seltzer J, et al. The diagnosis of cardiac arrhythmias: a prospective multi-</text>
<text top="349" left="167" width="616" height="19" font="1">center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event </text>
<text top="367" left="167" width="341" height="19" font="1">monitoring. J Cardiovasc Electrophysiol. 2007;18:241-7. </text>
<text top="385" left="81" width="64" height="19" font="1">S3.2.3-11. </text>
<text top="385" left="167" width="595" height="19" font="1">Sivakumaran S, Krahn AD, Klein GJ, et al. A prospective randomized comparison of loop recorders </text>
<text top="404" left="167" width="545" height="19" font="1">versus Holter monitors in patients with syncope or presyncope. Am J Med. 2003;115:1-5. </text>
<text top="422" left="81" width="64" height="19" font="1">S3.2.3-12. </text>
<text top="422" left="167" width="566" height="19" font="1">Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility of a novel leadless arrhythmia </text>
<text top="440" left="167" width="304" height="19" font="1">monitoring device. Am J Cardiol. 2013;112:520-4. </text>
<text top="458" left="81" width="64" height="19" font="1">S3.2.3-13. </text>
<text top="458" left="167" width="567" height="19" font="1">Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and </text>
<text top="477" left="167" width="629" height="19" font="1">management of patients with syncope: a report of the American College of Cardiology/American Heart </text>
<text top="495" left="167" width="589" height="19" font="1">Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. </text>
<text top="513" left="167" width="121" height="19" font="1">2017;136:e60–122. </text>
<text top="531" left="81" width="4" height="21" font="8"> </text>
<text top="552" left="81" width="710" height="23" font="4"><b>3.2.4. Imaging in Patients With Documented or Suspected Bradycardia or Conduction Disorders</b></text>
<text top="555" left="791" width="3" height="19" font="1"> </text>
<text top="594" left="81" width="57" height="19" font="1">S3.2.4-1. </text>
<text top="594" left="167" width="550" height="19" font="1">Schneider JF, Thomas HE Jr, Kreger BE, et al. Newly acquired left bundle-branch block: the </text>
<text top="612" left="167" width="328" height="19" font="1">Framingham study. Ann Intern Med. 1979;90:303-10. </text>
<text top="630" left="81" width="57" height="19" font="1">S3.2.4-2. </text>
<text top="630" left="167" width="588" height="19" font="1">Schneider JF, Thomas HE Jr, Sorlie P, et al. Comparative features of newly acquired left and right </text>
<text top="649" left="167" width="619" height="19" font="1">bundle branch block in the general population: the Framingham study. Am J Cardiol. 1981;47:931-40. </text>
<text top="667" left="81" width="57" height="19" font="1">S3.2.4-3. </text>
<text top="667" left="167" width="621" height="19" font="1">Talreja D, Gruver C, Sklenar J, et al. Efficient utilization of echocardiography for the assessment of left </text>
<text top="685" left="167" width="353" height="19" font="1">ventricular systolic function. Am Heart J. 2000;139:394-8. </text>
<text top="704" left="81" width="57" height="19" font="1">S3.2.4-4. </text>
<text top="704" left="167" width="575" height="19" font="1">Dhingra R, Ho Nam B, Benjamin EJ, et al. Cross-sectional relations of electrocardiographic QRS </text>
<text top="722" left="167" width="615" height="19" font="1">duration to left ventricular dimensions: the Framingham Heart Study. J Am Coll Cardiol. 2005;45:685-</text>
<text top="740" left="167" width="15" height="19" font="1">9. </text>
<text top="759" left="81" width="57" height="19" font="1">S3.2.4-5. </text>
<text top="759" left="167" width="607" height="19" font="1">Dhingra R, Pencina MJ, Wang TJ, et al. Electrocardiographic QRS duration and the risk of congestive </text>
<text top="777" left="167" width="451" height="19" font="1">heart failure: the Framingham Heart Study. Hypertension. 2006;47:861-7. </text>
<text top="795" left="81" width="57" height="19" font="1">S3.2.4-6. </text>
<text top="795" left="167" width="571" height="19" font="1">Badheka AO, Singh V, Patel NJ, et al. QRS duration on electrocardiography and cardiovascular </text>
<text top="814" left="167" width="624" height="19" font="1">mortality (from the National Health and Nutrition Examination Survey-III). Am J Cardiol. 2013;112:671-</text>
<text top="832" left="167" width="15" height="19" font="1">7. </text>
<text top="850" left="81" width="57" height="19" font="1">S3.2.4-7. </text>
<text top="850" left="167" width="595" height="19" font="1">Bogale N, Orn S, James M, et al. Usefulness of either or both left and right bundle branch block at </text>
<text top="869" left="167" width="626" height="19" font="1">baseline or during follow-up for predicting death in patients following acute myocardial infarction. Am </text>
<text top="887" left="167" width="162" height="19" font="1">J Cardiol. 2007;99:647-50. </text>
<text top="905" left="81" width="57" height="19" font="1">S3.2.4-8. </text>
<text top="905" left="167" width="624" height="19" font="1">Eriksson P, Hansson PO, Eriksson H, et al. Bundle-branch block in a general male population: the study </text>
<text top="923" left="167" width="308" height="19" font="1">of men born 1913. Circulation. 1998;98:2494-500. </text>
<text top="942" left="81" width="57" height="19" font="1">S3.2.4-9. </text>
<text top="942" left="167" width="585" height="19" font="1">Fahy GJ, Pinski SL, Miller DP, et al. Natural history of isolated bundle branch block. Am J Cardiol. </text>
<text top="960" left="167" width="111" height="19" font="1">1996;77:1185-90. </text>
<text top="978" left="81" width="64" height="19" font="1">S3.2.4-10. </text>
<text top="978" left="167" width="607" height="19" font="1">Imanishi R, Seto S, Ichimaru S, et al. Prognostic significance of incident complete left bundle branch </text>
<text top="997" left="167" width="412" height="19" font="1">block observed over a 40-year period. Am J Cardiol. 2006;98:644-8. </text>
<text top="1015" left="81" width="64" height="19" font="1">S3.2.4-11. </text>
<text top="1015" left="167" width="616" height="19" font="1">Chiu DT, Shapiro NI, Sun BC, et al. Are echocardiography, telemetry, ambulatory electrocardiography </text>
<text top="1033" left="167" width="613" height="19" font="1">monitoring, and cardiac enzymes in emergency department patients presenting with syncope useful </text>
<text top="1052" left="167" width="392" height="19" font="1">tests? A preliminary investigation. J Emerg Med. 2014;47:113-8. </text>
<text top="1070" left="81" width="64" height="19" font="1">S3.2.4-12. </text>
<text top="1070" left="167" width="598" height="19" font="1">Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR </text>
<text top="1088" left="167" width="606" height="19" font="1">2011 appropriate use criteria for echocardiography: a report of the American College of Cardiology </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="72" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">72</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="167" width="600" height="19" font="1">Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American </text>
<text top="129" left="167" width="603" height="19" font="1">Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart </text>
<text top="147" left="167" width="598" height="19" font="1">Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care </text>
<text top="165" left="167" width="594" height="19" font="1">Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic </text>
<text top="184" left="167" width="549" height="19" font="1">Resonance American College of Chest Physicians. J Am Soc Echocardiogr. 2011;24:229-67. </text>
<text top="202" left="81" width="64" height="19" font="1">S3.2.4-13. </text>
<text top="202" left="167" width="584" height="19" font="1">Menozzi C, Brignole M, Alboni P, et al. The natural course of untreated sick sinus syndrome and </text>
<text top="221" left="167" width="586" height="19" font="1">identification of the variables predictive of unfavorable outcome. Am J Cardiol. 1998;82:1205-9. </text>
<text top="239" left="81" width="64" height="19" font="1">S3.2.4-14. </text>
<text top="239" left="167" width="622" height="19" font="1">Bluemke DA, Achenbach S, Budoff M, et al. Noninvasive coronary artery imaging: magnetic resonance </text>
<text top="257" left="167" width="610" height="19" font="1">angiography and multidetector computed tomography angiography: a scientific statement from the </text>
<text top="275" left="167" width="610" height="19" font="1">american heart association committee on cardiovascular imaging and intervention of the council on </text>
<text top="294" left="167" width="611" height="19" font="1">cardiovascular radiology and intervention, and the councils on clinical cardiology and cardiovascular </text>
<text top="312" left="167" width="323" height="19" font="1">disease in the young. Circulation. 2008;118:586-606. </text>
<text top="330" left="81" width="64" height="19" font="1">S3.2.4-15. </text>
<text top="330" left="167" width="620" height="19" font="1">Bokhari S, Castano A, Pozniakoff T, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-</text>
<text top="349" left="167" width="616" height="19" font="1">chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ </text>
<text top="367" left="167" width="228" height="19" font="1">Cardiovasc Imaging. 2013;6:195-201. </text>
<text top="385" left="81" width="64" height="19" font="1">S3.2.4-16. </text>
<text top="385" left="167" width="628" height="19" font="1">Cheong B, Huber S, Muthupillai R, et al. Evaluation of myocardial iron overload by T(2)* Cardiovascular </text>
<text top="404" left="167" width="382" height="19" font="1">Magnetic Resonance Imaging. Tex Heart Inst J. 2005;32:448-9. </text>
<text top="422" left="81" width="64" height="19" font="1">S3.2.4-17. </text>
<text top="422" left="167" width="600" height="19" font="1">Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular </text>
<text top="440" left="167" width="451" height="19" font="1">magnetic resonance in cardiac amyloidosis. Circulation. 2015;132:1570-9. </text>
<text top="458" left="81" width="64" height="19" font="1">S3.2.4-18. </text>
<text top="458" left="167" width="581" height="19" font="1">Franco A, Javidi S, Ruehm SG. Delayed myocardial enhancement in cardiac magnetic resonance </text>
<text top="477" left="167" width="248" height="19" font="1">imaging. J Radiol Case Rep. 2015;9:6-18. </text>
<text top="495" left="81" width="64" height="19" font="1">S3.2.4-19. </text>
<text top="495" left="167" width="588" height="19" font="1">Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in </text>
<text top="513" left="167" width="440" height="19" font="1">suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501-11. </text>
<text top="532" left="81" width="64" height="19" font="1">S3.2.4-20. </text>
<text top="532" left="167" width="629" height="19" font="1">Haq M, Pawar S, Berk JL, et al. Can 99mTc-pyrophosphate aid in early detection of cardiac involvement </text>
<text top="550" left="167" width="512" height="19" font="1">in asymptomatic variant TTR amyloidosis? JACC Cardiovasc Imaging. 2017;10:713-4. </text>
<text top="568" left="81" width="64" height="19" font="1">S3.2.4-21. </text>
<text top="568" left="167" width="614" height="19" font="1">Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 </text>
<text top="587" left="167" width="582" height="19" font="1">appropriate use criteria for cardiac computed tomography. A report of the American College of </text>
<text top="605" left="167" width="612" height="19" font="1">Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed </text>
<text top="623" left="167" width="586" height="19" font="1">Tomography, the American College of Radiology, the American Heart Association, the American </text>
<text top="642" left="167" width="623" height="19" font="1">Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society </text>
<text top="660" left="167" width="600" height="19" font="1">for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the </text>
<text top="678" left="167" width="489" height="19" font="1">Society for Cardiovascular Magnetic Resonance. Circulation. 2010;122:e525–55. </text>
<text top="696" left="81" width="64" height="19" font="1">S3.2.4-22. </text>
<text top="696" left="167" width="603" height="19" font="1">Mendu ML, McAvay G, Lampert R, et al. Yield of diagnostic tests in evaluating syncopal episodes in </text>
<text top="715" left="167" width="326" height="19" font="1">older patients. Arch Intern Med. 2009;169:1299-305. </text>
<text top="733" left="81" width="64" height="19" font="1">S3.2.4-23. </text>
<text top="733" left="167" width="617" height="19" font="1">Recchia D, Barzilai B. Echocardiography in the evaluation of patients with syncope. J Gen Intern Med. </text>
<text top="752" left="167" width="103" height="19" font="1">1995;10:649-55. </text>
<text top="770" left="81" width="64" height="19" font="1">S3.2.4-24. </text>
<text top="770" left="167" width="584" height="19" font="1">Sarasin FP, Junod AF, Carballo D, et al. Role of echocardiography in the evaluation of syncope: a </text>
<text top="788" left="167" width="252" height="19" font="1">prospective study. Heart. 2002;88:363-7. </text>
<text top="806" left="81" width="4" height="21" font="8"> </text>
<text top="826" left="81" width="629" height="23" font="4"><b>3.2.5. Laboratory Testing in Patients With Documented or Suspected Bradycardia or </b></text>
<text top="851" left="81" width="165" height="23" font="4"><b>Conduction Disorders </b></text>
<text top="886" left="81" width="57" height="19" font="1">S3.2.5-1. </text>
<text top="886" left="167" width="625" height="19" font="1">Chon SB, Kwak YH, Hwang SS, et al. Severe hyperkalemia can be detected immediately by quantitative </text>
<text top="904" left="167" width="586" height="19" font="1">electrocardiography and clinical history in patients with symptomatic or extreme bradycardia: a </text>
<text top="923" left="167" width="417" height="19" font="1">retrospective cross-sectional study. J Crit Care. 2013;28:1112.e7-13. </text>
<text top="941" left="81" width="57" height="19" font="1">S3.2.5-2. </text>
<text top="941" left="167" width="599" height="19" font="1">Mandell BF. Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum. </text>
<text top="959" left="167" width="103" height="19" font="1">1987;17:126-41. </text>
<text top="978" left="81" width="57" height="19" font="1">S3.2.5-3. </text>
<text top="978" left="167" width="603" height="19" font="1">Nakayama Y, Ohno M, Yonemura S, et al. A case of transient 2:1 atrioventricular block, resolved by </text>
<text top="996" left="167" width="618" height="19" font="1">thyroxine supplementation for subclinical hypothyroidism. Pacing Clin Electrophysiol. 2006;29:106-8. </text>
<text top="1014" left="81" width="57" height="19" font="1">S3.2.5-4. </text>
<text top="1014" left="167" width="516" height="19" font="1">Noble K, Isles C. Hyperkalaemia causing profound bradycardia. Heart. 2006;92:1063. </text>
<text top="1032" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="73" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">73</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="110" left="81" width="668" height="23" font="4"><b>3.2.7. Sleep Apnea Evaluation and Treatment in Patients With Documented or Suspected </b></text>
<text top="136" left="81" width="283" height="23" font="4"><b>Bradycardia or Conduction Disorders  </b></text>
<text top="170" left="81" width="57" height="19" font="1">S3.2.7-1. </text>
<text top="170" left="167" width="619" height="19" font="1">Tilkian AG, Guilleminault C, Schroeder JS, et al. Sleep-induced apnea syndrome. Prevalence of cardiac </text>
<text top="188" left="167" width="483" height="19" font="1">arrhythmias and their reversal after tracheostomy. Am J Med. 1977;63:348-58. </text>
<text top="207" left="81" width="57" height="19" font="1">S3.2.7-2. </text>
<text top="207" left="167" width="623" height="19" font="1">Guilleminault C, Connolly SJ, Winkle RA. Cardiac arrhythmia and conduction disturbances during sleep </text>
<text top="225" left="167" width="448" height="19" font="1">in 400 patients with sleep apnea syndrome. Am J Cardiol. 1983;52:490-4. </text>
<text top="243" left="81" width="57" height="19" font="1">S3.2.7-3. </text>
<text top="243" left="167" width="610" height="19" font="1">Shepard JW Jr, Garrison MW, Grither DA, et al. Relationship of ventricular ectopy to oxyhemoglobin </text>
<text top="262" left="167" width="477" height="19" font="1">desaturation in patients with obstructive sleep apnea. Chest. 1985;88:335-40. </text>
<text top="280" left="81" width="57" height="19" font="1">S3.2.7-4. </text>
<text top="280" left="167" width="620" height="19" font="1">Shepard JW Jr. Gas exchange and hemodynamics during sleep. Med Clin North Am. 1985;69:1243-64. </text>
<text top="298" left="81" width="57" height="19" font="1">S3.2.7-5. </text>
<text top="298" left="167" width="584" height="19" font="1">Hoffstein V, Mateika S. Cardiac arrhythmias, snoring, and sleep apnea. Chest. 1994;106:466-71. </text>
<text top="317" left="81" width="57" height="19" font="1">S3.2.7-6. </text>
<text top="317" left="167" width="614" height="19" font="1">Boudoulas H, Schmidt HS, Clark RW, et al. Anthropometric characteristics, cardiac abnormalities and </text>
<text top="335" left="167" width="528" height="19" font="1">adrenergic activity in patients with primary disorders of sleep. J Med. 1983;14:223-38. </text>
<text top="353" left="81" width="57" height="19" font="1">S3.2.7-7. </text>
<text top="353" left="167" width="598" height="19" font="1">Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnal arrhythmias with sleep-disordered </text>
<text top="372" left="167" width="518" height="19" font="1">breathing: the Sleep Heart Health study. Am J Respir Crit Care Med. 2006;173:910-6. </text>
<text top="390" left="81" width="57" height="19" font="1">S3.2.7-8. </text>
<text top="390" left="167" width="626" height="19" font="1">Miller WP. Cardiac arrhythmias and conduction disturbances in the sleep apnea syndrome. Prevalence </text>
<text top="408" left="167" width="276" height="19" font="1">and significance. Am J Med. 1982;73:317-21. </text>
<text top="426" left="81" width="57" height="19" font="1">S3.2.7-9. </text>
<text top="426" left="167" width="629" height="19" font="1">Flemons WW, Remmers JE, Gillis AM. Sleep apnea and cardiac arrhythmias. Is there a relationship? Am </text>
<text top="445" left="167" width="204" height="19" font="1">Rev Respir Dis. 1993;148:618-21. </text>
<text top="463" left="81" width="64" height="19" font="1">S3.2.7-10. </text>
<text top="463" left="167" width="594" height="19" font="1">Stegman SS, Burroughs JM, Henthorn RW. Asymptomatic bradyarrhythmias as a marker for sleep </text>
<text top="481" left="167" width="608" height="19" font="1">apnea: appropriate recognition and treatment may reduce the need for pacemaker therapy. Pacing </text>
<text top="500" left="167" width="230" height="19" font="1">Clin Electrophysiol. 1996;19:899-904. </text>
<text top="518" left="81" width="64" height="19" font="1">S3.2.7-11. </text>
<text top="518" left="167" width="609" height="19" font="1">Garrigue S, Pepin JL, Defaye P, et al. High prevalence of sleep apnea syndrome in patients with long-</text>
<text top="536" left="167" width="582" height="19" font="1">term pacing: the European Multicenter Polysomnographic study. Circulation. 2007;115:1703-9. </text>
<text top="555" left="81" width="64" height="19" font="1">S3.2.7-12. </text>
<text top="555" left="167" width="629" height="19" font="1">Becker H, Brandenburg U, Peter JH, et al. Reversal of sinus arrest and atrioventricular conduction block </text>
<text top="573" left="167" width="609" height="19" font="1">in patients with sleep apnea during nasal continuous positive airway pressure. Am J Respir Crit Care </text>
<text top="591" left="167" width="139" height="19" font="1">Med. 1995;151:215-8. </text>
<text top="610" left="81" width="64" height="19" font="1">S3.2.7-13. </text>
<text top="610" left="167" width="622" height="19" font="1">Koehler U, Fus E, Grimm W, et al. Heart block in patients with obstructive sleep apnoea: pathogenetic </text>
<text top="628" left="167" width="375" height="19" font="1">factors and effects of treatment. Eur Respir J. 1998;11:434-9. </text>
<text top="646" left="81" width="64" height="19" font="1">S3.2.7-14. </text>
<text top="646" left="167" width="554" height="19" font="1">Grimm W, Koehler U, Fus E, et al. Outcome of patients with sleep apnea-associated severe </text>
<text top="665" left="167" width="608" height="19" font="1">bradyarrhythmias after continuous positive airway pressure therapy. Am J Cardiol. 2000;86:688-92, </text>
<text top="683" left="167" width="22" height="19" font="1">a9. </text>
<text top="701" left="81" width="64" height="19" font="1">S3.2.7-15. </text>
<text top="701" left="167" width="602" height="19" font="1">Harbison J, O'Reilly P, McNicholas WT. Cardiac rhythm disturbances in the obstructive sleep apnea </text>
<text top="720" left="167" width="586" height="19" font="1">syndrome: effects of nasal continuous positive airway pressure therapy. Chest. 2000;118:591-5. </text>
<text top="738" left="81" width="64" height="19" font="1">S3.2.7-16. </text>
<text top="738" left="167" width="602" height="19" font="1">Daccarett M, Segerson NM, Hamdan AL, et al. Relation of daytime bradyarrhythmias with high risk </text>
<text top="756" left="167" width="351" height="19" font="1">features of sleep apnea. Am J Cardiol. 2008;101:1147-50. </text>
<text top="774" left="81" width="4" height="21" font="8"> </text>
<text top="794" left="81" width="181" height="27" font="27"><b>3.3. Invasive Testing </b></text>
<text top="824" left="81" width="705" height="23" font="4"><b>3.3.1. Implantable Cardiac Monitor in Patients With Documented or Suspected Bradycardia or </b></text>
<text top="850" left="81" width="165" height="23" font="4"><b>Conduction Disorders </b></text>
<text top="884" left="81" width="57" height="19" font="1">S3.3.1-1. </text>
<text top="884" left="167" width="556" height="19" font="1">Farwell DJ, Freemantle N, Sulke AN. Use of implantable loop recorders in the diagnosis and </text>
<text top="903" left="167" width="342" height="19" font="1">management of syncope. Eur Heart J. 2004;25:1257-63. </text>
<text top="921" left="81" width="57" height="19" font="1">S3.3.1-2. </text>
<text top="921" left="167" width="596" height="19" font="1">Krahn AD, Klein GJ, Yee R, et al. Randomized assessment of syncope trial: conventional diagnostic </text>
<text top="939" left="167" width="469" height="19" font="1">testing versus a prolonged monitoring strategy. Circulation. 2001;104:46-51. </text>
<text top="957" left="81" width="57" height="19" font="1">S3.3.1-3. </text>
<text top="957" left="167" width="572" height="19" font="1">Podoleanu C, DaCosta A, Defaye P, et al. Early use of an implantable loop recorder in syncope </text>
<text top="976" left="167" width="606" height="19" font="1">evaluation: a randomized study in the context of the French healthcare system (FRESH study). Arch </text>
<text top="994" left="167" width="206" height="19" font="1">Cardiovasc Dis. 2014;107:546-52. </text>
<text top="1012" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="74" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">74</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="110" left="81" width="668" height="23" font="4"><b>3.3.2. Electrophysiology Study in Patients With Documented or Suspected Bradycardia or </b></text>
<text top="136" left="81" width="165" height="23" font="4"><b>Conduction Disorders </b></text>
<text top="170" left="81" width="57" height="19" font="1">S3.3.2-1. </text>
<text top="170" left="167" width="610" height="19" font="1">DiMarco JP, Garan H, Ruskin JN. Approach to the patient with recurrent syncope of unknown cause. </text>
<text top="188" left="167" width="275" height="19" font="1">Mod Concepts Cardiovasc Dis. 1983;52:11-6. </text>
<text top="207" left="81" width="57" height="19" font="1">S3.3.2-2. </text>
<text top="207" left="167" width="628" height="19" font="1">Fisher JD. Role of electrophysiologic testing in the diagnosis and treatment of patients with known and </text>
<text top="225" left="167" width="478" height="19" font="1">suspected bradycardias and tachycardias. Prog Cardiovasc Dis. 1981;24:25-90. </text>
<text top="243" left="81" width="57" height="19" font="1">S3.3.2-3. </text>
<text top="243" left="167" width="620" height="19" font="1">Gulamhusein S, Naccarelli GV, Ko PT, et al. Value and limitations of clinical electrophysiologic study in </text>
<text top="262" left="167" width="461" height="19" font="1">assessment of patients with unexplained syncope. Am J Med. 1982;73:A53. </text>
<text top="280" left="81" width="57" height="19" font="1">S3.3.2-4. </text>
<text top="280" left="167" width="609" height="19" font="1">Krol RB, Morady F, Flaker GC, et al. Electrophysiologic testing in patients with unexplained syncope: </text>
<text top="298" left="167" width="504" height="19" font="1">Clinical and noninvasive predictors of outcome. J Am Coll Cardiol. 1987;10:358-63. </text>
<text top="317" left="81" width="57" height="19" font="1">S3.3.2-5. </text>
<text top="317" left="167" width="581" height="19" font="1">Denniss AR, Ross DL, Richards DA, et al. Electrophysiologic studies in patients with unexplained </text>
<text top="335" left="167" width="232" height="19" font="1">syncope. Int J Cardiol. 1992;35:211-7. </text>
<text top="353" left="81" width="4" height="21" font="8"> </text>
<text top="373" left="81" width="547" height="31" font="2"><b>4. Bradycardia Attributable to Sinus Node Dysfunction  </b></text>
<text top="411" left="81" width="449" height="27" font="27"><b>4.1. Acute Management of Sinus Node Dysfunction </b></text>
<text top="442" left="81" width="553" height="23" font="38"><i><b>4.1.1. Acute Management of Reversible Causes of Sinus Node Dysfunction </b></i></text>
<text top="476" left="81" width="57" height="19" font="1">S4.1.1-1. </text>
<text top="476" left="167" width="555" height="19" font="1">Da Costa D, Brady WJ, Edhouse J. Bradycardias and atrioventricular conduction block. BMJ. </text>
<text top="494" left="167" width="103" height="19" font="1">2002;324:535-8. </text>
<text top="513" left="81" width="57" height="19" font="1">S4.1.1-2. </text>
<text top="513" left="167" width="584" height="19" font="1">Alboni P, Baggioni GF, Scarfo S, et al. Role of sinus node artery disease in sick sinus syndrome in </text>
<text top="531" left="167" width="437" height="19" font="1">inferior wall acute myocardial infarction. Am J Cardiol. 1991;67:1180-4. </text>
<text top="549" left="81" width="57" height="19" font="1">S4.1.1-3. </text>
<text top="549" left="167" width="576" height="19" font="1">Ando G, Gaspardone A, Proietti I. Acute thrombosis of the sinus node artery: arrhythmological </text>
<text top="568" left="167" width="198" height="19" font="1">implications. Heart. 2003;89:E5. </text>
<text top="586" left="81" width="57" height="19" font="1">S4.1.1-4. </text>
<text top="586" left="167" width="550" height="19" font="1">Rokseth R, Hatle L. Sinus arrest in acute myocardial infarction. Br Heart J. 1971;33:639-42. </text>
<text top="604" left="81" width="57" height="19" font="1">S4.1.1-5. </text>
<text top="604" left="167" width="577" height="19" font="1">Zehender M, Meinertz T, Keul J, et al. ECG variants and cardiac arrhythmias in athletes: clinical </text>
<text top="623" left="167" width="427" height="19" font="1">relevance and prognostic importance. Am Heart J. 1990;119:1378-91. </text>
<text top="641" left="81" width="57" height="19" font="1">S4.1.1-6. </text>
<text top="641" left="167" width="601" height="19" font="1">Jackson LR 2nd, Rathakrishnan B, Campbell K, et al. Sinus node dysfunction and atrial fibrillation: a </text>
<text top="659" left="167" width="422" height="19" font="1">reversible phenomenon? Pacing Clin Electrophysiol. 2017;40:442-50. </text>
<text top="678" left="81" width="57" height="19" font="1">S4.1.1-7. </text>
<text top="678" left="167" width="629" height="19" font="1">Pasic M, Musci M, Siniawski H, et al. Transient sinus node dysfunction after the Cox-Maze III procedure </text>
<text top="696" left="167" width="553" height="19" font="1">in patients with organic heart disease and chronic fixed atrial fibrillation. J Am Coll Cardiol. </text>
<text top="714" left="167" width="103" height="19" font="1">1998;32:1040-7. </text>
<text top="732" left="81" width="57" height="19" font="1">S4.1.1-8. </text>
<text top="732" left="167" width="623" height="19" font="1">Shin H, Yozu R, Higashi S, et al. Sinus node function after mitral valve surgery using the superior septal </text>
<text top="751" left="167" width="276" height="19" font="1">approach. Ann Thorac Surg. 2001;71:587-90. </text>
<text top="769" left="81" width="57" height="19" font="1">S4.1.1-9. </text>
<text top="769" left="167" width="596" height="19" font="1">Cleveland RJ, Nelson RJ, Zeilenga DW, et al. Atrial pacing following open-heart surgery. Arch Surg. </text>
<text top="787" left="167" width="96" height="19" font="1">1972;105:26-9. </text>
<text top="806" left="81" width="64" height="19" font="1">S4.1.1-10. </text>
<text top="806" left="167" width="619" height="19" font="1">Peretto G, Durante A, Limite LR, et al. Postoperative arrhythmias after cardiac surgery: incidence, risk </text>
<text top="824" left="167" width="470" height="19" font="1">factors, and therapeutic management. Cardiol Res Pract. 2014;2014:615987. </text>
<text top="842" left="81" width="64" height="19" font="1">S4.1.1-11. </text>
<text top="842" left="167" width="618" height="19" font="1">Franklin SM, Thihalolipavan S, Fontaine JM. Sinus bradycardia in habitual cocaine users. Am J Cardiol. </text>
<text top="861" left="167" width="111" height="19" font="1">2017;119:1611-5. </text>
<text top="879" left="81" width="64" height="19" font="1">S4.1.1-12. </text>
<text top="879" left="167" width="628" height="19" font="1">Ettinger PO, Regan TJ, Oldewurtel HA. Hyperkalemia, cardiac conduction, and the electrocardiogram: a </text>
<text top="897" left="167" width="225" height="19" font="1">review. Am Heart J. 1974;88:360-71. </text>
<text top="916" left="81" width="64" height="19" font="1">S4.1.1-13. </text>
<text top="916" left="167" width="573" height="19" font="1">Lee G, McGavigan AD, Hillock RJ, et al. A grave case of bradycardia. Pacing Clin Electrophysiol. </text>
<text top="934" left="167" width="103" height="19" font="1">2006;29:788-90. </text>
<text top="952" left="81" width="64" height="19" font="1">S4.1.1-14. </text>
<text top="952" left="167" width="584" height="19" font="1">Bolognesi R, Tsialtas D, Bolognesi MG, et al. Marked sinus bradycardia and QT prolongation in a </text>
<text top="970" left="167" width="527" height="19" font="1">diabetic patient with severe hypoglycemia. J Diabetes Complications. 2011;25:349-51. </text>
<text top="989" left="81" width="64" height="19" font="1">S4.1.1-15. </text>
<text top="989" left="167" width="595" height="19" font="1">Luebbert JJ, Lee FA, Rosenfeld LE. Pacemaker therapy for early and late sinus node dysfunction in </text>
<text top="1007" left="167" width="567" height="19" font="1">orthotopic heart transplant recipients: a single-center experience. Pacing Clin Electrophysiol. </text>
<text top="1025" left="167" width="111" height="19" font="1">2008;31:1108-12. </text>
<text top="1044" left="81" width="64" height="19" font="1">S4.1.1-16. </text>
<text top="1044" left="167" width="557" height="19" font="1">Bertolet BD, Eagle DA, Conti JB, et al. Bradycardia after heart transplantation: reversal with </text>
<text top="1062" left="167" width="288" height="19" font="1">theophylline. J Am Coll Cardiol. 1996;28:396-9. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="75" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">75</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="64" height="19" font="1">S4.1.1-17. </text>
<text top="111" left="167" width="622" height="19" font="1">Heinz G, Hirschl M, Buxbaum P, et al. Sinus node dysfunction after orthotopic cardiac transplantation: </text>
<text top="129" left="167" width="580" height="19" font="1">postoperative incidence and long-term implications. Pacing Clin Electrophysiol. 1992;15:731-7. </text>
<text top="147" left="81" width="64" height="19" font="1">S4.1.1-18. </text>
<text top="147" left="167" width="585" height="19" font="1">Santinelli V, Chiariello M, Clarizia M, et al. Sick sinus syndrome: the role of hypervagotonia. Int J </text>
<text top="165" left="167" width="139" height="19" font="1">Cardiol. 1984;5:532-5. </text>
<text top="184" left="81" width="64" height="19" font="1">S4.1.1-19. </text>
<text top="184" left="167" width="581" height="19" font="1">Desai JM, Scheinman MM, Strauss HC, et al. Electrophysiologic effects on combined autonomic </text>
<text top="202" left="167" width="454" height="19" font="1">blockade in patients with sinus node disease. Circulation. 1981;63:953-60. </text>
<text top="221" left="81" width="64" height="19" font="1">S4.1.1-20. </text>
<text top="221" left="167" width="599" height="19" font="1">Thomsen JH, Hassager C, Bro-Jeppesen J, et al. Sinus bradycardia during hypothermia in comatose </text>
<text top="239" left="167" width="614" height="19" font="1">survivors of out-of-hospital cardiac arrest - a new early marker of favorable outcome? Resuscitation. </text>
<text top="257" left="167" width="96" height="19" font="1">2015;89:36-42. </text>
<text top="275" left="81" width="64" height="19" font="1">S4.1.1-21. </text>
<text top="275" left="167" width="626" height="19" font="1">Mattu A, Brady WJ, Perron AD. Electrocardiographic manifestations of hypothermia. Am J Emerg Med. </text>
<text top="294" left="167" width="103" height="19" font="1">2002;20:314-26. </text>
<text top="312" left="81" width="64" height="19" font="1">S4.1.1-22. </text>
<text top="312" left="167" width="437" height="19" font="1">Grais IM, Sowers JR. Thyroid and the heart. Am J Med. 2014;127:691-8. </text>
<text top="330" left="81" width="64" height="19" font="1">S4.1.1-23. </text>
<text top="330" left="167" width="607" height="19" font="1">Secher NH, Sander Jensen K, Werner C, et al. Bradycardia during severe but reversible hypovolemic </text>
<text top="349" left="167" width="260" height="19" font="1">shock in man. Circ Shock. 1984;14:267-74. </text>
<text top="367" left="81" width="64" height="19" font="1">S4.1.1-24. </text>
<text top="367" left="167" width="615" height="19" font="1">Zwillich C, Devlin T, White D, et al. Bradycardia during sleep apnea. Characteristics and mechanism. J </text>
<text top="385" left="167" width="181" height="19" font="1">Clin Invest. 1982;69:1286-92. </text>
<text top="404" left="81" width="64" height="19" font="1">S4.1.1-25. </text>
<text top="404" left="167" width="595" height="19" font="1">Grmec S, Strnad M, Podgorsek D. Comparison of the characteristics and outcome among patients </text>
<text top="422" left="167" width="590" height="19" font="1">suffering from out-of-hospital primary cardiac arrest and drowning victims in cardiac arrest. Int J </text>
<text top="440" left="167" width="158" height="19" font="1">Emerg Med. 2009;2:7-12. </text>
<text top="458" left="81" width="64" height="19" font="1">S4.1.1-26. </text>
<text top="458" left="167" width="611" height="19" font="1">Myers MG, Norris JW, Hachinski VC, et al. Cardiac sequelae of acute stroke. Stroke. 1982;13:838-42. </text>
<text top="477" left="81" width="64" height="19" font="1">S4.1.1-27. </text>
<text top="477" left="167" width="591" height="19" font="1">Cunha BA. The diagnostic significance of relative bradycardia in infectious disease. Clin Microbiol </text>
<text top="495" left="167" width="130" height="19" font="1">Infect. 2000;6:633-4. </text>
<text top="513" left="81" width="64" height="19" font="1">S4.1.1-28. </text>
<text top="513" left="167" width="620" height="19" font="1">Woolf PK, Lorsung EM, Edwards KS, et al. Electrocardiographic findings in children with Lyme disease. </text>
<text top="532" left="167" width="213" height="19" font="1">Pediatr Emerg Care. 1991;7:334-6. </text>
<text top="550" left="81" width="64" height="19" font="1">S4.1.1-29. </text>
<text top="550" left="167" width="611" height="19" font="1">Gee SW, Karsies TJ. Listeria meningitis-associated bradyarrhythmia treated with isoproterenol. Am J </text>
<text top="568" left="167" width="192" height="19" font="1">Emerg Med. 2015;33:306.e1-2. </text>
<text top="587" left="81" width="64" height="19" font="1">S4.1.1-30. </text>
<text top="587" left="167" width="589" height="19" font="1">Narayan D, Huang MT, Mathew PK. Bradycardia and asystole requiring permanent pacemaker in </text>
<text top="605" left="167" width="333" height="19" font="1">Guillain-Barre syndrome. Am Heart J. 1984;108:426-8. </text>
<text top="623" left="81" width="64" height="19" font="1">S4.1.1-31. </text>
<text top="623" left="167" width="619" height="19" font="1">Ma G, Brady WJ, Pollack M, et al. Electrocardiographic manifestations: digitalis toxicity. J Emerg Med. </text>
<text top="642" left="167" width="103" height="19" font="1">2001;20:145-52. </text>
<text top="660" left="81" width="64" height="19" font="1">S4.1.1-32. </text>
<text top="660" left="167" width="622" height="19" font="1">Talati SN, Aslam AF, Vasavada B. Sinus node dysfunction in association with chronic lithium therapy: a </text>
<text top="678" left="167" width="387" height="19" font="1">case report and review of literature. Am J Ther. 2009;16:274-8. </text>
<text top="696" left="81" width="4" height="21" font="8"> </text>
<text top="716" left="81" width="342" height="23" font="4"><b>4.1.2. Acute Medical Therapy for Bradycardia </b></text>
<text top="758" left="81" width="408" height="21" font="7"><b>4.1.2.1. Atropine and Beta-Agonists for Bradycardia to SND </b></text>
<text top="791" left="81" width="704" height="19" font="1">S4.1.2.1-1.  Brady WJ, Swart G, DeBehnke DJ, et al. The efficacy of atropine in the treatment of hemodynamically </text>
<text top="809" left="167" width="542" height="19" font="1">unstable bradycardia and atrioventricular block: prehospital and emergency department </text>
<text top="827" left="167" width="281" height="19" font="1">considerations. Resuscitation. 1999;41:47-55. </text>
<text top="846" left="81" width="699" height="19" font="1">S4.1.2.1-2.  Scheinman MM, Thorburn D, Abbott JA. Use of atropine in patients with acute myocardial infarction </text>
<text top="864" left="167" width="316" height="19" font="1">and sinus bradycardia. Circulation. 1975;52:627-33. </text>
<text top="882" left="81" width="608" height="19" font="1">S4.1.2.1-3.  Swart G, Brady WJ Jr, DeBehnke DJ, et al. Acute myocardial infarction complicated by </text>
<text top="901" left="167" width="626" height="19" font="1">hemodynamically unstable bradyarrhythmia: prehospital and ED treatment with atropine. Am J Emerg </text>
<text top="919" left="167" width="139" height="19" font="1">Med. 1999;17:647-52. </text>
<text top="937" left="81" width="690" height="19" font="1">S4.1.2.1-4.  Warren JV, Lewis RP. Beneficial effects of atropine in the pre-hospital phase of coronary care. Am J </text>
<text top="956" left="167" width="146" height="19" font="1">Cardiol. 1976;37:68-72. </text>
<text top="974" left="81" width="697" height="19" font="1">S4.1.2.1-5.  Gee SW, Karsies TJ. Listeria meningitis-associated bradyarrhythmia treated with isoproterenol. Am J </text>
<text top="992" left="167" width="192" height="19" font="1">Emerg Med. 2015;33:306.e1-2. </text>
<text top="1011" left="81" width="686" height="19" font="1">S4.1.2.1-6.  Herman SC, Zhou J. Isoproterenol infusion for treatment of refractory symptomatic bradycardia in </text>
<text top="1029" left="167" width="618" height="19" font="1">parturients with congenital complete heart block. Int J Obstet Anesth. 2011;20:361-3; author reply 3. </text>
<text top="1047" left="81" width="700" height="19" font="1">S4.1.2.1-7.  Mandel WJ, Hayakawa H, Allen HN, et al. Assessment of sinus node function in patients with the sick </text>
<text top="1065" left="167" width="271" height="19" font="1">sinus syndrome. Circulation. 1972;46:761-9. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="76" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">76</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="685" height="19" font="1">S4.1.2.1-8.  Ogawa H, Inoue T, Miwa S, et al. Heart rate responses to autonomic drugs in sick sinus syndrome--</text>
<text top="129" left="167" width="488" height="19" font="1">correlation with syncope and electrophysiologic data. Jpn Circ J. 1991;55:15-23. </text>
<text top="147" left="81" width="713" height="19" font="1">S4.1.2.1-9.  Sodeck GH, Domanovits H, Meron G, et al. Compromising bradycardia: management in the emergency </text>
<text top="165" left="167" width="272" height="19" font="1">department. Resuscitation. 2007;73:96-102. </text>
<text top="184" left="81" width="704" height="19" font="1">S4.1.2.1-10.  Strauss HC, Bigger JT, Saroff AL, et al. Electrophysiologic evaluation of sinus node function in patients </text>
<text top="202" left="167" width="354" height="19" font="1">with sinus node dysfunction. Circulation. 1976;53:763-76. </text>
<text top="221" left="81" width="712" height="19" font="1">S4.1.2.1-11.  Morrison LJ, Long J, Vermeulen M, et al. A randomized controlled feasibility trial comparing safety and </text>
<text top="239" left="167" width="565" height="19" font="1">effectiveness of prehospital pacing versus conventional treatment: 'PrePACE'. Resuscitation. </text>
<text top="257" left="167" width="96" height="19" font="1">2008;76:341-9. </text>
<text top="275" left="81" width="715" height="19" font="1">S4.1.2.1-12.  Bernheim A, Fatio R, Kiowski W, et al. Atropine often results in complete atrioventricular block or sinus </text>
<text top="294" left="167" width="558" height="19" font="1">arrest after cardiac transplantation: an unpredictable and dose-independent phenomenon. </text>
<text top="312" left="167" width="207" height="19" font="1">Transplantation. 2004;77:1181-5. </text>
<text top="330" left="81" width="679" height="19" font="1">S4.1.2.1-13.  Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult advanced cardiovascular life support. 2015 </text>
<text top="349" left="167" width="592" height="19" font="1">American Heart Association guidelines update for cardiopulmonary resuscitation and emergency </text>
<text top="367" left="167" width="243" height="19" font="1">cardiovascular care. 2015;132:S444-64. </text>
<text top="385" left="81" width="4" height="21" font="8"> </text>
<text top="405" left="81" width="687" height="21" font="7"><b>4.1.2.2. Therapy of Beta Blocker and Calcium Channel Blocker Mediated Bradycardia Attributable</b> <b>to </b></text>
<text top="428" left="81" width="205" height="21" font="7"><b>SND or Atrioventricular Block </b></text>
<text top="461" left="81" width="679" height="19" font="1">S4.1.2.2-1.  Howarth DM, Dawson AH, Smith AJ, et al. Calcium channel blocking drug overdose: an Australian </text>
<text top="479" left="167" width="246" height="19" font="1">series. Hum Exp Toxicol. 1994;13:161-6. </text>
<text top="497" left="81" width="707" height="19" font="1">S4.1.2.2-2.  Ramoska EA, Spiller HA, Winter M, et al. A one-year evaluation of calcium channel blocker overdoses: </text>
<text top="516" left="167" width="360" height="19" font="1">toxicity and treatment. Ann Emerg Med. 1993;22:196-200. </text>
<text top="534" left="81" width="705" height="19" font="1">S4.1.2.2-3.  St-Onge M, Dube PA, Gosselin S, et al. Treatment for calcium channel blocker poisoning: a systematic </text>
<text top="552" left="167" width="270" height="19" font="1">review. Clin Toxicol (Phila). 2014;52:926-44. </text>
<text top="571" left="81" width="679" height="19" font="1">S4.1.2.2-4.  Bailey B. Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. J </text>
<text top="589" left="167" width="234" height="19" font="1">Toxicol Clin Toxicol. 2003;41:595-602. </text>
<text top="607" left="81" width="668" height="19" font="1">S4.1.2.2-5.  Love JN, Sachdeva DK, Bessman ES, et al. A potential role for glucagon in the treatment of drug-</text>
<text top="626" left="167" width="359" height="19" font="1">induced symptomatic bradycardia. Chest. 1998;114:323-6. </text>
<text top="644" left="81" width="669" height="19" font="1">S4.1.2.2-6.  Engebretsen KM, Kaczmarek KM, Morgan J, et al. High-dose insulin therapy in beta-blocker and </text>
<text top="662" left="167" width="439" height="19" font="1">calcium channel-blocker poisoning. Clin Toxicol (Phila). 2011;49:277-83. </text>
<text top="680" left="81" width="662" height="19" font="1">S4.1.2.2-7.  Woodward C, Pourmand A, Mazer-Amirshahi M. High dose insulin therapy, an evidence based </text>
<text top="699" left="167" width="620" height="19" font="1">approach to beta blocker/calcium channel blocker toxicity. DARU Journal of Pharmaceutical Sciences. </text>
<text top="717" left="167" width="76" height="19" font="1">2014;22:36. </text>
<text top="735" left="81" width="4" height="21" font="8"> </text>
<text top="755" left="81" width="699" height="21" font="7"><b>4.1.2.3. Therapy of Digoxin Mediated Bradycardia Attributable to Either SND or Atrioventricular Block </b></text>
<text top="788" left="81" width="660" height="19" font="1">S4.1.2.3-1.  Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis </text>
<text top="806" left="167" width="572" height="19" font="1">intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. </text>
<text top="824" left="167" width="184" height="19" font="1">Circulation. 1990;81:1744-52. </text>
<text top="843" left="81" width="686" height="19" font="1">S4.1.2.3-2.  Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin </text>
<text top="861" left="167" width="196" height="19" font="1">Toxicol (Phila). 2014;52:824-36. </text>
<text top="879" left="81" width="666" height="19" font="1">S4.1.2.3-3.  Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune Fab therapy in the management of </text>
<text top="897" left="167" width="586" height="19" font="1">digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll </text>
<text top="916" left="167" width="146" height="19" font="1">Cardiol. 1991;17:590-8. </text>
<text top="934" left="81" width="712" height="19" font="1">S4.1.2.3-4.  Lapostolle F, Borron SW, Verdier C, et al. Assessment of digoxin antibody use in patients with elevated </text>
<text top="952" left="167" width="551" height="19" font="1">serum digoxin following chronic or acute exposure. Intensive Care Med. 2008;34:1448-53. </text>
<text top="971" left="81" width="702" height="19" font="1">S4.1.2.3-5.  Lapostolle F, Borron SW, Verdier C, et al. Digoxin-specific Fab fragments as single first-line therapy in </text>
<text top="989" left="167" width="312" height="19" font="1">digitalis poisoning. Crit Care Med. 2008;36:3014-8. </text>
<text top="1007" left="81" width="706" height="19" font="1">S4.1.2.3-6.  Smith TW, Butler VP Jr, Haber E, et al. Treatment of life-threatening digitalis intoxication with digoxin-</text>
<text top="1026" left="167" width="549" height="19" font="1">specific Fab antibody fragments: experience in 26 cases. N Engl J Med. 1982;307:1357-62. </text>
<text top="1044" left="81" width="676" height="19" font="1">S4.1.2.3-7.  Wenger TL. Experience with digoxin immune Fab (ovine) in patients with renal impairment. Am J </text>
<text top="1062" left="167" width="259" height="19" font="1">Emerg Med. 1991;9:21-3; discussion 33-4. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="77" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">77</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="698" height="19" font="1">S4.1.2.3-8.  Wenger TL, Butler VP Jr, Haber E, et al. Treatment of 63 severely digitalis-toxic patients with digoxin-</text>
<text top="129" left="167" width="394" height="19" font="1">specific antibody fragments. J Am Coll Cardiol. 1985;5:118a-23a. </text>
<text top="147" left="81" width="714" height="19" font="1">S4.1.2.3-9.  Mowry JB, Burdmann EA, Anseeuw K, et al. Extracorporeal treatment for digoxin poisoning: systematic </text>
<text top="165" left="167" width="586" height="19" font="1">review and recommendations from the EXTRIP Workgroup. Clin Toxicol (Phila). 2016;54:103-14. </text>
<text top="183" left="81" width="4" height="21" font="8"> </text>
<text top="204" left="81" width="518" height="21" font="7"><b>4.1.2.4. Aminophylline or Theophylline for Bradycardia Attributable to SND </b></text>
<text top="236" left="81" width="714" height="19" font="1">S4.1.2.4-1.  Rothman SA, Jeevanandam V, Seeber CP, et al. Electrophysiologic effects of intravenous aminophylline </text>
<text top="254" left="167" width="612" height="19" font="1">in heart transplant recipients with sinus node dysfunction. J Heart Lung Transplant. 1995;14:429-35. </text>
<text top="273" left="81" width="695" height="19" font="1">S4.1.2.4-2.  Redmond JM, Zehr KJ, Gillinov MA, et al. Use of theophylline for treatment of prolonged sinus node </text>
<text top="291" left="167" width="588" height="19" font="1">dysfunction in human orthotopic heart transplantation. J Heart Lung Transplant. 1993;12:133-8; </text>
<text top="309" left="167" width="93" height="19" font="1">discussion 8-9. </text>
<text top="328" left="81" width="714" height="19" font="1">S4.1.2.4-3.  Heinz G, Kratochwill C, Buxbaum P, et al. Immediate normalization of profound sinus node dysfunction </text>
<text top="346" left="167" width="468" height="19" font="1">by aminophylline after cardiac transplantation. Am J Cardiol. 1993;71:346-9. </text>
<text top="364" left="81" width="643" height="19" font="1">S4.1.2.4-4.  Bertolet BD, Eagle DA, Conti JB, et al. Bradycardia after heart transplantation: reversal with </text>
<text top="383" left="167" width="288" height="19" font="1">theophylline. J Am Coll Cardiol. 1996;28:396-9. </text>
<text top="401" left="81" width="711" height="19" font="1">S4.1.2.4-5.  Schulz-Stubner S. The use of small-dose theophylline for the treatment of bradycardia in patients with </text>
<text top="419" left="167" width="318" height="19" font="1">spinal cord injury. Anesth Analg. 2005;101:1809-11. </text>
<text top="438" left="81" width="682" height="19" font="1">S4.1.2.4-6.  Sadaka F, Naydenov SK, Ponzillo JJ. Theophylline for bradycardia secondary to cervical spinal cord </text>
<text top="456" left="167" width="242" height="19" font="1">injury. Neurocrit Care. 2010;13:389-92. </text>
<text top="474" left="81" width="693" height="19" font="1">S4.1.2.4-7.  Pasnoori VR, Leesar MA. Use of aminophylline in the treatment of severe symptomatic bradycardia </text>
<text top="492" left="167" width="296" height="19" font="1">resistant to atropine. Cardiol Rev. 2004;12:65-8. </text>
<text top="511" left="81" width="704" height="19" font="1">S4.1.2.4-8.  Brady WJ, Swart G, DeBehnke DJ, et al. The efficacy of atropine in the treatment of hemodynamically </text>
<text top="529" left="167" width="542" height="19" font="1">unstable bradycardia and atrioventricular block: prehospital and emergency department </text>
<text top="547" left="167" width="281" height="19" font="1">considerations. Resuscitation. 1999;41:47-55. </text>
<text top="566" left="81" width="699" height="19" font="1">S4.1.2.4-9.  Scheinman MM, Thorburn D, Abbott JA. Use of atropine in patients with acute myocardial infarction </text>
<text top="584" left="167" width="316" height="19" font="1">and sinus bradycardia. Circulation. 1975;52:627-33. </text>
<text top="602" left="81" width="608" height="19" font="1">S4.1.2.4-10.  Swart G, Brady WJ Jr, DeBehnke DJ, et al. Acute myocardial infarction complicated by </text>
<text top="621" left="167" width="626" height="19" font="1">hemodynamically unstable bradyarrhythmia: prehospital and ED treatment with atropine. Am J Emerg </text>
<text top="639" left="167" width="139" height="19" font="1">Med. 1999;17:647-52. </text>
<text top="657" left="81" width="690" height="19" font="1">S4.1.2.4-11.  Warren JV, Lewis RP. Beneficial effects of atropine in the pre-hospital phase of coronary care. Am J </text>
<text top="676" left="167" width="146" height="19" font="1">Cardiol. 1976;37:68-72. </text>
<text top="694" left="81" width="664" height="19" font="1">S4.1.2.4-12.  Feigl D, Ashkenazy J, Kishon Y. Early and late atrioventricular block in acute inferior myocardial </text>
<text top="712" left="167" width="255" height="19" font="1">infarction. J Am Coll Cardiol. 1984;4:35-8. </text>
<text top="730" left="81" width="712" height="19" font="1">S4.1.2.4-13.  Morrison LJ, Long J, Vermeulen M, et al. A randomized controlled feasibility trial comparing safety and </text>
<text top="749" left="167" width="565" height="19" font="1">effectiveness of prehospital pacing versus conventional treatment: 'PrePACE'. Resuscitation. </text>
<text top="767" left="167" width="96" height="19" font="1">2008;76:341-9. </text>
<text top="786" left="81" width="700" height="19" font="1">S4.1.2.4-14.  Mandel WJ, Hayakawa H, Allen HN, et al. Assessment of sinus node function in patients with the sick </text>
<text top="804" left="167" width="271" height="19" font="1">sinus syndrome. Circulation. 1972;46:761-9. </text>
<text top="822" left="81" width="685" height="19" font="1">S4.1.2.4-15.  Ogawa H, Inoue T, Miwa S, et al. Heart rate responses to autonomic drugs in sick sinus syndrome--</text>
<text top="840" left="167" width="488" height="19" font="1">correlation with syncope and electrophysiologic data. Jpn Circ J. 1991;55:15-23. </text>
<text top="859" left="81" width="704" height="19" font="1">S4.1.2.4-16.  Strauss HC, Bigger JT, Saroff AL, et al. Electrophysiologic evaluation of sinus node function in patients </text>
<text top="877" left="167" width="354" height="19" font="1">with sinus node dysfunction. Circulation. 1976;53:763-76. </text>
<text top="895" left="81" width="697" height="19" font="1">S4.1.2.4-17.  Gee SW, Karsies TJ. Listeria meningitis-associated bradyarrhythmia treated with isoproterenol. Am J </text>
<text top="914" left="167" width="192" height="19" font="1">Emerg Med. 2015;33:306.e1-2. </text>
<text top="932" left="81" width="686" height="19" font="1">S4.1.2.4-18.  Herman SC, Zhou J. Isoproterenol infusion for treatment of refractory symptomatic bradycardia in </text>
<text top="950" left="167" width="618" height="19" font="1">parturients with congenital complete heart block. Int J Obstet Anesth. 2011;20:361-3; author reply 3. </text>
<text top="969" left="81" width="713" height="19" font="1">S4.1.2.4-19.  Sodeck GH, Domanovits H, Meron G, et al. Compromising bradycardia: management in the emergency </text>
<text top="987" left="167" width="272" height="19" font="1">department. Resuscitation. 2007;73:96-102. </text>
<text top="1005" left="81" width="692" height="19" font="1">S4.1.2.4-20.  Chihrin SM, Mohamed U, Yee R, et al. Utility of isoproterenol in unmasking latent escape rhythm in </text>
<text top="1024" left="167" width="609" height="19" font="1">pacemaker dependent patients undergoing pacemaker replacement. Am J Cardiol. 2008;101:631-3. </text>
<text top="1042" left="81" width="679" height="19" font="1">S4.1.2.4-21.  Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult advanced cardiovascular life support. 2015 </text>
<text top="1060" left="167" width="592" height="19" font="1">American Heart Association guidelines update for cardiopulmonary resuscitation and emergency </text>
<text top="1078" left="167" width="243" height="19" font="1">cardiovascular care. 2015;132:S444-64. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="78" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">78</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="679" height="19" font="1">S4.1.2.4-22.  Howarth DM, Dawson AH, Smith AJ, et al. Calcium channel blocking drug overdose: an Australian </text>
<text top="129" left="167" width="246" height="19" font="1">series. Hum Exp Toxicol. 1994;13:161-6. </text>
<text top="147" left="81" width="707" height="19" font="1">S4.1.2.4-23.  Ramoska EA, Spiller HA, Winter M, et al. A one-year evaluation of calcium channel blocker overdoses: </text>
<text top="165" left="167" width="360" height="19" font="1">toxicity and treatment. Ann Emerg Med. 1993;22:196-200. </text>
<text top="184" left="81" width="705" height="19" font="1">S4.1.2.4-24.  St-Onge M, Dube PA, Gosselin S, et al. Treatment for calcium channel blocker poisoning: a systematic </text>
<text top="202" left="167" width="270" height="19" font="1">review. Clin Toxicol (Phila). 2014;52:926-44. </text>
<text top="221" left="81" width="679" height="19" font="1">S4.1.2.4-25.  Bailey B. Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. J </text>
<text top="239" left="167" width="234" height="19" font="1">Toxicol Clin Toxicol. 2003;41:595-602. </text>
<text top="257" left="81" width="668" height="19" font="1">S4.1.2.4-26.  Love JN, Sachdeva DK, Bessman ES, et al. A potential role for glucagon in the treatment of drug-</text>
<text top="275" left="167" width="359" height="19" font="1">induced symptomatic bradycardia. Chest. 1998;114:323-6. </text>
<text top="294" left="81" width="669" height="19" font="1">S4.1.2.4-27.  Engebretsen KM, Kaczmarek KM, Morgan J, et al. High-dose insulin therapy in beta-blocker and </text>
<text top="312" left="167" width="439" height="19" font="1">calcium channel-blocker poisoning. Clin Toxicol (Phila). 2011;49:277-83. </text>
<text top="330" left="81" width="672" height="19" font="1">S4.1.2.4-28.  Greene SL, Gawarammana I, Wood DM, et al. Relative safety of hyperinsulinaemia/euglycaemia </text>
<text top="349" left="167" width="616" height="19" font="1">therapy in the management of calcium channel blocker overdose: a prospective observational study. </text>
<text top="367" left="167" width="237" height="19" font="1">Intensive Care Med. 2007;33:2019-24. </text>
<text top="385" left="81" width="660" height="19" font="1">S4.1.2.4-29.  Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis </text>
<text top="404" left="167" width="572" height="19" font="1">intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. </text>
<text top="422" left="167" width="184" height="19" font="1">Circulation. 1990;81:1744-52. </text>
<text top="440" left="81" width="686" height="19" font="1">S4.1.2.4-30.  Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin </text>
<text top="458" left="167" width="196" height="19" font="1">Toxicol (Phila). 2014;52:824-36. </text>
<text top="477" left="81" width="666" height="19" font="1">S4.1.2.4-31.  Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune Fab therapy in the management of </text>
<text top="495" left="167" width="586" height="19" font="1">digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll </text>
<text top="513" left="167" width="146" height="19" font="1">Cardiol. 1991;17:590-8. </text>
<text top="532" left="81" width="702" height="19" font="1">S4.1.2.4-32.  Lapostolle F, Borron SW, Verdier C, et al. Digoxin-specific Fab fragments as single first-line therapy in </text>
<text top="550" left="167" width="312" height="19" font="1">digitalis poisoning. Crit Care Med. 2008;36:3014-8. </text>
<text top="568" left="81" width="712" height="19" font="1">S4.1.2.4-33.  Lapostolle F, Borron SW, Verdier C, et al. Assessment of digoxin antibody use in patients with elevated </text>
<text top="587" left="167" width="551" height="19" font="1">serum digoxin following chronic or acute exposure. Intensive Care Med. 2008;34:1448-53. </text>
<text top="605" left="81" width="706" height="19" font="1">S4.1.2.4-34.  Smith TW, Butler VP Jr, Haber E, et al. Treatment of life-threatening digitalis intoxication with digoxin-</text>
<text top="623" left="167" width="549" height="19" font="1">specific Fab antibody fragments: experience in 26 cases. N Engl J Med. 1982;307:1357-62. </text>
<text top="642" left="81" width="676" height="19" font="1">S4.1.2.4-35.  Wenger TL. Experience with digoxin immune Fab (ovine) in patients with renal impairment. Am J </text>
<text top="660" left="167" width="259" height="19" font="1">Emerg Med. 1991;9:21-3; discussion 33-4. </text>
<text top="678" left="81" width="698" height="19" font="1">S4.1.2.4-36.  Wenger TL, Butler VP Jr, Haber E, et al. Treatment of 63 severely digitalis-toxic patients with digoxin-</text>
<text top="696" left="167" width="394" height="19" font="1">specific antibody fragments. J Am Coll Cardiol. 1985;5:118a-23a. </text>
<text top="714" left="81" width="4" height="21" font="8"> </text>
<text top="735" left="81" width="457" height="23" font="38"><i><b>4.1.3. Temporary Pacing for Bradycardia Attributable to SND </b></i></text>
<text top="769" left="81" width="57" height="19" font="1">S4.1.3-1. </text>
<text top="769" left="167" width="582" height="19" font="1">Austin JL, Preis LK, Crampton RS, et al. Analysis of pacemaker malfunction and complications of </text>
<text top="787" left="167" width="447" height="19" font="1">temporary pacing in the coronary care unit. Am J Cardiol. 1982;49:301-6. </text>
<text top="806" left="81" width="57" height="19" font="1">S4.1.3-2. </text>
<text top="806" left="167" width="610" height="19" font="1">Betts TR. Regional survey of temporary transvenous pacing procedures and complications. Postgrad </text>
<text top="824" left="167" width="139" height="19" font="1">Med J. 2003;79:463-5. </text>
<text top="842" left="81" width="57" height="19" font="1">S4.1.3-3. </text>
<text top="842" left="167" width="615" height="19" font="1">Bjornstad CC, Gjertsen E, Thorup F, et al. Temporary cardiac pacemaker treatment in five Norwegian </text>
<text top="861" left="167" width="339" height="19" font="1">regional hospitals. Scand Cardiovasc J. 2012;46:137-43. </text>
<text top="879" left="81" width="57" height="19" font="1">S4.1.3-4. </text>
<text top="879" left="167" width="610" height="19" font="1">Ferguson JD, Banning AP, Bashir Y. Randomised trial of temporary cardiac pacing with semirigid and </text>
<text top="897" left="167" width="378" height="19" font="1">balloon-flotation electrode catheters. Lancet. 1997;349:1883. </text>
<text top="916" left="81" width="57" height="19" font="1">S4.1.3-5. </text>
<text top="916" left="167" width="595" height="19" font="1">Garcia Guerrero JJ, Fernandez de la Concha Castaneda J, Lopez Quero D, et al. Lower incidence of </text>
<text top="934" left="167" width="601" height="19" font="1">venous thrombosis with temporary active-fixation lead implantation in mobile patients. Europace. </text>
<text top="952" left="167" width="103" height="19" font="1">2010;12:1604-7. </text>
<text top="971" left="81" width="57" height="19" font="1">S4.1.3-6. </text>
<text top="971" left="167" width="614" height="19" font="1">Hynes JK, Holmes DR Jr, Harrison CE. Five-year experience with temporary pacemaker therapy in the </text>
<text top="989" left="167" width="314" height="19" font="1">coronary care unit. Mayo Clin Proc. 1983;58:122-6. </text>
<text top="1007" left="81" width="57" height="19" font="1">S4.1.3-7. </text>
<text top="1007" left="167" width="578" height="19" font="1">Jou YL, Hsu HP, Tuan TC, et al. Trends of temporary pacemaker implant and underlying disease </text>
<text top="1026" left="167" width="338" height="19" font="1">substrate. Pacing Clin Electrophysiol. 2010;33:1475-84. </text>
<text top="1044" left="81" width="57" height="19" font="1">S4.1.3-8. </text>
<text top="1044" left="167" width="609" height="19" font="1">Jowett NI, Thompson DR, Pohl JE. Temporary transvenous cardiac pacing: 6 years experience in one </text>
<text top="1062" left="167" width="315" height="19" font="1">coronary care unit. Postgrad Med J. 1989;65:211-5. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="79" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">79</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="57" height="19" font="1">S4.1.3-9. </text>
<text top="111" left="167" width="608" height="19" font="1">López Ayerbe J, Villuendas Sabaté R, García García C, et al. Temporary pacemakers: current use and </text>
<text top="129" left="167" width="505" height="19" font="1">complications. Revista Española de Cardiología (English Edition). 2004;57:1045-52. </text>
<text top="147" left="81" width="64" height="19" font="1">S4.1.3-10. </text>
<text top="147" left="167" width="605" height="19" font="1">McCann P. A review of temporary cardiac pacing wires. Indian Pacing Electrophysiol J. 2007;7:40-9. </text>
<text top="165" left="81" width="64" height="19" font="1">S4.1.3-11. </text>
<text top="165" left="167" width="599" height="19" font="1">Muñoz Bono J, Prieto Palomino MA, Macías Guarasa I, et al. Efficacy and safety of non-permanent </text>
<text top="184" left="167" width="608" height="19" font="1">transvenous pacemaker implantation in an intensive care unit. Medicina Intensiva (English Edition). </text>
<text top="202" left="167" width="96" height="19" font="1">2011;35:410-6. </text>
<text top="221" left="81" width="64" height="19" font="1">S4.1.3-12. </text>
<text top="221" left="167" width="614" height="19" font="1">Nolewajka AJ, Goddard MD, Brown TC. Temporary transvenous pacing and femoral vein thrombosis. </text>
<text top="239" left="167" width="176" height="19" font="1">Circulation. 1980;62:646-50. </text>
<text top="257" left="81" width="64" height="19" font="1">S4.1.3-13. </text>
<text top="257" left="167" width="610" height="19" font="1">Smith I, Monk TG, White PF. Comparison of transesophageal atrial pacing with anticholinergic drugs </text>
<text top="275" left="167" width="487" height="19" font="1">for the treatment of intraoperative bradycardia. Anesth Analg. 1994;78:245-52. </text>
<text top="294" left="81" width="64" height="19" font="1">S4.1.3-14. </text>
<text top="294" left="167" width="626" height="19" font="1">Sodeck GH, Domanovits H, Meron G, et al. Compromising bradycardia: management in the emergency </text>
<text top="312" left="167" width="272" height="19" font="1">department. Resuscitation. 2007;73:96-102. </text>
<text top="330" left="81" width="64" height="19" font="1">S4.1.3-15. </text>
<text top="330" left="167" width="604" height="19" font="1">Weinstein J, Gnoj J, Mazzara JT, et al. Temporary transvenous pacing via the percutaneous femoral </text>
<text top="349" left="167" width="484" height="19" font="1">vein approach. A prospective study of 100 cases. Am Heart J. 1973;85:695-705. </text>
<text top="367" left="81" width="64" height="19" font="1">S4.1.3-16. </text>
<text top="367" left="167" width="556" height="19" font="1">Bektas F, Soyuncu S. The efficacy of transcutaneous cardiac pacing in ED. Am J Emerg Med. </text>
<text top="385" left="167" width="103" height="19" font="1">2016;34:2090-3. </text>
<text top="404" left="81" width="64" height="19" font="1">S4.1.3-17. </text>
<text top="404" left="167" width="574" height="19" font="1">Clinton JE, Zoll PM, Zoll R, et al. Emergency noninvasive external cardiac pacing. J Emerg Med. </text>
<text top="422" left="167" width="96" height="19" font="1">1985;2:155-62. </text>
<text top="440" left="81" width="64" height="19" font="1">S4.1.3-18. </text>
<text top="440" left="167" width="575" height="19" font="1">Hedges JR, Feero S, Shultz B, et al. Prehospital transcutaneous cardiac pacing for symptomatic </text>
<text top="458" left="167" width="345" height="19" font="1">bradycardia. Pacing Clin Electrophysiol. 1991;14:1473-8. </text>
<text top="477" left="81" width="64" height="19" font="1">S4.1.3-19. </text>
<text top="477" left="167" width="626" height="19" font="1">Morrison LJ, Long J, Vermeulen M, et al. A randomized controlled feasibility trial comparing safety and </text>
<text top="495" left="167" width="565" height="19" font="1">effectiveness of prehospital pacing versus conventional treatment: 'PrePACE'. Resuscitation. </text>
<text top="513" left="167" width="96" height="19" font="1">2008;76:341-9. </text>
<text top="532" left="81" width="64" height="19" font="1">S4.1.3-20. </text>
<text top="532" left="167" width="560" height="19" font="1">Sherbino J, Verbeek PR, MacDonald RD, et al. Prehospital transcutaneous cardiac pacing for </text>
<text top="550" left="167" width="572" height="19" font="1">symptomatic bradycardia or bradyasystolic cardiac arrest: a systematic review. Resuscitation. </text>
<text top="568" left="167" width="111" height="19" font="1">2006;70:193-200. </text>
<text top="587" left="81" width="64" height="19" font="1">S4.1.3-21. </text>
<text top="587" left="167" width="563" height="19" font="1">Zoll PM, Zoll RH, Falk RH, et al. External noninvasive temporary cardiac pacing: clinical trials. </text>
<text top="605" left="167" width="176" height="19" font="1">Circulation. 1985;71:937-44. </text>
<text top="623" left="81" width="64" height="19" font="1">S4.1.3-22. </text>
<text top="623" left="167" width="575" height="19" font="1">Murphy JJ. Current practice and complications of temporary transvenous cardiac pacing. BMJ. </text>
<text top="642" left="167" width="99" height="19" font="1">1996;312:1134. </text>
<text top="660" left="81" width="4" height="21" font="8"> </text>
<text top="680" left="81" width="619" height="27" font="27"><b>4.2. Chronic Therapy/Management of Bradycardia Attributable to SND </b></text>
<text top="710" left="81" width="703" height="23" font="38"><i><b>4.2.1. General Principles of Chronic Therapy/Management of Bradycardia Attributable to SND </b></i></text>
<text top="744" left="81" width="57" height="19" font="1">S4.2.1-1. </text>
<text top="744" left="167" width="503" height="19" font="1">Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by 24 hour continuous </text>
<text top="763" left="167" width="606" height="19" font="1">electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J </text>
<text top="781" left="167" width="146" height="19" font="1">Cardiol. 1977;39:390-5. </text>
<text top="799" left="81" width="57" height="19" font="1">S4.2.1-2. </text>
<text top="799" left="167" width="592" height="19" font="1">Meytes I, Kaplinsky E, Yahini JH, et al. Wenckebach A-V block: a frequent feature following heavy </text>
<text top="818" left="167" width="284" height="19" font="1">physical training. Am Heart J. 1975;90:426-30. </text>
<text top="836" left="81" width="57" height="19" font="1">S4.2.1-3. </text>
<text top="836" left="167" width="595" height="19" font="1">Northcote RJ, Canning GP, Ballantyne D. Electrocardiographic findings in male veteran endurance </text>
<text top="854" left="167" width="226" height="19" font="1">athletes. Br Heart J. 1989;61:155-60. </text>
<text top="873" left="81" width="57" height="19" font="1">S4.2.1-4. </text>
<text top="873" left="167" width="604" height="19" font="1">Viitasalo MT, Kala R, Eisalo A. Ambulatory electrocardiographic recording in endurance athletes. Br </text>
<text top="891" left="167" width="153" height="19" font="1">Heart J. 1982;47:213-20. </text>
<text top="909" left="81" width="57" height="19" font="1">S4.2.1-5. </text>
<text top="909" left="167" width="611" height="19" font="1">Gadler F, Valzania C, Linde C. Current use of implantable electrical devices in Sweden: data from the </text>
<text top="928" left="167" width="596" height="19" font="1">Swedish pacemaker and implantable cardioverter-defibrillator registry. Europace. 2015;17:69-77. </text>
<text top="946" left="81" width="57" height="19" font="1">S4.2.1-6. </text>
<text top="946" left="167" width="592" height="19" font="1">Armaganijan LV, Toff WD, Nielsen JC, et al. Are elderly patients at increased risk of complications </text>
<text top="964" left="167" width="611" height="19" font="1">following pacemaker implantation? A meta-analysis of randomized trials. Pacing Clin Electrophysiol. </text>
<text top="982" left="167" width="96" height="19" font="1">2012;35:131-4. </text>
<text top="1001" left="81" width="57" height="19" font="1">S4.2.1-7. </text>
<text top="1001" left="167" width="552" height="19" font="1">Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on </text>
<text top="1019" left="167" width="576" height="19" font="1">cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. </text>
<text top="1037" left="167" width="111" height="19" font="1">2017;14:e503-51. </text>
<text top="1055" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="80" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">80</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="110" left="81" width="451" height="23" font="38"><i><b>4.2.3. Additional Testing of Bradycardia Attributable to SND </b></i></text>
<text top="145" left="81" width="57" height="19" font="1">S4.2.3-1. </text>
<text top="145" left="167" width="593" height="19" font="1">Alboni P, Filippi L, Pirani R, et al. Reproducibility of electrophysiological parameters of sinus node </text>
<text top="163" left="167" width="365" height="19" font="1">following autonomic blockade. Int J Cardiol. 1983;4:431-42. </text>
<text top="181" left="81" width="57" height="19" font="1">S4.2.3-2. </text>
<text top="181" left="167" width="585" height="19" font="1">Bergfeldt L, Vallin H, Rosenqvist M, et al. Sinus node recovery time assessment revisited: role of </text>
<text top="200" left="167" width="629" height="19" font="1">pharmacologic blockade of the autonomic nervous system. J Cardiovasc Electrophysiol. 1996;7:95-101. </text>
<text top="218" left="81" width="57" height="19" font="1">S4.2.3-3. </text>
<text top="218" left="167" width="597" height="19" font="1">Narula OS, Shantha N, Vasquez M, et al. A new method for measurement of sinoatrial conduction </text>
<text top="236" left="167" width="211" height="19" font="1">time. Circulation. 1978;58:706-14. </text>
<text top="255" left="81" width="57" height="19" font="1">S4.2.3-4. </text>
<text top="255" left="167" width="621" height="19" font="1">Reiffel JA, Kuehnert MJ. Electrophysiological testing of sinus node function: diagnostic and prognostic </text>
<text top="273" left="167" width="613" height="19" font="1">application-including updated information from sinus node electrograms. Pacing Clin Electrophysiol. </text>
<text top="291" left="167" width="103" height="19" font="1">1994;17:349-65. </text>
<text top="310" left="81" width="57" height="19" font="1">S4.2.3-5. </text>
<text top="310" left="167" width="617" height="19" font="1">Strauss HC, Saroff AL, Bigger JT Jr, et al. Premature atrial stimulation as a key to the understanding of </text>
<text top="328" left="167" width="601" height="19" font="1">sinoatrial conduction in man. Presentation of data and critical review of the literature. Circulation. </text>
<text top="346" left="167" width="96" height="19" font="1">1973;47:86-93. </text>
<text top="365" left="81" width="57" height="19" font="1">S4.2.3-6. </text>
<text top="365" left="167" width="581" height="19" font="1">Denniss AR, Ross DL, Richards DA, et al. Electrophysiologic studies in patients with unexplained </text>
<text top="383" left="167" width="232" height="19" font="1">syncope. Int J Cardiol. 1992;35:211-7. </text>
<text top="401" left="81" width="57" height="19" font="1">S4.2.3-7. </text>
<text top="401" left="167" width="629" height="19" font="1">de Marneffe M, Jacobs P, Englert M. Reproducibility of electrophysiologic parameters of extrinsic sinus </text>
<text top="420" left="167" width="555" height="19" font="1">node function in patients with and without sick sinus syndrome. Pacing Clin Electrophysiol. </text>
<text top="438" left="167" width="88" height="19" font="1">1986;9:482-9. </text>
<text top="456" left="81" width="4" height="21" font="8"> </text>
<text top="476" left="81" width="712" height="23" font="38"><i><b>4.3.4. Permanent Pacing for Chronic Therapy/Management of Bradycardia Attributable to SND </b></i></text>
<text top="510" left="81" width="57" height="19" font="1">S4.3.4-1. </text>
<text top="510" left="167" width="610" height="19" font="1">Sharma AD, Rizo-Patron C, Hallstrom AP, et al. Percent right ventricular pacing predicts outcomes in </text>
<text top="529" left="167" width="279" height="19" font="1">the DAVID trial. Heart Rhythm. 2005;2:830-4. </text>
<text top="547" left="81" width="57" height="19" font="1">S4.3.4-2. </text>
<text top="547" left="167" width="585" height="19" font="1">Sweeney MO, Prinzen FW. A new paradigm for physiologic ventricular pacing. J Am Coll Cardiol. </text>
<text top="565" left="167" width="96" height="19" font="1">2006;47:282-8. </text>
<text top="584" left="81" width="57" height="19" font="1">S4.3.4-3. </text>
<text top="584" left="167" width="612" height="19" font="1">Alboni P, Menozzi C, Brignole M, et al. Effects of permanent pacemaker and oral theophylline in sick </text>
<text top="602" left="167" width="585" height="19" font="1">sinus syndrome the THEOPACE study: a randomized controlled trial. Circulation. 1997;96:260-6. </text>
<text top="620" left="81" width="57" height="19" font="1">S4.3.4-4. </text>
<text top="620" left="167" width="619" height="19" font="1">Saito D, Matsubara K, Yamanari H, et al. Effects of oral theophylline on sick sinus syndrome. J Am Coll </text>
<text top="639" left="167" width="169" height="19" font="1">Cardiol. 1993;21:1199-204. </text>
<text top="657" left="81" width="4" height="21" font="8"> </text>
<text top="677" left="81" width="702" height="21" font="7"><b>4.3.4.1. Permanent Pacing Techniques and Methods for Chronic Therapy/Management of Bradycardia </b></text>
<text top="700" left="81" width="139" height="21" font="7"><b>Attributable to SND </b></text>
<text top="732" left="81" width="702" height="19" font="1">S4.3.4.1-1.  Andersen HR, Nielsen JC, Thomsen PE, et al. Long-term follow-up of patients from a randomised trial </text>
<text top="751" left="167" width="515" height="19" font="1">of atrial versus ventricular pacing for sick-sinus syndrome. Lancet. 1997;350:1210-6. </text>
<text top="769" left="81" width="715" height="19" font="1">S4.3.4.1-2.  Connolly SJ, Kerr CR, Gent M, et al. Effects of physiologic pacing versus ventricular pacing on the risk of </text>
<text top="787" left="167" width="608" height="19" font="1">stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N </text>
<text top="806" left="167" width="191" height="19" font="1">Engl J Med. 2000;342:1385-91. </text>
<text top="824" left="81" width="674" height="19" font="1">S4.3.4.1-3.  Lamas GA, Lee KL, Sweeney MO, et al. Ventricular pacing or dual-chamber pacing for sinus-node </text>
<text top="842" left="167" width="283" height="19" font="1">dysfunction. N Engl J Med. 2002;346:1854-62. </text>
<text top="861" left="81" width="702" height="19" font="1">S4.3.4.1-4.  Lamas GA, Orav EJ, Stambler BS, et al. Quality of life and clinical outcomes in elderly patients treated </text>
<text top="879" left="167" width="604" height="19" font="1">with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in the Elderly </text>
<text top="897" left="167" width="297" height="19" font="1">Investigators. N Engl J Med. 1998;338:1097-104. </text>
<text top="916" left="81" width="666" height="19" font="1">S4.3.4.1-5.  Brandt NH, Kirkfeldt RE, Nielsen JC, et al. Single lead atrial vs. dual chamber pacing in sick sinus </text>
<text top="934" left="167" width="517" height="19" font="1">syndrome: extended register-based follow-up in the DANPACE trial. Europace. 2016; </text>
<text top="952" left="81" width="707" height="19" font="1">S4.3.4.1-6.  Sweeney MO, Bank AJ, Nsah E, et al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-</text>
<text top="971" left="167" width="284" height="19" font="1">node disease. N Engl J Med. 2007;357:1000-8. </text>
<text top="989" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="81" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">81</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="110" left="81" width="522" height="31" font="2"><b>5. Bradycardia Attributable to Atrioventricular Block </b></text>
<text top="148" left="81" width="214" height="27" font="27"><b>5.2. Acute Management </b></text>
<text top="179" left="81" width="706" height="23" font="38"><i><b>5.2.1. Acute Management of Reversible Causes of Bradycardia Attributable to Atrioventricular </b></i></text>
<text top="204" left="81" width="48" height="23" font="38"><i><b>Block  </b></i></text>
<text top="238" left="81" width="57" height="19" font="1">S5.2.1-1. </text>
<text top="238" left="167" width="574" height="19" font="1">Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis </text>
<text top="257" left="167" width="572" height="19" font="1">intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. </text>
<text top="275" left="167" width="184" height="19" font="1">Circulation. 1990;81:1744-52. </text>
<text top="293" left="81" width="57" height="19" font="1">S5.2.1-2. </text>
<text top="293" left="167" width="595" height="19" font="1">Forrester JD, Mead P. Third-degree heart block associated with lyme carditis: review of published </text>
<text top="312" left="167" width="249" height="19" font="1">cases. Clin Infect Dis. 2014;59:996-1000. </text>
<text top="330" left="81" width="57" height="19" font="1">S5.2.1-3. </text>
<text top="330" left="167" width="580" height="19" font="1">Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune Fab therapy in the management of </text>
<text top="348" left="167" width="586" height="19" font="1">digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll </text>
<text top="367" left="167" width="146" height="19" font="1">Cardiol. 1991;17:590-8. </text>
<text top="385" left="81" width="57" height="19" font="1">S5.2.1-4. </text>
<text top="385" left="167" width="569" height="19" font="1">van der Linde MR. Lyme carditis: clinical characteristics of 105 cases. Scand J Infect Dis Suppl. </text>
<text top="403" left="167" width="88" height="19" font="1">1991;77:81-4. </text>
<text top="422" left="81" width="57" height="19" font="1">S5.2.1-5. </text>
<text top="422" left="167" width="627" height="19" font="1">McAlister HF, Klementowicz PT, Andrews C, et al. Lyme carditis: an important cause of reversible heart </text>
<text top="440" left="167" width="254" height="19" font="1">block. Ann Intern Med. 1989;110:339-45. </text>
<text top="458" left="81" width="57" height="19" font="1">S5.2.1-6. </text>
<text top="458" left="167" width="621" height="19" font="1">Kenneback G, Tabrizi F, Lindell P, et al. High-degree atrioventricular block during anti-arrhythmic drug </text>
<text top="477" left="167" width="619" height="19" font="1">treatment: use of a pacemaker with a bradycardia-detection algorithm to study the time course after </text>
<text top="495" left="167" width="267" height="19" font="1">drug withdrawal. Europace. 2007;9:186-91. </text>
<text top="513" left="81" width="57" height="19" font="1">S5.2.1-7. </text>
<text top="513" left="167" width="629" height="19" font="1">Knudsen MB, Thogersen AM, Hjortshoj SP, et al. The impact of drug discontinuation in patients treated </text>
<text top="532" left="167" width="624" height="19" font="1">with temporary pacemaker due to atrioventricular block. J Cardiovasc Electrophysiol. 2013;24:1255-8. </text>
<text top="550" left="81" width="57" height="19" font="1">S5.2.1-8. </text>
<text top="550" left="167" width="604" height="19" font="1">Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients with drug-induced atrioventricular </text>
<text top="568" left="167" width="305" height="19" font="1">block. Pacing Clin Electrophysiol. 2012;35:804-10. </text>
<text top="586" left="81" width="57" height="19" font="1">S5.2.1-9. </text>
<text top="586" left="167" width="621" height="19" font="1">Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation </text>
<text top="605" left="167" width="322" height="19" font="1">of the culprit drug. J Am Coll Cardiol. 2004;44:105-8. </text>
<text top="623" left="81" width="64" height="19" font="1">S5.2.1-10. </text>
<text top="623" left="167" width="562" height="19" font="1">Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of </text>
<text top="641" left="167" width="610" height="19" font="1">atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol. 2011;4:303-9. </text>
<text top="660" left="81" width="64" height="19" font="1">S5.2.1-11. </text>
<text top="660" left="167" width="583" height="19" font="1">Sadek MM, Yung D, Birnie DH, et al. Corticosteroid therapy for cardiac sarcoidosis: a systematic </text>
<text top="678" left="167" width="244" height="19" font="1">review. Can J Cardiol. 2013;29:1034-41. </text>
<text top="696" left="81" width="64" height="19" font="1">S5.2.1-12. </text>
<text top="696" left="167" width="597" height="19" font="1">Ozcan KS, Osmonov D, Erdinler I, et al. Atrioventricular block in patients with thyroid dysfunction: </text>
<text top="715" left="167" width="581" height="19" font="1">prognosis after treatment with hormone supplementation or antithyroid medication. J Cardiol. </text>
<text top="733" left="167" width="103" height="19" font="1">2012;60:327-32. </text>
<text top="751" left="81" width="4" height="21" font="8"> </text>
<text top="771" left="81" width="624" height="23" font="38"><i><b>5.2.2. Acute Medical Therapy for Bradycardia Attributable to Atrioventricular Block </b></i></text>
<text top="806" left="81" width="57" height="19" font="1">S5.2.2-1. </text>
<text top="806" left="167" width="618" height="19" font="1">Brady WJ, Swart G, DeBehnke DJ, et al. The efficacy of atropine in the treatment of hemodynamically </text>
<text top="824" left="167" width="542" height="19" font="1">unstable bradycardia and atrioventricular block: prehospital and emergency department </text>
<text top="842" left="167" width="281" height="19" font="1">considerations. Resuscitation. 1999;41:47-55. </text>
<text top="861" left="81" width="57" height="19" font="1">S5.2.2-2. </text>
<text top="861" left="167" width="578" height="19" font="1">Feigl D, Ashkenazy J, Kishon Y. Early and late atrioventricular block in acute inferior myocardial </text>
<text top="879" left="167" width="255" height="19" font="1">infarction. J Am Coll Cardiol. 1984;4:35-8. </text>
<text top="897" left="81" width="57" height="19" font="1">S5.2.2-3. </text>
<text top="897" left="167" width="626" height="19" font="1">Sodeck GH, Domanovits H, Meron G, et al. Compromising bradycardia: management in the emergency </text>
<text top="915" left="167" width="272" height="19" font="1">department. Resuscitation. 2007;73:96-102. </text>
<text top="934" left="81" width="57" height="19" font="1">S5.2.2-4. </text>
<text top="934" left="167" width="606" height="19" font="1">Chihrin SM, Mohamed U, Yee R, et al. Utility of isoproterenol in unmasking latent escape rhythm in </text>
<text top="952" left="167" width="609" height="19" font="1">pacemaker dependent patients undergoing pacemaker replacement. Am J Cardiol. 2008;101:631-3. </text>
<text top="970" left="81" width="57" height="19" font="1">S5.2.2-5. </text>
<text top="970" left="167" width="561" height="19" font="1">Dhingra RC, Winslow E, Pouget JM, et al. The effect of isoproterenol on atrioventricular and </text>
<text top="989" left="167" width="360" height="19" font="1">intraventricular conduction. Am J Cardiol. 1973;32:629-36. </text>
<text top="1007" left="81" width="57" height="19" font="1">S5.2.2-6. </text>
<text top="1007" left="167" width="614" height="19" font="1">Hatle L, Rokseth R. Conservative treatment of AV block in acute myocardial infarction. Results in 105 </text>
<text top="1025" left="167" width="310" height="19" font="1">consecutive patients. Br Heart J. 1971;33:595-600. </text>
<text top="1044" left="81" width="57" height="19" font="1">S5.2.2-7. </text>
<text top="1044" left="167" width="626" height="19" font="1">Morrison LJ, Long J, Vermeulen M, et al. A randomized controlled feasibility trial comparing safety and </text>
<text top="1062" left="167" width="565" height="19" font="1">effectiveness of prehospital pacing versus conventional treatment: 'PrePACE'. Resuscitation. </text>
<text top="1080" left="167" width="96" height="19" font="1">2008;76:341-9. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="82" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">82</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="57" height="19" font="1">S5.2.2-8. </text>
<text top="111" left="167" width="610" height="19" font="1">Altun A, Kirdar C, Ozbay G. Effect of aminophylline in patients with atropine-resistant late advanced </text>
<text top="129" left="167" width="579" height="19" font="1">atrioventricular block during acute inferior myocardial infarction. Clin Cardiol. 1998;21:759-62. </text>
<text top="147" left="81" width="57" height="19" font="1">S5.2.2-9. </text>
<text top="147" left="167" width="622" height="19" font="1">Bertolet BD, McMurtrie EB, Hill JA, et al. Theophylline for the treatment of atrioventricular block after </text>
<text top="165" left="167" width="352" height="19" font="1">myocardial infarction. Ann Intern Med. 1995;123:509-11. </text>
<text top="184" left="81" width="64" height="19" font="1">S5.2.2-10. </text>
<text top="184" left="167" width="580" height="19" font="1">Goodfellow J, Walker PR. Reversal of atropine-resistant atrioventricular block with intravenous </text>
<text top="202" left="167" width="621" height="19" font="1">aminophylline in the early phase of inferior wall acute myocardial infarction following treatment with </text>
<text top="221" left="167" width="260" height="19" font="1">streptokinase. Eur Heart J. 1995;16:862-5. </text>
<text top="239" left="81" width="64" height="19" font="1">S5.2.2-11. </text>
<text top="239" left="167" width="592" height="19" font="1">Hurley KF, Magee K, Green R. Aminophylline for bradyasystolic cardiac arrest in adults. Cochrane </text>
<text top="257" left="167" width="221" height="19" font="1">Database Syst Rev. 2015;Cd006781. </text>
<text top="275" left="81" width="4" height="21" font="8"> </text>
<text top="295" left="81" width="378" height="23" font="38"><i><b>5.2.3. Temporary Pacing for Atrioventricular Block </b></i></text>
<text top="330" left="81" width="57" height="19" font="1">S5.2.3-1. </text>
<text top="330" left="167" width="615" height="19" font="1">Bjornstad CC, Gjertsen E, Thorup F, et al. Temporary cardiac pacemaker treatment in five Norwegian </text>
<text top="348" left="167" width="339" height="19" font="1">regional hospitals. Scand Cardiovasc J. 2012;46:137-43. </text>
<text top="366" left="81" width="57" height="19" font="1">S5.2.3-2. </text>
<text top="366" left="167" width="575" height="19" font="1">Murphy JJ. Current practice and complications of temporary transvenous cardiac pacing. BMJ. </text>
<text top="385" left="167" width="99" height="19" font="1">1996;312:1134. </text>
<text top="403" left="81" width="57" height="19" font="1">S5.2.3-3. </text>
<text top="403" left="167" width="610" height="19" font="1">Betts TR. Regional survey of temporary transvenous pacing procedures and complications. Postgrad </text>
<text top="421" left="167" width="139" height="19" font="1">Med J. 2003;79:463-5. </text>
<text top="440" left="81" width="57" height="19" font="1">S5.2.3-4. </text>
<text top="440" left="167" width="614" height="19" font="1">Hynes JK, Holmes DR Jr, Harrison CE. Five-year experience with temporary pacemaker therapy in the </text>
<text top="458" left="167" width="314" height="19" font="1">coronary care unit. Mayo Clin Proc. 1983;58:122-6. </text>
<text top="476" left="81" width="57" height="19" font="1">S5.2.3-5. </text>
<text top="476" left="167" width="608" height="19" font="1">López Ayerbe J, Villuendas Sabaté R, García García C, et al. Temporary pacemakers: current use and </text>
<text top="495" left="167" width="505" height="19" font="1">complications. Revista Española de Cardiología (English Edition). 2004;57:1045-52. </text>
<text top="513" left="81" width="57" height="19" font="1">S5.2.3-6. </text>
<text top="513" left="167" width="610" height="19" font="1">Ferguson JD, Banning AP, Bashir Y. Randomised trial of temporary cardiac pacing with semirigid and </text>
<text top="531" left="167" width="378" height="19" font="1">balloon-flotation electrode catheters. Lancet. 1997;349:1883. </text>
<text top="550" left="81" width="57" height="19" font="1">S5.2.3-7. </text>
<text top="550" left="167" width="566" height="19" font="1">Lang R, David D, Klein HO, et al. The use of the balloon-tipped floating catheter in temporary </text>
<text top="568" left="167" width="423" height="19" font="1">transvenous cardiac pacing. Pacing Clin Electrophysiol. 1981;4:491-6. </text>
<text top="586" left="81" width="57" height="19" font="1">S5.2.3-8. </text>
<text top="586" left="167" width="620" height="19" font="1">Braun MU, Rauwolf T, Bock M, et al. Percutaneous lead implantation connected to an external device </text>
<text top="604" left="167" width="623" height="19" font="1">in stimulation-dependent patients with systemic infection--a prospective and controlled study. Pacing </text>
<text top="623" left="167" width="215" height="19" font="1">Clin Electrophysiol. 2006;29:875-9. </text>
<text top="641" left="81" width="57" height="19" font="1">S5.2.3-9. </text>
<text top="641" left="167" width="625" height="19" font="1">Chihrin SM, Mohammed U, Yee R, et al. Utility and cost effectiveness of temporary pacing using active </text>
<text top="659" left="167" width="625" height="19" font="1">fixation leads and an externally placed reusable permanent pacemaker. Am J Cardiol. 2006;98:1613-5. </text>
<text top="678" left="81" width="64" height="19" font="1">S5.2.3-10. </text>
<text top="678" left="167" width="626" height="19" font="1">de Cock CC, Van Campen CM, In't Veld JA, et al. Utility and safety of prolonged temporary transvenous </text>
<text top="696" left="167" width="615" height="19" font="1">pacing using an active-fixation lead: comparison with a conventional lead. Pacing Clin Electrophysiol. </text>
<text top="714" left="167" width="103" height="19" font="1">2003;26:1245-8. </text>
<text top="733" left="81" width="64" height="19" font="1">S5.2.3-11. </text>
<text top="733" left="167" width="618" height="19" font="1">Kawata H, Pretorius V, Phan H, et al. Utility and safety of temporary pacing using active fixation leads </text>
<text top="751" left="167" width="620" height="19" font="1">and externalized re-usable permanent pacemakers after lead extraction. Europace. 2013;15:1287-91. </text>
<text top="769" left="81" width="64" height="19" font="1">S5.2.3-12. </text>
<text top="769" left="167" width="613" height="19" font="1">Kornberger A, Schmid E, Kalender G, et al. Bridge to recovery or permanent system implantation: an </text>
<text top="788" left="167" width="621" height="19" font="1">eight-year single-center experience in transvenous semipermanent pacing. Pacing Clin Electrophysiol. </text>
<text top="806" left="167" width="119" height="19" font="1">2013;36:1096-103. </text>
<text top="824" left="81" width="64" height="19" font="1">S5.2.3-13. </text>
<text top="824" left="167" width="572" height="19" font="1">Lever N, Ferguson JD, Bashir Y, et al. Prolonged temporary cardiac pacing using subcutaneous </text>
<text top="842" left="167" width="450" height="19" font="1">tunnelled active-fixation permanent pacing leads. Heart. 2003;89:209-10. </text>
<text top="861" left="81" width="64" height="19" font="1">S5.2.3-14. </text>
<text top="861" left="167" width="603" height="19" font="1">Zei PC, Eckart RE, Epstein LM. Modified temporary cardiac pacing using transvenous active fixation </text>
<text top="879" left="167" width="513" height="19" font="1">leads and external re-sterilized pulse generators. J Am Coll Cardiol. 2006;47:1487-9. </text>
<text top="898" left="81" width="64" height="19" font="1">S5.2.3-15. </text>
<text top="898" left="167" width="626" height="19" font="1">Morrison LJ, Long J, Vermeulen M, et al. A randomized controlled feasibility trial comparing safety and </text>
<text top="916" left="167" width="565" height="19" font="1">effectiveness of prehospital pacing versus conventional treatment: 'PrePACE'. Resuscitation. </text>
<text top="934" left="167" width="96" height="19" font="1">2008;76:341-9. </text>
<text top="952" left="81" width="64" height="19" font="1">S5.2.3-16. </text>
<text top="952" left="167" width="582" height="19" font="1">Cummins RO, Graves JR, Larsen MP, et al. Out-of-hospital transcutaneous pacing by emergency </text>
<text top="971" left="167" width="571" height="19" font="1">medical technicians in patients with asystolic cardiac arrest. N Engl J Med. 1993;328:1377-82. </text>
<text top="989" left="81" width="64" height="19" font="1">S5.2.3-17. </text>
<text top="989" left="167" width="594" height="19" font="1">Barthell E, Troiano P, Olson D, et al. Prehospital external cardiac pacing: a prospective, controlled </text>
<text top="1007" left="167" width="285" height="19" font="1">clinical trial. Ann Emerg Med. 1988;17:1221-6. </text>
<text top="1026" left="81" width="64" height="19" font="1">S5.2.3-18. </text>
<text top="1026" left="167" width="575" height="19" font="1">Hedges JR, Feero S, Shultz B, et al. Prehospital transcutaneous cardiac pacing for symptomatic </text>
<text top="1044" left="167" width="345" height="19" font="1">bradycardia. Pacing Clin Electrophysiol. 1991;14:1473-8. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="83" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">83</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="64" height="19" font="1">S5.2.3-19. </text>
<text top="111" left="167" width="560" height="19" font="1">Sherbino J, Verbeek PR, MacDonald RD, et al. Prehospital transcutaneous cardiac pacing for </text>
<text top="129" left="167" width="572" height="19" font="1">symptomatic bradycardia or bradyasystolic cardiac arrest: a systematic review. Resuscitation. </text>
<text top="147" left="167" width="111" height="19" font="1">2006;70:193-200. </text>
<text top="165" left="81" width="64" height="19" font="1">S5.2.3-20. </text>
<text top="165" left="167" width="563" height="19" font="1">Zoll PM, Zoll RH, Falk RH, et al. External noninvasive temporary cardiac pacing: clinical trials. </text>
<text top="184" left="167" width="176" height="19" font="1">Circulation. 1985;71:937-44. </text>
<text top="202" left="81" width="4" height="21" font="8"> </text>
<text top="222" left="81" width="577" height="27" font="27"><b>5.3. Chronic Therapy/Management of Bradycardia Attributable to </b></text>
<text top="247" left="81" width="195" height="27" font="27"><b>Atrioventricular Block </b></text>
<text top="278" left="81" width="45" height="19" font="1">S5.3-1. </text>
<text top="278" left="167" width="612" height="19" font="1">Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological </text>
<text top="296" left="167" width="604" height="19" font="1">therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the management of heart </text>
<text top="315" left="167" width="594" height="19" font="1">failure: a report of the American College of Cardiology/American Heart Association Task Force on </text>
<text top="333" left="167" width="611" height="19" font="1">Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282-93. </text>
<text top="351" left="81" width="45" height="19" font="1">S5.3-2. </text>
<text top="351" left="167" width="629" height="19" font="1">Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a </text>
<text top="370" left="167" width="610" height="19" font="1">report of the American College of Cardiology Foundation/American Heart Association Task Force on </text>
<text top="388" left="167" width="325" height="19" font="1">Practice Guidelines. Circulation. 2013;128:e240–327. </text>
<text top="406" left="81" width="4" height="21" font="8"> </text>
<text top="426" left="81" width="668" height="23" font="38"><i><b>5.3.1. General Principles of Chronic Therapy/Management of Bradycardia Attributable to </b></i></text>
<text top="451" left="81" width="167" height="23" font="38"><i><b>Atrioventricular Block </b></i></text>
<text top="486" left="81" width="45" height="19" font="1">S5.3-1. </text>
<text top="486" left="167" width="621" height="19" font="1">Dhingra RC, Denes P, Wu D, et al. The significance of second degree atrioventricular block and bundle </text>
<text top="504" left="167" width="545" height="19" font="1">branch block. Observations regarding site and type of block. Circulation. 1974;49:638-46. </text>
<text top="523" left="81" width="45" height="19" font="1">S5.3-2. </text>
<text top="523" left="167" width="625" height="19" font="1">Dhingra RC, Wyndham C, Bauernfeind R, et al. Significance of block distal to the His bundle induced by </text>
<text top="541" left="167" width="521" height="19" font="1">atrial pacing in patients with chronic bifascicular block. Circulation. 1979;60:1455-64. </text>
<text top="559" left="81" width="45" height="19" font="1">S5.3-3. </text>
<text top="559" left="167" width="599" height="19" font="1">Strasberg B, Amat YLF, Dhingra RC, et al. Natural history of chronic second-degree atrioventricular </text>
<text top="577" left="167" width="254" height="19" font="1">nodal block. Circulation. 1981;63:1043-9. </text>
<text top="596" left="81" width="45" height="19" font="1">S5.3-4. </text>
<text top="596" left="167" width="611" height="19" font="1">Gadler F, Valzania C, Linde C. Current use of implantable electrical devices in Sweden: data from the </text>
<text top="614" left="167" width="596" height="19" font="1">Swedish pacemaker and implantable cardioverter-defibrillator registry. Europace. 2015;17:69-77. </text>
<text top="632" left="81" width="45" height="19" font="1">S5.3-5. </text>
<text top="632" left="167" width="592" height="19" font="1">Armaganijan LV, Toff WD, Nielsen JC, et al. Are elderly patients at increased risk of complications </text>
<text top="651" left="167" width="611" height="19" font="1">following pacemaker implantation? A meta-analysis of randomized trials. Pacing Clin Electrophysiol. </text>
<text top="669" left="167" width="96" height="19" font="1">2012;35:131-4. </text>
<text top="687" left="81" width="45" height="19" font="1">S5.3-6. </text>
<text top="687" left="167" width="552" height="19" font="1">Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on </text>
<text top="706" left="167" width="576" height="19" font="1">cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. </text>
<text top="724" left="167" width="111" height="19" font="1">2017;14:e503-51. </text>
<text top="742" left="81" width="45" height="19" font="1">S5.3-7. </text>
<text top="742" left="167" width="581" height="19" font="1">Lee JZ, Ling J, Diehl NN, et al. Mortality and cerebrovascular events after heart rhythm disorder </text>
<text top="761" left="167" width="337" height="19" font="1">management procedures. Circulation. 2018;137:24-33. </text>
<text top="779" left="81" width="45" height="19" font="1">S5.3-8. </text>
<text top="779" left="167" width="606" height="19" font="1">Barold SS. Indications for permanent cardiac pacing in first-degree AV block: class I, II, or III? Pacing </text>
<text top="797" left="167" width="223" height="19" font="1">Clin Electrophysiol. 1996;19:747-51. </text>
<text top="815" left="81" width="45" height="19" font="1">S5.3-9. </text>
<text top="815" left="167" width="627" height="19" font="1">Kim YH, O'Nunain S, Trouton T, et al. Pseudo-pacemaker syndrome following inadvertent fast pathway </text>
<text top="834" left="167" width="616" height="19" font="1">ablation for atrioventricular nodal reentrant tachycardia. J Cardiovasc Electrophysiol. 1993;4:178-82. </text>
<text top="852" left="81" width="53" height="19" font="1">S5.3-10. </text>
<text top="852" left="167" width="574" height="19" font="1">Barold SS, Ilercil A, Leonelli F, et al. First-degree atrioventricular block. Clinical manifestations, </text>
<text top="871" left="167" width="611" height="19" font="1">indications for pacing, pacemaker management &amp; consequences during cardiac resynchronization. J </text>
<text top="889" left="167" width="268" height="19" font="1">Interv Card Electrophysiol. 2006;17:139-52. </text>
<text top="907" left="81" width="4" height="21" font="8"> </text>
<text top="927" left="81" width="536" height="23" font="38"><i><b>5.3.2. Transient/Potentially Reversible Causes of Atrioventricular Block  </b></i></text>
<text top="961" left="81" width="57" height="19" font="1">S5.3.2-1. </text>
<text top="961" left="167" width="616" height="19" font="1">Panic G, Stanulovic V, Popov T. Atrio-ventricular block as the first presentation of disseminated Lyme </text>
<text top="980" left="167" width="242" height="19" font="1">disease. Int J Cardiol. 2011;150:e104-6. </text>
<text top="998" left="81" width="57" height="19" font="1">S5.3.2-2. </text>
<text top="998" left="167" width="468" height="19" font="1">Zipes DP. Second-degree atrioventricular block. Circulation. 1979;60:465-72. </text>
<text top="1016" left="81" width="57" height="19" font="1">S5.3.2-3. </text>
<text top="1016" left="167" width="606" height="19" font="1">Robinson ML, Kobayashi T, Higgins Y, et al. Lyme carditis. Infect Dis Clin North Am. 2015;29:255-68. </text>
<text top="1035" left="81" width="57" height="19" font="1">S5.3.2-4. </text>
<text top="1035" left="167" width="607" height="19" font="1">Carano N, Bo I, Tchana B, et al. Adams-Stokes attack as the first symptom of acute rheumatic fever: </text>
<text top="1053" left="167" width="510" height="19" font="1">report of an adolescent case and review of the literature. Ital J Pediatr. 2012;38:61. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="84" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">84</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="57" height="19" font="1">S5.3.2-5. </text>
<text top="111" left="167" width="619" height="19" font="1">Guerrero-Marquez FJ, Arana-Rueda E, Pedrote A. Idiopathic paroxysmal atrio-ventricular block. What </text>
<text top="129" left="167" width="303" height="19" font="1">is the mechanism? J Atr Fibrillation. 2016;9:1449. </text>
<text top="147" left="81" width="57" height="19" font="1">S5.3.2-6. </text>
<text top="147" left="167" width="611" height="19" font="1">Gadler F, Valzania C, Linde C. Current use of implantable electrical devices in Sweden: data from the </text>
<text top="165" left="167" width="596" height="19" font="1">Swedish pacemaker and implantable cardioverter-defibrillator registry. Europace. 2015;17:69-77. </text>
<text top="184" left="81" width="57" height="19" font="1">S5.3.2-7. </text>
<text top="184" left="167" width="592" height="19" font="1">Armaganijan LV, Toff WD, Nielsen JC, et al. Are elderly patients at increased risk of complications </text>
<text top="202" left="167" width="611" height="19" font="1">following pacemaker implantation? A meta-analysis of randomized trials. Pacing Clin Electrophysiol. </text>
<text top="221" left="167" width="96" height="19" font="1">2012;35:131-4. </text>
<text top="239" left="81" width="57" height="19" font="1">S5.3.2-8. </text>
<text top="239" left="167" width="552" height="19" font="1">Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on </text>
<text top="257" left="167" width="576" height="19" font="1">cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. </text>
<text top="275" left="167" width="111" height="19" font="1">2017;14:e503-51. </text>
<text top="294" left="81" width="57" height="19" font="1">S5.3.2-9. </text>
<text top="294" left="167" width="581" height="19" font="1">Lee JZ, Ling J, Diehl NN, et al. Mortality and cerebrovascular events after heart rhythm disorder </text>
<text top="312" left="167" width="337" height="19" font="1">management Procedures. Circulation. 2018;137:24-33. </text>
<text top="330" left="81" width="64" height="19" font="1">S5.3.2-10. </text>
<text top="330" left="167" width="618" height="19" font="1">Alboni P, Holz A, Brignole M. Vagally mediated atrioventricular block: pathophysiology and diagnosis. </text>
<text top="349" left="167" width="137" height="19" font="1">Heart. 2013;99:904-8. </text>
<text top="367" left="81" width="4" height="21" font="8"> </text>
<text top="387" left="81" width="676" height="23" font="38"><i><b>5.3.3. Additional Testing for Chronic Therapy/Management of Bradycardia Attributable to </b></i></text>
<text top="412" left="81" width="167" height="23" font="38"><i><b>Atrioventricular Block </b></i></text>
<text top="447" left="81" width="57" height="19" font="1">S5.3.3-1. </text>
<text top="447" left="167" width="612" height="19" font="1">Giada F, Gulizia M, Francese M, et al. Recurrent unexplained palpitations (RUP) study comparison of </text>
<text top="465" left="167" width="622" height="19" font="1">implantable loop recorder versus conventional diagnostic strategy. J Am Coll Cardiol. 2007;49:1951-6. </text>
<text top="483" left="81" width="57" height="19" font="1">S5.3.3-2. </text>
<text top="483" left="167" width="592" height="19" font="1">Kinlay S, Leitch JW, Neil A, et al. Cardiac event recorders yield more diagnoses and are more cost-</text>
<text top="501" left="167" width="613" height="19" font="1">effective than 48-hour Holter monitoring in patients with palpitations. A controlled clinical trial. Ann </text>
<text top="520" left="167" width="179" height="19" font="1">Intern Med. 1996;124:16-20. </text>
<text top="538" left="81" width="57" height="19" font="1">S5.3.3-3. </text>
<text top="538" left="167" width="572" height="19" font="1">Podoleanu C, DaCosta A, Defaye P, et al. Early use of an implantable loop recorder in syncope </text>
<text top="556" left="167" width="606" height="19" font="1">evaluation: a randomized study in the context of the French healthcare system (FRESH study). Arch </text>
<text top="575" left="167" width="206" height="19" font="1">Cardiovasc Dis. 2014;107:546-52. </text>
<text top="593" left="81" width="57" height="19" font="1">S5.3.3-4. </text>
<text top="593" left="167" width="595" height="19" font="1">Sivakumaran S, Krahn AD, Klein GJ, et al. A prospective randomized comparison of loop recorders </text>
<text top="611" left="167" width="545" height="19" font="1">versus Holter monitors in patients with syncope or presyncope. Am J Med. 2003;115:1-5. </text>
<text top="630" left="81" width="57" height="19" font="1">S5.3.3-5. </text>
<text top="630" left="167" width="599" height="19" font="1">Bakst A, Goldberg B, Schamroth L. Significance of exercise-induced second degree atrioventricular </text>
<text top="648" left="167" width="202" height="19" font="1">block. Br Heart J. 1975;37:984-6. </text>
<text top="666" left="81" width="57" height="19" font="1">S5.3.3-6. </text>
<text top="666" left="167" width="615" height="19" font="1">Shetty RK, Agarwal S, Ganiga Sanjeeva NC, et al. Trifascicular block progressing to complete AV block </text>
<text top="685" left="167" width="591" height="19" font="1">on exercise: a rare presentation demonstrating the usefulness of exercise testing. BMJ Case Rep. </text>
<text top="703" left="167" width="72" height="19" font="1">2015;2015: </text>
<text top="721" left="81" width="57" height="19" font="1">S5.3.3-7. </text>
<text top="721" left="167" width="628" height="19" font="1">Fisher JD. Role of electrophysiologic testing in the diagnosis and treatment of patients with known and </text>
<text top="740" left="167" width="478" height="19" font="1">suspected bradycardias and tachycardias. Prog Cardiovasc Dis. 1981;24:25-90. </text>
<text top="758" left="81" width="57" height="19" font="1">S5.3.3-8. </text>
<text top="758" left="167" width="570" height="19" font="1">Katritsis DG, Josephson ME. Electrophysiological testing for the investigation of bradycardias. </text>
<text top="776" left="167" width="262" height="19" font="1">Arrhythm Electrophysiol Rev. 2017;6:24-8. </text>
<text top="795" left="81" width="57" height="19" font="1">S5.3.3-9. </text>
<text top="795" left="167" width="468" height="19" font="1">Zipes DP. Second-degree atrioventricular block. Circulation. 1979;60:465-72. </text>
<text top="813" left="81" width="64" height="19" font="1">S5.3.3-10. </text>
<text top="813" left="167" width="609" height="19" font="1">Mangiardi LM, Bonamini R, Conte M, et al. Bedside evaluation of atrioventricular block with narrow </text>
<text top="831" left="167" width="582" height="19" font="1">QRS complexes: usefulness of carotid sinus massage and atropine administration. Am J Cardiol. </text>
<text top="849" left="167" width="111" height="19" font="1">1982;49:1136-45. </text>
<text top="868" left="81" width="64" height="19" font="1">S5.3.3-11. </text>
<text top="868" left="167" width="592" height="19" font="1">Twidale N, Heddle WF, Tonkin AM. Procainamide administration during electrophysiology study--</text>
<text top="886" left="167" width="567" height="19" font="1">utility as a provocative test for intermittent atrioventricular block. Pacing Clin Electrophysiol. </text>
<text top="904" left="167" width="111" height="19" font="1">1988;11:1388-97. </text>
<text top="923" left="81" width="64" height="19" font="1">S5.3.3-12. </text>
<text top="923" left="167" width="624" height="19" font="1">Brembilla-Perrot B, Muhanna I, Nippert M, et al. Paradoxical effect of isoprenaline infusion. Europace. </text>
<text top="941" left="167" width="88" height="19" font="1">2005;7:621-7. </text>
<text top="959" left="81" width="4" height="21" font="7"><b> </b></text>
<text top="979" left="81" width="187" height="23" font="38"><i><b>5.3.4. Permanent Pacing </b></i></text>
<text top="1014" left="81" width="57" height="19" font="1">S5.3.4-1. </text>
<text top="1014" left="167" width="621" height="19" font="1">Dhingra RC, Denes P, Wu D, et al. The significance of second degree atrioventricular block and bundle </text>
<text top="1032" left="167" width="545" height="19" font="1">branch block. Observations regarding site and type of block. Circulation. 1974;49:638-46. </text>
<text top="1050" left="81" width="57" height="19" font="1">S5.3.4-2. </text>
<text top="1050" left="167" width="610" height="19" font="1">Ector H, Rolies L, De Geest H. Dynamic electrocardiography and ventricular pauses of 3 seconds and </text>
<text top="1069" left="167" width="532" height="19" font="1">more: etiology and therapeutic implications. Pacing Clin Electrophysiol. 1983;6:548-51. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="85" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">85</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="57" height="19" font="1">S5.3.4-3. </text>
<text top="111" left="167" width="617" height="19" font="1">Edhag O, Swahn A. Prognosis of patients with complete heart block or arrhythmic syncope who were </text>
<text top="129" left="167" width="616" height="19" font="1">not treated with artificial pacemakers. A long-term follow-up study of 101 patients. Acta Med Scand. </text>
<text top="147" left="167" width="111" height="19" font="1">1976;200:457-63. </text>
<text top="165" left="81" width="57" height="19" font="1">S5.3.4-4. </text>
<text top="165" left="167" width="570" height="19" font="1">Shaw DB, Eraut D. Prevalence and morbidity of heart block in Devon. Br Med J. 1970;1:144-7. </text>
<text top="184" left="81" width="57" height="19" font="1">S5.3.4-5. </text>
<text top="184" left="167" width="587" height="19" font="1">Shaw DB, Kekwick CA, Veale D, et al. Survival in second degree atrioventricular block. Br Heart J. </text>
<text top="202" left="167" width="103" height="19" font="1">1985;53:587-93. </text>
<text top="221" left="81" width="57" height="19" font="1">S5.3.4-6. </text>
<text top="221" left="167" width="608" height="19" font="1">Simon AB, Zloto AE. Atrioventricular block: natural history after permanent ventricular pacing. Am J </text>
<text top="239" left="167" width="146" height="19" font="1">Cardiol. 1978;41:500-7. </text>
<text top="257" left="81" width="57" height="19" font="1">S5.3.4-7. </text>
<text top="257" left="167" width="599" height="19" font="1">Strasberg B, Amat YLF, Dhingra RC, et al. Natural history of chronic second-degree atrioventricular </text>
<text top="275" left="167" width="254" height="19" font="1">nodal block. Circulation. 1981;63:1043-9. </text>
<text top="294" left="81" width="57" height="19" font="1">S5.3.4-8. </text>
<text top="294" left="167" width="587" height="19" font="1">Bhakta D, Shen C, Kron J, et al. Pacemaker and implantable cardioverter-defibrillator use in a US </text>
<text top="312" left="167" width="522" height="19" font="1">myotonic dystrophy type 1 population. J Cardiovasc Electrophysiol. 2011;22:1369-75. </text>
<text top="330" left="81" width="57" height="19" font="1">S5.3.4-9. </text>
<text top="330" left="167" width="585" height="19" font="1">Facenda-Lorenzo M, Hernandez-Afonso J, Rodriguez-Esteban M, et al. Cardiac manifestations in </text>
<text top="349" left="167" width="612" height="19" font="1">myotonic dystrophy type 1 patients followed using a standard protocol in a specialized unit. Rev Esp </text>
<text top="367" left="167" width="203" height="19" font="1">Cardiol (Engl Ed). 2013;66:193-7. </text>
<text top="385" left="81" width="64" height="19" font="1">S5.3.4-10. </text>
<text top="385" left="167" width="502" height="19" font="1">Groh WJ. Arrhythmias in the muscular dystrophies. Heart Rhythm. 2012;9:1890-5. </text>
<text top="404" left="81" width="64" height="19" font="1">S5.3.4-11. </text>
<text top="404" left="167" width="608" height="19" font="1">Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic </text>
<text top="422" left="167" width="314" height="19" font="1">dystrophy type 1. N Engl J Med. 2008;358:2688-97. </text>
<text top="440" left="81" width="64" height="19" font="1">S5.3.4-12. </text>
<text top="440" left="167" width="603" height="19" font="1">Ha AH, Tarnopolsky MA, Bergstra TG, et al. Predictors of atrio-ventricular conduction disease, long-</text>
<text top="458" left="167" width="567" height="19" font="1">term outcomes in patients with myotonic dystrophy types I and II. Pacing Clin Electrophysiol. </text>
<text top="477" left="167" width="103" height="19" font="1">2012;35:1262-9. </text>
<text top="495" left="81" width="64" height="19" font="1">S5.3.4-13. </text>
<text top="495" left="167" width="584" height="19" font="1">Kabunga P, Lau AK, Phan K, et al. Systematic review of cardiac electrical disease in Kearns-Sayre </text>
<text top="513" left="167" width="437" height="19" font="1">syndrome and mitochondrial cytopathy. Int J Cardiol. 2015;181:303-10. </text>
<text top="532" left="81" width="64" height="19" font="1">S5.3.4-14. </text>
<text top="532" left="167" width="589" height="19" font="1">Lazarus A, Varin J, Babuty D, et al. Long-term follow-up of arrhythmias in patients with myotonic </text>
<text top="550" left="167" width="549" height="19" font="1">dystrophy treated by pacing: a multicenter diagnostic pacemaker study. J Am Coll Cardiol. </text>
<text top="568" left="167" width="111" height="19" font="1">2002;40:1645-52. </text>
<text top="587" left="81" width="64" height="19" font="1">S5.3.4-15. </text>
<text top="587" left="167" width="625" height="19" font="1">Wahbi K, Meune C, Porcher R, et al. Electrophysiological study with prophylactic pacing and survival in </text>
<text top="605" left="167" width="562" height="19" font="1">adults with myotonic dystrophy and conduction system disease. JAMA. 2012;307:1292-301. </text>
<text top="623" left="81" width="64" height="19" font="1">S5.3.4-16. </text>
<text top="623" left="167" width="610" height="19" font="1">Hilgard J, Ezri MD, Denes P. Significance of ventricular pauses of three seconds or more detected on </text>
<text top="642" left="167" width="409" height="19" font="1">twenty-four-hour Holter recordings. Am J Cardiol. 1985;55:1005-8. </text>
<text top="660" left="81" width="64" height="19" font="1">S5.3.4-17. </text>
<text top="660" left="167" width="594" height="19" font="1">Saxon LA, Albert BH, Uretz EF, et al. Permanent pacemaker placement in chronic atrial fibrillation </text>
<text top="678" left="167" width="545" height="19" font="1">associated with intermittent AV block and cerebral symptoms. Pacing Clin Electrophysiol. </text>
<text top="696" left="167" width="96" height="19" font="1">1990;13:724-9. </text>
<text top="715" left="81" width="64" height="19" font="1">S5.3.4-18. </text>
<text top="715" left="167" width="584" height="19" font="1">O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-</text>
<text top="733" left="167" width="621" height="19" font="1">elevation myocardial infarction: a report of the American College of Cardiology Foundation/American </text>
<text top="752" left="167" width="523" height="19" font="1">Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362–425. </text>
<text top="770" left="81" width="64" height="19" font="1">S5.3.4-19. </text>
<text top="770" left="167" width="577" height="19" font="1">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of </text>
<text top="788" left="167" width="578" height="19" font="1">patients with non-ST-elevation acute coronary syndromes: a report of the American College of </text>
<text top="806" left="167" width="625" height="19" font="1">Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344–</text>
<text top="825" left="167" width="30" height="19" font="1">426. </text>
<text top="843" left="81" width="64" height="19" font="1">S5.3.4-20. </text>
<text top="843" left="167" width="621" height="19" font="1">Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of </text>
<text top="861" left="167" width="567" height="19" font="1">clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial </text>
<text top="880" left="167" width="611" height="19" font="1">infarction. Second Chinese Cardiac Study (CCS-2) Collaborative Group. J Cardiovasc Risk. 2000;7:435-</text>
<text top="898" left="167" width="22" height="19" font="1">41. </text>
<text top="916" left="81" width="64" height="19" font="1">S5.3.4-21. </text>
<text top="916" left="167" width="618" height="19" font="1">Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N </text>
<text top="935" left="167" width="184" height="19" font="1">Engl J Med. 2001;344:1651-8. </text>
<text top="953" left="81" width="64" height="19" font="1">S5.3.4-22. </text>
<text top="953" left="167" width="588" height="19" font="1">Dargie HJ. Design and methodology of the CAPRICORN trial - a randomised double blind placebo </text>
<text top="971" left="167" width="625" height="19" font="1">controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular </text>
<text top="990" left="167" width="438" height="19" font="1">dysfunction after myocardial infarction. Eur J Heart Fail. 2000;2:325-32. </text>
<text top="1008" left="81" width="64" height="19" font="1">S5.3.4-23. </text>
<text top="1008" left="167" width="618" height="19" font="1">Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure </text>
<text top="1026" left="167" width="627" height="19" font="1">and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker </text>
<text top="1044" left="167" width="404" height="19" font="1">therapy for sinus node dysfunction. Circulation. 2003;107:2932-7. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="86" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">86</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="64" height="19" font="1">S5.3.4-24. </text>
<text top="111" left="167" width="569" height="19" font="1">Kiehl EL, Makki T, Kumar R, et al. Incidence and predictors of right ventricular pacing-induced </text>
<text top="129" left="167" width="628" height="19" font="1">cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic </text>
<text top="147" left="167" width="254" height="19" font="1">function. Heart Rhythm. 2016;13:2272-8. </text>
<text top="165" left="81" width="64" height="19" font="1">S5.3.4-25. </text>
<text top="165" left="167" width="572" height="19" font="1">Kato Y, Morimoto S, Uemura A, et al. Efficacy of corticosteroids in sarcoidosis presenting with </text>
<text top="184" left="167" width="441" height="19" font="1">atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:133-7. </text>
<text top="202" left="81" width="64" height="19" font="1">S5.3.4-26. </text>
<text top="202" left="167" width="622" height="19" font="1">Reisinger J, Dubrey SW, Lavalley M, et al. Electrophysiologic abnormalities in AL (primary) amyloidosis </text>
<text top="221" left="167" width="380" height="19" font="1">with cardiac involvement. J Am Coll Cardiol. 1997;30:1046-51. </text>
<text top="239" left="81" width="64" height="19" font="1">S5.3.4-27. </text>
<text top="239" left="167" width="583" height="19" font="1">Sadek MM, Yung D, Birnie DH, et al. Corticosteroid therapy for cardiac sarcoidosis: a systematic </text>
<text top="257" left="167" width="244" height="19" font="1">review. Can J Cardiol. 2013;29:1034-41. </text>
<text top="275" left="81" width="64" height="19" font="1">S5.3.4-28. </text>
<text top="275" left="167" width="619" height="19" font="1">Sayed RH, Rogers D, Khan F, et al. A study of implanted cardiac rhythm recorders in advanced cardiac </text>
<text top="294" left="167" width="289" height="19" font="1">AL amyloidosis. Eur Heart J. 2015;36:1098-105. </text>
<text top="312" left="81" width="64" height="19" font="1">S5.3.4-29. </text>
<text top="312" left="167" width="620" height="19" font="1">Takaya Y, Kusano KF, Nakamura K, et al. Outcomes in patients with high-degree atrioventricular block </text>
<text top="330" left="167" width="489" height="19" font="1">as the initial manifestation of cardiac sarcoidosis. Am J Cardiol. 2015;115:505-9. </text>
<text top="349" left="81" width="64" height="19" font="1">S5.3.4-30. </text>
<text top="349" left="167" width="629" height="19" font="1">Zhou Y, Lower EE, Li HP, et al. Cardiac sarcoidosis: the impact of age and implanted devices on survival. </text>
<text top="367" left="167" width="152" height="19" font="1">Chest. 2017;151:139-48. </text>
<text top="385" left="81" width="64" height="19" font="1">S5.3.4-31. </text>
<text top="385" left="167" width="546" height="19" font="1">Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated cardiomyopathy with </text>
<text top="404" left="167" width="567" height="19" font="1">atrioventricular block: a lamin A/C defect-related disease. J Am Coll Cardiol. 2002;39:981-90. </text>
<text top="422" left="81" width="64" height="19" font="1">S5.3.4-32. </text>
<text top="422" left="167" width="571" height="19" font="1">Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter-defibrillators in lamin A/C </text>
<text top="440" left="167" width="519" height="19" font="1">mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492-8. </text>
<text top="458" left="81" width="64" height="19" font="1">S5.3.4-33. </text>
<text top="458" left="167" width="611" height="19" font="1">Hasselberg NE, Edvardsen T, Petri H, et al. Risk prediction of ventricular arrhythmias and myocardial </text>
<text top="477" left="167" width="471" height="19" font="1">function in Lamin A/C mutation positive subjects. Europace. 2014;16:563-71. </text>
<text top="495" left="81" width="64" height="19" font="1">S5.3.4-34. </text>
<text top="495" left="167" width="606" height="19" font="1">Barold SS. Indications for permanent cardiac pacing in first-degree AV block: class I, II, or III? Pacing </text>
<text top="513" left="167" width="223" height="19" font="1">Clin Electrophysiol. 1996;19:747-51. </text>
<text top="532" left="81" width="64" height="19" font="1">S5.3.4-35. </text>
<text top="532" left="167" width="608" height="19" font="1">Birkhahn RH, Gaeta TJ, Tloczkowski J, et al. Emergency medicine-trained physicians are proficient in </text>
<text top="550" left="167" width="465" height="19" font="1">the insertion of transvenous pacemakers. Ann Emerg Med. 2004;43:469-74. </text>
<text top="568" left="81" width="64" height="19" font="1">S5.3.4-36. </text>
<text top="568" left="167" width="610" height="19" font="1">Ferguson JD, Banning AP, Bashir Y. Randomised trial of temporary cardiac pacing with semirigid and </text>
<text top="587" left="167" width="378" height="19" font="1">balloon-flotation electrode catheters. Lancet. 1997;349:1883. </text>
<text top="605" left="81" width="64" height="19" font="1">S5.3.4-37. </text>
<text top="605" left="167" width="627" height="19" font="1">Kim YH, O'Nunain S, Trouton T, et al. Pseudo-pacemaker syndrome following inadvertent fast pathway </text>
<text top="623" left="167" width="616" height="19" font="1">ablation for atrioventricular nodal reentrant tachycardia. J Cardiovasc Electrophysiol. 1993;4:178-82. </text>
<text top="641" left="81" width="4" height="21" font="8"> </text>
<text top="661" left="81" width="702" height="21" font="7"><b>5.3.4.1. Permanent Pacing Techniques and Methods for Chronic Therapy/Management of Bradycardia </b></text>
<text top="684" left="81" width="260" height="21" font="7"><b>Attributable to Atrioventricular Block</b> </text>
<text top="717" left="81" width="702" height="19" font="1">S5.3.4.1-1.  Lamas GA, Orav EJ, Stambler BS, et al. Quality of life and clinical outcomes in elderly patients treated </text>
<text top="735" left="167" width="604" height="19" font="1">with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in the Elderly </text>
<text top="754" left="167" width="297" height="19" font="1">Investigators. N Engl J Med. 1998;338:1097-104. </text>
<text top="772" left="81" width="674" height="19" font="1">S5.3.4.1-2.  Lamas GA, Lee KL, Sweeney MO, et al. Ventricular pacing or dual-chamber pacing for sinus-node </text>
<text top="790" left="167" width="283" height="19" font="1">dysfunction. N Engl J Med. 2002;346:1854-62. </text>
<text top="809" left="81" width="715" height="19" font="1">S5.3.4.1-3.  Connolly SJ, Kerr CR, Gent M, et al. Effects of physiologic pacing versus ventricular pacing on the risk of </text>
<text top="827" left="167" width="608" height="19" font="1">stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N </text>
<text top="845" left="167" width="191" height="19" font="1">Engl J Med. 2000;342:1385-91. </text>
<text top="863" left="81" width="700" height="19" font="1">S5.3.4.1-4.  Kerr CR, Connolly SJ, Abdollah H, et al. Canadian Trial of Physiological Pacing: effects of physiological </text>
<text top="882" left="167" width="400" height="19" font="1">pacing during long-term follow-up. Circulation. 2004;109:357-62. </text>
<text top="900" left="81" width="705" height="19" font="1">S5.3.4.1-5.  Dretzke J, Toff WD, Lip GY, et al. Dual chamber versus single chamber ventricular pacemakers for sick </text>
<text top="919" left="167" width="546" height="19" font="1">sinus syndrome and atrioventricular block. Cochrane Database Syst Rev. 2004;CD003710. </text>
<text top="937" left="81" width="704" height="19" font="1">S5.3.4.1-6.  Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure </text>
<text top="955" left="167" width="627" height="19" font="1">and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker </text>
<text top="973" left="167" width="404" height="19" font="1">therapy for sinus node dysfunction. Circulation. 2003;107:2932-7. </text>
<text top="992" left="81" width="692" height="19" font="1">S5.3.4.1-7.  Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients </text>
<text top="1010" left="167" width="608" height="19" font="1">with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. </text>
<text top="1028" left="167" width="157" height="19" font="1">Jama. 2002;288:3115-23. </text>
<text top="1047" left="81" width="638" height="19" font="1">S5.3.4.1-8.  Toff WD, Camm AJ, Skehan JD. Single-chamber versus dual-chamber pacing for high-grade </text>
<text top="1065" left="167" width="334" height="19" font="1">atrioventricular block. N Engl J Med. 2005;353:145-55. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="87" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">87</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="685" height="19" font="1">S5.3.4.1-9.  Link MS, Hellkamp AS, Estes NA 3rd, et al. High incidence of pacemaker syndrome in patients with </text>
<text top="129" left="167" width="629" height="19" font="1">sinus node dysfunction treated with ventricular-based pacing in the Mode Selection Trial (MOST). J Am </text>
<text top="147" left="167" width="188" height="19" font="1">Coll Cardiol. 2004;43:2066-71. </text>
<text top="165" left="81" width="714" height="19" font="1">S5.3.4.1-10.  Ellenbogen KA, Stambler BS, Orav EJ, et al. Clinical characteristics of patients intolerant to VVIR pacing. </text>
<text top="184" left="167" width="178" height="19" font="1">Am J Cardiol. 2000;86:59-63. </text>
<text top="202" left="81" width="707" height="19" font="1">S5.3.4.1-11.  Kindermann M, Hennen B, Jung J, et al. Biventricular versus conventional right ventricular stimulation </text>
<text top="221" left="167" width="552" height="19" font="1">for patients with standard pacing indication and left ventricular dysfunction: the Homburg </text>
<text top="239" left="167" width="490" height="19" font="1">Biventricular Pacing Evaluation (HOBIPACE). J Am Coll Cardiol. 2006;47:1927-37. </text>
<text top="257" left="81" width="676" height="19" font="1">S5.3.4.1-12.  Vatankulu MA, Goktekin O, Kaya MG, et al. Effect of long-term resynchronization therapy on left </text>
<text top="275" left="167" width="575" height="19" font="1">ventricular remodeling in pacemaker patients upgraded to biventricular devices. Am J Cardiol. </text>
<text top="294" left="167" width="111" height="19" font="1">2009;103:1280-4. </text>
<text top="312" left="81" width="687" height="19" font="1">S5.3.4.1-13.  Gierula J, Cubbon RM, Jamil HA, et al. Cardiac resynchronization therapy in pacemaker-dependent </text>
<text top="330" left="167" width="431" height="19" font="1">patients with left ventricular dysfunction. Europace. 2013;15:1609-14. </text>
<text top="349" left="81" width="652" height="19" font="1">S5.3.4.1-14.  Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy in patients undergoing </text>
<text top="367" left="167" width="594" height="19" font="1">atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J. </text>
<text top="385" left="167" width="103" height="19" font="1">2011;32:2420-9. </text>
<text top="404" left="81" width="702" height="19" font="1">S5.3.4.1-15.  Yu CM, Chan JY, Zhang Q, et al. Biventricular pacing in patients with bradycardia and normal ejection </text>
<text top="422" left="167" width="259" height="19" font="1">fraction. N Engl J Med. 2009;361:2123-34. </text>
<text top="440" left="81" width="704" height="19" font="1">S5.3.4.1-16.  Albertsen AE, Mortensen PT, Jensen HK, et al. Adverse effect of right ventricular pacing prevented by </text>
<text top="458" left="167" width="581" height="19" font="1">biventricular pacing during long-term follow-up: a randomized comparison. Eur J Echocardiogr. </text>
<text top="477" left="167" width="103" height="19" font="1">2011;12:767-72. </text>
<text top="495" left="81" width="671" height="19" font="1">S5.3.4.1-17.  Brignole M, Botto GL, Mont L, et al. Predictors of clinical efficacy of 'Ablate and Pace' therapy in </text>
<text top="513" left="167" width="413" height="19" font="1">patients with permanent atrial fibrillation. Heart. 2012;98:297-302. </text>
<text top="532" left="81" width="687" height="19" font="1">S5.3.4.1-18.  Curtis AB, Worley SJ, Adamson PB, et al. Biventricular pacing for atrioventricular block and systolic </text>
<text top="550" left="167" width="283" height="19" font="1">dysfunction. N Engl J Med. 2013;368:1585-93. </text>
<text top="568" left="81" width="712" height="19" font="1">S5.3.4.1-19.  Slotwiner DJ, Raitt MH, Del-Carpio Munoz F, et al. Impact of physiologic versus right ventricular pacing </text>
<text top="587" left="167" width="607" height="19" font="1">among patients with left ventricular ejection fraction greater than 35%: a systematic review for the </text>
<text top="605" left="167" width="607" height="19" font="1">2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and </text>
<text top="623" left="167" width="620" height="19" font="1">cardiac conduction delay: a report of the American College of Cardiology/American Heart Association </text>
<text top="642" left="167" width="605" height="19" font="1">Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;In press. </text>
<text top="660" left="81" width="692" height="19" font="1">S5.3.4.1-20.  Brignole M, Gammage M, Puggioni E, et al. Comparative assessment of right, left, and biventricular </text>
<text top="678" left="167" width="495" height="19" font="1">pacing in patients with permanent atrial fibrillation. Eur Heart J. 2005;26:712-22. </text>
<text top="696" left="81" width="683" height="19" font="1">S5.3.4.1-21.  Stockburger M, Gomez-Doblas JJ, Lamas G, et al. Preventing ventricular dysfunction in pacemaker </text>
<text top="715" left="167" width="598" height="19" font="1">patients without advanced heart failure: results from a multicentre international randomized trial </text>
<text top="733" left="167" width="294" height="19" font="1">(PREVENT-HF). Eur J Heart Fail. 2011;13:633-41. </text>
<text top="752" left="81" width="668" height="19" font="1">S5.3.4.1-22.  Kronborg MB, Mortensen PT, Poulsen SH, et al. His or para-His pacing preserves left ventricular </text>
<text top="770" left="167" width="549" height="19" font="1">function in atrioventricular block: a double-blind, randomized, crossover study. Europace. </text>
<text top="788" left="167" width="111" height="19" font="1">2014;16:1189-96. </text>
<text top="806" left="81" width="702" height="19" font="1">S5.3.4.1-23.  Lustgarten DL, Crespo EM, Arkhipova-Jenkins I, et al. His-bundle pacing versus biventricular pacing in </text>
<text top="825" left="167" width="554" height="19" font="1">cardiac resynchronization therapy patients: a crossover design comparison. Heart Rhythm. </text>
<text top="843" left="167" width="111" height="19" font="1">2015;12:1548-57. </text>
<text top="861" left="81" width="689" height="19" font="1">S5.3.4.1-24.  Sharma PS, Dandamudi G, Naperkowski A, et al. Permanent His-bundle pacing is feasible, safe, and </text>
<text top="880" left="167" width="575" height="19" font="1">superior to right ventricular pacing in routine clinical practice. Heart Rhythm. 2015;12:305-12. </text>
<text top="898" left="81" width="694" height="19" font="1">S5.3.4.1-25.  Occhetta E, Bortnik M, Magnani A, et al. Prevention of ventricular desynchronization by permanent </text>
<text top="916" left="167" width="579" height="19" font="1">para-Hisian pacing after atrioventricular node ablation in chronic atrial fibrillation: a crossover, </text>
<text top="935" left="167" width="615" height="19" font="1">blinded, randomized study versus apical right ventricular pacing. J Am Coll Cardiol. 2006;47:1938-45. </text>
<text top="953" left="81" width="662" height="19" font="1">S5.3.4.1-26.  Ellenbogen KA, Hellkamp AS, Wilkoff BL, et al. Complications arising after implantation of DDD </text>
<text top="971" left="167" width="397" height="19" font="1">pacemakers: the MOST experience. Am J Cardiol. 2003;92:740-1. </text>
<text top="990" left="81" width="647" height="19" font="1">S5.3.4.1-27.  Udo EO, Zuithoff NP, van Hemel NM, et al. Incidence and predictors of short- and long-term </text>
<text top="1008" left="167" width="569" height="19" font="1">complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm. 2012;9:728-35. </text>
<text top="1026" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="88" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">88</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="110" left="81" width="637" height="31" font="2"><b>6. Conduction Disorders (With 1:1 Atrioventricular Conduction)  </b></text>
<text top="149" left="81" width="350" height="27" font="27"><b>6.1. Evaluation of Conduction Disorders </b></text>
<text top="187" left="81" width="45" height="19" font="1">S6.1-1. </text>
<text top="187" left="167" width="585" height="19" font="1">Fahy GJ, Pinski SL, Miller DP, et al. Natural history of isolated bundle branch block. Am J Cardiol. </text>
<text top="206" left="167" width="111" height="19" font="1">1996;77:1185-90. </text>
<text top="224" left="81" width="45" height="19" font="1">S6.1-2. </text>
<text top="224" left="167" width="550" height="19" font="1">Schneider JF, Thomas HE Jr, Kreger BE, et al. Newly acquired left bundle-branch block: the </text>
<text top="242" left="167" width="328" height="19" font="1">Framingham study. Ann Intern Med. 1979;90:303-10. </text>
<text top="261" left="81" width="45" height="19" font="1">S6.1-3. </text>
<text top="261" left="167" width="621" height="19" font="1">Talreja D, Gruver C, Sklenar J, et al. Efficient utilization of echocardiography for the assessment of left </text>
<text top="279" left="167" width="353" height="19" font="1">ventricular systolic function. Am Heart J. 2000;139:394-8. </text>
<text top="297" left="81" width="45" height="19" font="1">S6.1-4. </text>
<text top="297" left="167" width="598" height="19" font="1">Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour Holter monitoring with 14-day </text>
<text top="316" left="167" width="526" height="19" font="1">novel adhesive patch electrocardiographic monitoring. Am J Med. 2014;127:95.e11-7. </text>
<text top="334" left="81" width="45" height="19" font="1">S6.1-5. </text>
<text top="334" left="167" width="604" height="19" font="1">Brown AP, Dawkins KD, Davies JG. Detection of arrhythmias: use of a patient-activated ambulatory </text>
<text top="352" left="167" width="518" height="19" font="1">electrocardiogram device with a solid-state memory loop. Br Heart J. 1987;58:251-3. </text>
<text top="370" left="81" width="45" height="19" font="1">S6.1-6. </text>
<text top="370" left="167" width="619" height="19" font="1">Joshi AK, Kowey PR, Prystowsky EN, et al. First experience with a mobile cardiac outpatient telemetry </text>
<text top="389" left="167" width="614" height="19" font="1">(MCOT) system for the diagnosis and management of cardiac arrhythmia. Am J Cardiol. 2005;95:878-</text>
<text top="407" left="167" width="22" height="19" font="1">81. </text>
<text top="425" left="81" width="45" height="19" font="1">S6.1-7. </text>
<text top="425" left="167" width="619" height="19" font="1">Locati ET, Moya A, Oliveira M, et al. External prolonged electrocardiogram monitoring in unexplained </text>
<text top="444" left="167" width="547" height="19" font="1">syncope and palpitations: results of the SYNARR-Flash study. Europace. 2016;18:1265-72. </text>
<text top="462" left="81" width="45" height="19" font="1">S6.1-8. </text>
<text top="462" left="167" width="590" height="19" font="1">Reiffel JA, Schwarzberg R, Murry M. Comparison of autotriggered memory loop recorders versus </text>
<text top="480" left="167" width="585" height="19" font="1">standard loop recorders versus 24-hour Holter monitors for arrhythmia detection. Am J Cardiol. </text>
<text top="499" left="167" width="103" height="19" font="1">2005;95:1055-9. </text>
<text top="517" left="81" width="45" height="19" font="1">S6.1-9. </text>
<text top="517" left="167" width="598" height="19" font="1">Rothman SA, Laughlin JC, Seltzer J, et al. The diagnosis of cardiac arrhythmias: a prospective multi-</text>
<text top="535" left="167" width="616" height="19" font="1">center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event </text>
<text top="554" left="167" width="341" height="19" font="1">monitoring. J Cardiovasc Electrophysiol. 2007;18:241-7. </text>
<text top="572" left="81" width="53" height="19" font="1">S6.1-10. </text>
<text top="572" left="167" width="595" height="19" font="1">Sivakumaran S, Krahn AD, Klein GJ, et al. A prospective randomized comparison of loop recorders </text>
<text top="590" left="167" width="545" height="19" font="1">versus Holter monitors in patients with syncope or presyncope. Am J Med. 2003;115:1-5. </text>
<text top="608" left="81" width="53" height="19" font="1">S6.1-11. </text>
<text top="608" left="167" width="566" height="19" font="1">Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility of a novel leadless arrhythmia </text>
<text top="627" left="167" width="304" height="19" font="1">monitoring device. Am J Cardiol. 2013;112:520-4. </text>
<text top="645" left="81" width="53" height="19" font="1">S6.1-12. </text>
<text top="645" left="167" width="616" height="19" font="1">Chiu DT, Shapiro NI, Sun BC, et al. Are echocardiography, telemetry, ambulatory electrocardiography </text>
<text top="664" left="167" width="613" height="19" font="1">monitoring, and cardiac enzymes in emergency department patients presenting with syncope useful </text>
<text top="682" left="167" width="392" height="19" font="1">tests? A preliminary investigation. J Emerg Med. 2014;47:113-8. </text>
<text top="700" left="81" width="53" height="19" font="1">S6.1-13. </text>
<text top="700" left="167" width="598" height="19" font="1">Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR </text>
<text top="718" left="167" width="606" height="19" font="1">2011 appropriate use criteria for echocardiography: a report of the American College of Cardiology </text>
<text top="737" left="167" width="600" height="19" font="1">Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American </text>
<text top="755" left="167" width="603" height="19" font="1">Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart </text>
<text top="773" left="167" width="598" height="19" font="1">Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care </text>
<text top="792" left="167" width="593" height="19" font="1">Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic </text>
<text top="810" left="167" width="549" height="19" font="1">Resonance American College of Chest Physicians. J Am Soc Echocardiogr. 2011;24:229-67. </text>
<text top="828" left="81" width="53" height="19" font="1">S6.1-14. </text>
<text top="828" left="167" width="621" height="19" font="1">McAnulty JH, Rahimtoola SH, Murphy E, et al. Natural history of &#34;high-risk&#34; bundle-branch block: final </text>
<text top="847" left="167" width="381" height="19" font="1">report of a prospective study. N Engl J Med. 1982;307:137-43. </text>
<text top="865" left="81" width="53" height="19" font="1">S6.1-15. </text>
<text top="865" left="167" width="610" height="19" font="1">Mahmod M, Karamitsos TD, Suttie JJ, et al. Prevalence of cardiomyopathy in asymptomatic patients </text>
<text top="883" left="167" width="627" height="19" font="1">with left bundle branch block referred for cardiovascular magnetic resonance imaging. Int J Cardiovasc </text>
<text top="901" left="167" width="167" height="19" font="1">Imaging. 2012;28:1133-40. </text>
<text top="919" left="81" width="4" height="21" font="8"> </text>
<text top="940" left="81" width="715" height="27" font="27"><b>6.2. Management of Conduction Disorders (With 1:1 Atrioventricular Conduction) </b></text>
<text top="978" left="81" width="45" height="19" font="1">S6.2-1. </text>
<text top="978" left="167" width="617" height="19" font="1">Scheinman MM, Peters RW, Suave MJ, et al. Value of the H-Q interval in patients with bundle branch </text>
<text top="997" left="167" width="520" height="19" font="1">block and the role of prophylactic permanent pacing. Am J Cardiol. 1982;50:1316-22. </text>
<text top="1015" left="81" width="45" height="19" font="1">S6.2-2. </text>
<text top="1015" left="167" width="557" height="19" font="1">Morady F, Higgins J, Peters RW, et al. Electrophysiologic testing in bundle branch block and </text>
<text top="1033" left="167" width="322" height="19" font="1">unexplained syncope. Am J Cardiol. 1984;54:587-91. </text>
<text top="1052" left="81" width="45" height="19" font="1">S6.2-3. </text>
<text top="1052" left="167" width="606" height="19" font="1">Kubis M, Svejda J. Indication of permanent pacing after acute myocardial infarction complicated by </text>
<text top="1070" left="167" width="373" height="19" font="1">combined intraventricular block. Cor Vasa. 1982;24:295-301. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="89" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">89</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="45" height="19" font="1">S6.2-4. </text>
<text top="111" left="167" width="602" height="19" font="1">Khambatta S, Nguyen DL, Beckman TJ, et al. Kearns-Sayre syndrome: a case series of 35 adults and </text>
<text top="129" left="167" width="244" height="19" font="1">children. Int J Gen Med. 2014;7:325-32. </text>
<text top="147" left="81" width="45" height="19" font="1">S6.2-5. </text>
<text top="147" left="167" width="629" height="19" font="1">Polak PE, Zijlstra F, Roelandt JR. Indications for pacemaker implantation in the Kearns-Sayre syndrome. </text>
<text top="165" left="167" width="169" height="19" font="1">Eur Heart J. 1989;10:281-2. </text>
<text top="184" left="81" width="45" height="19" font="1">S6.2-6. </text>
<text top="184" left="167" width="628" height="19" font="1">O'Mahony C, Coats C, Cardona M, et al. Incidence and predictors of anti-bradycardia pacing in patients </text>
<text top="202" left="167" width="351" height="19" font="1">with Anderson-Fabry disease. Europace. 2011;13:1781-8. </text>
<text top="221" left="81" width="45" height="19" font="1">S6.2-7. </text>
<text top="221" left="167" width="576" height="19" font="1">Sene T, Lidove O, Sebbah J, et al. Cardiac device implantation in Fabry disease: A retrospective </text>
<text top="239" left="167" width="356" height="19" font="1">monocentric study. Medicine (Baltimore). 2016;95:e4996. </text>
<text top="257" left="81" width="45" height="19" font="1">S6.2-8. </text>
<text top="257" left="167" width="587" height="19" font="1">Witt CM, Wu G, Yang D, et al. Outcomes with left bundle branch block and mildly to moderately </text>
<text top="275" left="167" width="407" height="19" font="1">reduced left ventricular function. JACC Heart Fail. 2016;4:897-903. </text>
<text top="294" left="81" width="45" height="19" font="1">S6.2-9. </text>
<text top="294" left="167" width="598" height="19" font="1">Chung ES, Katra RP, Ghio S, et al. Cardiac resynchronization therapy may benefit patients with left </text>
<text top="312" left="167" width="574" height="19" font="1">ventricular ejection fraction &gt;35%: a PROSPECT trial substudy. Eur J Heart Fail. 2010;12:581-7. </text>
<text top="330" left="81" width="53" height="19" font="1">S6.2-10. </text>
<text top="330" left="167" width="597" height="19" font="1">Peters RW, Scheinman MM, Modin C, et al. Prophylactic permanent pacemakers for patients with </text>
<text top="349" left="167" width="351" height="19" font="1">chronic bundle branch block. Am J Med. 1979;66:978-85. </text>
<text top="367" left="81" width="53" height="19" font="1">S6.2-11. </text>
<text top="367" left="167" width="604" height="19" font="1">DePasquale NP, Bruno MS. Natural history of combined right bundle branch block and left anterior </text>
<text top="385" left="167" width="439" height="19" font="1">hemiblock (bilateral bundle branch block). Am J Med. 1973;54:297-303. </text>
<text top="404" left="81" width="53" height="19" font="1">S6.2-12. </text>
<text top="404" left="167" width="611" height="19" font="1">Gadler F, Valzania C, Linde C. Current use of implantable electrical devices in Sweden: data from the </text>
<text top="422" left="167" width="596" height="19" font="1">Swedish pacemaker and implantable cardioverter-defibrillator registry. Europace. 2015;17:69-77. </text>
<text top="440" left="81" width="53" height="19" font="1">S6.2-13. </text>
<text top="440" left="167" width="592" height="19" font="1">Armaganijan LV, Toff WD, Nielsen JC, et al. Are elderly patients at increased risk of complications </text>
<text top="458" left="167" width="611" height="19" font="1">following pacemaker implantation? A meta-analysis of randomized trials. Pacing Clin Electrophysiol. </text>
<text top="477" left="167" width="96" height="19" font="1">2012;35:131-4. </text>
<text top="495" left="81" width="53" height="19" font="1">S6.2-14. </text>
<text top="495" left="167" width="552" height="19" font="1">Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on </text>
<text top="513" left="167" width="576" height="19" font="1">cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. </text>
<text top="532" left="167" width="111" height="19" font="1">2017;14:e503-51. </text>
<text top="550" left="81" width="53" height="19" font="1">S6.2-15. </text>
<text top="550" left="167" width="581" height="19" font="1">Lee JZ, Ling J, Diehl NN, et al. Mortality and cerebrovascular events after heart rhythm disorder </text>
<text top="568" left="167" width="337" height="19" font="1">management procedures. Circulation. 2018;137:24-33. </text>
<text top="586" left="81" width="4" height="21" font="8"> </text>
<text top="606" left="81" width="223" height="31" font="2"><b>7. Special Populations </b></text>
<text top="649" left="81" width="282" height="27" font="27"><b>7.1. Perioperative Management </b></text>
<text top="688" left="81" width="598" height="23" font="38"><i><b>7.1.1. Patients at Risk for Bradycardia During Noncardiac Surgery or Procedures </b></i></text>
<text top="722" left="81" width="57" height="19" font="1">S7.1.1-1. </text>
<text top="722" left="167" width="607" height="19" font="1">Gauss A, Hubner C, Meierhenrich R, et al. Perioperative transcutaneous pacemaker in patients with </text>
<text top="741" left="167" width="628" height="19" font="1">chronic bifascicular block or left bundle branch block and additional first-degree atrioventricular block. </text>
<text top="759" left="167" width="251" height="19" font="1">Acta Anaesthesiol Scand. 1999;43:731-6. </text>
<text top="777" left="81" width="57" height="19" font="1">S7.1.1-2. </text>
<text top="777" left="167" width="560" height="19" font="1">Im SH, Han MH, Kim SH, et al. Transcutaneous temporary cardiac pacing in carotid stenting: </text>
<text top="795" left="167" width="577" height="19" font="1">noninvasive prevention of angioplasty-induced bradycardia and hypotension. J Endovasc Ther. </text>
<text top="814" left="167" width="96" height="19" font="1">2008;15:110-6. </text>
<text top="832" left="81" width="57" height="19" font="1">S7.1.1-3. </text>
<text top="832" left="167" width="619" height="19" font="1">Marrocco-Trischitta MM, Mazzone P, Vitale R, et al. Temporary transvenous pacemaker implantation </text>
<text top="850" left="167" width="601" height="19" font="1">during carotid endarterectomy in patients with trifascicular block. Ann Vasc Surg. 2016;34:206-11. </text>
<text top="869" left="81" width="57" height="19" font="1">S7.1.1-4. </text>
<text top="869" left="167" width="599" height="19" font="1">Morris D, Mulvihill D, Lew WY. Risk of developing complete heart block during bedside pulmonary </text>
<text top="887" left="167" width="617" height="19" font="1">artery catheterization in patients with left bundle-branch block. Arch Intern Med. 1987;147:2005-10. </text>
<text top="905" left="81" width="57" height="19" font="1">S7.1.1-5. </text>
<text top="905" left="167" width="625" height="19" font="1">Unnikrishnan D, Idris N, Varshneya N. Complete heart block during central venous catheter placement </text>
<text top="924" left="167" width="511" height="19" font="1">in a patient with pre-existing left bundle branch block. Br J Anaesth. 2003;91:747-9. </text>
<text top="942" left="81" width="4" height="21" font="8"> </text>
<text top="962" left="81" width="612" height="23" font="38"><i><b>7.1.2. Postoperative Bradycardia and Conduction Disorders After Cardiac Surgery  </b></i></text>
<text top="996" left="81" width="220" height="21" font="7"><b>7.1.2.1. Coronary Artery Bypass </b></text>
<text top="1029" left="81" width="640" height="19" font="1">S7.1.2.1-1.  Caspi Y, Safadi T, Ammar R, et al. The significance of bundle branch block in the immediate </text>
<text top="1047" left="167" width="621" height="19" font="1">postoperative electrocardiograms of patients undergoing coronary artery bypass. J Thorac Cardiovasc </text>
<text top="1065" left="167" width="130" height="19" font="1">Surg. 1987;93:442-6. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="90" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">90</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="681" height="19" font="1">S7.1.2.1-2.  Cook DJ, Bailon JM, Douglas TT, et al. Changing incidence, type, and natural history of conduction </text>
<text top="129" left="167" width="489" height="19" font="1">defects after coronary artery bypass grafting. Ann Thorac Surg. 2005;80:1732-7. </text>
<text top="147" left="81" width="709" height="19" font="1">S7.1.2.1-3.  Mackstaller LL, Alpert JS. Atrial fibrillation: a review of mechanism, etiology, and therapy. Clin Cardiol. </text>
<text top="165" left="167" width="103" height="19" font="1">1997;20:640-50. </text>
<text top="184" left="81" width="694" height="19" font="1">S7.1.2.1-4.  Ngaage DL, Schaff HV, Mullany CJ, et al. Does preoperative atrial fibrillation influence early and late </text>
<text top="202" left="167" width="541" height="19" font="1">outcomes of coronary artery bypass grafting? J Thorac Cardiovasc Surg. 2007;133:182-9. </text>
<text top="221" left="81" width="711" height="19" font="1">S7.1.2.1-5.  Puskas JD, Sharoni E, Williams WH, et al. Is routine use of temporary epicardial pacing wires necessary </text>
<text top="239" left="167" width="503" height="19" font="1">after either OPCAB or conventional CABG/CPB? Heart Surg Forum. 2003;6:E103-6. </text>
<text top="257" left="81" width="707" height="19" font="1">S7.1.2.1-6.  Satinsky JD, Collins JJ Jr, Dalen JE. Conduction defects after cardiac surgery. Circulation. 1974;50:Ii170-</text>
<text top="275" left="167" width="15" height="19" font="1">4. </text>
<text top="294" left="81" width="675" height="19" font="1">S7.1.2.1-7.  Tuzcu EM, Emre A, Goormastic M, et al. Incidence and prognostic significance of intraventricular </text>
<text top="312" left="167" width="560" height="19" font="1">conduction abnormalities after coronary bypass surgery. J Am Coll Cardiol. 1990;16:607-10. </text>
<text top="330" left="81" width="714" height="19" font="1">S7.1.2.1-8.  Yesil M, Bayata S, Arikan E, et al. Should we revascularize before implanting a pacemaker? Clin Cardiol. </text>
<text top="349" left="167" width="111" height="19" font="1">2008;31:498-501. </text>
<text top="367" left="81" width="709" height="19" font="1">S7.1.2.1-9.  Zeldis SM, Morganroth J, Horowitz LN, et al. Fascicular conduction distrubances after coronary bypass </text>
<text top="385" left="167" width="231" height="19" font="1">surgery. Am J Cardiol. 1978;41:860-4. </text>
<text top="404" left="81" width="663" height="19" font="1">S7.1.2.1-10.  Bethea BT, Salazar JD, Grega MA, et al. Determining the utility of temporary pacing wires after </text>
<text top="422" left="167" width="399" height="19" font="1">coronary artery bypass surgery. Ann Thorac Surg. 2005;79:104-7. </text>
<text top="440" left="81" width="702" height="19" font="1">S7.1.2.1-11.  Bougioukas I, Jebran AF, Grossmann M, et al. Is there a correlation between late re-exploration after </text>
<text top="458" left="167" width="562" height="19" font="1">cardiac surgery and removal of epicardial pacemaker wires? J Cardiothorac Surg. 2017;12:3. </text>
<text top="477" left="81" width="4" height="21" font="8"> </text>
<text top="497" left="81" width="156" height="21" font="7"><b>7.1.2.2. Surgery for AF </b></text>
<text top="529" left="81" width="700" height="19" font="1">S7.1.2.2-1.  Gammie JS, Haddad M, Milford-Beland S, et al. Atrial fibrillation correction surgery: lessons from the </text>
<text top="547" left="167" width="557" height="19" font="1">Society of Thoracic Surgeons National Cardiac Database. Ann Thorac Surg. 2008;85:909-14. </text>
<text top="566" left="81" width="682" height="19" font="1">S7.1.2.2-2.  Gillinov AM, Gelijns AC, Parides MK, et al. Surgical ablation of atrial fibrillation during mitral-valve </text>
<text top="584" left="167" width="265" height="19" font="1">surgery. N Engl J Med. 2015;372:1399-409. </text>
<text top="602" left="81" width="709" height="19" font="1">S7.1.2.2-3.  Phan K, Xie A, La Meir M, et al. Surgical ablation for treatment of atrial fibrillation in cardiac surgery: a </text>
<text top="621" left="167" width="506" height="19" font="1">cumulative meta-analysis of randomised controlled trials. Heart. 2014;100:722-30. </text>
<text top="639" left="81" width="704" height="19" font="1">S7.1.2.2-4.  Saint LL, Damiano RJ Jr, Cuculich PS, et al. Incremental risk of the Cox-Maze IV procedure for patients </text>
<text top="657" left="167" width="600" height="19" font="1">with atrial fibrillation undergoing mitral valve surgery. J Thorac Cardiovasc Surg. 2013;146:1072-7. </text>
<text top="675" left="81" width="4" height="21" font="8"> </text>
<text top="695" left="81" width="171" height="21" font="7"><b>7.1.2.3. Valvular Surgery </b></text>
<text top="727" left="81" width="330" height="19" font="15"><i>7.1.2.3.1. Surgical Aortic Valve Replacement or Repair </i></text>
<text top="758" left="81" width="710" height="19" font="1">S7.1.2.3.1-1.  Bagur R, Manazzoni JM, Dumont É, et al. Permanent pacemaker implantation following isolated aortic </text>
<text top="776" left="167" width="543" height="19" font="1">valve replacement in a large cohort of elderly patients with severe aortic stenosis. Heart. </text>
<text top="795" left="167" width="111" height="19" font="1">2011;97:1687-94. </text>
<text top="813" left="81" width="702" height="19" font="1">S7.1.2.3.1-2.  Dawkins S, Hobson AR, Kalra PR, et al. Permanent pacemaker implantation after isolated aortic valve </text>
<text top="831" left="167" width="530" height="19" font="1">replacement: incidence, indications, and predictors. Ann Thorac Surg. 2008;85:108-12. </text>
<text top="849" left="81" width="704" height="19" font="1">S7.1.2.3.1-3.  Limongelli G, Ducceschi V, D'Andrea A, et al. Risk factors for pacemaker implantation following aortic </text>
<text top="868" left="167" width="423" height="19" font="1">valve replacement: a single centre experience. Heart. 2003;89:901-4. </text>
<text top="886" left="81" width="646" height="19" font="1">S7.1.2.3.1-4.  Baraki H, Al Ahmad A, Jeng-Singh S, et al. Pacemaker dependency after isolated aortic valve </text>
<text top="905" left="167" width="565" height="19" font="1">replacement: do conductance disorders recover over time? Interact Cardiovasc Thorac Surg. </text>
<text top="923" left="167" width="103" height="19" font="1">2013;16:476-81. </text>
<text top="941" left="81" width="716" height="19" font="1">S7.1.2.3.1-5.  Greason KL, Lahr BD, Stulak JM, et al. Long-term mortality effect of early pacemaker implantation after </text>
<text top="959" left="167" width="434" height="19" font="1">surgical aortic valve replacement. Ann Thorac Surg. 2017;104:1259-64. </text>
<text top="977" left="81" width="4" height="21" font="8"> </text>
<text top="997" left="81" width="188" height="19" font="15"><i>7.1.2.3.2. Mitral Valve Surgery </i></text>
<text top="1028" left="81" width="662" height="19" font="1">S7.1.2.3.2-1.  Berdajs D, Schurr UP, Wagner A, et al. Incidence and pathophysiology of atrioventricular block </text>
<text top="1046" left="167" width="599" height="19" font="1">following mitral valve replacement and ring annuloplasty. Eur J Cardiothorac Surg. 2008;34:55-61. </text>
<text top="1065" left="81" width="672" height="19" font="1">S7.1.2.3.2-2.  Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-year outcomes of surgical treatment of severe </text>
<text top="1083" left="167" width="380" height="19" font="1">ischemic mitral regurgitation. N Engl J Med. 2016;374:344-53. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="91" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">91</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="713" height="19" font="1">S7.1.2.3.2-3.  Levin R, Leacche M, Petracek MR, et al. Extending the Use of the Pacing Pulmonary Artery Catheter for </text>
<text top="129" left="167" width="534" height="19" font="1">Safe Minimally Invasive Cardiac Surgery. J Cardiothor Vasc Anesthesia. 2010;24:568-73. </text>
<text top="147" left="81" width="4" height="21" font="8"> </text>
<text top="167" left="81" width="205" height="19" font="15"><i>7.1.2.3.3. Tricuspid Valve Surgery </i></text>
<text top="197" left="81" width="669" height="19" font="1">S7.1.2.3.3-1.  Chikwe J, Itagaki S, Anyanwu A, et al. Impact of concomitant tricuspid annuloplasty on tricuspid </text>
<text top="216" left="167" width="595" height="19" font="1">regurgitation, right ventricular function, and pulmonary artery hypertension after repair of mitral </text>
<text top="234" left="167" width="307" height="19" font="1">valve prolapse. J Am Coll Cardiol. 2015;65:1931-8. </text>
<text top="252" left="81" width="669" height="19" font="1">S7.1.2.3.3-2.  Jokinen JJ, Turpeinen AK, Pitkanen O, et al. Pacemaker therapy after tricuspid valve operations: </text>
<text top="271" left="167" width="558" height="19" font="1">implications on mortality, morbidity, and quality of life. Ann Thorac Surg. 2009;87:1806-14. </text>
<text top="289" left="81" width="681" height="19" font="1">S7.1.2.3.3-3.  McCarthy PM, Bhudia SK, Rajeswaran J, et al. Tricuspid valve repair: durability and risk factors for </text>
<text top="307" left="167" width="314" height="19" font="1">failure. J Thorac Cardiovasc Surg. 2004;127:674-85. </text>
<text top="326" left="81" width="689" height="19" font="1">S7.1.2.3.3-4.  Scully HE, Armstrong CS. Tricuspid valve replacement. Fifteen years of experience with mechanical </text>
<text top="344" left="167" width="465" height="19" font="1">prostheses and bioprostheses. J Thorac Cardiovasc Surg. 1995;109:1035-41. </text>
<text top="362" left="81" width="694" height="19" font="1">S7.1.2.3.3-5.  de Cock CC, Vinkers M, Van Campe LC, et al. Long-term outcome of patients with multiple (&gt; or = 3) </text>
<text top="381" left="167" width="595" height="19" font="1">noninfected transvenous leads: a clinical and echocardiographic study. Pacing Clin Electrophysiol. </text>
<text top="399" left="167" width="96" height="19" font="1">2000;23:423-6. </text>
<text top="417" left="81" width="4" height="21" font="8"> </text>
<text top="437" left="81" width="335" height="21" font="7"><b>7.1.2.4. Transcatheter Aortic Valve Replacement </b></text>
<text top="469" left="81" width="692" height="19" font="1">S7.1.2.4-1.  Piazza N, Onuma Y, Jesserun E, et al. Early and persistent intraventricular conduction abnormalities </text>
<text top="488" left="167" width="561" height="19" font="1">and requirements for pacemaking after percutaneous replacement of the aortic valve. JACC </text>
<text top="506" left="167" width="201" height="19" font="1">Cardiovasc Interv. 2008;1:310-6. </text>
<text top="524" left="81" width="695" height="19" font="1">S7.1.2.4-2.  Siontis GC, Juni P, Pilgrim T, et al. Predictors of permanent pacemaker implantation in patients with </text>
<text top="543" left="167" width="562" height="19" font="1">severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol. 2014;64:129-40. </text>
<text top="561" left="81" width="693" height="19" font="1">S7.1.2.4-3.  Boerlage-Van Dijk K, Kooiman KM, Yong ZY, et al. Predictors and permanency of cardiac conduction </text>
<text top="579" left="167" width="553" height="19" font="1">disorders and necessity of pacing after transcatheter aortic valve implantation. Pacing Clin </text>
<text top="598" left="167" width="197" height="19" font="1">Electrophysiol. 2014;37:1520-9. </text>
<text top="616" left="81" width="702" height="19" font="1">S7.1.2.4-4.  Regueiro A, Abdul-Jawad Altisent O, Del Trigo M, et al. Impact of new-onset left bundle branch block </text>
<text top="634" left="167" width="613" height="19" font="1">and periprocedural permanent pacemaker implantation on clinical outcomes in patients undergoing </text>
<text top="653" left="167" width="624" height="19" font="1">transcatheter aortic valve replacement: a systematic review and meta-analysis. Circ Cardiovasc Interv. </text>
<text top="671" left="167" width="106" height="19" font="1">2016;9:e003635. </text>
<text top="689" left="81" width="698" height="19" font="1">S7.1.2.4-5.  Watanabe Y, Kozuma K, Hioki H, et al. Pre-existing right bundle branch block increases risk for death </text>
<text top="707" left="167" width="623" height="19" font="1">after transcatheter aortic valve replacement with a balloon-expandable valve. JACC Cardiovasc Interv. </text>
<text top="726" left="167" width="96" height="19" font="1">2016;9:2210-6. </text>
<text top="744" left="81" width="692" height="19" font="1">S7.1.2.4-6.  Egger F, Nurnberg M, Rohla M, et al. High-degree atrioventricular block in patients with preexisting </text>
<text top="762" left="167" width="620" height="19" font="1">bundle branch block or bundle branch block occurring during transcatheter aortic valve implantation. </text>
<text top="781" left="167" width="204" height="19" font="1">Heart Rhythm. 2014;11:2176-82. </text>
<text top="799" left="81" width="686" height="19" font="1">S7.1.2.4-7.  Roten L, Wenaweser P, Delacretaz E, et al. Incidence and predictors of atrioventricular conduction </text>
<text top="817" left="167" width="554" height="19" font="1">impairment after transcatheter aortic valve implantation. Am J Cardiol. 2010;106:1473-80. </text>
<text top="836" left="81" width="661" height="19" font="1">S7.1.2.4-8.  Nazif TM, Dizon JM, Hahn RT, et al. Predictors and clinical outcomes of permanent pacemaker </text>
<text top="854" left="167" width="575" height="19" font="1">implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic </text>
<text top="872" left="167" width="474" height="19" font="1">TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv. 2015;8:60-9. </text>
<text top="891" left="81" width="698" height="19" font="1">S7.1.2.4-9.  Urena M, Mok M, Serra V, et al. Predictive factors and long-term clinical consequences of persistent </text>
<text top="909" left="167" width="618" height="19" font="1">left bundle branch block following transcatheter aortic valve implantation with a balloon-expandable </text>
<text top="927" left="167" width="259" height="19" font="1">valve. J Am Coll Cardiol. 2012;60:1743-52. </text>
<text top="946" left="81" width="653" height="19" font="1">S7.1.2.4-10.  Testa L, Latib A, De Marco F, et al. Clinical impact of persistent left bundle-branch block after </text>
<text top="964" left="167" width="619" height="19" font="1">transcatheter aortic valve implantation with CoreValve Revalving System. Circulation. 2013;127:1300-</text>
<text top="982" left="167" width="15" height="19" font="1">7. </text>
<text top="1000" left="81" width="4" height="21" font="8"> </text>
<text top="1020" left="81" width="511" height="21" font="7"><b>7.1.2.5. Heart Transplant, Surgical Myectomy, and Alcohol Septal Ablation </b></text>
<text top="1052" left="81" width="558" height="19" font="15"><i>7.1.2.5.1. Surgical Myectomy and Alcohol Septal Ablation for Hypertrophic Cardiomyopathy </i></text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="92" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">92</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="714" height="19" font="1">S7.1.2.5.1-1.  Axelsson A, Weibring K, Havndrup O, et al. Atrioventricular conduction after alcohol septal ablation for </text>
<text top="129" left="167" width="564" height="19" font="1">obstructive hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2014;15:214-21. </text>
<text top="147" left="81" width="710" height="19" font="1">S7.1.2.5.1-2.  El-Jack SS, Nasif M, Blake JW, et al. Predictors of complete heart block after alcohol septal ablation for </text>
<text top="165" left="167" width="621" height="19" font="1">hypertrophic cardiomyopathy and the timing of pacemaker implantation. J Interv Cardiol. 2007;20:73-</text>
<text top="184" left="167" width="15" height="19" font="1">6. </text>
<text top="202" left="81" width="698" height="19" font="1">S7.1.2.5.1-3.  Liebregts M, Faber L, Jensen MK, et al. Outcomes of alcohol septal ablation in younger patients with </text>
<text top="221" left="167" width="518" height="19" font="1">obstructive hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2017;10:1134-43. </text>
<text top="239" left="81" width="685" height="19" font="1">S7.1.2.5.1-4.  Veselka J, Lawrenz T, Stellbrink C, et al. Low incidence of procedure-related major adverse cardiac </text>
<text top="257" left="167" width="618" height="19" font="1">events after alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy. Can J </text>
<text top="275" left="167" width="161" height="19" font="1">Cardiol. 2013;29:1415-21. </text>
<text top="294" left="81" width="703" height="19" font="1">S7.1.2.5.1-5.  Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden </text>
<text top="312" left="167" width="443" height="19" font="1">cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405-12. </text>
<text top="330" left="81" width="696" height="19" font="1">S7.1.2.5.1-6.  Thavikulwat AC, Tomson TT, Knight BP, et al. Appropriate implantable defibrillator therapy in adults </text>
<text top="349" left="167" width="493" height="19" font="1">with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2016;27:953-60. </text>
<text top="367" left="81" width="687" height="19" font="1">S7.1.2.5.1-7.  Wang W, Lian Z, Rowin EJ, et al. Prognostic implications of nonsustained ventricular tachycardia in </text>
<text top="385" left="167" width="624" height="19" font="1">high-risk patients with hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2017;10:e004604. </text>
<text top="404" left="81" width="684" height="19" font="1">S7.1.2.5.1-8.  Balt JC, Wijffels MC, Boersma LV, et al. Continuous rhythm monitoring for ventricular arrhythmias </text>
<text top="422" left="167" width="544" height="19" font="1">after alcohol septal ablation for hypertrophic cardiomyopathy. Heart. 2014;100:1865-70. </text>
<text top="440" left="81" width="682" height="19" font="1">S7.1.2.5.1-9.  Lawrenz T, Lieder F, Bartelsmeier M, et al. Predictors of complete heart block after transcoronary </text>
<text top="458" left="167" width="586" height="19" font="1">ablation of septal hypertrophy: results of a prospective electrophysiological investigation in 172 </text>
<text top="477" left="167" width="565" height="19" font="1">patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007;49:2356-63. </text>
<text top="495" left="81" width="4" height="21" font="8"> </text>
<text top="515" left="81" width="579" height="27" font="27"><b>7.2. Bradycardia Management for Adult Congenital Heart Disease  </b></text>
<text top="554" left="81" width="45" height="19" font="1">S7.2-1. </text>
<text top="554" left="167" width="577" height="19" font="1">Albin G, Hayes DL, Holmes DR Jr. Sinus node dysfunction in pediatric and young adult patients: </text>
<text top="572" left="167" width="609" height="19" font="1">treatment by implantation of a permanent pacemaker in 39 cases. Mayo Clin Proc. 1985;60:667-72. </text>
<text top="590" left="81" width="45" height="19" font="1">S7.2-2. </text>
<text top="590" left="167" width="590" height="19" font="1">Diller GP, Dimopoulos K, Okonko D, et al. Heart rate response during exercise predicts survival in </text>
<text top="609" left="167" width="439" height="19" font="1">adults with congenital heart disease. J Am Coll Cardiol. 2006;48:1250-6. </text>
<text top="627" left="81" width="45" height="19" font="1">S7.2-3. </text>
<text top="627" left="167" width="620" height="19" font="1">Fishberger SB, Wernovsky G, Gentles TL, et al. Factors that influence the development of atrial flutter </text>
<text top="645" left="167" width="422" height="19" font="1">after the Fontan operation. J Thorac Cardiovasc Surg. 1997;113:80-6. </text>
<text top="664" left="81" width="45" height="19" font="1">S7.2-4. </text>
<text top="664" left="167" width="628" height="19" font="1">Gelatt M, Hamilton RM, McCrindle BW, et al. Arrhythmia and mortality after the Mustard procedure: a </text>
<text top="682" left="167" width="427" height="19" font="1">30-year single-center experience. J Am Coll Cardiol. 1997;29:194-201. </text>
<text top="700" left="81" width="45" height="19" font="1">S7.2-5. </text>
<text top="700" left="167" width="611" height="19" font="1">Helbing WA, Hansen B, Ottenkamp J, et al. Long-term results of atrial correction for transposition of </text>
<text top="719" left="167" width="569" height="19" font="1">the great arteries. Comparison of Mustard and Senning operations. J Thorac Cardiovasc Surg. </text>
<text top="737" left="167" width="111" height="19" font="1">1994;108:363-72. </text>
<text top="755" left="81" width="45" height="19" font="1">S7.2-6. </text>
<text top="755" left="167" width="612" height="19" font="1">Sanders P, Morton JB, Kistler PM, et al. Electrophysiological and electroanatomic characterization of </text>
<text top="773" left="167" width="614" height="19" font="1">the atria in sinus node disease: evidence of diffuse atrial remodeling. Circulation. 2004;109:1514-22. </text>
<text top="792" left="81" width="45" height="19" font="1">S7.2-7. </text>
<text top="792" left="167" width="611" height="19" font="1">Connelly MS, Liu PP, Williams WG, et al. Congenitally corrected transposition of the great arteries in </text>
<text top="810" left="167" width="506" height="19" font="1">the adult: functional status and complications. J Am Coll Cardiol. 1996;27:1238-43. </text>
<text top="828" left="81" width="45" height="19" font="1">S7.2-8. </text>
<text top="828" left="167" width="547" height="19" font="1">Graham TP Jr, Bernard YD, Mellen BG, et al. Long-term outcome in congenitally corrected </text>
<text top="847" left="167" width="590" height="19" font="1">transposition of the great arteries: a multi-institutional study. J Am Coll Cardiol. 2000;36:255-61. </text>
<text top="865" left="81" width="45" height="19" font="1">S7.2-9. </text>
<text top="865" left="167" width="597" height="19" font="1">Lundstrom U, Bull C, Wyse RK, et al. The natural and &#34;unnatural&#34; history of congenitally corrected </text>
<text top="883" left="167" width="274" height="19" font="1">transposition. Am J Cardiol. 1990;65:1222-9. </text>
<text top="902" left="81" width="53" height="19" font="1">S7.2-10. </text>
<text top="902" left="167" width="596" height="19" font="1">Dewey RC, Capeless MA, Levy AM. Use of ambulatory electrocardiographic monitoring to identify </text>
<text top="920" left="167" width="532" height="19" font="1">high-risk patients with congenital complete heart block. N Engl J Med. 1987;316:835-9. </text>
<text top="938" left="81" width="53" height="19" font="1">S7.2-11. </text>
<text top="938" left="167" width="606" height="19" font="1">Michaelsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioventricular block in adult </text>
<text top="957" left="167" width="322" height="19" font="1">life. A prospective study. Circulation. 1995;92:442-9. </text>
<text top="975" left="81" width="53" height="19" font="1">S7.2-12. </text>
<text top="975" left="167" width="599" height="19" font="1">Glikson M, Dearani JA, Hyberger LK, et al. Indications, effectiveness, and long-term dependency in </text>
<text top="993" left="167" width="441" height="19" font="1">permanent pacing after cardiac surgery. Am J Cardiol. 1997;80:1309-13. </text>
<text top="1011" left="81" width="53" height="19" font="1">S7.2-13. </text>
<text top="1011" left="167" width="630" height="19" font="1">Kim MH, Deeb GM, Eagle KA, et al. Complete atrioventricular block after valvular heart surgery and the </text>
<text top="1030" left="167" width="430" height="19" font="1">timing of pacemaker implantation. Am J Cardiol. 2001;87:649-51, a10. </text>
<text top="1048" left="81" width="53" height="19" font="1">S7.2-14. </text>
<text top="1048" left="167" width="604" height="19" font="1">Rhodes LA, Walsh EP, Gamble WJ, et al. Benefits and potential risks of atrial antitachycardia pacing </text>
<text top="1066" left="167" width="517" height="19" font="1">after repair of congenital heart disease. Pacing Clin Electrophysiol. 1995;18:1005-16. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="93" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">93</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="53" height="19" font="1">S7.2-15. </text>
<text top="111" left="167" width="615" height="19" font="1">Stephenson EA, Casavant D, Tuzi J, et al. Efficacy of atrial antitachycardia pacing using the Medtronic </text>
<text top="129" left="167" width="546" height="19" font="1">AT500 pacemaker in patients with congenital heart disease. Am J Cardiol. 2003;92:871-6. </text>
<text top="147" left="81" width="53" height="19" font="1">S7.2-16. </text>
<text top="147" left="167" width="598" height="19" font="1">Janousek J, Paul T, Luhmer I, et al. Atrial baffle procedures for complete transposition of the great </text>
<text top="165" left="167" width="625" height="19" font="1">arteries: natural course of sinus node dysfunction and risk factors for dysrhythmias and sudden death. </text>
<text top="184" left="167" width="156" height="19" font="1">Z Kardiol. 1994;83:933-8. </text>
<text top="202" left="81" width="53" height="19" font="1">S7.2-17. </text>
<text top="202" left="167" width="589" height="19" font="1">DeSimone CV, Friedman PA, Noheria A, et al. Stroke or transient ischemic attack in patients with </text>
<text top="221" left="167" width="602" height="19" font="1">transvenous pacemaker or defibrillator and echocardiographically detected patent foramen ovale. </text>
<text top="239" left="167" width="191" height="19" font="1">Circulation. 2013;128:1433-41. </text>
<text top="257" left="81" width="53" height="19" font="1">S7.2-18. </text>
<text top="257" left="167" width="625" height="19" font="1">Khairy P, Landzberg MJ, Gatzoulis MA, et al. Transvenous pacing leads and systemic thromboemboli in </text>
<text top="275" left="167" width="517" height="19" font="1">patients with intracardiac shunts: a multicenter study. Circulation. 2006;113:2391-7. </text>
<text top="293" left="81" width="4" height="21" font="8"> </text>
<text top="314" left="81" width="551" height="27" font="27"><b>7.3. Management of Bradycardia in Patients With an Acute MI  </b></text>
<text top="352" left="81" width="45" height="19" font="1">S7.3-1. </text>
<text top="352" left="167" width="585" height="19" font="1">Auffret V, Loirat A, Leurent G, et al. High-degree atrioventricular block complicating ST segment </text>
<text top="371" left="167" width="486" height="19" font="1">elevation myocardial infarction in the contemporary era. Heart. 2016;102:40-9. </text>
<text top="389" left="81" width="45" height="19" font="1">S7.3-2. </text>
<text top="389" left="167" width="614" height="19" font="1">Hynes JK, Holmes DR Jr, Harrison CE. Five-year experience with temporary pacemaker therapy in the </text>
<text top="407" left="167" width="314" height="19" font="1">coronary care unit. Mayo Clin Proc. 1983;58:122-6. </text>
<text top="426" left="81" width="45" height="19" font="1">S7.3-3. </text>
<text top="426" left="167" width="609" height="19" font="1">Jowett NI, Thompson DR, Pohl JE. Temporary transvenous cardiac pacing: 6 years experience in one </text>
<text top="444" left="167" width="315" height="19" font="1">coronary care unit. Postgrad Med J. 1989;65:211-5. </text>
<text top="462" left="81" width="45" height="19" font="1">S7.3-4. </text>
<text top="462" left="167" width="606" height="19" font="1">Kim HL, Kim SH, Seo JB, et al. Influence of second- and third-degree heart block on 30-day outcome </text>
<text top="480" left="167" width="610" height="19" font="1">following acute myocardial infarction in the drug-eluting stent era. Am J Cardiol. 2014;114:1658-62. </text>
<text top="499" left="81" width="45" height="19" font="1">S7.3-5. </text>
<text top="499" left="167" width="545" height="19" font="1">Ginks WR, Sutton R, Oh W, et al. Long-term prognosis after acute anterior infarction with </text>
<text top="517" left="167" width="300" height="19" font="1">atrioventricular block. Br Heart J. 1977;39:186-9. </text>
<text top="535" left="81" width="45" height="19" font="1">S7.3-6. </text>
<text top="535" left="167" width="616" height="19" font="1">Singh SM, FitzGerald G, Yan AT, et al. High-grade atrioventricular block in acute coronary syndromes: </text>
<text top="554" left="167" width="540" height="19" font="1">insights from the Global Registry of Acute Coronary Events. Eur Heart J. 2015;36:976-83. </text>
<text top="572" left="81" width="45" height="19" font="1">S7.3-7. </text>
<text top="572" left="167" width="593" height="19" font="1">Watson RD, Glover DR, Page AJ, et al. The Birmingham Trial of permanent pacing in patients with </text>
<text top="590" left="167" width="629" height="19" font="1">intraventricular conduction disorders after acute myocardial infarction. Am Heart J. 1984;108:496-501. </text>
<text top="609" left="81" width="45" height="19" font="1">S7.3-8. </text>
<text top="609" left="167" width="599" height="19" font="1">Ritter WS, Atkins JM, Blomqvist CG, et al. Permanent pacing in patients with transient trifascicular </text>
<text top="627" left="167" width="431" height="19" font="1">block during acute myocardial infarction. Am J Cardiol. 1976;38:205-8. </text>
<text top="645" left="81" width="45" height="19" font="1">S7.3-9. </text>
<text top="645" left="167" width="578" height="19" font="1">Feigl D, Ashkenazy J, Kishon Y. Early and late atrioventricular block in acute inferior myocardial </text>
<text top="664" left="167" width="255" height="19" font="1">infarction. J Am Coll Cardiol. 1984;4:35-8. </text>
<text top="682" left="81" width="53" height="19" font="1">S7.3-10. </text>
<text top="682" left="167" width="613" height="19" font="1">Scheinman MM, Thorburn D, Abbott JA. Use of atropine in patients with acute myocardial infarction </text>
<text top="700" left="167" width="316" height="19" font="1">and sinus bradycardia. Circulation. 1975;52:627-33. </text>
<text top="719" left="81" width="53" height="19" font="1">S7.3-11. </text>
<text top="719" left="167" width="521" height="19" font="1">Swart G, Brady WJ Jr, DeBehnke DJ, et al. Acute myocardial infarction complicated by </text>
<text top="737" left="167" width="626" height="19" font="1">hemodynamically unstable bradyarrhythmia: prehospital and ED treatment with atropine. Am J Emerg </text>
<text top="755" left="167" width="139" height="19" font="1">Med. 1999;17:647-52. </text>
<text top="773" left="81" width="53" height="19" font="1">S7.3-12. </text>
<text top="773" left="167" width="614" height="19" font="1">Gang UJ, Hvelplund A, Pedersen S, et al. High-degree atrioventricular block complicating ST-segment </text>
<text top="792" left="167" width="614" height="19" font="1">elevation myocardial infarction in the era of primary percutaneous coronary intervention. Europace. </text>
<text top="810" left="167" width="111" height="19" font="1">2012;14:1639-45. </text>
<text top="828" left="81" width="53" height="19" font="1">S7.3-13. </text>
<text top="828" left="167" width="611" height="19" font="1">Gadler F, Valzania C, Linde C. Current use of implantable electrical devices in Sweden: data from the </text>
<text top="847" left="167" width="596" height="19" font="1">Swedish pacemaker and implantable cardioverter-defibrillator registry. Europace. 2015;17:69-77. </text>
<text top="865" left="81" width="53" height="19" font="1">S7.3-14. </text>
<text top="865" left="167" width="592" height="19" font="1">Armaganijan LV, Toff WD, Nielsen JC, et al. Are elderly patients at increased risk of complications </text>
<text top="883" left="167" width="611" height="19" font="1">following pacemaker implantation? A meta-analysis of randomized trials. Pacing Clin Electrophysiol. </text>
<text top="902" left="167" width="96" height="19" font="1">2012;35:131-4. </text>
<text top="920" left="81" width="53" height="19" font="1">S7.3-15. </text>
<text top="920" left="167" width="552" height="19" font="1">Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on </text>
<text top="938" left="167" width="576" height="19" font="1">cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. </text>
<text top="957" left="167" width="111" height="19" font="1">2017;14:e503-51. </text>
<text top="975" left="81" width="53" height="19" font="1">S7.3-16. </text>
<text top="975" left="167" width="581" height="19" font="1">Lee JZ, Ling J, Diehl NN, et al. Mortality and cerebrovascular events after heart rhythm disorder </text>
<text top="993" left="167" width="337" height="19" font="1">management procedures. Circulation. 2018;137:24-33. </text>
<text top="1011" left="81" width="53" height="19" font="1">S7.3-17. </text>
<text top="1011" left="167" width="582" height="19" font="1">Col JJ, Weinberg SL. The incidence and mortality of intraventricular conduction defects in acute </text>
<text top="1030" left="167" width="323" height="19" font="1">myocardial infarction. Am J Cardiol. 1972;29:344-50. </text>
<text top="1048" left="81" width="53" height="19" font="1">S7.3-18. </text>
<text top="1048" left="167" width="617" height="19" font="1">Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating </text>
<text top="1066" left="167" width="578" height="19" font="1">acute myocardial infarction. 2. Indications for temporary and permanent pacemaker insertion. </text>
<text top="1085" left="167" width="176" height="19" font="1">Circulation. 1978;58:689-99. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="94" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">94</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="111" left="81" width="53" height="19" font="1">S7.3-19. </text>
<text top="111" left="167" width="617" height="19" font="1">Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating </text>
<text top="129" left="167" width="595" height="19" font="1">acute myocardial infarction. 1. Clinical characteristics, hospital mortality, and one-year follow-up. </text>
<text top="147" left="167" width="176" height="19" font="1">Circulation. 1978;58:679-88. </text>
<text top="165" left="81" width="4" height="21" font="8"> </text>
<text top="185" left="81" width="225" height="27" font="27"><b>7.4. Neurologic Disorders </b></text>
<text top="224" left="81" width="111" height="23" font="38"><i><b>7.4.1. Epilepsy </b></i></text>
<text top="258" left="81" width="60" height="19" font="1">S.7.4.1-1. </text>
<text top="258" left="167" width="551" height="19" font="1">Bestawros M, Darbar D, Arain A, et al. Ictal asystole and ictal syncope: insights into clinical </text>
<text top="277" left="167" width="366" height="19" font="1">management. Circ Arrhythm Electrophysiol. 2015;8:159-64. </text>
<text top="295" left="81" width="60" height="19" font="1">S.7.4.1-2. </text>
<text top="295" left="167" width="616" height="19" font="1">Lanz M, Oehl B, Brandt A, et al. Seizure induced cardiac asystole in epilepsy patients undergoing long </text>
<text top="313" left="167" width="328" height="19" font="1">term video-EEG monitoring. Seizure. 2011;20:167-72. </text>
<text top="332" left="81" width="60" height="19" font="1">S.7.4.1-3. </text>
<text top="332" left="167" width="610" height="19" font="1">Schuele SU, Bermeo AC, Alexopoulos AV, et al. Video-electrographic and clinical features in patients </text>
<text top="350" left="167" width="290" height="19" font="1">with ictal asystole. Neurology. 2007;69:434-41. </text>
<text top="368" left="81" width="60" height="19" font="1">S.7.4.1-4. </text>
<text top="368" left="167" width="581" height="19" font="1">Tenyi D, Gyimesi C, Kupo P, et al. Ictal asystole: a systematic review. Epilepsia. 2017;58:356-62. </text>
<text top="386" left="81" width="4" height="21" font="8"> </text>
<text top="406" left="81" width="718" height="31" font="2"><b>8. Evaluation of the Risks for Ventricular Arrhythmias in Patients Who </b></text>
<text top="440" left="81" width="268" height="31" font="2"><b>Require Permanent Pacing </b></text>
<text top="483" left="81" width="34" height="19" font="1">S8-1. </text>
<text top="483" left="167" width="571" height="19" font="1">Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter-defibrillators in lamin A/C </text>
<text top="501" left="167" width="519" height="19" font="1">mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492-8. </text>
<text top="520" left="81" width="34" height="19" font="1">S8-2. </text>
<text top="520" left="167" width="611" height="19" font="1">Gadler F, Valzania C, Linde C. Current use of implantable electrical devices in Sweden: data from the </text>
<text top="538" left="167" width="596" height="19" font="1">Swedish pacemaker and implantable cardioverter-defibrillator registry. Europace. 2015;17:69-77. </text>
<text top="556" left="81" width="34" height="19" font="1">S8-3. </text>
<text top="556" left="167" width="610" height="19" font="1">Gupta N, Kiley ML, Anthony F, et al. Multi-Center, Community-Based Cardiac Implantable Electronic </text>
<text top="575" left="167" width="602" height="19" font="1">Devices Registry: population, device utilization, and outcomes. J Am Heart Assoc. 2016;5:e002798. </text>
<text top="593" left="81" width="34" height="19" font="1">S8-4. </text>
<text top="593" left="167" width="601" height="19" font="1">Kirkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic device </text>
<text top="611" left="167" width="608" height="19" font="1">implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014;35:1186-</text>
<text top="630" left="167" width="22" height="19" font="1">94. </text>
<text top="648" left="81" width="34" height="19" font="1">S8-5. </text>
<text top="648" left="167" width="617" height="19" font="1">Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden </text>
<text top="666" left="167" width="443" height="19" font="1">cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405-12. </text>
<text top="685" left="81" width="34" height="19" font="1">S8-6. </text>
<text top="685" left="167" width="562" height="19" font="1">Sochala M, Wahbi K, Sorbets E, et al. Risk for complications after pacemaker or cardioverter </text>
<text top="703" left="167" width="624" height="19" font="1">defibrillator implantations in patients with myotonic dystrophy type 1. J Neuromuscul Dis. 2017;4:175-</text>
<text top="721" left="167" width="22" height="19" font="1">81. </text>
<text top="739" left="81" width="34" height="19" font="1">S8-7. </text>
<text top="739" left="167" width="620" height="19" font="1">Takaya Y, Kusano KF, Nakamura K, et al. Outcomes in patients with high-degree atrioventricular block </text>
<text top="758" left="167" width="489" height="19" font="1">as the initial manifestation of cardiac sarcoidosis. Am J Cardiol. 2015;115:505-9. </text>
<text top="776" left="81" width="4" height="21" font="8"> </text>
<text top="796" left="81" width="270" height="31" font="2"><b>9. Shared Decision-Making </b></text>
<text top="839" left="81" width="34" height="19" font="1">S9-1. </text>
<text top="839" left="167" width="596" height="19" font="1">Ottenberg AL, Mueller PS, Topazian RJ, et al. &#34;It's not broke, so let's not try to fix it&#34;: why patients </text>
<text top="857" left="167" width="609" height="19" font="1">decline a cardiovascular implantable electronic device. Pacing Clin Electrophysiol. 2014;37:1306-14. </text>
<text top="876" left="81" width="34" height="19" font="1">S9-2. </text>
<text top="876" left="167" width="616" height="19" font="1">Lewis KB, Stacey D, Matlock DD. Making decisions about implantable cardioverter-defibrillators from </text>
<text top="894" left="167" width="602" height="19" font="1">implantation to end of life: an integrative review of patients' perspectives. Patient. 2014;7:243-60. </text>
<text top="912" left="81" width="34" height="19" font="1">S9-3. </text>
<text top="912" left="167" width="612" height="19" font="1">Stewart GC, Weintraub JR, Pratibhu PP, et al. Patient expectations from implantable defibrillators to </text>
<text top="930" left="167" width="359" height="19" font="1">prevent death in heart failure. J Card Fail. 2010;16:106-13. </text>
<text top="949" left="81" width="34" height="19" font="1">S9-4. </text>
<text top="949" left="167" width="583" height="19" font="1">Hauptman PJ, Chibnall JT, Guild C, et al. Patient perceptions, physician communication, and the </text>
<text top="967" left="167" width="453" height="19" font="1">implantable cardioverter-defibrillator. JAMA Intern Med. 2013;173:571-7. </text>
<text top="985" left="81" width="34" height="19" font="1">S9-5. </text>
<text top="985" left="167" width="617" height="19" font="1">Yuhas J, Mattocks K, Gravelin L, et al. Patients' attitudes and perceptions of implantable cardioverter-</text>
<text top="1004" left="167" width="578" height="19" font="1">defibrillators: potential barriers to appropriate primary prophylaxis. Pacing Clin Electrophysiol. </text>
<text top="1022" left="167" width="111" height="19" font="1">2012;35:1179-87. </text>
<text top="1040" left="81" width="34" height="19" font="1">S9-6. </text>
<text top="1040" left="167" width="598" height="19" font="1">Elwyn G, Edwards A, Kinnersley P, et al. Shared decision making and the concept of equipoise: the </text>
<text top="1059" left="167" width="535" height="19" font="1">competences of involving patients in healthcare choices. Br J Gen Pract. 2000;50:892-9. </text>
<text top="1077" left="81" width="4" height="21" font="8"> </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="95" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="81" width="129" height="19" font="0"><b>Kusumoto FM, et al. </b></text>
<text top="72" left="81" width="412" height="19" font="0"><b>2018 Bradycardia Clinical Practice Guidelines: Executive Summary </b></text>
<text top="1129" left="81" width="3" height="17" font="31"><i><b> </b></i></text>
<text top="1129" left="383" width="30" height="17" font="17">Page<b> </b></text>
<text top="1127" left="412" width="15" height="19" font="1">95</text>
<text top="1126" left="428" width="4" height="21" font="8"> </text>
<text top="110" left="81" width="426" height="31" font="2"><b>10. Discontinuation of Pacemaker Therapy </b></text>
<text top="153" left="81" width="42" height="19" font="1">S10-1. </text>
<text top="153" left="167" width="627" height="19" font="1">Iskos D, Lurie KG, Sakaguchi S, et al. Termination of implantable pacemaker therapy: experience in five </text>
<text top="172" left="167" width="272" height="19" font="1">patients. Ann Intern Med. 1997;126:787-90. </text>
<text top="190" left="81" width="42" height="19" font="1">S10-2. </text>
<text top="190" left="167" width="604" height="19" font="1">Martinelli M, Costa R, Nishioka S, et al. Criteria for pacemaker explant in patients without a precise </text>
<text top="208" left="167" width="500" height="19" font="1">indication for pacemaker implantation. Pacing Clin Electrophysiol. 2002;25:272-7. </text>
<text top="592" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<outline>
<item page="5">Top 10 Take-Home Messages</item>
<item page="6">Preamble</item>
<item page="7">1. Introduction</item>
<outline>
<item page="7">1.1. Methodology and Evidence Review</item>
<item page="7">1.2. Organization of the Writing Committee</item>
<item page="7">1.3. Document Review and Approval</item>
<item page="8">1.4. Scope of the Guideline</item>
<item page="10">1.5. Class of Recommendation and Level of Evidence</item>
<item page="12">1.6. Abbreviations</item>
</outline>
<item page="13">2. Epidemiology and Definitions</item>
<outline>
<item page="13">2.1. Definitions</item>
</outline>
<item page="15">3. General Evaluation of Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<outline>
<item page="15">3.1. History and Physical Examination of Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="23">3.2. Noninvasive Evaluation</item>
<outline>
<item page="23">3.2.1. Resting ECG in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="23">3.2.2. Exercise Electrocardiographic Testing in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="23">3.2.3. Ambulatory Electrocardiography in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="25">3.2.4. Imaging in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="25">3.2.5. Laboratory Testing in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="26">3.2.6. Genetic Testing in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="26">3.2.7. Sleep Apnea Evaluation and Treatment in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
</outline>
<item page="27">3.3. Invasive Testing</item>
<outline>
<item page="27">3.3.1. Implantable Cardiac Monitor in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="27">3.3.2. Electrophysiology Study in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
</outline>
</outline>
<item page="28">4. Bradycardia Attributable to Sinus Node Dysfunction</item>
<outline>
<item page="28">4.1. Acute Management of Sinus Node Dysfunction</item>
<outline>
<item page="30">4.1.1. Acute Management of Reversible Causes of Sinus Node Dysfunction</item>
<item page="31">4.1.2. Acute Medical Therapy for Bradycardia</item>
<outline>
<item page="31">4.1.2.1. Atropine and Beta-Agonists for Bradycardia to SND</item>
<item page="32">4.1.2.2. Therapy of Beta Blocker and Calcium Channel Blocker Mediated Bradycardia Attributable to SND or Atrioventricular Block</item>
<item page="33">4.1.2.3. Therapy of Digoxin Mediated Bradycardia Attributable to Either SND or Atrioventricular Block</item>
<item page="33">4.1.2.4. Aminophylline or Theophylline for Bradycardia Attributable to SND</item>
</outline>
<item page="33">4.1.3. Temporary Pacing for Bradycardia Attributable to SND</item>
</outline>
<item page="35">4.2. Chronic Therapy/Management of Bradycardia Attributable to SND</item>
<outline>
<item page="35">4.2.1. General Principles of Chronic Therapy/Management of Bradycardia Attributable to SND</item>
<item page="35">4.2.2. Transient/Reversible Causes (Including Medications) of Bradycardia Attributable to SND</item>
<item page="35">4.2.3. Additional Testing of Bradycardia Attributable to SND</item>
<item page="36">4.3.4. Permanent Pacing for Chronic Therapy/Management of Bradycardia Attributable to SND</item>
<outline>
<item page="36">4.3.4.1. Permanent Pacing Techniques and Methods for Chronic Therapy/Management of Bradycardia Attributable to SND</item>
</outline>
</outline>
</outline>
<item page="38">5. Bradycardia Attributable to Atrioventricular Block</item>
<outline>
<item page="38">5.1. Pathophysiology, Etiology, and Classification of Bradycardia Attributable to Atrioventricular Block</item>
<item page="39">5.2. Acute Management</item>
<outline>
<item page="39">5.2.1. Acute Management of Reversible Causes of Bradycardia Attributable to Atrioventricular Block</item>
<item page="40">5.2.2. Acute Medical Therapy for Bradycardia Attributable to Atrioventricular Block</item>
<item page="40">5.2.3. Temporary Pacing for Atrioventricular Block</item>
</outline>
<item page="41">5.3. Chronic Therapy/Management of Bradycardia Attributable to Atrioventricular Block</item>
<outline>
<item page="43">5.3.1. General Principles of Chronic Therapy/Management of Bradycardia Attributable to Atrioventricular Block</item>
<item page="43">5.3.2. Transient/Potentially Reversible Causes of Atrioventricular Block</item>
<item page="44">5.3.3. Additional Testing for Chronic Therapy/Management of Bradycardia Attributable to Atrioventricular Block</item>
<item page="44">5.3.4. Permanent Pacing</item>
<outline>
<item page="46">5.3.4.1. Permanent Pacing Techniques and Methods for Chronic Therapy/Management of Bradycardia Attributable to Atrioventricular Block</item>
</outline>
</outline>
</outline>
<item page="47">6. Conduction Disorders (With 1:1 Atrioventricular Conduction)</item>
<outline>
<item page="47">6.1. Evaluation of Conduction Disorders</item>
<item page="50">6.2. Management of Conduction Disorders (With 1:1 Atrioventricular Conduction)</item>
</outline>
<item page="52">7. Special Populations</item>
<outline>
<item page="52">7.1. Perioperative Management</item>
<outline>
<item page="52">7.1.1. Patients at Risk for Bradycardia During Noncardiac Surgery or Procedures</item>
<item page="52">7.1.2. Postoperative Bradycardia and Conduction Disorders After Cardiac Surgery</item>
<outline>
<item page="52">7.1.2.1. Coronary Artery Bypass</item>
<item page="53">7.1.2.2. Surgery for AF</item>
<item page="53">7.1.2.3. Valvular Surgery</item>
<outline>
<item page="53">7.1.2.3.1. Surgical Aortic Valve Replacement or Repair</item>
<item page="54">7.1.2.3.2. Mitral Valve Surgery</item>
<item page="54">7.1.2.3.3. Tricuspid Valve Surgery</item>
</outline>
<item page="55">7.1.2.4. Transcatheter Aortic Valve Replacement</item>
<item page="55">7.1.2.5. Heart Transplant, Surgical Myectomy, and Alcohol Septal Ablation</item>
<outline>
<item page="55">7.1.2.5.1. Surgical Myectomy and Alcohol Septal Ablation for Hypertrophic Cardiomyopathy</item>
</outline>
</outline>
</outline>
<item page="56">7.2. Bradycardia Management for Adult Congenital Heart Disease</item>
<item page="57">7.3. Management of Bradycardia in Patients With an Acute MI</item>
<item page="57">7.4. Neurologic Disorders</item>
<outline>
<item page="57">7.4.1. Epilepsy</item>
</outline>
</outline>
<item page="58">8. Evaluation of the Risks for Ventricular Arrhythmias in Patients Who Require Permanent Pacing</item>
<item page="58">9. Shared Decision-Making</item>
<item page="59">10. Discontinuation of Pacemaker Therapy</item>
<item page="61">Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay (July 2018)</item>
<item page="64">Appendix 2. Abbreviated Reviewer Relationships With Industry and Other Entities—2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay (August 2018)*</item>
<item page="67">References</item>
<item page="67">Preamble</item>
<item page="67">1. Introduction</item>
<item page="67">1.4. Scope of the Guideline</item>
<item page="69">1.5. Class of Recommendation and Level of Evidence</item>
<item page="69">2. Epidemiology and Definitions</item>
<outline>
<item page="69">2.1. Definitions</item>
</outline>
<item page="70">3. General Evaluation of Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<outline>
<item page="70">3.1. History and Physical Examination of Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="70">3.2. Noninvasive Evaluation</item>
<outline>
<item page="70">3.2.1. Resting ECG in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="70">3.2.2. Exercise Electrocardiographic Testing in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="70">3.2.3. Ambulatory Electrocardiography in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="71">3.2.4. Imaging in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="72">3.2.5. Laboratory Testing in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="73">3.2.7. Sleep Apnea Evaluation and Treatment in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
</outline>
<item page="73">3.3. Invasive Testing</item>
<outline>
<item page="73">3.3.1. Implantable Cardiac Monitor in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
<item page="74">3.3.2. Electrophysiology Study in Patients With Documented or Suspected Bradycardia or Conduction Disorders</item>
</outline>
</outline>
<item page="74">4. Bradycardia Attributable to Sinus Node Dysfunction</item>
<outline>
<item page="74">4.1. Acute Management of Sinus Node Dysfunction</item>
<outline>
<item page="74">4.1.1. Acute Management of Reversible Causes of Sinus Node Dysfunction</item>
<item page="75">4.1.2. Acute Medical Therapy for Bradycardia</item>
<outline>
<item page="75">4.1.2.1. Atropine and Beta-Agonists for Bradycardia to SND</item>
<item page="76">4.1.2.2. Therapy of Beta Blocker and Calcium Channel Blocker Mediated Bradycardia Attributable to SND or Atrioventricular Block</item>
<item page="76">4.1.2.3. Therapy of Digoxin Mediated Bradycardia Attributable to Either SND or Atrioventricular Block</item>
<item page="77">4.1.2.4. Aminophylline or Theophylline for Bradycardia Attributable to SND</item>
</outline>
<item page="78">4.1.3. Temporary Pacing for Bradycardia Attributable to SND</item>
</outline>
<item page="79">4.2. Chronic Therapy/Management of Bradycardia Attributable to SND</item>
<outline>
<item page="79">4.2.1. General Principles of Chronic Therapy/Management of Bradycardia Attributable to SND</item>
<item page="80">4.2.3. Additional Testing of Bradycardia Attributable to SND</item>
<item page="80">4.3.4. Permanent Pacing for Chronic Therapy/Management of Bradycardia Attributable to SND</item>
<outline>
<item page="80">4.3.4.1. Permanent Pacing Techniques and Methods for Chronic Therapy/Management of Bradycardia Attributable to SND</item>
</outline>
</outline>
</outline>
<item page="81">5. Bradycardia Attributable to Atrioventricular Block</item>
<outline>
<item page="81">5.2. Acute Management</item>
<outline>
<item page="81">5.2.1. Acute Management of Reversible Causes of Bradycardia Attributable to Atrioventricular Block</item>
<item page="81">5.2.2. Acute Medical Therapy for Bradycardia Attributable to Atrioventricular Block</item>
<item page="82">5.2.3. Temporary Pacing for Atrioventricular Block</item>
</outline>
<item page="83">5.3. Chronic Therapy/Management of Bradycardia Attributable to Atrioventricular Block</item>
<outline>
<item page="83">5.3.1. General Principles of Chronic Therapy/Management of Bradycardia Attributable to Atrioventricular Block</item>
<item page="83">5.3.2. Transient/Potentially Reversible Causes of Atrioventricular Block</item>
<item page="84">5.3.3. Additional Testing for Chronic Therapy/Management of Bradycardia Attributable to Atrioventricular Block</item>
<item page="84">5.3.4. Permanent Pacing</item>
<outline>
<item page="86">5.3.4.1. Permanent Pacing Techniques and Methods for Chronic Therapy/Management of Bradycardia Attributable to Atrioventricular Block</item>
</outline>
</outline>
</outline>
<item page="88">6. Conduction Disorders (With 1:1 Atrioventricular Conduction)</item>
<outline>
<item page="88">6.1. Evaluation of Conduction Disorders</item>
<item page="88">6.2. Management of Conduction Disorders (With 1:1 Atrioventricular Conduction)</item>
</outline>
<item page="89">7. Special Populations</item>
<outline>
<item page="89">7.1. Perioperative Management</item>
<outline>
<item page="89">7.1.1. Patients at Risk for Bradycardia During Noncardiac Surgery or Procedures</item>
<item page="89">7.1.2. Postoperative Bradycardia and Conduction Disorders After Cardiac Surgery</item>
<outline>
<item page="89">7.1.2.1. Coronary Artery Bypass</item>
<item page="90">7.1.2.2. Surgery for AF</item>
<item page="90">7.1.2.3. Valvular Surgery</item>
<outline>
<item page="90">7.1.2.3.1. Surgical Aortic Valve Replacement or Repair</item>
<item page="90">7.1.2.3.2. Mitral Valve Surgery</item>
<item page="91">7.1.2.3.3. Tricuspid Valve Surgery</item>
</outline>
<item page="91">7.1.2.4. Transcatheter Aortic Valve Replacement</item>
<item page="91">7.1.2.5. Heart Transplant, Surgical Myectomy, and Alcohol Septal Ablation</item>
<outline>
<item page="91">7.1.2.5.1. Surgical Myectomy and Alcohol Septal Ablation for Hypertrophic Cardiomyopathy</item>
</outline>
</outline>
</outline>
<item page="92">7.2. Bradycardia Management for Adult Congenital Heart Disease</item>
<item page="93">7.3. Management of Bradycardia in Patients With an Acute MI</item>
<item page="94">7.4. Neurologic Disorders</item>
<outline>
<item page="94">7.4.1. Epilepsy</item>
</outline>
</outline>
<item page="94">8. Evaluation of the Risks for Ventricular Arrhythmias in Patients Who Require Permanent Pacing</item>
<item page="94">9. Shared Decision-Making</item>
<item page="95">10. Discontinuation of Pacemaker Therapy</item>
</outline>
</pdf2xml>
